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Abstract 
Anthocyanins are polyphenol pigments responsible for the blue/red colouring of many fruits 
and vegetables whose consumption is associated with reduced risk of cardiovascular 
disease. Due to instability at neutral pH and reported low bioavailability of anthocyanins, the 
focus has shifted to their phenolic metabolites to explain the observed bioactivity. The 
hypothesis of the present study was that greater sensitivity and higher throughput could be 
achieved by developing existing analytical methodology, metabolite biomarkers of 
anthocyanin intake could be identified, and physiologically relevant anthocyanin metabolite 
profiles could reduce expression of proinflammatory cytokines in vitro. Stability of cyanidin-
3-glucoside and 17 metabolites in serum was assessed. Unlike the parent anthocyanin, 
metabolite recovery was unaffected by either pH or freeze/thaw cycling suggesting that 
acidification and aliquoting of samples may be unnecessary for quantifying anthocyanin 
metabolites only. HPLC-ESI-MS/MS methodology was developed to increase sensitivity and 
sample throughput. Initial and developed methods were validated against FDA guidelines 
and found to have acceptable linearity, specificity and sensitivity with limits of detection of 
9.5 ± 13.0 nM and 96.7 ± 541.7 nM respectively. Accuracy and precision were acceptable at 
50 µM but outside guidelines at 1.56 µM and 0.098 µM for both methods. Biomarkers of 
anthocyanin intake were explored using samples from a 13C-labelled cyanidin-3-glucoside 
trial to compare 13C-labelled metabolites against 12C metabolites from the background diet. 
Gallic acid was consistently found above background levels in urine and represented the best 
biomarker candidate. Finally, effect of anthocyanin metabolite profiles on proinflammatory 
cytokines in CD40L and TNF-α-stimulated HUVEC was investigated. Incubation with 
metabolite profiles reduced expression of sVCAM-1 by 47-58% and IL-6 by 16-37% following 
TNF-α stimulation. In conclusion, the present thesis develops methodology for the 
quantification of anthocyanin metabolites in biological matrices and provides insight into 
their use as biomarkers of anthocyanin intake and role in maintaining cardiovascular health. 
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Chapter 1. Anthocyanins: A Review of Current Literature 
 
1.1. Introduction 
Polyphenols are a group of phytochemicals that can be divided into four main subgroups: 
flavonoids, lignans, stilbenes, and tannins (Table 1.1). These groups retain a basic multiple 
aromatic ring structure differentiated by various functional groups and are found in many 
dietary sources including fruits, vegetables, tea, and chocolate (Manach et al. 2004, Crozier 
et al. 2009). Interest in polyphenols as bioactive dietary components grew in the early 1990s 
as epidemiological studies reported a link between increased polyphenol intake and reduced 
mortality (Hertog et al. 1993, Hertog et al. 1994) with initial theories to explain these 
observations focusing on the antioxidant properties of polyphenols (Rice-Evans 1995, 
Hollman et al. 1996). Whilst the consensus has moved away from free-radical scavenging as 
a mechanism for their bioactivity (Scalbert et al. 2005), polyphenol-rich diets have continued 
to be linked to a range of beneficial health effects relating to cognition (Lamport et al. 2012, 
Rabassa et al. 2015), obesity (Wu et al. 2003, Hughes et al. 2008), cancer prevention (Hui et 
al. 2013, Zamora-Ros et al. 2013), and cardiovascular disease (Tresserra-Rimbau et al. 2014, 
Rangel-Huerta et al. 2015). 
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Table 1.1 Polyphenol subgroups, common structures, and main dietary sources. 
Subgroup Structure 
Main dietary 
sources  
Flavonoids 
 
 
 
Fruit and vegetables 
Lignans 
 
 
 
Flax seed, sesame 
seed, cereals 
Stilbenes 
 
 
 
Almonds, grapes 
Tanninsa 
 
 
 
Cocoa, black and 
green tea, berries, 
walnuts, wine 
R, functional group (-H, -OH, -OCH3). aTannins exist as polymers consisting of gallic acid, flavone or 
phloroglucinaldehyde monomers. Adapted from (Scalbert and Williamson 2000, Neveu et al. 2010). 
 
With over 6,000 compounds identified to date across a wide range of fruits and vegetables 
(Harborne and Williams 2000), flavonoids are the most commonly consumed polyphenol 
group and have been widely studied in relation to their bioavailability and bioactivity (Kay et 
al. 2012, Thilakarathna and Rupasinghe 2013, Rodriguez-Mateos et al. 2014). Flavonoid 
compounds share the same phenolic structure and can be further divided into six main 
subgroups based on the functional groups attached to the heterocyclic C-ring: 
anthocyanidins, flavan-3-ols, flavanones, flavones, flavonols, and isoflavonoids (Table 1.2).  
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Table 1.2 Flavonoid subgroups, common structures and main dietary sources. 
Subgroup Structure Main dietary sources  
Anthocyanidins 
 
 
Berries, blackcurrants, black 
grapes, red cabbage 
Flavan-3-ols 
 
Cocoa, black and green tea, 
apples 
Flavanones 
 
Oranges, grapefruit, lemons 
Flavones 
 
Globe artichoke, celery, 
oregano, sage, thyme 
Flavonols 
 
Black and green tea, onions, 
cumin 
Isoflavonoids 
 
 
Soybean 
R, functional group (-H, -OH, -OCH3). Adapted from (Crozier et al. 2009, Neveu et al. 2010). 
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Anthocyanins (from Greek, Anthos meaning flower and kyanos meaning blue) are the more 
stable, glycosylated form of anthocyanidins found in plants (Castañeda-Ovando et al. 2009). 
One of three main plant pigment groups alongside betalains and carotenoids, anthocyanins 
are water-soluble pigments responsible for the red/blue colour of the flowers, leaves and 
fruit of many plants including dietary sources such as berries, grapes and red cabbage 
(Crozier et al. 2009, Del Rio et al. 2010a). Anthocyanin consumption has been linked to a 
range of health benefits including reduced rates of obesity (Prior et al. 2008, Wu et al. 2013), 
improved cognition (Kent et al. 2015, Whyte et al. 2015), reduced risk of cancer (Peiffer et 
al. 2014, Charepalli et al. 2015), and cardiovascular disease (Cassidy et al. 2013, Wang et al. 
2014a). However, due to the reported low bioavailability of anthocyanins (Scalbert and 
Williamson 2000, Kay et al. 2005, Manach et al. 2005), recent studies have suggested that 
the phenolic metabolites of anthocyanins may be responsible for the observed bioactivity 
(di Gesso et al. 2015, Warner et al. 2016). The present study focuses on the stability of 
anthocyanin metabolites in biological samples, their utility as biomarkers of anthocyanin 
intake and their effect on early-stage biomarkers of cardiovascular disease.  
 
1.2. Chemistry 
The basic anthocyanin structure is based on the 2-phenylbenzopyrylium (flavylium) cation 
with substitutions in the glycosylation, acylation, hydroxylation, and methoxylation 
differentiating between the 600+ anthocyanin compounds identified to date (Wallace 2011). 
The aglycones, known as anthocyanidins, contain conjugated double bonds that show 
absorption maxima within the visible spectrum between 465 – 550 nm (resulting in the 
red/blue colour visible to the human eye) and within the UV spectrum between 270 – 280 
nm (Hong and Wrolstad 1990). 23 anthocyanidins have been identified to date with six 
predominant anthocyanidins (cyanidin, delphinidin, pelargonidin, peonidin, petunidin, and 
malvidin), differing in the number and position of hydroxyl and methoxy groups on the cation 
B-ring, accounting for over 90% of identified anthocyanins (Figure 1.1) (Castañeda-Ovando 
et al. 2009, Wallace 2011). 
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Figure 1.1 Common structures of anthocyanidins. 
 
R1, R2, functional groups (-H, -OH, -OCH3). Adapted from (Kong et al. 2003). 
 
Glycosylation of anthocyanidins to form anthocyanins is essential in plants to improve 
stability and solubility of the pigments in water (Stintzing and Carle 2004). Glycosylation 
typically occurs at the 3-hydroxyl or 5-hydroxyl positions but can also occur at the 3’, 4’, 5’ 
or 7-hydroxyl positions (Fossen et al. 2003, Crozier et al. 2009). Anthocyanins exist most 
commonly as monoglycosides containing glucose, galactose, rhamnose, arabinose, or xylose 
moieties but di- and triglycosides containing rutinose, sambubiose and sophorose have also 
been identified (Wu et al. 2004, Del Rio et al. 2010a). Cyanidin-3-glucoside is the most 
commonly consumed anthocyanin in the western diet (Wu et al. 2006).  
Anthocyanins can also be acylated via ester bonding of aromatic phenolic acids and aliphatic 
dicarboxylic acids to the glycoside molecule. Common phenolic acids acylated to 
anthocyanins include hydroxycinnamic acids such as coumaric acid, and hydroxybenzoic 
acids such as gallic acid (Harborne 1958, Sadilova et al. 2006). 
Whilst more stable than the anthocyanidin aglycones, anthocyanins are still relatively 
unstable compounds that are sensitive to a range of environmental conditions including 
temperature, presence of enzymes, proteins and metallic ions, solvents, light and pH (Rein 
2005, Castañeda-Ovando et al. 2009). Anthocyanins are particularly sensitive to changes in 
pH; most stable in acidic conditions and susceptible to degradation into their A- and B-ring 
derivatives at neutral pH (Figure 1.2). 
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Figure 1.2 pH-dependent structures of anthocyanins. 
  
R, functional group (-H, -OH, -OCH3, glycoside). Adapted from (McGhie and Walton 2007, Castañeda-Ovando 
et al. 2009). 
 
1.3. Role in Nature 
Anthocyanins are produced by a wide range of plants and stored in the vacuoles where they 
act as pigments amongst other roles (Gould 2004). Anthocyanin synthesis occurs within the 
cytosol, beginning with coumaroyl-CoA and malonyl-CoA precursors, and involves enzymes 
from various families including glucosyltransferases, cytochromes p450, and 2-oxoglutarate-
dependent dioxygenases (Tanaka et al. 2008). The most visible role of anthocyanins in plants 
is to provide colour to leaves, petals, and fruit to attract animals for pollination and seed 
dispersal (Gould 2004, Stintzing and Carle 2004). A number of additional functions for 
anthocyanins within plants have been suggested including absorption of high-intensity light 
to protect chloroplasts from photoinhibition (Pietrini et al. 2002), protection of plant tissues 
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from photooxidative damage during nutrient retrieval following autumn senescence (Feild 
et al. 2001), and osmotic adjustment of cells to protect tissues during drought and freezing 
temperatures (Chalker-Scott 1999). 
 
1.4. Dietary Consumption 
Anthocyanins are present in many commonly consumed fruits and vegetables that display 
red, blue or purple colouring with the main dietary sources of anthocyanins being grapes 
and berries (Wu et al. 2006). Even within particular fruit or vegetable species, anthocyanin 
content can vary considerably depending on a range of factors including cultivar, growing 
conditions, maturity, processing, and storage conditions (Anttonen and Karjalainen 2005, 
Amarowicz et al. 2009, Wang et al. 2009) but typical anthocyanin concentrations can range 
between 4 mg/100 g fresh weight (FW) in red lettuce and 1317 mg/100 g FW in black 
elderberry (Table 1.3).  
 
Table 1.3 Anthocyanin content of common dietary sources. 
Dietary source 
Mean content (mg/100 g FW) 
Cy Dp Pg Pn Mv Pt Total 
Black elderberry 1315 - 2 - - - 1317 
Blackcurrant 187 392 2 1 - 10 592 
Red cabbage 210 - - - - - 210 
Blackberry 173 - - - - - 173 
Highbush blueberry 10 46 - 2 48 29 135 
Aubergine - 86 - - - - 86 
Strawberry 5 - 68 - - - 73 
Black grape 1 3 - 6 59 3 72 
Red raspberry 65 - 6 - 1 - 72 
American cranberry 14 - - 36 - - 50 
Red onion 3 7 - - - - 10 
Red lettuce 4 - - - - - 4 
Mean content represents combined total for all glycosylated forms of anthocyanidins. Cy, cyanidin; Dp, 
delphinidin; Pg, pelargonidin; Pn, peonidin; Mv, malvidin; Pt, petunidin. Adapted from (Neveu et al. 2010, 
Bhagwat et al. 2011). 
 
Estimated intakes of anthocyanins within global diets range between 3 to 65 mg/day [3 
mg/day, USA (Chun et al. 2007); 28 mg/day, China (Li et al. 2013); 57 mg/day, France (Pérez-
Jiménez et al. 2011); 19 – 65 mg/day, Europe (Zamora-Ros et al. 2011)] with intakes of over 
500 mg of anthocyanins achievable within a single serving of anthocyanin-rich foods (Table 
1.3). The accuracy of anthocyanin intake estimates is dependent on the quality of data 
obtained from dietary assessment methods, such as food frequency questionnaires (FFQs), 
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and the suitability of data contained within anthocyanin content databases, such as Phenol-
Explorer (Neveu et al. 2010) or USDA Database for the Flavonoid Content of Selected Foods 
(Bhagwat et al. 2011). Alternatively, dietary intake can be monitored via the detection of 
characteristic metabolites within the body known as biomarkers of intake (Hedrick et al. 
2012) but while a small number of biomarkers for consumption of anthocyanin-rich foods 
have been suggested (van Dorsten et al. 2010, Urpi‐Sarda et al. 2015), these have yet to be 
accepted as robust metabolic biomarkers of anthocyanin intake. 
 
1.5. Bioavailability 
Studies investigating the bioavailability of flavonoids have reported anthocyanins to be 
amongst the least bioavailable of the flavonoid sub-classes with plasma concentrations of 
anthocyanins in the nanomolar range compared to micromolar concentrations achieved by 
more bioavailable flavonoid groups such as flavanones or isoflavonoids (Manach et al. 2005). 
Plasma/serum concentrations of anthocyanins have been reported to peak around 2 to 200 
nM at 0.5 to 4 hours following consumption, with typically less than 1% of the intake 
recovered in the urine (Table 1.4). The low concentrations of anthocyanins observed 
following consumption, combined with the sensitivity of the anthocyanin structure to 
changes in pH and temperature, prompted suggestions that anthocyanins may be subject to 
rapid degradation to their phenolic acid derivatives within the body. The degradation 
products could then be further metabolised, resulting in considerable underestimation of 
anthocyanin bioavailability until the contribution of these phenolic metabolites was 
quantified (Kay 2006, Kay et al. 2009). This theory is supported by recent studies that have 
reported the detection of phenolic acid metabolites within plasma/serum and urine 
following consumption of anthocyanins (Rodriguez-Mateos et al. 2013, de Ferrars et al. 
2014b, Pimpão et al. 2015). Importantly, a recent human feeding trial was able to 
demonstrate a direct link between the parent anthocyanins and the phenolic metabolites 
via the use of stable isotope-labelled cyanidin-3-glucoside (Czank et al. 2013). This study 
used five 13C labels within the aglycone structure, three on the A-ring and two on the B-ring, 
to trace the lineage of the phenolic metabolites identified in biological samples through the 
A-ring and B-ring degradants, phloroglucinaldehyde and protocatechuic acid respectively, 
back to the parent 13C5-C3G compound. However, despite a comprehensive sampling regime 
involving serum, urine, faeces, and breath samples being collected, only 43.9% of the 
ingested 13C label was recovered leaving the fate of over half of the labelled compound 
unknown, possibly remaining in the lower intestine. 
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Table 1.4 Pharmacokinetic data from human anthocyanin bioavailability studies. 
Dietary source 
Anthocyanin 
intake (mg) 
Study 
duration (h) 
Plasma/serum 
Cmax (nM) 
Plasma/serum 
Tmax (h) 
Plasma/serum 
T1/2 (h) 
Urinary 
recovery (%) 
Reference 
Red cabbage 648 24 86.39 2.0 2.73 0.09 (Wiczkowski et al. 2016) 
Fermented red cabbage 554 24 64.02 2.0 3.02 0.07 (Wiczkowski et al. 2016) 
Grape and blueberry juice 277 24 13.19 1.2 - - (Kuntz et al. 2015b) 
Grape and blueberry smoothie 325 24 9.86 1.3 - - (Kuntz et al. 2015b) 
Blueberry juice 216 24 - - - 0.0752 (Kalt et al. 2014) 
Cranberry juice 95 3 4.64 3 - 0.79 (Milbury et al. 2010) 
Bilberry and lingonberry purée 650 48 138 1.5 - - (Nurmi et al. 2009) 
Blood orange juice 71 24 1.9 0.5 - 1.2 (Vitaglione et al. 2007) 
Cranberry juice 651 24 - - - 5.00 (Ohnishi et al. 2006) 
Chokeberry extract 721 24 96.1 2.8 1.5 0.15 (Kay et al. 2005) 
Blackberry 431 24 - - - 0.16 (Felgines et al. 2005) 
Hibiscus extract 147 7 7.6 1.5 2.6 0.018 (Frank et al. 2005) 
Elderberry juice 3570 5 - - - 0.053 (Bitsch et al. 2004b) 
Blackcurrant juice 145 7 - - 1.7 0.04 (Bitsch et al. 2004a) 
Elderberry extract 147 7 - - 1.7 0.37 (Bitsch et al. 2004a) 
Chokeberry extract 1300 24 592 - - - (Kay et al. 2004) 
Red wine 280 7 222.7 0.5 1.83 0.23 (Frank et al. 2003) 
Red grape juice 283 7 95.5 1.5 1.52 0.18 (Frank et al. 2003) 
Blackcurrant juice 345 7 - - - 0.029 (McGhie et al. 2003) 
Boysenberry extract 189 7 - - - 0.064 (McGhie et al. 2003) 
Blueberry extract 439 7 - - - 0.020 (McGhie et al. 2003) 
Strawberry 77 24 - - - 1.9 (Felgines et al. 2003) 
Blackcurrant juice 1239 4 - 0.7 - 0.07 (Nielsen et al. 2003) 
Blackcurrant juice 716 4 - 0.7 - 0.05 (Nielsen et al. 2003) 
Elderberry juice 1900 6 - - - 0.03 (Mülleder et al. 2002) 
Blueberry extract 1200 4 29.2 4.0 - 0.003 (Mazza et al. 2002) 
Blueberry 690 6 - - - 0.004 (Wu et al. 2002) 
Red wine 68 6 1.47 0.3 - 0.03 (Bub et al. 2001) 
Dealcoholised red wine  56 6 1.7 1.5 - 0.03 (Bub et al. 2001) 
Red grape juice 117 6 2.8 3.0 - 0.03 (Bub et al. 2001) 
Cmax, maximal concentration; Tmax, time of maximal concentration; T1/2, half-life of elimination. Adapted from (Fernandes et al. 2015). 
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1.6. Metabolism 
The low bioavailability of anthocyanins was previously believed to be a result of poor 
absorption within the body. However, whilst the absorption of anthocyanins is not yet fully 
understood, recent studies have demonstrated that the low concentrations observed within 
the circulation following consumption is likely due to the extensive degradation, metabolism 
and catabolism of anthocyanins within the gastrointestinal tract and subsequent phase I and 
II metabolism within the liver and kidneys (Kay 2006, Fang 2014, Fernandes et al. 2015).  
The rapid appearance of anthocyanins within the blood following consumption (Milbury et 
al. 2002, Mullen et al. 2008) has led to suggestions that the first site for anthocyanin 
absorption in the gastrointestinal tract is the stomach. However, despite a limited number 
of studies reporting evidence claiming to support gastric absorption, this is not believed to 
be a major route due to the size and polarity of anthocyanins. One possible mechanism that 
has been suggested is via an anion membrane carrier protein expressed by epithelial cells in 
the stomach called bilitranslocase. Previous work has observed interaction between 
anthocyanins and bilitranslocase (Passamonti et al. 2002) but transport of anthocyanins via 
bilitranslocase has yet to be demonstrated and is thought to be unlikely due to the 
predominance of anthocyanins in the cation form in the acidic environment present within 
the stomach. Recent studies have reported transport of anthocyanins by MKN-28 
differentiated adenocarcinoma stomach epithelial cells (Fernandes et al. 2012), possibly via 
the GLUT1 and GLUT3 glucose transporters (Oliveira et al. 2015) but this has yet to be 
observed in other cell models or in vivo. A small number of studies have reported gastric 
absorption of anthocyanins in rats (Talavéra et al. 2003, Passamonti et al. 2005, Vanzo et al. 
2008) but due to differences in absorption, distribution, metabolism, and excretion (ADME) 
mechanisms between rats and humans, and the lack of supporting studies demonstrating in 
vivo gastric absorption in humans, further work is required to establish the extent of the 
stomach’s role in the absorption of anthocyanins.  
One of the main areas of anthocyanin absorption is thought to be in the lumen of the small 
intestine and this absorption can be broken down into two routes (Figure 1.3). The first 
potential route involves direct absorption of the glycosylated anthocyanin via sodium-
dependent glucose transporter-1 (SGLT-1) which is present in the membrane of intestinal 
epithelium cells. Studies investigating absorption of the structurally similar quercetin-4’-
glucoside, have demonstrated that the intact glucoside can be detected in intestinal 
epithelium cells following incubation and that this absorption is reduced in the presence of 
phloridzin, an SGLT-1 inhibitor (Walgren et al. 2000, Day et al. 2003).  
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Figure 1.3 Potential mechanisms for anthocyanin metabolism and absorption. 
 
CβG, cytosolic β-glucosidase; COMT, catechol-O-methyltransferase; LPH, Lactase phloridzin hydrolase; MRP, 
multidrug resistance protein; SGLT-1, Sodium-dependent glucose transporter-1; SULT, sulfotransferase; UDPGT, 
uridine 5’-diphospho-glucuronosyltransferase. Adapted from (Kay 2006). 
 
A recent study has reported decreased absorption of cyanidin-3-glucoside by human 
intestinal epithelial (Caco-2) cells following inhibition of SGLT-1 and glucose transporter 2 
(GLUT2) suggesting that there may be a range of glucose transporters involved in the 
intestinal absorption of anthocyanins (Zou et al. 2014). Once inside the cell, the flavonoid 
glycoside is able to diffuse across the basolateral membrane and enter the portal circulation. 
Glycosides inside the cells are hydrolysed by cytosolic β-glucosidase (CβG) to produce the 
flavonoid aglycone (Figure 1.3) (Day et al. 1998, Lambert et al. 1999). These metabolised 
compounds are then able to enter the hepatic portal circulation. 
The second possible route of absorption in the small intestine involves deglycosylation of 
the hydrophilic anthocyanin molecule by lactase phloridzin hydrolase (LPH) to produce the 
anthocyanidin aglycone molecule (Figure 1.3). Following deglycosylation, the more 
lipophilic, less polar aglycone is able to passively diffuse across the epithelial cell membrane 
and into the cytosol. It is thought that anthocyanins may be a substrate for LPH as other 
structurally similar flavonoid glycosides have been shown to be hydrolysed by LPH (Day et 
al. 2000, Sesink et al. 2003) and it has been demonstrated that the uptake of quercetin 
glycosides is reduced in the presence of LPH inhibitors (Day et al. 2003). However, possibly 
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due to the difficulties caused by the instability of anthocyanins at neutral pH, there has been 
limited investigation of the enzymatic deglycosylation of anthocyanins and hydrolysis of 
anthocyanins by LPH or any other β-glucosidase has yet to be demonstrated either in vitro 
or in vivo. Some studies have suggested that anthocyanins may not be hydrolysed by LPH 
(Németh et al. 2003) and could instead act as substrates for α-glucosidases (Williamson 
2013). Further research is required to confirm the mechanisms involved in intestinal 
deglycosylation of anthocyanins. 
Inside the epithelial cytosol the aglycone is subject to phase II metabolism reactions with 
enzymes such as catechol-O-methyltransferase (COMT), sulfotransferase (SULT) and uridine 
5’-diphospho-glucuronosyltransferase (UDPGT) (Figure 1.3). These enzymes catalyse 
conjugation reactions leading to methyl, sulfate and glucuronide conjugates of the flavonoid 
aglycone respectively. These conjugate molecules are then able to cross the cell membrane 
into the portal circulation either by passive diffusion or via active transport by multidrug 
resistance proteins (MRP). MRP can also efflux flavonoid glycosides and metabolites back 
across the epithelium into the small intestine (Figure 1.3). From the portal circulation the 
flavonoid molecules are transported to the liver where they may undergo phase I 
metabolism (hydroxylation and demethylation) but this is believed to be minimal as it would 
not achieve the goal of increasing polarity for excretion via the kidneys. The liver is also a 
site for further methyl, sulfate and glucuronide conjugation reactions before the conjugated 
metabolites are released into the systemic circulation and unconjugated metabolites are 
recirculated back into the small intestine via enterohepatic circulation. Conjugation to 
glutathione, a tripeptide present in millimolar concentrations in the cytosol, is also possible 
during this process. Glutathione is made up of glutamic acid, cysteine and glycine and it has 
been reported to form conjugates with quercetin in vivo (Hong and Mitchell 2006) and there 
is some work showing formation of anthocyanin-glutathione conjugates in vitro (Fernandes 
et al. 2009) but this has yet to be proven to occur in vivo. 
Anthocyanin aglycones present in the small intestine that are not absorbed will degrade over 
time as a result of the neutral pH, aided by the gut microbiota. This degradation of the 
aglycone will produce aldehyde and phenolic acid derivatives that are able to diffuse across 
the apical membrane into the epithelium (Figure 1.3). Within the cytosol, the degradation 
products are subject to the same conjugation reactions and MRP recycling as the aglycones. 
The degradation products and their conjugated forms can then enter the portal circulation 
for transport to the liver. 
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Anthocyanin glycosides and metabolites that are unabsorbed after passing through the small 
intestine will then enter the large intestine. In the large intestine these compounds can be 
metabolised by the colonic microbiota (Figure 1.3). There is evidence to suggest that 
metabolism by colonic bacteria may play an important role in the overall bioavailability of 
anthocyanins (Keppler and Humpf 2005, Forester and Waterhouse 2008, Selma et al. 2009, 
Sánchez-Patán et al. 2012, Czank et al. 2013). Differences in the microbiota population of 
the colon may influence the types and levels of anthocyanin metabolites seen in the 
circulation (Selma et al. 2009, Boto-Ordóñez et al. 2014). Anthocyanins can be 
deglycosylated in the colon and the aglycone absorbed across the intestinal epithelium. 
Alternatively, aglycones can undergo ring fission by the colonic microflora and the 
degradation products can be dehydroxylated and demethylated prior to absorption (Selma 
et al. 2009). Any metabolites not absorbed during transit through the large intestine will be 
excreted, along with any remaining parent anthocyanins, via the faeces (Figure 1.3) (Czank 
et al. 2013). 
 
1.7. Cardiovascular Health 
Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels including 
coronary heart disease, peripheral artery disease, and stroke. CVD is the number one cause 
of death globally with an estimated 17.5 million deaths caused by CVD in 2012 representing 
nearly a third of total deaths worldwide (World Health Organisation 2014). 
Recent epidemiological studies have reported a link between increased anthocyanin intake 
and improved cardiovascular health. Specifically, studies have reported a 9% reduction in 
risk of CVD mortality from diets containing anthocyanins compared to an anthocyanin-free 
diet (Mink et al. 2007), an increase in anthocyanin intake from 6 mg/day to 19 mg/day was 
associated with an 8% reduction in risk of hypertension (Cassidy et al. 2011), an increase in 
anthocyanin intake from 8 mg/day to 24 mg/day was associated with a 3 mm Hg reduction 
in central systolic blood pressure (Jennings et al. 2012), and an increase in anthocyanin 
intake from 1.8 mg/day to 32 mg/day was associated with a decrease in a range of 
inflammatory biomarkers (Cassidy et al. 2015). A recent systematic review of 14 cohort 
studies reported an 11% reduced risk of CVD mortality when comparing the highest and 
lowest categories of anthocyanin intake (Wang et al. 2014a). 
Randomised controlled trials (RCTs) investigating the effect of anthocyanin consumption 
have also observed positive effects on markers of cardiovascular health. Recent studies have 
shown that 4 hours after intake of a cranberry juice drink (containing 835 mg polyphenols, 
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of which 94 mg were anthocyanins) flow-mediated dilation (FMD) increased from 7.7% to 
8.7% (Dohadwala et al. 2011), carotid-femoral PWV was reduced from 8.3 m/s to 7.8 m/s 
after 4 weeks consumption of the same cranberry juice drink (Dohadwala et al. 2011) and 
intake of a blueberry drink (containing between 319 – 1791 mg polyphenols, of which 
between 129 – 724 mg were anthocyanins) improved FMD within 6 hours of consumption 
(Rodriguez-Mateos et al. 2013). A recent meta-analysis of 22 RCTs observed significant 
improvement of a range of cardiovascular risk factors including low-density lipoprotein 
(LDL)-cholesterol levels and systolic blood pressure following consumption of anthocyanin-
rich foods (Huang et al. 2016). 
Inflammation is the process by which the body defends itself against tissue damage from 
harmful agents via the migration of leukocytes to the site of injury, infection, or other insult. 
(Libby et al. 2002). Inflammation can be classified as either acute or chronic. Acute 
inflammation is the term used to describe the immediate immune response and is generally 
seen as beneficial in the healing process (Libby et al. 2002). Chronic inflammation is the long-
term, persistent state of immune response associated with the development of many 
disorders including atherosclerosis (Epstein and Ross 1999).  
Atherosclerosis is the process by which vascular walls develop lesions and plaques resulting 
in thickening, hardening and occlusion of blood vessels (Figure 1.4).  
Progression of atherosclerosis can take many decades and is initially characterised as a 
chronic state of endothelial dysfunction. In the healthy endothelium, blood pressure is 
regulated via the production of various vasodilators and vasoconstrictors by enzymes within 
endothelial cells, such as the production of nitric oxide (NO) from L-arginine by endothelial 
nitric oxide synthase (eNOS) (Zhao et al. 2015). This process is disrupted following activation 
of the endothelium by stimuli such as smoking or high levels of LDL cholesterol, as production 
of NO is reduced and levels of reactive oxygen species (ROS) such as superoxide (O2-) increase 
leading to the formation of hydrogen peroxide (H2O2) by superoxide dismutase (SOD) (Cai 
2005). The build-up of H2O2 within the endothelium results in expression of inducible nitric 
oxide synthase (iNOS) to boost production of NO to quench the ROS, and upregulation of 
cytokines such as NF-κB to trigger an inflammatory response to defend against injury whilst 
the causative agent is removed (Aktan 2004).  
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Figure 1.4 Progression of atherosclerosis. 
 
ROS, reactive oxygen species; oxLDL, oxidised low-density lipoprotein; SMC, smooth muscle cells. Adapted from 
(Epstein and Ross 1999, Vassiliadis et al. 2012). 
 
If the causative agent persists, chronic inflammation ensues and levels of peroxynitrite 
(ONOO-) increase due to the reaction between NO and O2- resulting in increased levels of 
oxidised low-density lipoprotein (oxLDL), monocyte infiltration, and lipid accumulation 
within the endothelium (Graham et al. 1993, Epstein and Ross 1999). The end result of this 
process is the formation of fatty streaks and fibrotic plaques within the endothelium that 
can occlude blood vessels and rupture causing potentially fatal ischemia and infarction (Libby 
et al. 2002, Hansson 2005). 
Following proatherogenic stimuli, expression of adhesion molecules such as selectins and 
cell adhesion molecules is upregulated within activated arterial endothelial cells leading to 
the recruitment and infiltration of leukocytes (Figure 1.5).  
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Figure 1.5 Selectins and adhesion molecules involved in the initial stages of atherosclerosis. 
 
ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; PECAM, platelet endothelial cell 
adhesion molecule. Adapted from (Blankenberg et al. 2003). 
 
The initial stages of atherosclerotic progression are facilitated by the interaction between 
leukocyte-expressed L-selectin and endothelium-expressed E- and P-selectins which 
promotes the rolling and tethering of leukocytes at the endothelial surface (Blankenberg et 
al. 2003). Intercellular adhesion molecules (ICAM) -1, -2, and -3, platelet endothelial cell 
adhesion molecule-1 (PECAM-1), and vascular cell adhesion molecule-1 (VCAM-1) are 
expressed at endothelial cell junctions and interact with leukocyte-expressed integrins β1 
and β2 to promote the adhesion of leukocytes to the endothelium before migration into the 
intercellular matrix (Blankenberg et al. 2003). VCAM-1 is induced by various cytokines 
including tumour necrosis factor-α (TNF-α) and cluster of differentiation 40 ligand (CD40L) 
(Karmann et al. 1995, Maaser et al. 2001), and also has a role in signalling the endothelial 
shape change that allows leukocytes to pass through the endothelium via interaction with 
integrin α4β1 and activation of NADPH oxidase (NOX) (Matheny et al. 2000). A number of 
studies have investigated the effect of anthocyanins on the expression of VCAM-1 as a 
possible mechanism for downregulating the inflammatory response and inhibiting 
atherosclerotic progression. Inhibition of VCAM-1 expression in endothelial cells following 
incubation with anthocyanins has been reported by in vitro studies (Xia et al. 2009, Chao et 
al. 2013, Huang et al. 2014, Kuntz et al. 2015a) while consumption of anthocyanins has been 
shown to reduce levels of circulating VCAM-1 in human (Zhu et al. 2013) and animal trials 
(Miyazaki et al. 2008). 
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In addition to cell adhesion molecules, many other cytokines and chemokines are 
upregulated within leukocytes and vascular endothelial cells as part of the inflammatory 
response to proatherogenic stimuli. These proinflammatory signalling molecules mediate 
every stage of the atherosclerotic process with an extensive range of cytokines reported to 
be involved including monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) 
stimulating the transmigration of leukocytes across the vascular endothelium (Libby et al. 
2002, Tedgui and Mallat 2006),  activation of T-cells induced by TNF-α and IL-2 (Epstein and 
Ross 1999), macrophage colony-stimulating factor (M-CSF) and IL-1 promoting the 
differentiation of monocytes into macrophages and lipid-filled foam cells (Epstein and Ross 
1999), and proliferation of smooth muscle cells induced by fibroblast growth factor 2 (FGF2) 
and IL-6 (Epstein and Ross 1999, Tedgui and Mallat 2006).  
During chronic inflammation, a number of signalling pathways are stimulated that act as 
positive feedback loops, perpetuating the inflammatory response. CD40L is a 
proinflammatory cytokine, part of the TNF family of proteins, and is produced by leukocytes, 
platelets and vascular cells in response to induction by various proinflammatory cytokines 
such as IL-1, IL-3, IL-4, interferon-γ (IFN-γ), and TNF-α (Tedgui and Mallat 2006, Pamukcu et 
al. 2011). CD40L binds to the CD40 receptor to stimulate the mitogen-activated protein 
kinase (MAPK) and nuclear factor-κB (NF-κB) signalling pathways which can also be activated 
via the binding of TNF-α to its receptor, TNF receptor 1 (TNFR1) leading to the upregulation 
of many proinflammatory cytokines and adhesion molecules (Figure 1.6). 
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Figure 1.6 Activation of MAPK and NF-κB signalling pathways via TNF-α and CD40L stimulation. 
 
CD40(L), cluster of differentiation 40 (ligand); ERK, extracellular signal-regulated kinase; IκBα, NF-κB inhibitory 
protein; IKK, inhibitory-κB kinase; JNK, c-Jun N-terminal kinase; MKK, mitogen-activated protein kinase kinase; 
P, phosphate; p38, mitogen-activated protein kinase; p50, nuclear factor-κB p50 subunit; p65, NF-κB p65 
subunit; TNF-α, tumour necrosis factor-α; TNFR1, TNF receptor 1. Adapted from (Pamukcu et al. 2011, Hayden 
and Ghosh 2014, Sabio and Davis 2014). 
 
Inactive NF-κB exists in the cytosol of leukocytes and vascular cells and consists of two 
subunits, P50 and P65, bound to NF-κB inhibitory protein (IκBα) (Hayden and Ghosh 2014). 
TNF-α and CD40L act upon NF-κB via two distinct pathways; the canonical signalling pathway 
is activated by TNF-α while CD40L activates the non-canonical signalling pathway (Brasier 
2010). Both pathways result in the upregulation of inhibitory-κB kinase (IKK) which signals 
the activation of NF-κB via phosphorylation and subsequent degradation of IκBα (Pamukcu 
et al. 2011). This allows NF-κB to translocate into the nucleus where it triggers the expression 
of various proinflammatory cytokines including IL-6 and TNF-α (Brasier 2010). A number of 
studies have reported the ability of anthocyanins to inhibit NF-κB activation and 
translocation in vitro (Paixão et al. 2012, Lee et al. 2014) and in vivo (Blanco-Colio et al. 2000, 
Karlsen et al. 2007) suggesting a possible mechanism for the observed bioactivity of 
anthocyanins. 
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MAPKs are a family of cytokines consisting of extracellular signal-regulated kinases (ERKs), 
p38, and c-Jun N-terminal kinases (JNKs) (Sabio and Davis 2014). The MAPK signalling 
pathway is activated by many of the same proinflammatory cytokines as the NF-κB 
pathway, including TNF-α and CD40L (Pamukcu et al. 2011, Hayden and Ghosh 2014), which 
act via downstream signalling to induce mitogen-activated protein kinase kinases (MKKs) 
activation of MAPKs and subsequent expression of proinflammatory cytokines, including 
TNF-α (Sabio and Davis 2014). Recent in vitro studies demonstrating inhibition of MAPK 
signalling by anthocyanins suggest that this pathway may also play a role in the bioactive 
effect exerted by anthocyanins (Xia et al. 2009, Xie et al. 2011, Jeong et al. 2013). 
 
1.8. Summary and Aims 
Anthocyanins are phytochemicals commonly consumed within the normal diet and their 
consumption has been associated with a reduced risk of cardiovascular disease (Wallace et 
al. 2016). However, the poor bioavailability of anthocyanins observed in feeding trials 
(Manach et al. 2005) combined with the results of recent studies demonstrating the 
extensive metabolism of anthocyanins in vivo (Czank et al. 2013, de Ferrars et al. 2014b) has 
shifted the focus onto the phenolic metabolites of anthocyanins to explain the reported 
bioactivity.  
The present study intended to provide information on the analysis and clinical utility of 
anthocyanin metabolites by seeking to achieve the following aims: 
 
1. Determine best practice for storage of clinical samples to maximise anthocyanin 
metabolite recovery (Chapter 2). 
Whilst the factors affecting the stability of anthocyanins in biological matrices are 
understood (Sadilova et al. 2006, Woodward et al. 2009), little is known about the stability 
of phenolic metabolites. The present thesis investigated the effect of pH and freeze/thaw 
cycling during storage on the recovery of anthocyanin metabolites in biological samples. 
2. Increase the sensitivity and throughput of current methodology for quantifying 
anthocyanin metabolites in biological samples (Chapter 3). 
An HPLC-ESI-MS/MS method capable of detecting over 35 phenolic metabolites of 
anthocyanins in clinical samples has recently been reported (de Ferrars et al. 2014c). 
However, results from a recent tracer study utilising this method to track the metabolism of 
an isotopically-labelled anthocyanin molecule in vivo have suggest that many more 
 Page | 32 
metabolites remain undetected (Czank et al. 2013). In order to gain a comprehensive 
understanding of anthocyanin metabolism, more sensitive analytical methods are needed. 
The present thesis explored the effect of using ammonium-buffered mobile phase on 
method sensitivity. In addition, alternative sample preparation techniques were investigated 
and HPLC parameters were optimised with the aim of increasing the throughput of the 
methodology. 
3. Validate methodology for quantifying anthocyanin metabolites in biological samples 
(Chapter 4). 
To have confidence in the reliability of the results obtained when quantifying anthocyanin 
metabolites in biological samples, the developed methods were validated according to 
accepted guidelines. The present study conducted validations of both the previously 
reported method (de Ferrars et al. 2014c) and the newly-developed method described in 
Chapter 3. 
4. Determine the viability of phenolic metabolites as biomarkers of anthocyanin intake 
(Chapter 5). 
Studies investigating the bioactivity of anthocyanins typically use traditional methods such 
as food frequency questionnaires to measure anthocyanin intake (Cassidy et al. 2015) 
leading to possible inaccuracies (Thompson et al. 2010). An alternative method for 
monitoring dietary intake is to analyse the concentration of characteristic metabolites in 
biological samples (Hedrick et al. 2012). The present study used samples from a recent 13C-
labelled anthocyanin feeding trial (Czank et al. 2013) to investigate the phenolic metabolites 
as potential biomarkers of anthocyanin intake. 
5. Determine the effect of anthocyanin metabolic profiles on inflammatory biomarkers 
in a vascular cell model (Chapter 6). 
Whilst the in vitro bioactivity of anthocyanins has been extensively studied (Speciale et al. 
2014), few studies have explored the bioactivity of the phenolic metabolites. Studies that 
have investigated the bioactivity of anthocyanin metabolites have used metabolite 
compounds either in isolation (Amin et al. 2015, Edwards et al. 2015) or in equimolar 
combinations (di Gesso et al. 2015, Warner et al. 2016), neither of which accurately 
represent the in vivo situation (Czank et al. 2013). The present study incubated TNF-α and 
CD40L-stimulated human umbilical vein endothelial cells (HUVEC) with previously reported 
anthocyanin metabolite profiles (de Ferrars et al. 2014a) to investigate the effect on 
expression of sVCAM-1 and IL-6 proinflammatory cytokines. 
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Chapter 2. Investigating the Effect of Acidification and 
Freeze/thaw Cycles on Anthocyanin Metabolite Stability in 
Clinical Samples. 
 
2.1. Introduction 
Epidemiological studies have shown that diets high in anthocyanins are associated with 
beneficial health effects, including reducing the risk of cardiovascular disease (CVD) (Hollman 
et al. 1996, de Pascual-Teresa et al. 2010, Cassidy et al. 2011, Jennings et al. 2012, Cassidy 
et al. 2013). This epidemiological evidence has prompted many researchers to investigate 
the bioavailability and bioactivity of anthocyanins in clinical interventions (Mazza et al. 2002, 
Milbury et al. 2002, Felgines et al. 2003, Hooper et al. 2008, Dohadwala et al. 2011). Typically 
these studies involve asking volunteers to ingest a high dose of anthocyanins either through 
consuming food or beverages containing high concentrations of these pigments or via an 
anthocyanin extract. Biological samples such as blood and urine are then collected and 
stored in freezers until analyses of anthocyanin levels take place. The standard procedure is 
to first acidify the samples to pH 1-3 using either formic acid or hydrochloric acid (Mülleder 
et al. 2002, Mullen et al. 2008) prior to storage due to anthocyanins structural instability at 
neutral pH (Jurd 1963, Castañeda-Ovando et al. 2009). In recent years the focus of many 
investigations into anthocyanin bioactivity has shifted towards exploring their degradation 
products and phase II metabolites because of the observed low bioavailability of the parent 
anthocyanins (Kay et al. 2009). It is not clear what effect acidification of clinical samples has 
on the metabolite profiles observed. 
It is also unclear how stable phenolic metabolites of anthocyanins are through multiple 
freeze/thaw cycles. This information is important for clinical studies involving phenolic 
metabolites as often samples are thawed for analysis and refrozen. Presently the effect of 
multiple freeze thaw cycles on metabolite stability/recovery is unknown. Previous work on 
the parent anthocyanins suggests that they are stable in acidified solution through at least 
six freeze/thaw cycles (Woodward et al. 2009). However, little work has been done to 
investigate the stability of phenolic metabolites of anthocyanins. 
The present study aimed to provide information on the effect of acidification and 
freeze/thaw cycling on the stability of phenolic metabolites of anthocyanins in clinical 
samples. The hypothesis was that the phenolic metabolites would demonstrate greater 
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stability in clinical samples when stored at neutral pH and following multiple freeze/thaw 
cycles than the parent anthocyanins. To investigate this hypothesis, serum samples were 
spiked with a mixed standard containing cyanidin-3-glucoside and 17 of its phenolic 
metabolites. The spiked serum samples were then split into two groups; one group was 
acidified to pH 2.4 using formic acid while the other group was left unacidified. The two 
spiked serum sample groups were then split into two further groups; one group was put 
through five freeze/thaw cycles while the other group was stored at -80°C and only thawed 
once prior to analysis. All samples were stored at -80°C and analysed at five time-points to 
monitor the effect of acidification and freeze/thaw on metabolite stability over time. It is 
intended that the findings of the present study will inform future clinical studies of the 
appropriate sample preparation procedures required to maximise anthocyanin metabolite 
recovery from biological samples.  
 
2.2. Methods 
2.2.1. Materials and reagents 
Acetonitrile and methanol were purchased from Fisher Scientific (Loughborough, UK). 
Strata-X™ 33 µm polymeric sorbent 500 mg/6 mL solid-phase extraction cartridges, Kinetex® 
pentafluorophenyl (PFP) high-performance liquid chromatography (HPLC) column (2.6 µm, 
100 x 4.6 mm, 100 Å) and SecurityGuard® cartridges (PFP, 4.6 x 2.0 mm) were purchased 
from Phenomenex (Macclesfield, UK). Cyanidin-3-glucoside (kuromanin chloride) was 
purchased from Extrasynthese (Genay, France). The phase II conjugates of phenolic acids 
(protocatechuic acid-3-glucuronide, protocatechuic acid-4-glucuronide, protocatechuic 
acid-3-sulfate, protocatechuic acid-4-sulfate, isovanillic acid-3-glucuronide, vanillic acid-4-
glucuronide, isovanillic acid-3-sulfate, vanillic acid-4-sulfate, benzoic acid-4-glucuronide) 
were synthesised by the School of Chemistry and Centre for Biomolecular Sciences, 
University of St. Andrews (UK) using published methods (Zhang et al. 2012). Methyl 3,4-
dihydroxybenzoate (3,4-dihydroxy-benzoic acid methyl ester) was purchased from Alfa 
Aesar (Heysham, UK). All other materials, reagents, and standards were purchased from 
Sigma-Aldrich (Dorset, UK), including: Acrodisc PTFE syringe filters (13 mm, 0.45 µm), human 
serum from human male AB plasma (Product No.: H4522), formic acid (FA), dimethyl 
sulfoxide (DMSO), 4-hydroxybenzaldehyde, ferulic acid (4-hydroxy-3-methoxycinnamic 
acid), hippuric acid (benzoylaminoacetic acid), isovanillic acid (3-hydroxy-4-methoxybenzoic 
acid), protocatechuic acid (PCA, 3,4-dihydroxybenzoic acid), phloroglucinaldehyde (PGA, 
2,4,6-trihydroxybenzaldehyde), phloridzin (phloridzin dihydrate), scopoletin (7-hydroxy-5-
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methoxycoumarin), and vanillic acid (4-hydroxy-3-methoxybenzoic acid). Water was 
18MΩ/cm Milli-Q quality and all solvents were LC-MS grade. 
2.2.2. Solid-phase extraction (SPE) 
40 mL of commercially-sourced human serum was extracted via SPE following previously 
reported methodology (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, SPE cartridges 
were preconditioned with 6 mL of acidified methanol (acidified to pH 2.4 using formic acid) 
followed by 6 mL of acidified water (acidified to pH 2.4 using formic acid). Cartridges were 
loaded with 1 mL acidified water followed by 1 mL of serum. Samples were eluted at a flow 
rate of approximately 1 drop/second. Cartridges were washed with 12 mL of acidified water 
before being dried under vacuum for 30 mins. 5 mL of acidified methanol was added to the 
cartridges and left to soak for 10 mins before the samples were eluted with a total of 7mL 
acidified methanol. The eluent was evaporated to approximately 50 μL on a rotary 
evaporator (Thermo SPD Speedvac). Following evaporation, half the samples were 
reconstituted with 200 μL water and half reconstituted with 200 μL of acidified water. The 
samples were then sonicated for 10 mins with the ultrasonic water bath kept cool using ice, 
followed by vortex mixing for 10 seconds and filtration through a 0.45 µm syringe filter. 
Filtrates were combined to provide approximately 5 mL of non-acidified extracted matrix 
and 5 mL of acidified extracted matrix to be used as blank serum during sample preparation. 
2.2.3. Sample Preparation 
A mixed standard was composed of cyanidin-3-glucoside and 17 of its serum metabolites, as 
reported following consumption of 13C-labelled cyanidin-3-glucoside (Czank et al. 2013, de 
Ferrars et al. 2014a). The 18 compounds included in the mixed standard were cyanidin-3-
glucoside, 4-hydroxybenzaldehyde, benzoic acid-4-glucuronide, ferulic acid, hippuric acid, 
isovanillic acid, isovanillic acid-3-glucuronide, isovanillic acid-3-sulfate, methyl 3,4-
dihydroxybenzoate, protocatechuic acid, protocatechuic acid-3-glucuronide, protocatechuic 
acid-3-sulfate, protocatechuic acid-4-glucuronide, protocatechuic acid-4-sulfate, 
phloroglucinaldehyde, vanillic acid, vanillic acid-4-glucuronide, and vanillic acid-4-sulfate 
(Figure 2.1).  
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Figure 2.1 Compounds included in the mixed standard; cyanidin-3-glucoside and 17 of its phenolic metabolites as reported following consumption of 13C-labelled cyanidin-3-glucoside. 
 
Adapted from (Czank et al. 2013, de Ferrars et al. 2014a). 
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The non-acidified and acidified blank serum samples were each split into four 1 mL aliquots 
before the mixed standard was added along with either water for the non-acidified samples 
or formic acid for the acidified samples, and two internal standards, scopoletin and 
phloridzin, to give 1 µM non-acidified and acidified samples (Figure 2.2). The non-acidified 
and acidified samples were then split into six smaller aliquots; one aliquot was used as the 
freeze/thaw sample (frozen, thawed and analysed every 48 hours over 240 hours for a total 
of five occasions) while the other five aliquots were used as control samples (one aliquot 
thawed and analysed every 48 hours over 240 hours). 
 
Figure 2.2 Experimental design of anthocyanin metabolite stability study showing acidified vs non-acidified 
serum samples and freeze/thaw vs control serum samples. 
 
Samples were prepared in solid-phase extracted commercial serum at 1 µM using a mixed standard 
containing cyanidin-3-glucoside and 17 of its metabolite. Samples were stored at -80°C between analyses. 
 
One freeze/thaw cycle consisted of 48 hours storage at -80°C followed by 20 min defrost at 
ambient room temperature prior to analysis. Metabolite concentrations were monitored at 
each time-point by HPLC-ESI-MS/MS analysis with samples stored at -80°C between 
analyses. By this method, differences in the stability of the metabolites within the non-
acidified and acidified samples as well as the freeze/thaw and control samples could be 
identified. 
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2.2.4. Chromatography 
HPLC-ESI-MS/MS analysis was carried out using an Agilent (Stockport, UK) 1200 series HPLC 
equipped with a Diode Array Detector (DAD) coupled to an AB SCIEX (Warrington, UK) 3200 
series QTRAP® MS/MS system with Turbo V™ electrospray ionisation source using 
previously established methods (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, a 
Kinetex® pentafluorophenyl (PFP) (2.6 µm, 100 x 4.6 mm) RP-HPLC column was used with a 
PFP SecurityGuard® cartridge (4.6 x 2.0 mm). The column temperature was set at 37°C, 
injector temperature of 4°C and injection volume of 5 µL. Mobile Phase A was 0.1% (v/v) 
formic acid in water and Mobile Phase B was 0.1% (v/v) formic acid in acetonitrile at a flow 
rate of 1.5 mL min-1 at 0 min, 1 mL min-1 at 7 to 14 min and 1.5 mL min-1 at 14 to 32 min. The 
gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% 
B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min, 1% B at 29 to 32 
min. 
MS/MS source parameters included ionspray voltage, -4000 V / +5500 V; temperature, 
700°C; curtain gas, 40 psi; nebulizer gas and auxiliary gas, 60 psi. Scheduled multiple reaction 
monitoring (sMRM) scans were performed using parameters optimised for the detection of 
analytical standards (Table 2.1).  
Samples were analysed in negative and positive ionisation modes. Retention time and the 
detection of three or more of the relevant ion transitions were used to confirm the identity 
of the metabolites. For quantification, the peak area of the most intense ion transition was 
used. Metabolite concentrations were calculated by comparison of the analyte peak area 
and the scopoletin internal standard peak area at each time-point. 
2.2.5. Statistical analysis 
Two-way analysis of variance (ANOVA) with Bonferroni post-hoc test was performed on four 
replicates using SPSS for Windows statistical software package (version 22, IBM, New York, 
USA). Significance was determined at the 5% confidence level. Statistical analysis was 
conducted on raw data with mean values graphed as percentage metabolite concentration 
relative to the initial 1 µM concentration with error bars representing standard deviation. 
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Table 2.1 sMRM schedule used to analyse the extracted serum samples on the AB SCIEX 3200 QTRAP® 
instrument. 
Compound 
Transitions (m/z) 
precursor/product ions 
Scan time range 
(min) 
Scan 
mode 
Benzoic acid-4-glucuronide 313/175,113,93* 2.0 – 4.0 - 
Protocatechuic acid-4-glucuronide 329.01/153*,113,109 2.4 – 4.4 - 
Protocatechuic acid 153.01/108*,91,81 3.2 – 5.2 - 
Protocatechuic acid-3-glucuronide 329.01/153*,113,109 3.4 – 5.4 - 
Vanillic acid-4-glucuronide 343.01/167,152,113* 4.6 – 6.6 - 
Isovanillic acid-3-glucuronide 343.01/167,152,113* 4.6 – 6.6 - 
Hippuric acid 177.9/133.9*,77.1,131.8 5.0 – 7.0 - 
Protocatechuic acid-3/4-sulfatea 233.01/153,109*,189 6.3 – 8.3 - 
4-hydroxybenzaldehyde 121.2/107.8,92*,65.1 7.0 – 9.0 - 
Isovanillic acid 169.01/151.1,125,93* 7.3 – 11.3 + 
Vanillic acid 167.03/152*,123,108 8.8 – 10.8 - 
(Iso)vanillic acid-3/4-sulfatea 247/167*,152,108 8.9 – 10.9 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 11.5 – 13.5 - 
Cyanidin-3-glucoside 449/287*,213,137 11.9 – 15.9 + 
Phloroglucinaldehyde 153/151*,125,107 13.7 – 15.7 - 
Ferulic acid 193/178,149,134* 17.8 – 19.8 - 
Scopoletin 193/133.2*,122,94.1 17.1 – 21.1 + 
Scopoletin 191/104*,147.9,120 18.1 – 20.1 - 
Phloridzin 437/275,169,107* 22.1 – 26.1 + 
Phloridzin 435/273*,167,123,81 23.1 – 25.1 - 
*Transition used for quantitation. aIsomers of this metabolite were unresolvable using this HPLC-ESI-MS/MS 
method so were quantified as a single analyte. 
 
2.3. Results 
2.3.1. Acid effect 
Metabolite concentrations within the control (not subjected to freeze/thaw cycling) serum 
samples were analysed, for both the non-acidified and acidified groups, every 48 hours for a 
total of 240 hours. The results of the two groups were then compared using statistical 
methods (Table 2.2).  
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Table 2.2 Statistical significance of the effect of acidification on anthocyanin metabolite stability in serum when stored at -80°C for 240 hours. 
Analyte 
Time effect  
(p-value) 
Acid effect  
(p-value) 
Time*Acid effect 
(p-value) 
Time 
0 hoursa 48 hoursa 96 hoursa 144 hoursa 192 hoursa 240 hoursa 
4-hydroxybenzaldehyde 0.018 NS NS a a b b b b 
Benzoic acid-4-glucuronide 0.043 NS NS a a a a a a 
Cyanidin-3-glucoside NS <0.001 NS NS NS NS NS NS NS 
Ferulic acid NS NS NS NS NS NS NS NS NS 
Hippuric acid NS NS 0.030 NS NS NS NS NS NS 
Isovanillic acid 0.010 NS NS a,b b c,d a,d a,b,c,d c,d 
Isovanillic acid-3-glucuronide NS NS NS NS NS NS NS NS NS 
(Iso)vanillic acid-3/4-sulfate NS NS NS NS NS NS NS NS NS 
Methyl 3,4-dihydroxybenzoate 0.006 NS NS a a b b,c c c 
Protocatechuic acid 0.044 NS NS a a,b b,c c c c 
Protocatechuic acid-3-glucuronide NS NS NS NS NS NS NS NS NS 
Protocatechuic acid-3/4-sulfate NS NS NS NS NS NS NS NS NS 
Protocatechuic acid-4-glucuronide NS NS NS NS NS NS NS NS NS 
Phloroglucinaldehyde 0.045 NS NS a,b b a a,b a a 
Vanillic acid NS NS NS NS NS NS NS NS NS 
Vanillic acid-4-glucuronide NS NS NS NS NS NS NS NS NS 
p≤0.05, n=4, two-way repeated measures ANOVA with Bonferroni post-hoc test. NS, not statistically significant. aDifferent letters represent statistical differences between groups. Time effect 
indicates that there was a significant change in metabolite concentration compared to the initial 1 µM concentration during the 240 hour study period. Acid effect indicates that the difference 
in sample pH resulted in significantly different metabolite concentrations in the acidified samples compared to the non-acidified samples. Time*Acid effect indicates that the sample pH had a 
differential effect on metabolite concentration depending on the time-point. 
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A significant time effect was observed for six analytes: 4-hydroxybenzaldehyde, benzoic acid-
4-glucuronide, isovanillic acid, methyl 3,4-dihydroxybenzoate, protocatechuic acid, and 
phloroglucinaldehyde. This indicates that these metabolites showed a significant change in 
concentration compared to the initial 1 µM concentration during the 240 hour study period. 
Five of the six metabolites (4-hydroxybenzaldehyde, benzoic acid-4-glucuronide, methyl 3,4-
dihydroxybenzoate, protocatechuic acid, and phloroglucinaldehyde) demonstrated an 
increase in concentration compared to the initial 1 µM concentration after the 240 hour 
study period. Of the six analytes showing a significant time effect, post-hoc Bonferroni test 
indicated that four of these metabolites (4-hydroxybenzaldehyde, isovanillic acid, methyl 
3,4-dihydroxybenzoate, protocatechuic acid) were significantly different from the initial 
concentration of 1 µM following 96 hours storage (p≤0.05) (Figure 2.3). Benzoic acid-4-
glucuronide also showed an increase in concentration following 96 hours storage, however, 
post-hoc analysis suggested there were no statistically significant differences between 
individual timepoints, likely due to the variation in concentration observed with this 
metabolite. A significant acid effect was observed for cyanidin-3-glucoside indicating that 
the difference in sample pH resulted in significantly different cyanidin-3-glucoside 
concentrations in the acidified samples compared to the non-acidified samples. Cyanidin-3-
glucoside was found at a higher percentage concentration compared to the initial 
concentration in the acidified samples (97.2 ± 14.9%) relative to the non-acidified samples 
(36.5 ± 7.6%) after 240 hours. A significant interaction effect between time and sample pH 
was observed for hippuric acid indicating that the sample pH had a differential effect on the 
stability of this metabolite depending on the time-point.  
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Figure 2.3 Metabolite concentration as a percentage of initial concentration in acidified and non-acidified serum samples across 240 hours of storage at -80°C. 
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Figure 2.3 (Continued) 
 
(A) 4-hydroxybenzaldehyde. (B) benzoic acid-4-glucuronide. (C) cyanidin-3-glucoside. (D) hippuric acid. (E) isovanillic acid. (F) methyl 3,4-dihydroxybenzoate. (G) protocatechuic acid. (H) 
phloroglucinaldehyde. Raw data corrected relative to the scopoletin internal standard. Results expressed as mean ± SD, n=4. 
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2.3.2. Freeze/thaw effect 
Metabolite concentrations within the acidified serum samples were analysed, for both the 
control (not subjected to freeze/thaw cycling) and freeze/thaw groups, every 48 hours for a 
total of five freeze/thaw cycles over 240 hours. The results of the two groups were then 
compared using statistical methods (Table 2.3). A significant time effect was observed for 
ten analytes: 4-hydroxybenzaldehyde, cyanidin-3-glucoside, ferulic acid, isovanillic acid, 
methyl 3,4-dihydroxybenzoate, protocatechuic acid, protocatechuic acid-3/4-sulfate, 
phloroglucinaldehyde, vanillic acid, and vanillic acid-4-sulfate. This indicates that these 
metabolites showed a significant change in concentration compared to the initial 1 µM 
concentration during the five freeze/thaw cycles or 240 hour study period. Eight of the ten 
metabolites (4-hydroxybenzaldehyde, ferulic acid, methyl 3,4-dihydroxybenzoate, 
protocatechuic acid, protocatechuic acid-3/4-sulfate, phloroglucinaldehyde, vanillic acid, 
and vanillic acid-4-glucuronide) demonstrated an increase in concentration compared to the 
initial 1 µM concentration after the five freeze/thaw cycles or 240 hour study period. 
Of the ten analytes showing a significant time effect, post-hoc Bonferroni test indicated that 
six of these metabolites (4-hydroxybenzaldehyde, isovanillic acid, methyl 3,4-
dihydroxybenzoate, protocatechuic acid, protocatechuic acid-3/4-sulfate, vanillic acid-4-
glucuronide) were significantly different from the initial concentration of 1 µM following two 
freeze/thaw cycles or 96 hours (p≤0.05) (Figure 2.4). A significant freeze/thaw effect was 
observed for cyanidin-3-glucoside indicating that the difference in the number of 
freeze/thaw cycles to which the sample groups were subjected resulted in significantly 
different cyanidin-3-glucoside concentrations in the control samples compared to the 
freeze/thaw samples. Cyanidin-3-glucoside was found at a higher percentage concentration 
compared to the initial concentration in the control samples (97.2 ± 14.9%) relative to the 
freeze/thaw samples (15.3 ± 5.5%) after five freeze/thaw cycles. A significant interaction 
effect between time and the number of freeze/thaw cycles was observed for cyanidin-3-
glucoside and vanillic acid-4-glucuronide indicating that the number of freeze/thaw cycles 
had a differential effect on the stability of these metabolites depending on the time-point. 
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Table 2.3 Statistical significance of the effect of five freeze/thaw cycles on anthocyanin metabolite stability in serum. 
Analyte 
Time effect  
(p-value) 
FT effect  
(p-value) 
Time*FT effect  
(p-value) 
Freeze/thaw cycles 
0a 1a 2a 3a 4a 5a 
4-hydroxybenzaldehyde 0.018 NS NS a a b b b b 
Benzoic acid-4-glucuronide NS NS NS NS NS NS NS NS NS 
Cyanidin-3-glucoside 0.008 <0.001 0.005 a a,b a,b a b c 
Ferulic acid 0.011 NS NS a,b,c b a,b a,c c a,c 
Hippuric acid NS NS NS NS NS NS NS NS NS 
Isovanillic acid 0.022 NS NS a a,b b b a,b a,b 
Isovanillic acid-3-glucuronide NS NS NS NS NS NS NS NS NS 
(Iso)vanillic acid-3/4-sulfate NS NS NS NS NS NS NS NS NS 
Methyl 3,4-dihydroxybenzoate 0.027 NS NS a b c c,d d d 
Protocatechuic acid 0.015 NS NS a b b b a,b b 
Protocatechuic acid-3-glucuronide NS NS NS NS NS NS NS NS NS 
Protocatechuic acid-3/4-sulfate 0.042 NS NS a b b,c c c c 
Protocatechuic acid-4-glucuronide NS NS NS NS NS NS NS NS NS 
Phloroglucinaldehyde 0.016 NS NS a,b a b,c c,d e d,e 
Vanillic acid 0.013 NS NS a,b b a,b,c c,d d a,c,d 
Vanillic acid-4-glucuronide <0.001 NS 0.003 a b c b,c b,c b,c 
p≤0.05, n=4, two-way repeated measures ANOVA with Bonferroni post-hoc test. FT, freeze/thaw; NS, not statistically significant. aDifferent letters represent statistical differences between 
groups. Time effect indicates that there was a significant change in metabolite concentration compared to the initial 1 µM concentration during the five freeze/thaw cycles or 240 hour study 
period. FT effect indicates that the difference in the number of freeze/thaw cycles to which the sample groups were subjected resulted in significantly different metabolite concentrations in 
the control samples (not subjected to freeze/thaw cycling) compared to the freeze/thaw samples. Time*FT effect indicates that the number of freeze/thaw cycles had a differential effect on 
metabolite concentration depending on the time-point. 
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Figure 2.4 Metabolite concentration as a percentage of initial concentration in control and freeze/thaw serum samples across five freeze/thaw cycles. 
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Figure 2.4 (Continued) 
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Figure 2.4 (Continued) 
 
(A) 4-hydroxybenzaldehyde. (B) cyanidin-3-glucoside. (C) ferulic acid. (D) isovanillic acid. (E) methyl 3,4-dihydroxybenzoate. (F) protocatechuic acid. (G) protocatechuic acid-3/4-sulfate. 
(H) phloroglucinaldehyde. (I) vanillic acid. (J) vanillic acid-4-glucuronide. Raw data corrected relative to the scopoletin internal standard. Results expressed as mean ± SD, n=4. 
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2.4. Discussion 
The present study aimed to inform future clinical studies by providing information on how 
the stability of anthocyanins and their phenolic serum metabolites is affected by different 
storage conditions. The effect of acidifying serum samples to pH 2.4 using formic acid prior 
to storage was investigated by monitoring metabolite concentrations in non-acidified and 
acidified serum samples stored at -80°C for 240 hours. This analysis found that, of the 16 
analytes tested, only the parent anthocyanin, cyanidin-3-glucoside, was affected by sample 
storage pH. After 48 hours, cyanidin-3-glucoside concentration in the non-acidified samples 
had decreased to 33.3 ± 8.7% of the initial concentration while there was no change in the 
acidified samples. The structural instability of anthocyanins in mildly acidic, neutral and basic 
environments is well-established (Rein 2005, Fleschhut et al. 2006, Woodward et al. 2009), 
however, the effect of pH on the stability on phenolic metabolites of anthocyanins is less 
clear. The results of the present study suggest that the stability of phenolic metabolites in 
serum samples is unaffected by pH. As a result, future clinical studies looking to detect 
metabolites of anthocyanins and not the parent anthocyanins themselves, may wish to 
consider foregoing the time-consuming process of sample acidification prior to storage due 
to the minimal effect on metabolite recovery. 
The effect of submitting serum samples to numerous freeze/thaw cycles was also 
investigated by monitoring metabolite concentrations in samples stored continuously at -
80°C (i.e. control samples not subjected to freeze/thaw cycling) and samples exposed to 
between one and five freeze/thaw cycles. This analysis also found that it was only cyanidin-
3-glucoside that was affected by freeze/thaw cycling. Following one freeze/thaw cycle, 
cyanidin-3-glucoside concentration had decreased to 77.6 ± 19.0% of the starting 
concentration and continued decreasing until it had reached 15.3 ± 5.5% following five 
freeze/thaw cycles. At the equivalent time-points, cyanidin-3-glucoside concentration in the 
control was unaltered. This observation contradicts previous work carried out within our lab 
that showed that anthocyanins are stable through at least six freeze/thaw cycles (Woodward 
et al. 2009). However, whilst the present study used a solid-phase extracted serum matrix, 
the previous study investigated the stability of anthocyanins in an acidified buffer solution 
(10 mM Na/K phosphate buffer in 2% HCl). Woodward et al. reported increased stability of 
anthocyanin compounds over 24 hours at 37°C in the buffer solution compared to water. 
This suggests that the presence of the buffer salts is important in maintaining the stability of 
the anthocyanin compounds. The removal of buffer salts along with proteins and other 
impurities from the serum matrix during the SPE process may explain the instability of 
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cyanidin-3-glucoside caused by freeze/thaw cycling observed in the present study. Little 
work has been done to establish the effect of freeze/thaw cycling on the stability of phenolic 
metabolites of anthocyanins. The results of the present study suggest that future clinical 
studies looking to detect metabolites of anthocyanins, and not the parent anthocyanins 
themselves, should not be concerned with subjecting clinical samples to up to five 
freeze/thaw cycles due to the minimal effect on metabolite recovery. 
Across both analyses, 11 of the 16 metabolites tested showed a significant change in 
concentration compared to the initial concentration during the five freeze/thaw cycles or 
240 hour study period with an average change in concentration of 43.3 ± 34.7% after 48 
hours or 1 freeze/thaw cycle. Of the 11 metabolites that showed a significant change in 
concentration, nine exhibited an increase in metabolite concentration compared to the 
initial concentration during the study period. With regards to phloroglucinaldehyde and 
protocatechuic acid, this increase in concentration may be explained by the degradation of 
the parent anthocyanin, cyanidin-3-glucoside, into its A-ring and B-ring derivatives; 
(phloroglucinaldehyde and protocatechuic acid, respectively) a process has been reported 
to take place rapidly in vitro (Woodward et al. 2009). However, spontaneous formation of 
the remaining phenolic metabolites has not been demonstrated in vivo and does not provide 
an adequate explanation for the increase in methylated, sulfated and glucuronidated phase 
II metabolites which are mainly formed within the liver in the presence of 
methyltransferase, sulfotransferase and UDP-glucuronosyltransferase proteins (Kay 2006). 
A more likely explanation for the observed increases in metabolite concentration is that they 
are the result of the variability of the analytical method leading to poor reproducibility of 
the sample analysis. Whilst the scopoletin internal standard peak areas were within the 
normal expected range (Table 2.4), the scopoletin response at the final time-point had 
decreased to 78.1 ± 10.1% of the response at the first time-point (Figure 2.5) which suggests 
that changes in internal standard response are responsible for the changes in metabolite 
concentration across time-points. Future studies would benefit from using alternative 
methods of accounting for sample variation such as isotope-labelled internal standards. 
Another possible explanation for the increases in concentration observed during this study 
is the reduction in matrix effects during the study. Condensation of ion suppressing factors 
such as proteins and phospholipids that remained within the extracted matrix would lead to 
an increase in analyte response over the length of the study. This issue could be addressed 
in the future by comparing samples against both a fresh standard curve prepared on the day 
of analysis and a standard curve subject to the same storage protocol as the samples. 
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Table 2.4 Variation in scopoletin internal standard peak areas using the HPLC-ESI-MS/MS method. 
Ionisation 
mode 
Present study Overall 
Mean peak area 
(counts per second) 
Mean peak area 
(counts per second) 
Peak area range 
(counts per second) 
Negative 1.86 x 106 ± 1.98 x 105 1.43 x 106 ± 4.51 x 105 4.05 x 105 – 2.38 x 106 
Positive 3.00 x 106 ± 2.36 x 105 3.34 x 106 ± 9.43 x 105 4.18 x 105 – 5.02 x 106 
Scopoletin peak areas observed in both negative and positive ionisation modes, during the sample 
runs associated with the metabolite stability study (Present study) and during the sample runs 
associated with the entire project (Overall) to assess the relative response of the internal standard. 
Results expressed as mean ± SD, or min – max range. 
 
 
 
 
 
 
Figure 2.5 Scopoletin internal standard peak area as a percentage of initial peak area during the present study. 
 
(A) Acid effect samples. (B) freeze/thaw effect samples. Results expressed as mean ± SD, n=4. 
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The present study suggests that while the parent anthocyanins are sensitive to pH and 
freeze/thaw cycling, the stability of phenolic metabolites in serum samples is unaffected by 
either the serum pH or the number of freeze/thaw cycles to which samples are subjected as 
phenolic metabolites were found to maintain their initial concentrations during the study 
period. 
Future studies should investigate the stability of phenolic metabolites in urine samples to 
establish whether acidification or freeze/thaw cycles affects stability in this matrix. The 
present study spiked a mixed standard of anthocyanin metabolites into a pre-extracted 
serum matrix. Future studies may wish to investigate the stability of anthocyanin 
metabolites in a matrix that more closely matches the clinical situation where serum samples 
are collected, acidified and frozen prior to extraction and further storage. As reported 
previously (Woodward et al. 2009), the mix of buffer salts and proteins present in serum 
may affect the stability of anthocyanins and their metabolites in storage and further 
investigation of this effect may yield important information about the optimal storage 
procedures for clinical samples containing anthocyanins and their phenolic metabolites. 
 
2.5. Conclusion 
The present study provides valuable information for future clinical studies investigating 
anthocyanins and their phenolic metabolites. The results of the present study suggest that 
the stability of phenolic metabolites in serum samples is unaffected by either sample pH or 
number of freeze/thaw cycles to which samples are subjected whereas the stability of the 
parent anthocyanins are affected by both factors. Future clinical studies that are interested 
in the phenolic metabolites of anthocyanins and not the parent anthocyanins themselves, 
may wish to reduce the burden of sample processing by foregoing sample acidification and 
sample aliquoting to minimise the number of freeze/thaw cycles as the effect on metabolite 
recovery is likely to be minimal. 
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Chapter 3. Development of HPLC-ESI-MS/MS Methods for 
Quantifying Anthocyanin Metabolites in Human Serum and 
Urine. 
 
3.1. Introduction 
Diets including a high intake of anthocyanins have been linked to a reduced risk of 
cardiovascular disease (Jennings et al. 2012, Cassidy et al. 2013) but due to the low 
bioavailability of the parent anthocyanins (Felgines et al. 2003, Kay et al. 2005) it has been 
suggested that the observed bioactivity may be caused by the phenolic metabolites of 
anthocyanins (Czank et al. 2013, Rodriguez-Mateos et al. 2013). An HPLC-ESI-MS/MS (HPLC 
coupled to an electrospray ionisation source and tandem mass spectrometer) method was 
developed previously by our group for the detection and quantification of anthocyanin 
metabolites in biological samples (Czank et al. 2013, de Ferrars et al. 2014c). However, the 
nanomolar concentrations at which many of these metabolites are reported (Czank et al. 
2013, de Ferrars et al. 2014a) are close to the limits of detection (LOD) for the current HPLC-
ESI-MS/MS method, making reliable detection and accurate quantification difficult. In 
addition, the current HPLC-ESI-MS/MS method utilises solid-phase extraction (SPE) of serum 
and urine samples and had a run time of 32 minutes per sample resulting in time-consuming 
sample extraction and long run times when analysing large numbers of samples.  
Mobile phase additives such as ammonium formate and ammonium acetate have been 
shown to have mixed results depending on the analytes tested (Mallet et al. 2004) but 
previous studies have demonstrated that when analysing flavonoids, sensitivity can be 
optimised through the use of ammonium buffers in the mobile phase (Rauha et al. 2001, de 
Rijke et al. 2003). To improve the reliability of quantification for the metabolites found at 
low concentrations and enable detection of any novel metabolites present at levels below 
the LOD of the current method, it was hypothesised that improvements in ionisation 
efficiency may be achieved via the addition of ammonium buffer salts to the aqueous mobile 
phase.  
SPE can be a time-consuming method of sample extraction but is important for mass 
spectrometric analysis of serum or plasma samples due to the high level of salts, proteins, 
and phospholipids present in these matrices that, if not removed, can lead to ion suppression 
and reduced sensitivity (Bylda et al. 2014). Urine, however, has much lower levels of ion-
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suppressing matrix components (Adachi et al. 2006, Chang et al. 2007) and therefore it was 
hypothesised that urine sample extraction time may be reduced via the use of alternative 
techniques such as dilution (often referred to as ‘dilute-and-shoot’; D&S) and protein 
precipitation (PPT) without negatively affecting the sensitivity of the current method. 
Our current HPLC-ESI-MS/MS method is capable of chromatographically separating and 
quantifying over 40 phenolic metabolites of cyanidin-3-glucoside at nanomolar 
concentrations over a 32 minute run time (Czank et al. 2013, de Ferrars et al. 2014c). It was 
hypothesised that further development of this method via optimisation of HPLC parameters 
and the use of alternative column dimensions may enable similar or better chromatographic 
separation, peak shape and method sensitivity to be achieved within a shorter run time, 
therefore reducing sample analysis times. 
The aims of the present study were to improve method sensitivity via the use of ammonium-
buffered mobile phase, investigate alternative extraction techniques suitable for processing 
urine samples prior to analysis, and to reduce sample run time from 32 minutes.  
 
3.2. Methods 
3.2.1. Materials and reagents 
Acetonitrile and methanol were purchased from Fisher Scientific (Loughborough, UK). 
Strata-X™ 33 µm polymeric sorbent 500 mg/6 mL solid-phase extraction cartridges, Kinetex® 
pentafluorophenyl (PFP) high-performance liquid chromatography (HPLC) columns (2.6 µm, 
100 x 4.6 mm, 100 Å; 2.6 µm, 100 x 2.1 mm, 100 Å; 2.6 µm, 50 x 2.1 mm, 100 Å) and 
SecurityGuard® cartridges (PFP, 4.6 x 2.0 mm and 2.1 x 2.0 mm) were purchased from 
Phenomenex (Macclesfield, UK). Cyanidin-3-glucoside (kuromanin chloride) was purchased 
from Extrasynthese (Genay, France). The phase II conjugates of phenolic acids 
(protocatechuic acid-3-glucuronide, protocatechuic acid-4-glucuronide, protocatechuic 
acid-3-sulfate, protocatechuic acid-4-sulfate, isovanillic acid-3-glucuronide, vanillic acid-4-
glucuronide, isovanillic acid-3-sulfate, vanillic acid-4-sulfate, benzoic acid-4-glucuronide) 
were synthesised by the School of Chemistry and Centre for Biomolecular Sciences, 
University of St. Andrews (UK) using published methods (Zhang et al. 2012). Methyl 3, 4-
dihydroxybenzoate (3, 4-dihydroxy-benzoic acid methyl ester) was purchased from Alfa 
Aesar (Heysham, UK). All other materials, reagents, and standards were purchased from 
Sigma-Aldrich (Dorset, UK), including: Acrodisc PTFE syringe filters (13 mm, 0.45 µm), formic 
acid (FA), dimethyl sulfoxide (DMSO), 4-hydroxybenzaldehyde, ferulic acid (4-hydroxy-3-
methoxycinnamic acid), hippuric acid (benzoylaminoacetic acid), isovanillic acid (3-hydroxy-
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4-methoxybenzoic acid), protocatechuic acid (PCA, 3,4-dihydroxybenzoic acid), 
phloroglucinaldehyde (PGA, 2,4,6-trihydroxybenzaldehyde), phloridzin (phloridzin 
dihydrate), scopoletin (7-hydroxy-5-methoxycoumarin), and vanillic acid (4-hydroxy-3-
methoxybenzoic acid). Water was 18MΩ/cm Milli-Q quality and all solvents were LC-MS 
grade. 
3.2.2. Mobile phase development: sample preparation 
A mixed standard was composed of cyanidin-3-glucoside and 17 of its phenolic metabolites, 
as reported following consumption of 13C-labelled cyanidin-3-glucoside (Czank et al. 2013, 
de Ferrars et al. 2014a). The 18 compounds included in the mixed standard were cyanidin-
3-glucoside, 4-hydroxybenzaldehyde, benzoic acid-4-glucuronide, ferulic acid, hippuric acid, 
isovanillic acid, isovanillic acid-3-glucuronide, isovanillic acid-3-sulfate, methyl 3,4-
dihydroxybenzoate, phloroglucinaldehyde, protocatechuic acid, protocatechuic acid-3-
glucuronide, protocatechuic acid-3-sulfate, protocatechuic acid-4-glucuronide, 
protocatechuic acid-4-sulfate, vanillic acid, vanillic acid-4-glucuronide, and vanillic acid-4-
sulfate (Figure 3.1). The mixed standard was added to mobile phase diluent (0.1/5/94.9 v/v/v 
formic acid/methanol/water), along with scopoletin and phloridzin internal standards, to 
give 50 µM samples. 
Ammonium formate was dissolved in water to give three solutions at 10 mM which were 
then separately adjusted to pH 3, pH 4 and pH 5 using formic acid. Ammonium acetate was 
also dissolved in water to give three solutions at 10 mM which were then separately adjusted 
to pH 4, pH 5 and pH 6 using acetic acid. These solutions were used in place of Mobile Phase 
A (0.1% [v/v] formic acid in water [pH 2.4]) to investigate the effect of ammonium buffers 
on method sensitivity. 
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Figure 3.1 Compounds included in the mixed standard; cyanidin-3-glucoside and 17 of its phenolic metabolites as reported following consumption of 13C-labelled cyanidin-3-glucoside 
 
Adapted from (Czank et al. 2013, de Ferrars et al. 2014a). 
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3.2.3. Extraction method development: clinical intervention study design 
Banked urine samples from a previously conducted anthocyanin intervention (Czank et al. 
2013) were used for the present analysis. Briefly, samples were originally collected from 
healthy males (n=8; age, 27.8 ± 8.1 y; BMI, 23.2 ± 1.5 kg/m2) prior to (t=0 h) and after 
consuming a 500 mg bolus of isotopically labelled cyanidin-3-glucoside containing three 13C-
atoms on the A-ring and two 13C-atoms on the B-ring (6,8,10,3’,5’-13C5-C3G, hereafter 
referred to as 13C5-C3G). Participants were asked to arrive on the study day in a fasted state 
(minimum 8 h). Individual urine samples were collected during the 6 hour study day and total 
urine voids were collected during the 6-24h and 24-48 hour periods. An anthocyanin-free 
meal was provided between 2-4 hours post-bolus. Participants were asked to maintain a low 
anthocyanin diet for the next 48 hours. Participants were also asked to avoid any foods 
containing high levels of anthocyanins and 13C (Morrison et al. 2000) over the 7 day run-in 
period and during the intervention. Upon collection, the urine samples were combined with 
100 mg of ascorbate per 500 mL of urine and were also acidified manually to pH 2.4 using 
formic acid. All samples were stored at -80°C until analysis. 
3.2.4. Extraction method development: sample preparation 
A mixed standard was composed of cyanidin-3-glucoside and six of its serum metabolites, as 
reported following consumption of 13C-labelled cyanidin-3-glucoside (Czank et al. 2013, de 
Ferrars et al. 2014a). The seven compounds included in the mixed standard were cyanidin-
3-glucoside, benzoic acid-4-glucuronide, ferulic acid, hippuric acid, phloroglucinaldehyde, 
protocatechuic acid, and vanillic acid-4-sulfate. The mixed standard was added to pool 
acidified baseline urine from the 13C5-C3G intervention, along with phloridzin internal 
standard, to give 1 µM samples. 
3.2.5. Extraction method development: solid-phase extraction (SPE) 
1 µM samples were extracted via SPE following previously reported methodology (Czank et 
al. 2013, de Ferrars et al. 2014c). Briefly, SPE cartridges were preconditioned with 6 mL of 
acidified methanol (acidified to pH 2.4 using formic acid) followed by 6 mL of acidified water 
(acidified to pH 2.4 using formic acid). Cartridges were loaded with 1 mL acidified water 
followed by 1 mL of sample. Samples were eluted at a flow rate of approximately 1 
drop/second. Cartridges were washed with 12 mL of acidified water before being dried 
under vacuum for 30 mins. 5 mL of acidified methanol was added to the cartridges and left 
to soak for 10 mins before the samples were eluted with a total of 7 mL acidified methanol. 
For the 7x diluted samples (Figure 3.2), scopoletin volume control standard was added and 
the samples stored at -80°C until analysis. For the undiluted, 2x concentrated, and 4x 
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concentrated samples, the eluent was evaporated to approximately 50 μL on a rotary 
evaporator (Thermo SPD Speedvac). Following evaporation, the samples were reconstituted 
with either 200 μL, 450 μL, 950 μL of acidified water and scopoletin volume control standard 
added (Figure 3.2). The samples were then sonicated for 10 mins with the ultrasonic water 
bath kept cool using ice, followed by vortex mixing for 10 seconds and filtration through a 
0.45 µm syringe filter. Samples were stored at -80°C until analysis. 
3.2.6. Extraction method development: dilute-and-shoot (D&S) 
1 µM samples were extracted via D&S extraction based on previously reported methodology 
(Gustavsson et al. 2007, Fitzgerald et al. 2012, Warth et al. 2012). 200 µL samples were 
spiked with either 0 µL, 800 µL or 1800 µL of mobile phase diluent (0.1/5/94.9 v/v/v formic 
acid/methanol/water) (Figure 3.2) followed by vortex mixing for 10 seconds and filtration 
through a 0.45 µm syringe filter. Samples were stored at -80°C until analysis.  
3.2.7. Extraction method development: protein precipitation (PPT) 
1 µM samples were extracted via PPT based on previously reported methodology (Chang et 
al. 2007, Fernández-Peralbo and Luque de Castro 2012, Raju et al. 2012). 200 µL samples 
were spiked with 800 µL of acetonitrile containing 0.1% v/v formic acid, mixed by vortex for 
10 seconds, stored at -20°C for 30 mins and centrifuged at 4000 x g, 8°C for 10 mins. After 
centrifugation, the supernatant was removed, placed into a test tube and evaporated to 
dryness on a Thermo Speedvac concentrator. Samples were reconstituted with either 50 µL, 
100 µL, 200 µL or 1000 µL of mobile phase diluent (0.1/5/94.9 v/v/v formic 
acid/methanol/water) (Figure 3.2). Samples were sonicated for 10 mins with the ultrasonic 
water bath kept cool using ice, followed by vortex mixing for 10 seconds and filtration 
through a 0.45 µm syringe filter. Samples were stored at -80°C until analysis.  
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Figure 3.2 Experimental design of extraction method development protocol showing the differences between the various extraction methods tested. Current method is solid-phase 
extraction (4x concentrated) as previously reported. 
 
Adapted from (Czank et al. 2013, de Ferrars et al. 2014c). 
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3.2.8. Chromatography 
HPLC-ESI-MS/MS analysis was carried out using an Agilent (Stockport, UK) 1200 series HPLC 
equipped with a Diode Array Detector (DAD) coupled to an AB SCIEX (Warrington, UK) 3200 
series QTRAP® MS/MS system with Turbo V™ electrospray ionisation source using 
previously established methods (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, a 
Kinetex® pentafluorophenyl (PFP) (2.6 µm, 100 x 4.6 mm) RP-HPLC column was used with a 
PFP SecurityGuard® cartridge (4.6 x 2.0 mm). The column temperature was set at 37°C, 
injector temperature of 4°C and injection volume of 5 µL. Mobile Phase A was 0.1% (v/v) 
formic acid in water and Mobile Phase B was 0.1% (v/v) formic acid in acetonitrile at a flow 
rate of 1.5 mL min-1 at 0 min, 1 mL min-1 at 7 to 14 min and 1.5 mL min-1 at 14 to 32 min. The 
gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% 
B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min, 1% B at 29 to 32 
min. MS/MS source parameters included ionspray voltage, -4000 V / +5500 V; temperature, 
700°C; curtain gas, 40 psi; nebulizer gas and auxiliary gas, 60 psi. Multiple reaction 
monitoring (MRM) scans were performed using parameters optimised for the detection of 
analytical standards (Table 3.1). Samples were analysed in negative ionisation mode and in 
positive ionisation mode, with internal standards included in both methods. Retention time 
and the detection of three or more of the relevant ion transitions were used to confirm the 
identity of the metabolites. For quantification, the peak area of the most intense ion 
transition was used. A seven-point calibration (0 – 5 µM) curve was prepared for 
quantification of extraction method development samples by spiking a standard mixture of 
the compounds into a matched-matrix (blank urine) and coefficients of determination (R2) 
were established as linear (0.992 ± 0.010). 
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Table 3.1 MRM parameters used to analyse samples on the AB SCIEX 3200 QTRAP® instrument. 
Compound 
Transitions (m/z) 
precursor/product ion 
Scan mode 
Benzoic acid-4-glucuronide 313/175,113,93* - 
Protocatechuic acid-4-glucuronide 329.01/153*,113,109 - 
Protocatechuic acid 153.01/108*,91,81 - 
Protocatechuic acid-3-glucuronide 329.01/153*,113,109 - 
Vanillic acid-4-glucuronide 343.01/167,152,113* - 
Isovanillic acid-3-glucuronide 343.01/167,152,113* - 
Hippuric acid 177.9/133.9*,77.1,131.8 - 
Protocatechuic acid-3/4-sulfatea 233.01/153,109*,189 - 
4-hydroxybenzaldehyde 121.2/107.8,92*,65.1 - 
Isovanillic acid 169.01/151.1,125,93* + 
Vanillic acid 167.03/152*,123,108 - 
(Iso)vanillic acid-3/4-sulfatea 247/167*,152,108 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 - 
Cyanidin-3-glucoside 449/287*,213,137 + 
Phloroglucinaldehyde 153/151*,125,107 - 
Ferulic acid 193/178,149,134* - 
Scopoletin 193/133.2*,122,94.1 + 
Scopoletin 191/104*,147.9,120 - 
Phloridzin 437/275, 169, 107* + 
Phloridzin 435/273*,167,123 - 
*Transition used for quantitation. aIsomers of this metabolite were unresolvable using this HPLC-
ESI-MS/MS method so were quantified as a single analyte. 
 
3.2.9. Statistical analysis 
For mobile phase and extraction method development data, one-way analysis of variance 
(ANOVA) with LSD post-hoc test was performed on 20 (mobile phase) or nine (extraction 
method) replicates using SPSS for Windows statistical software package (version 22, IBM, 
New York, USA). Significance was determined at the 5% confidence level. Statistical analysis 
was conducted on raw data with mean values graphed as percentage of current method for 
signal-to-noise ratio and peak width (mobile phase), and LOD (extraction method) with error 
bars representing standard deviation. 
3.2.10. HPLC-ESI-MS/MS method development 
With the aim of developing a new method with a shorter run time while maintaining the 
current method sensitivity, peak shape, and resolution, the HPLC chromatographic 
conditions were further optimised with respect to column diameter (2.1 mm; 4.6 mm), 
column temperature (37°C; 40°C; 50°C; 60°C; 70°C), mobile phase flow rate (0.45 mL min-1 / 
0.3 mL min-1; 0.6 mL min-1; 0.6 mL min-1 / 0.4 mL min-1; 0.8 mL min-1; 1.5 mL min-1 / 1 mL min-
1), gradient profile (15 min [1% B at 0 min, 7.5% B at 7 min, 7.6% B at 9 min, 90% B at 9.5 to 
11.5 min, 1% B at 12 to 15 min]; 20 min [1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 
90% B at 14 to 17 min, 1% B at 17 to 20 min]; 32 min [1% B at 0 min, 7.5% B at 7 min, 7.6% B 
at 14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 
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25 to 28 min, 1% B at 29 to 32 min]), mobile phase formic acid concentration (0.1%; 1%), 
column length (50 mm; 100 mm), and injection volume (1 µL; 5 µL). 
A mixed standard was composed of cyanidin-3-glucoside and 17 of its serum metabolites, as 
reported following consumption of 13C-labelled cyanidin-3-glucoside (Czank et al. 2013, de 
Ferrars et al. 2014a) (Figure 3.1). The mixed standard was added to mobile phase diluent 
(0.1/5/94.9 v/v/v formic acid/methanol/water), along with scopoletin and phloridzin 
internal standards, to give 50 µM samples for use in method optimisation. 
 
3.3. Results 
3.3.1. Mobile phase development 
None of the six alternative mobile phases (10 mM ammonium formate, pH 3, pH 4, pH 5; 10 
mM ammonium acetate, pH 4, pH 5, pH 6) tested showed a significant increase in signal-to-
noise ratio compared to the current method using 0.1% formic acid mobile phase (pH 2.4) 
(Figure 3.3). 10 mM Ammonium formate adjusted to pH 3 showed a significant decrease 
(65.7 ± 32.8%) in signal-to-noise ratio compared to the current method. 
 
Figure 3.3 Signal-to-noise ratio observed using ammonium-buffered mobile phases compared to the 
current 0.1% formic acid mobile phase. 
 
Data expressed as mean ± SD, n=20 analytes. Significance relative to current method, *p≤0.05, one-way 
ANOVA with LSD post-hoc test. aDifferent letters represent statistical differences between groups, p≤0.05, 
one-way ANOVA with LSD post-hoc test. 
 
None of the six alternative mobile phases tested showed a significant change in peak width 
compared to the current method using 0.1% formic acid mobile phase (Figure 3.4).  
 
  
 Page | 63 
Figure 3.4 Peak width observed using ammonium-buffered mobile phases compared to the current 0.1% 
formic acid mobile phase. 
 
Data expressed as mean ± SD, n=20 analytes. Significance relative to current method, *p≤0.05, one-way 
ANOVA with LSD post-hoc test. aDifferent letters represent statistical differences between groups, p≤0.05, 
one-way ANOVA with LSD post-hoc test. 
 
3.3.2. Extraction method development 
None of the ten alternative extraction methods (SPE 7x diluted, undiluted, 2x concentrated; 
D&S 10x diluted, 5x diluted, undiluted; PPT 5x diluted, undiluted, 2x concentrated, 4x 
concentrated) showed a significant decrease in LOD compared to the current method using 
SPE (4x concentrated) (Figure 3.5). D&S (10x diluted) (472.9 ± 367.9%) and PPT (5x diluted) 
(359.6 ± 395.7%) showed significant increases in LOD compared to the current method. Of 
the ten alternative extraction methods tested, PPT (4x concentrated) showed the lowest 
LOD (11.3 ± 16.0 nM). 
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Figure 3.5 Limit of detection observed using alternative extraction methods compared to the current solid-phase extraction (4x concentrated) method. 
 
SPE, solid-phase extraction; D&S, dilute-and-shoot; PPT, protein precipitation. Data expressed as mean ± SD, n=9 analytes. Significance relative to current method, *p≤0.05, **p≤0.01, one-
way ANOVA with LSD post-hoc test. a,b,c,d,eDifferent letters represent statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
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3.3.3. HPLC-ESI-MS/MS method development 
The chromatographic conditions of the HPLC-ESI-MS/MS method for quantifying cyanidin-3-
glucoside and its phenolic metabolites in biological samples were optimised in order to 
reduce sample run time from 32 minutes while maintaining the sensitivity, peak shape, and 
separation of the initial method. 
Two column diameters were tested: 4.6 mm (as used by the initial 32 minute method) and 
2.1 mm. The 2.1 mm diameter column was deemed to be preferable based upon a visual 
assessment of reduced elution times for all analytes (Figure 3.6). 
 
Figure 3.6 Chromatography of initial 32 minute method using column diameter of 4.6 mm (A) and following 
optimisation of column diameter to 2.1 mm (B) during development of an HPLC-ESI-MS/MS method with 
reduced run time for the quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
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Five column temperatures were tested: 37°C (as used by the initial 32 minute method), 40°C, 
50°C, 60°C, and 70°C. Considerable changes in chromatography were observed following 
relatively small changes in column temperature with 40°C deemed to be preferable based 
upon a visual assessment of slightly improved peak shape and reduced elution time for some 
analytes, particularly the analytes eluting at between 2 and 10 minutes (Figure 3.7). 
 
Figure 3.7 Chromatography using column temperature of 37°C (A) and following optimisation of column 
temperature to 40°C (B) during development of an HPLC-ESI-MS/MS method with reduced run time for the 
quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
Five mobile phase flow rates were tested: 1.5 mL min-1 / 1.0 mL min-1 (as used by the initial 
32 minute method, using the 4.6 mm diameter column), 0.8 mL min-1, 0.6 mL min-1 / 0.4 mL 
min-1, 0.6 mL min-1, and 0.45 mL min-1 / 0.3 mL min-1. The four potential new flow rates were 
run using the 2.1 mm diameter column and compared against the original 1.5 mL min-1 / 1.0 
mL min-1 flow rate using the 4.6 mm diameter column due to column pressure limits. The 
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mobile phase flow rate of 0.6 mL min-1 was deemed to be preferable based upon a visual 
assessment of slightly improved peak shape for some analytes, particularly 
phloroglucinaldehyde, and reduced elution time for all analytes (Figure 3.8). 
 
Figure 3.8 Chromatography using mobile phase flow rate of 1.5 mL min-1 / 1.0 mL min-1 with 4.6 mm 
diameter column (A) and following optimisation of mobile phase flow rate to 0.6 mL min-1 with 2.1 mm 
diameter column (B) during development of an HPLC-ESI-MS/MS method with reduced run time for the 
quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
Three gradient profiles were tested: 32 minutes (1% B at 0 min, 7.5% B at 7 min, 7.6% B at 
14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 
25 to 28 min, 1% B at 29 to 32 min) (as used by the initial 32 minute method), 20 minutes 
(1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 90% B at 14 to 17 min, 1% B at 17 to 20 
min), and 15 minutes (1% B at 0 min, 7.5% B at 7 min, 7.6% B at 9 min, 90% B at 9.5 to 11.5 
min, 1% B at 12 to 15 min). The 15 minute gradient profile was deemed to be preferable 
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based upon a visual assessment of improved peak separation, particularly the analytes 
eluting between 1 and 3 minutes, and reduced elution time for all analytes (Figure 3.9). 
Figure 3.9 Chromatography using gradient profile of 32 minutes (1% B at 0 min, 7.5% B at 7 min, 7.6% B at 
14 min, 10% B at 17 min, 12% B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min, 1% 
B at 29 to 32 min) (A) and following optimisation of gradient profile to 15 minutes (1% B at 0 min, 7.5% B 
at 7 min, 7.6% B at 9 min, 90% B at 9.5 to 11.5 min, 1% B at 12 to 15 min) (B) during development of an 
HPLC-ESI-MS/MS method with reduced run time for the quantification of cyanidin-3-glucoside and its 
phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
Two mobile phase formic acid concentrations were tested: 0.1% (as used by the initial 32 
minute method) and 1%. The mobile phase formic acid concentration of 0.1% was deemed 
to be preferable based upon a visual assessment of increased peak height for most analytes, 
particularly the analytes eluting at between 1 and 3 minutes, and peak separation, 
particularly for ferulic acid and scopoletin (Figure 3.10). 
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Figure 3.10 Chromatography using mobile phase formic acid concentration of 1% (A) and optimised mobile 
phase formic acid concentration of 0.1% (B) during development of an HPLC-ESI-MS/MS method with 
reduced run time for the quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
Two column lengths were tested: 100 mm (as used by the initial 32 minute method) and 50 
mm. The column length of 50 mm was deemed to be preferable based upon a visual 
assessment of peak separation, particularly for hippuric acid and methyl 3,4-
dihydroxybenzoate (Figure 3.11). 
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Figure 3.11 Chromatography using column length of 100 mm (A) and following optimisation of column 
length to 50 mm (B) during development of an HPLC-ESI-MS/MS method with reduced run time for the 
quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
Two injection volumes were tested: 5 µL (as used by the initial 32 minute method) and 1 µL. 
The injection volume of 5 µL was deemed to be preferable based upon a visual assessment 
of improved peak separation, particularly for benzoic acid-4-glucuronide, protocatechuic 
acid-4-glucuronide and protocatechuic acid, and increased peak height for all analytes. This 
completed the development of the final optimised 15 minute method (Figure 3.12).  
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Figure 3.12 Chromatography using injection volume of 1 µL (A) and final optimised 15 minute method with 
injection volume of 5 µL (B) following development of an HPLC-ESI-MS/MS method with reduced run time 
for the quantification of cyanidin-3-glucoside and its phenolic metabolites. 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. 
 
3.4. Discussion 
An HPLC-ESI-MS/MS method capable of extracting, separating and quantifying over 40 
phenolic metabolites of cyanidin-3-glucoside in biological samples within a 32 minute run 
time was developed previously by our group (Czank et al. 2013, de Ferrars et al. 2014c). The 
present study aimed to develop this method further by exploring the effect of ammonium-
buffered mobile phases on method sensitivity, to test alternative sample extraction 
techniques to increase throughput during urine sample processing, and to reduce sample 
run time from 32 minutes via optimisation of HPLC parameters. 
Six ammonium-buffered mobile phases (10 mM ammonium formate, pH 3, pH 4, pH 5; 10 
mM ammonium acetate, pH 4, pH 5, pH 6) were assessed in comparison to the 0.1% formic 
acid solution used as the aqueous mobile phase in the current method. Ammonium formate 
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at pH 3 showed a decrease in signal-to-noise ratio compared to the current method while 
the remaining five ammonium-buffered mobile phases showed no significant change 
compared to the current method. None of the six ammonium-buffered mobile phases 
showed a significant change in peak width compared to the current method. The lack of 
significant change shown when using the ammonium-buffered mobile phases compared to 
the current method may be due to the variability in response observed from the 20 analytes 
tested. Whilst the mean signal-to-noise ratios as a percentage of the current method showed 
no significant change for five of the six ammonium-buffered mobile phases, individual 
analytes showed a wide variability of responses ranging from 5.8% for phloridzin (positive 
ionisation mode) using ammonium formate at pH 3 to 268.0% for vanillic acid-3/4-sulfate 
using ammonium acetate at pH 6. The difference in analyte response to change in mobile 
phase may be due caused by differences in the surface activity of the ammonium salts and 
analyte ions (Beaudry and Vachon 2006). Following droplet formation at the end of the spray 
needle, the charged particles with the highest surface activity will accumulate at the droplet 
surface, effectively blocking the evaporation into the gas phase of any ions at the centre of 
the droplet (Cech and Enke 2001, Zhou and Cook 2001, Henriksen et al. 2005). Surface 
activity has been linked to polarity (Henriksen et al. 2005) and small differences in the 
polarity of the metabolites may explain the difference in analyte response to change in 
mobile phase observed in the present study. This variation has been noted previously (Mallet 
et al. 2004) and can explain the difficulty in predicting the effect that mobile phase additives 
can have on the ionisation of structurally similar analytes as they compete with buffer salt 
ions within the ion source (Cech and Enke 2001). Despite the positive effect caused by some 
mobile phases on signal-to-noise ratio of some analytes, and due to prioritisation of 
qualitative detection and quantification of an extensive range of metabolites in the analytical 
method, it is necessary to compromise during method development and consider the effect 
that changes to the method have on analyte response as a whole. The lack of an overall 
significant increase in method sensitivity observed in the present study when using 
ammonium-buffered mobile phases means that the 0.1% formic acid mobile phase used by 
the current method should be considered optimal. 
Ten sample extraction methods (SPE 7x diluted, undiluted, 2x concentrated; D&S 10x 
diluted, 5x diluted, undiluted; PPT 5x diluted, undiluted, 2x concentrated, 4x concentrated) 
were assessed in comparison to the SPE 4x concentrated method used in our usual method. 
Eight of ten methods showed no significant change in LOD from the current method with 
D&S (10x diluted) and PPT (5x diluted) showing significant increases in LOD compared to the 
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current method. Sample concentration steps are commonly included in sample extraction 
methods prior to LC-MS analysis in order to increase the concentration, and therefore 
increase the signal-to-noise ratio, of the analytes of interest (Cooke et al. 2006, Grace et al. 
2007). However, it has been suggested that this approach can also result in concentration of 
matrix components which can lead to suppression of the analytes of interest during 
ionisation (Dams et al. 2003). Alternative sample extraction methods including a dilution 
step were included in the present study to investigate whether the current method was 
subject to this effect but no evidence was observed in this study as the four methods 
including dilution steps showed the highest LODs of the ten alternative methods tested. Of 
the eight methods that showed no significant change in LOD from the current method (SPE 
7x diluted, undiluted, 2x concentrated; D&S 5x diluted, undiluted; PPT undiluted, 2x 
concentrated, 4x concentrated), the three SPE methods were included to explore the effect 
of varying the dilution/concentration step but were not considered optimal for extraction of 
urine samples due to the lower throughput caused by the time needed to pre-condition, run 
samples through, and dry SPE cartridges which could take up to 4 hours compared to 
approximately 2 hours for PPT and 30 minutes for D&S. Of the remaining five methods (D&S 
5x diluted, undiluted; PPT undiluted, 2x concentrated, 4x concentrated), the two D&S 
methods, whilst showing no significant difference in LOD from the current method and the 
extraction method with the highest potential throughput, were not considered optimal due 
to the risk of accumulation of salts and impurities within the ion source resulting in loss of 
instrument sensitivity and increased risk of adduct formation. Of the remaining three 
methods (PPT undiluted, 2x concentrated, 4x concentrated), no significant difference in LOD 
was observed but PPT (4x concentrated) showed the lowest LOD and was therefore 
considered to be the optimal sample extraction method for processing urine samples. 
Seven HPLC parameters (column diameter, column temperature, mobile phase flow rate, 
gradient profile, mobile phase formic acid concentration, column length, injection volume) 
were optimised with the aim of achieving similar or better levels of method sensitivity, peak 
shape and resolution as the initial 32 minute HPLC-ESI-MS/MS method within a reduced run 
time. The PFP stationary phase had been previously reported to be optimal for separation of 
phenolic metabolites (de Ferrars et al. 2014c) and so the choice of stationary phase was not 
reassessed in the present study. However, the column diameter and length were assessed 
and it was found that the 50 x 2.1 mm PFP column was capable of achieving similar 
sensitivity, peak shape and resolution as the 100 x 4.6 mm PFP column used in the initial 32 
minute method. The use of the 50 x 2.1 mm column then facilitated a reduction in mobile 
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phase flow rate from 1.5 mL min-1 / 1 mL min-1 to 0.6 mL min-1. The reduction in flow rate 
has two advantages over the previous method; firstly, it improves evaporation within the 
ion source and therefore should improve ionisation efficiency, and secondly, mobile phase 
usage is reduced therefore lowering the cost of using this method. The use of the 50 x 2.1 
mm column also achieved acceptable peak resolution within a quicker timeframe which 
allowed for the HPLC gradient profile to be adjusted to reduce the overall run time. The initial 
ramp from 1% mobile phase B to 7.5% B at 7 min was unchanged as this was the period 
during which the majority of the analytes were eluted when using the 50 x 2.1 mm column. 
This meant that the ramp from 7.5% B to 7.6% B was less important for peak resolution in 
the new method compared to the initial method and so could be reduced from 7 minutes to 
2 minutes. At this point in the new method, few analytes remained to be eluted therefore 
the ramp up to the 90% B wash phase could be reduced from 9 minutes to 30 seconds. The 
90% B wash phase was also reduced from 3 minutes to 2 minutes. In total, these changes to 
the gradient profile reduced the run time from 32 minutes to 15 minutes per sample 
resulting in quicker analysis times and further reductions in method running costs. The 
concentration of 0.1% formic acid in the mobile phase optimised previously (de Ferrars et al. 
2014c) was reassessed in the present study due to the change in column and conditions but 
the original method was again found to be optimal. The injection volume of 5 µL used in the 
initial method was assessed due to the reduction in column length and diameter but the 
original method was also deemed to be preferable. In addition to these changes, the MS 
source gas (curtain, nebulizer, auxiliary) flows were amended in the optimised 15 minute 
method. This change was made based on advice received during an AB SCIEX engineer visit 
which stated that the high gas flows used in the previous method were too high and should 
be reduced as it would not affect the chromatography or sensitivity of the method but would 
increase the longevity of the nitrogen gas generator. Overall, a number of changes were 
made to the initial 32 minute method to yield an improved 15 minute method (Table 3.2). 
The method developed in the present study is capable of detecting an equal number of 
phenolic metabolites with comparable levels of sensitivity, in under half the run time (Figure 
3.13). The final optimised 15 minute method should be validated prior to use to assess the 
relative strengths and limitations of the method and to allow confidence in the results 
obtained when quantifying of anthocyanin metabolites in future studies. 
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Table 3.2 Comparison of initial 32 minute HPLC-ESI-MS/MS method and optimised 15 minute HPLC-ESI-
MS/MS method parameters. 
 Initial 32 minute method Optimised 15 minute method 
HPLC Agilent 1200 series with DAD Agilent 1200 series with DAD 
Column stationary phase PFP, 2.6 µm PFP, 2.6 µm 
Column length 100 mm 50 mm 
Column diameter 4.6 mm 2.1 mm 
Column temperature 37°C 40°C 
Guard cartridge PFP, 4.6 x 2.0 mm PFP, 2.1 x 2.0 mm 
Injector temperature 4°C 4°C 
Injection volume 5 µL 5 µL 
Mobile phase A 0.1 % (v/v) formic acid in water 0.1 % (v/v) formic acid in water 
Mobile phase B 0.1 % (v/v) formic acid in acetonitrile 0.1 % (v/v) formic acid in acetonitrile 
Flow rate 1.5 mL min-1 at 0 min 
1.0 mL min-1 at 7 to 14 min 
1.5 mL min-1 at 14 to 32 min 
0.6 mL min-1 
Gradient 1% B at 0 min 
7.5% B at 7 min 
7.6% B at 14 min 
10% B at 17 min 
12% B at 18.5 min 
12.5% B at 20 min 
30% B at 24 min 
90% B at 25 to 28 min 
1% B at 29 to 32 min 
1% B at 0 min 
7.5% B at 7 min 
7.6% B at 9 min 
90% B at 9.5 to 11.5 min 
1% B at 12 to 15 min 
   
Mass spectrometer AB SCIEX 3200 series QTRAP AB SCIEX 3200 series QTRAP 
Ion source Turbo V Turbo V 
Ionisation mode ESI, negative/positive ESI, negative/positive 
Voltage -4000 / +5500 V -4000 / +5500 V 
Temperature 700°C 700°C 
Curtain gas 40 psi 35 psi 
Nebuliser gas 60 psi 40 psi 
Auxiliary gas 60 psi 45 psi 
Column length, column diameter, column temperature, flow rate, and gradient changed based on optimisation 
of the method during the present study. Guard cartridge changed to match the amended column diameter. 
Curtain, nebulizer, and auxiliary gas flows changed following advice from an AB SCIEX engineer that the values 
used in the initial 32 minute method were too high. 
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Figure 3.13 Comparison of (A) initial 32 minute HPLC-ESI-MS/MS method and (B) optimised 15 
minute HPLC-ESI-MS/MS method chromatography 
 
1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 
7, hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, 
ferulic acid; 15, scopoletin; 16, phloridzin. 
 
3.5. Conclusion 
Ongoing development of methods for quantifying anthocyanins metabolites in biological 
samples is important for improving data quality when monitoring metabolites at nanomolar 
concentrations, and to allow for the detection of novel metabolites present at 
concentrations below the current limits of detection. The present study provides evidence 
that the use of ammonium-buffered mobile phase does not improve method sensitivity 
when quantifying anthocyanin metabolites and that the 0.1% formic acid mobile phase used 
by the previously reported HPLC-ESI-MS/MS method (Czank et al. 2013, de Ferrars et al. 
2014c) is optimal. The present study provides evidence that PPT may be used as a suitable 
alternative to SPE when extracting anthocyanin metabolites from clinical urine samples. The 
present study also reports further optimisation of the existing 32 minute HPLC-ESI-MS/MS 
method to produce a method capable of achieving similar sensitivity, resolution, and peak 
shape within a 15 minute run time.  
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Chapter 4. Validation of HPLC-ESI-MS/MS Methods for 
Quantifying Anthocyanin Metabolites in Human Serum and 
Urine. 
 
4.1. Introduction 
Anthocyanins have been extensively studied due to their reported health effects 
(McCullough et al. 2012, Cassidy et al. 2015) but recently the focus in this area has shifted 
towards the phenolic metabolites of anthocyanins to explain the observed bioactivity due to 
the low bioavailability of the parent anthocyanins (Wu et al. 2002, Kay et al. 2005). To 
facilitate further study of anthocyanin metabolites, reliable methods of detecting and 
quantifying these compounds in biological samples are required. To this end, an analytical 
method was developed using high performance liquid chromatography coupled to an 
electrospray ionisation tandem mass spectrometer (HPLC-ESI-MS/MS) capable of separating 
and quantifying cyanidin-3-glucoside and 17 of its phenolic metabolites in human serum 
samples within a 32 minute sample run time (Czank et al. 2013, de Ferrars et al. 2014c). 
Further development of this method to reduce sample run time, simplify sample 
preparation, and expand the number of quantifiable analytes through improved ionisation 
efficiency yielded a second analytical method capable of separating and quantifying 
cyanidin-3-glucoside and 54 of its phenolic metabolites in human urine samples within a 15 
minute sample run time. The present study describes the validation of these two methods.  
The phenolic metabolites included in the two methods were chosen based on those recently 
reported to be present in serum and urine following intake of cyanidin-3-glucoside (Czank et 
al. 2013, Rodriguez-Mateos et al. 2013, de Ferrars et al. 2014a, de Ferrars et al. 2014b). The 
design of the present study was based on published guidelines for bioanalytical method 
validation (Food and Drug Administration 2001, United Nations Office on Drugs and Crime 
2009) where specificity, limit of detection (LOD), linearity, accuracy, precision, and 
extraction efficiency were examined. These guidelines represent the gold standard in 
bioanalytical method validation and are typically used by pharmacological and toxicological 
studies in the pursuit of FDA drug approval where very high standards of methods for routine 
analysis are expected. Expectations for analytical method quality in nutritional research may 
be lower due to inherent difficulties such as inter-participant variation (de Roos 2013) but it 
is important that methods for analysing clinical samples from nutritional studies are 
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developed with these guidelines in mind. Some nutritional studies utilise the FDA and UN 
guidelines to validate their analytical method but these studies typically detect and quantify 
either single (Zeng et al. 2015, Ramalingam and Ko 2016) or small numbers of analytes (Wang 
et al. 2014b, Wei et al. 2016). Due to the difficulties involved in optimising methods to be 
both qualitative and quantitative for the high number of analytes included in the methods 
presented here, the present study was less focused on achieving the high standards laid out 
in the FDA and UN guidelines and more focused on using the guidelines to assess the relative 
strengths and limitations of the method and to provide information on situations in which 
the methods may be more or less appropriate to use. The aim of the present study was to 
answer the following questions:  
 Are the correct analytes being quantified? (Specificity) 
 What are the lowest metabolite concentrations that the methods are capable of 
detecting? (LOD) 
 Is the response linear over the relevant concentration range? (Linearity) 
 Are the calculated metabolite concentrations close to the ‘true’ concentrations? 
(Accuracy) 
 Are these results repeatable and reproducible? (Precision) 
 Are the compounds of interest recovered from the biological samples effectively and 
consistently by the sample preparation method? (Extraction efficiency) 
 
4.2. Methods 
4.2.1. Materials and reagents 
Acetonitrile and methanol were purchased from Fisher Scientific (Loughborough, UK). 
Strata-X™ 33 µm polymeric sorbent 500 mg/6 mL solid-phase extraction cartridges, Kinetex® 
pentafluorophenyl (PFP) high-performance liquid chromatography (HPLC) columns (2.6 µm, 
100 x 4.6 mm, 100 Å and 2.6 µm, 50 x 2.1 mm, 100 Å) and SecurityGuard® cartridges (PFP, 
4.6 x 2.0 mm and 2.1 x 2.0 mm) were purchased from Phenomenex (Macclesfield, UK). 
Cyanidin-3-glucoside (kuromanin chloride) was purchased from Extrasynthese (Genay, 
France). The phase II conjugates of phenolic acids (protocatechuic acid-3-glucuronide, 
protocatechuic acid-4-glucuronide, protocatechuic acid-3-sulfate, protocatechuic acid-4-
sulfate, isovanillic acid-3-glucuronide, vanillic acid-4-glucuronide, isovanillic acid-3-sulfate, 
vanillic acid-4-sulfate, benzoic acid-4-glucuronide) were synthesised by the School of 
Chemistry and Centre for Biomolecular Sciences, University of St. Andrews (UK) using 
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published methods (Zhang et al. 2012). 3-hydroxyhippuric acid and 4-hydroxyhippuric acid 
were purchased from Alfa Chemistry (Stony Brook, USA). Methyl 3,4-dihydroxybenzoate 
(3,4-dihydroxy-benzoic acid methyl ester) was purchased from Alfa Aesar (Heysham, UK). All 
other materials, reagents, and standards were purchased from Sigma-Aldrich (Dorset, UK), 
including: Acrodisc PTFE syringe filters (13 mm, 0.45 µm), human serum from human male 
AB plasma (Product No.: H4522) formic acid (FA), dimethyl sulfoxide (DMSO), 2,3-
dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 2-hydroxy-4-
methoxybenzoic acid, 2-hydroxybenzoic acid, 2-hydroxycinnamic acid, 3-(3-
hydroxyphenyl)propionic acid, 3-(4-hydroxy-3-methoxyphenyl)propionic acid, 3,4-
dihydroxybenzaldehyde, 3,4-dihydroxyphenylacetic acid, 3,5-dihydroxybenzoic acid, 3-
hydroxybenzoic acid, 3-hydroxyphenylacetic acid, 3-methylhippuric acid (N-[3-
methylbenzoyl]glycine), 3-(4-hydroxyphenyl)propionic acid, 4-hydroxybenzaldehyde, 4-
hydroxybenzoic acid, 4-hydroxybenzyl alcohol, 4-hydroxyphenylacetic acid, 4-
methylhippuric acid (N-[4-methylbenzoyl]glycine), α-hydroxyhippuric acid 
([benzoylamino]hydroxyacetic acid), benzoic acid, benzoylglutamic acid, caffeic acid (3,4-
dihydroxycinnamic acid), chlorogenic acid (3-[3,4-dihydroxycinnamoyl]quinic acid), ferulic 
acid (4-hydroxy-3-methoxycinnamic acid), gallic acid (3,4,5-trihydroxybenzoic acid), hippuric 
acid (benzoylaminoacetic acid), homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid), 
isoferulic acid (3-hydroxy-4-methoxycinnamic acid), isovanillic acid (3-hydroxy-4-
methoxybenzoic acid), kaempferol (3,4’,5,7-tetrahydroxyflavone), protocatechuic acid (PCA, 
3,4-dihydroxybenzoic acid), p-coumaric acid (trans-4-hydroxycinnamic acid), 
phloroglucinaldehyde (PGA, 2,4,6-trihydroxybenzaldehyde), phenylacetic acid, phloridzin 
(phloridzin dihydrate), rosmarinic acid ([R]-O-[3,4-dihydroxycinnamoyl]-3-[3,4- 
dihydroxyphenyl]lactic acid), scopoletin (7-hydroxy-5-methoxycoumarin), sinapic acid (4-
hydroxy-3,5-dimethoxy-cinnamic acid), syringic acid (4-hydroxy-3,5-dimethoxy-benzoic 
acid), trans-cinnamic acid, trans-3-hydroxycinnamic acid, and vanillic acid (4-hydroxy-3-
methoxybenzoic acid). Water was 18MΩ/cm Milli-Q quality and all solvents were LC-MS 
grade. 
4.2.2. Clinical intervention study design 
Banked urine samples from a previously conducted anthocyanin intervention (Czank et al. 
2013) were used for the present analysis. Briefly, samples were originally collected from 
healthy males (n=8; age, 27.8 ± 8.1 y; BMI, 23.2 ± 1.5 kg/m2) prior to (t=0 h) and after 
consuming a 500 mg bolus of isotopically labelled cyanidin-3-glucoside containing three 13C-
atoms on the A-ring and two 13C-atoms on the B-ring (6,8,10,3’,5’-13C5-C3G, hereafter 
 Page | 80 
referred to as 13C5-C3G). Participants were asked to arrive on the study day in a fasted state 
(minimum 8 h). Individual urine samples were collected during the 6 hour study day and total 
urine voids were collected during the 6-24h and 24-48 hour periods. An anthocyanin-free 
meal was provided between 2-4 hours post-bolus. Participants were asked to maintain a low 
anthocyanin diet for the next 48 hours. Participants were also asked to avoid any foods 
containing high levels of anthocyanins and 13C (Morrison et al. 2000) over the 7 day run-in 
period and during the intervention. Upon collection, the urine samples were combined with 
100 mg of ascorbate per 500 mL of urine and were also acidified manually to pH 2.4 using 
formic acid. All samples were stored at -80°C until analysis. 
4.2.3. Serum sample preparation: solid phase extraction (SPE) 
40 mL of commercially-sourced human serum was extracted via SPE following previously 
reported methodology (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, SPE cartridges 
were preconditioned with 6 mL of acidified methanol (acidified to pH 2.4 using formic acid) 
followed by 6 mL of acidified water (acidified to pH 2.4 using formic acid). Cartridges were 
loaded with 1 mL acidified water followed by 1 mL of serum. Samples were eluted at a flow 
rate of approximately 1 drop/second. Cartridges were washed with 12 mL of acidified water 
before being dried under vacuum for 30 mins. 5 mL of acidified methanol was added to the 
cartridges and left to soak for 10 mins before the samples were eluted with a total of 7mL 
acidified methanol. The eluent was evaporated to approximately 50 μL on a rotary 
evaporator (Thermo SPD Speedvac). Following evaporation, the samples were reconstituted 
with 200 μL of acidified water. The samples were then sonicated for 10 mins with the 
ultrasonic water bath kept cool using ice, followed by vortex mixing for 10 seconds and 
filtration through a 0.45 µm syringe filter. Filtrates were combined to provide approximately 
10 mL of extracted matrix to be used as ‘blank serum’ during sample preparation. 
4.2.4. Matrix-matched (serum) analytical standard preparation 
A mixed standard was composed of cyanidin-3-glucoside and 17 of its serum metabolites, as 
reported following consumption of 13C-labelled cyanidin-3-glucoside (Czank et al. 2013, de 
Ferrars et al. 2014a). The 18 compounds included in the mixed standard were cyanidin-3-
glucoside, 4-hydroxybenzaldehyde, benzoic acid-4-glucuronide, ferulic acid, hippuric acid, 
isovanillic acid, isovanillic acid-3-glucuronide, isovanillic acid-3-sulfate, methyl 3,4-
dihydroxybenzoate, protocatechuic acid, protocatechuic acid-3-glucuronide, protocatechuic 
acid-3-sulfate, protocatechuic acid-4-glucuronide, protocatechuic acid-4-sulfate, 
phloroglucinaldehyde, vanillic acid, vanillic acid-4-glucuronide, and vanillic acid-4-sulfate 
(Figure 4.1). 
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Figure 4.1 Compounds included in the mixed standard; cyanidin-3-glucoside and 17 of its phenolic metabolites as reported following consumption of 13C-labelled cyanidin-3-glucoside. 
 
Adapted from (Czank et al. 2013, de Ferrars et al. 2014a). 
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The mixed standard was added to the extracted commercial serum (‘blank serum’), along 
with scopoletin and phloridzin internal standards, to give 0.098 µM (Low), 1.56 µM (Mid) 
and 50 µM (High) samples. Stock solutions of each analyte were also added separately to 
‘blank serum’ to give individual 50 µM samples of each metabolite. 
4.2.5. Urine sample preparation: protein precipitation (PPT) 
20 mL of pooled acidified baseline urine was extracted via PPT. 1 mL of urine was spiked with 
4 mL of acetonitrile containing 0.1% v/v formic acid, mixed by vortex for 10 seconds, stored 
at -20°C for 30 mins and centrifuged at 4000 x g, 8°C for 10 mins. After centrifugation, the 
supernatant was removed, placed into a test tube and evaporated to dryness on a Thermo 
Speedvac concentrator. Samples were reconstituted in 250 µL of mobile phase diluent 
(0.1/5/94.9 v/v/v formic acid/methanol/water). Samples were sonicated for 10 mins with 
the ultrasonic water bath kept cool using ice, followed by vortex mixing for 10 seconds and 
filtration through a 0.45 µm syringe filter. Filtrates were combined to provide approximately 
5 mL of extracted matrix to be used as ‘blank urine’ during sample preparation. 
4.2.6. Matrix-matched (urine) analytical standard preparation 
A mixed standard was composed of cyanidin-3-glucoside and 54 of its recently identified 
urine metabolites (Czank et al. 2013, Rodriguez-Mateos et al. 2013, de Ferrars et al. 2014a, 
de Ferrars et al. 2014b) (Table 4.1). The mixed standard was added to the ‘blank urine’, along 
with scopoletin and phloridzin internal standards, to give 0.098 µM (Low), 1.56 µM (Mid) 
and 50 µM (High) samples. Stock solutions of each analyte were also added separately to 
‘blank urine’ to give individual 50 µM samples of each metabolite. 
 
Table 4.1 Metabolite composition of urine mixed standard. 
Compound 
2,3-dihydroxybenzoic acid 4-hydroxyhippuric acid Methyl 3,4-dihydroxybenzoate 
2,4-dihydroxybenzoic acid 4-hydroxyphenylacetic acid PCA 
2,5-dihydroxybenzoic acid 4-methylhippuric acid PCA-3-glucuronide 
2-hydroxy-4-methoxybenzoic acid α-hydroxyhippuric acid PCA-4-glucuronide 
2-hydroxybenzoic acid Benzoic acid PCA-3-sulfate 
2-hydroxycinnamic acid Benzoic acid-4-glucuronide PCA-4-sulfate 
3-(3-hydroxyphenyl)propionic acid Benzoylglutamic acid p-coumaric acid 
3-(4-hydroxy-3-
methoxyphenyl)propionic acid 
Caffeic acid PGA 
3,4-dihydroxybenzaldehyde Chlorogenic acid Phenylacetic acid 
3,4-dihydroxyphenylacetic acid Cyanidin-3-glucoside Rosmarinic acid 
3,5-dihydroxybenzoic acid Ferulic acid Sinapic acid 
3-hydroxybenzoic acid Gallic acid Syringic acid 
3-hydroxyhippuric acid  Hippuric acid trans-cinnamic acid 
3-hydroxyphenylacetic acid Homovanillic acid trans-3-hydroxycinnamic acid 
3-methylhippuric acid Isoferulic acid Vanillic acid 
3-(4-hydroxyphenyl)propionic acid Isovanillic acid Vanillic acid-4-glucuronide 
4-hydroxybenzaldehyde Isovanillic acid-3-glucuronide Vanillic acid-4-sulfate 
4-hydroxybenzoic acid Isovanillic acid-3-sulfate  
4-hydroxybenzyl alcohol Kaempferol  
 Page | 83 
In order to test the extraction efficiency of the PPT sample preparation method, additional 
samples were prepared by spiking pooled acidified baseline urine with the mixed standard 
and internal standards (phloridzin and scopoletin) to give 0.098 µM (Low), 1.56 µM (Mid), 
and 50 µM (High) samples. The samples were then processed using the PPT method and 
metabolite concentrations quantified against a calibration curve. 
4.2.7. Chromatography (32 minute run) 
HPLC-ESI-MS/MS analysis was carried out using an Agilent (Stockport, UK) 1200 series HPLC 
equipped with a Diode Array Detector (DAD) coupled to an AB SCIEX (Warrington, UK) 3200 
series QTRAP® MS/MS system with Turbo V™ electrospray ionisation source using 
previously established methods (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, a 
Kinetex® pentafluorophenyl (PFP) (2.6 µm, 100 x 4.6 mm) RP-HPLC column was used with a 
PFP SecurityGuard® cartridge (4.6 x 2.0 mm). The column temperature was set at 37°C, 
injector temperature of 4°C and injection volume of 5 µL. Mobile Phase A was 0.1% (v/v) 
formic acid in water and Mobile Phase B was 0.1% (v/v) formic acid in acetonitrile at a flow 
rate of 1.5 mL min-1 at 0 min, 1 mL min-1 at 7 to 14 min and 1.5 mL min-1 at 14 to 32 min. The 
gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% 
B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min, 1% B at 29 to 32 
min. MS/MS source parameters included ionspray voltage, -4000 V / +5500 V; temperature, 
700°C; curtain gas, 40 psi; nebulizer gas and auxiliary gas, 60 psi. Scheduled multiple reaction 
monitoring (sMRM) scans were performed using parameters optimised for the detection of 
the analytical standards (Table 4.2). 
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Table 4.2 sMRM schedule used to analyse serum samples on the AB SCIEX 3200 QTRAP® instrument. 
Compound 
Transitions (m/z) 
precursor/product ion 
Scan time 
range (min) 
Scan 
mode 
Benzoic acid-4-glucuronide 313/175,113,93* 2.0 – 4.0 - 
Protocatechuic acid-4-glucuronide 329.01/153*,113,109 2.4 – 4.4 - 
Protocatechuic acid 153.01/108*,91,81 3.2 – 5.2 - 
Protocatechuic acid-3-glucuronide 329.01/153*,113,109 3.4 – 5.4 - 
Vanillic acid-4-glucuronide 343.01/167,152,113* 4.6 – 6.6 - 
Isovanillic acid-3-glucuronide 343.01/167,152,113* 4.6 – 6.6 - 
Hippuric acid 177.9/133.9*,77.1,131.8 5.0 – 7.0 - 
Protocatechuic acid-3/4-sulfatea 233.01/153,109*,189 6.3 – 8.3 - 
4-hydroxybenzaldehyde 121.2/107.8,92*,65.1 7.0 – 9.0 - 
Isovanillic acid 169.01/151.1,125,93* 7.3 – 11.3 + 
Vanillic acid 167.03/152*,123,108 8.8 – 10.8 - 
(Iso)vanillic acid-3/4-sulfatea 247/167*,152,108 8.9 – 10.9 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 11.5 – 13.5 - 
Cyanidin-3-glucoside 449/287*,213,137 11.9 – 15.9 + 
Phloroglucinaldehyde 153/151*,125,107 13.7 – 15.7 - 
Ferulic acid 193/178,149,134* 17.8 – 19.8 - 
Scopoletin 193/133.2*,122,94.1 17.1 – 21.1 + 
Scopoletin 191/104*,147.9,120 18.1 – 20.1 - 
Phloridzin 437/275, 169, 107* 22.1 – 26.1 + 
Phloridzin 435/273*,167,123 23.1 – 25.1 - 
*Transition used for quantitation. aIsomers of this metabolite were unresolvable using this HPLC-ESI-MS/MS 
method so were quantified as a single analyte. 
 
Samples were analysed in negative ionisation mode and in positive ionisation mode, with 
internal standards included in both methods (Figure 4.2). Retention time and the detection 
of three or more of the relevant ion transitions were used to confirm the identity of the 
metabolites. For quantification, the peak area of the most intense ion transition was used. 
A ten-point calibration (0 – 25 µM) curve was prepared by spiking a standard mixture of the 
compounds into a matched-matrix (blank serum) and coefficients of determination (R2) were 
established as linear (0.996 ± 0.003). 
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Figure 4.2 sMRM chromatograms showing the separation of cyanidin-3-glucoside and its phenolic 
metabolites in serum using optimised negative (A) and positive (B) 32 minute HPLC-ESI-MS/MS methods. 
 
(A) 1, benzoic acid-4-glucuronide; 2, protocatechuic acid-4-glucuronide; 3, protocatechuic acid; 4, 
protocatechuic acid-3-glucuronide; 5, vanillic acid-4-glucuronide; 6, isovanillic acid-3-glucuronide; 7, 
hippuric acid; 8, protocatechuic acid-3/4-sulfate; 9, 4-hydroxybenzaldehyde; 10, vanillic acid; 11, 
(iso)vanillic acid-3/4-sulfate; 12, methyl 3,4-dihydroxybenzoate; 13, phloroglucinaldehyde; 14, ferulic acid; 
15, scopoletin; 16, phloridzin. (B) 1, isovanillic acid; 2, cyanidin-3-glucoside; 3, scopoletin; 4, phloridzin. 
 
4.2.8. Chromatography (15 minute run) 
HPLC-ESI-MS/MS analysis was carried out as described above with the following exceptions: 
a Kinetex® PFP (2.6 µm, 50 x 2.1 mm) RP-HPLC column was used with a PFP SecurityGuard® 
cartridge (2.1 x 2.0 mm), column temperature was set at 40°C, and mobile phase flow rate 
of 0.6 mL min-1 was used. The gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B 
at 9 min, 90% B at 9.5 to 11.5 min, 1% B at 12 to 15 min. MS/MS source curtain gas, 35 psi; 
nebulizer gas, 40 psi; auxiliary gas, 45 psi were used. sMRM scans were performed using 
parameters optimised for the detection of analytical standards (Table 4.3). 
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Table 4.3 sMRM schedule used to analyse urine samples on the AB SCIEX 3200 QTRAP® instrument. 
Compound 
Transitions (m/z) 
precursor/product ion 
Scan time 
range (min) 
Scan mode 
trans-Cinnamic acid 147/103*,79,64 0.0 – 1.5 - 
Gallic acid 169.2/125.1*,106.7,78.8 0.0 – 1.9 - 
Benzoic acid-4-glucuronide 313.1/175.1,113.1*,93.1 0.1 – 2.1 - 
Protocatechuic acid-4-glucuronide 329/153*,113,109 0.2 – 2.2 - 
α-hydroxyhippuric acid 194.3/176.3,148.3,73.3* 0.4 – 2.4 - 
Protocatechuic acid 153.1/108.1*,91.1,81.1 0.7 – 2.7 - 
Protocatechuic acid-3-glucuronide 329.1/153.1*,113.1,109.1 0.7 – 2.7 - 
4-hydroxyhippuric acid 194.2/150.2,100.2*,93.2 0.8 – 2.8 - 
2,3/2,4/2,5/3,5-dihydroxybenzoic acida 152.8/109*,107.8,90.8 1.1 – 3.1 - 
3,4-dihydroxyphenylacetic acid 167.2/123.2*,108.2,95.2 1.1 – 3.1 - 
3-hydroxyhippuric acid  194.1/150.1*,148.1,93.1 1.1 – 3.1 - 
4-hydroxybenzyl alcohol 123/121*,105,77 1.1 – 3.1 - 
Protocatechuic acid-3/4-sulfate 233.1/189.1,153.1,109.1* 1.1 – 3.1 - 
Vanillic acid-4-glucuronide 343.2/167.2,152.2,113.2* 1.3 – 3.3 - 
3,4-dihydroxybenzaldehyde 136.9/107.9*,92,81 1.6 – 3.6 - 
3/4-hydroxybenzoic acid 137.1/93.1*,75.1,65.1 1.8 – 3.8 - 
Hippuric acid 177.9/133.9*,131.8,77.1 2.0 – 4.0 - 
Isovanillic acid-3-glucuronide 343.1/167.1,152.1,113.1* 2.1 – 4.1 - 
Isovanillic acid-3-sulfate 247/167*,152,108 2.1 – 4.1 - 
4-hydroxyphenylacetic acid 151.2/123.2,107.2*,93.2 2.5 – 4.5 - 
Vanillic acid-4-sulfate 247.1/167.1*,152.1,108.1 2.9 – 4.9 - 
3-hydroxyphenylacetic acid 151.1/136.1,121.1,107.1* 3.0 – 5.0 - 
4-hydroxybenzaldehyde 121.2/107.8,92.2*,65.2 3.1 – 5.1 - 
Isovanillic acid 169.01/151.1,125,93* 3.8 – 7.8 + 
Vanillic acid 167.3/152.3*,123.3,108.3 4.4 – 6.4 - 
Caffeic acid 179/135*,106,89 5.1 – 7.1 - 
Benzoylglutamic acid 250/206*,162,121 5.2 – 7.2 - 
Homovanillic acid 181.1/166.1,137.1*,79.1 5.2 – 7.2 - 
Benzoic acid 121/93,92,77* 5.4 – 7.4 - 
Phenylacetic acid 135/119,91*,64 5.6 – 7.6 - 
Syringic acid 199/155.2,140*,125 5.6 – 9.6 + 
3-(4-hydroxyphenyl)propionic acid 165.1/121.1*,97.1,93.1 5.7 – 7.7 - 
3-(3-hydroxyphenyl)propionic acid 165/121*,119,106 6.2 – 8.2 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 6.2 – 8.2 - 
Chlorogenic acid 353/191*,161,127 6.6 – 8.6 - 
4-methylhippuric acid 192.2/148.2,146.2,91.2* 6.7 – 8.7 - 
3-methylhippuric acid 192.1/148.1,146.1,90.9* 6.8 – 8.8 - 
2-hydroxybenzoic acid 137/93*,75,65 7.0 – 9.0 - 
p-Coumaric acid 163/118.9*,116.9,92.9 7.1 – 9.1 - 
Phloroglucinaldehyde 153/151*,125,107 7.2 – 9.2 - 
3-(4-hydroxy-3-methoxyphenyl)propionic acid 195/136*,121,119 7.8 – 9.8 - 
trans-3-hydroxycinnamic acid 163.2/119.2*,93.2,91.2 8.4 – 10.4 - 
Cyanidin-3-glucoside 449/287*,213,137 8.8 – 12.8 + 
Scopoletin 193/133.2*,122,94.1 8.8 – 12.8 + 
Phloridzin 437/275,169,107* 8.9 – 12.9 + 
2-hydroxycinnamic acid 163/119*,117,93 9.8 – 11.8 - 
(Iso)ferulic acida 193.1/178.1,149.1,134.1* 9.8 – 11.8 - 
Scopoletin 191/147.9*,120,104 9.8 – 11.8 - 
Rosmarinic acid 359.1/197.1,179.1,161.1* 9.9 – 11.9 - 
Sinapic acid 223/208*,193,164 9.9 – 11.9 - 
Phloridzin 435.1/273.1,167.1*,123.1 9.9 – 11.9 - 
2-hydroxy-4-methoxybenzoic acid 167.1/123.1,108.1*,80.1 10.0 – 12.0 - 
Kaempferol 285/239*,229,211 10.1 – 12.1 - 
*Transition used for quantitation. aIsomers of this metabolite were unresolvable using this HPLC-ESI-MS/MS 
method so were quantified as a single analyte. 
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Samples were analysed in negative ionisation mode and in positive ionisation mode, with 
internal standards included in both methods (Figure 4.3). Retention time and the detection 
of three or more of the relevant ion transitions were used to confirm the identity of the 
metabolites. For quantification, the peak area of the most intense ion transition was used. 
An eleven-point calibration curve (0 – 50 µM) was prepared by spiking a standard mixture of 
the compounds into a matched-matrix (blank urine) and coefficients of determination (R2) 
were established as linear (0.995 ± 0.003). 
 
Figure 4.3 sMRM chromatograms showing the separation of cyanidin-3-glucoside and its phenolic 
metabolites in urine using optimised negative (A) and positive (B) 15 minute HPLC-ESI-MS/MS methods. 
 
(A) 1, trans-cinnamic acid; 2, gallic acid; 3, benzoic acid-4-glucuronide; 4, protocatechuic acid-4-
glucuronide; 5, α-hydroxyhippuric acid; 6, protocatechuic acid; 7, protocatechuic-3-glucuronide; 8, 4-
hydroxyhippuric acid; 9, 2,3/2,4/2,5/3,5-dihydroxybenzoic acid; 10, 3,4-dihydroxyphenylacetic acid; 11, 3-
hydroxyhippuric acid; 12, 4-hydroxybenzyl alcohol; 13, protocatechuic acid-3/4-sulfate; 14, vanillic acid-4-
glucuronide; 15, 3,4-dihydroxybenzaldehyde; 16, 3/4-hydroxybenzoic acid; 17, hippuric acid; 18, isovanillic 
acid-3-glucuronide; 19, isovanillic acid-3-sulfate; 20, 4-hydroxyphenylacetic acid; 21, vanillic acid-4-sulfate; 
22, 3-hydroxyphenylacetic acid; 23, 4-hydroxybenzaldehyde; 24, vanillic acid; 25, caffeic acid; 26, 
benzoylglutamic acid; 27, homovanillic acid; 28, benzoic acid; 29, phenylacetic acid; 30, 3-(4-
hydroxyphenyl)propionic acid; 31, 3-(3-hydroxyphenyl)propionic acid; 32, methyl 3,4-dihydroxybenzoate; 
33, chlorogenic acid; 34, 4-methylhippuric acid; 35, 3-methylhippuric acid; 36, 2-hydroxybenzoic acid; 37, 
p-coumaric acid; 38 phloroglucinaldehyde; 39, 3-(4-hydroxy-3-methoxyphenyl)propionic acid; 40, trans-3-
hydroxycinnamic acid; 41, 2-hydroxycinnamic acid; 42, (iso)ferulic acid; 43, scopoletin; 44, rosmarinic acid; 
45, sinapic acid; 46, phloridzin; 47, 2-hydroxy-4-methoxybenzoic acid; 48, kaempferol. (B) 1, isovanillic acid; 
2, syringic acid; 3, cyanidin-3-glucoside; 4, scopoletin; 5, phloridzin. 
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4.2.9. Validation criteria 
The validation criteria (specificity, limit of detection, linearity, accuracy, precision and 
extraction efficiency) (Table 4.4) and acceptable limits were selected based on published 
bioanalytical method validation guidelines (Food and Drug Administration 2001, United 
Nations Office on Drugs and Crime 2009).  
 
Table 4.4 Validation criteria and acceptable limits. 
Validation criteria Acceptable limit, n 
Specificity (Retention time) ≤2%, n=5 
Specificity (MRM transitions) ≤20%, n=5 
Limit of detection N/A 
Linearity ≥0.99, n=2 
Accuracy Low, 80 – 120%; Mid/High, 85 – 115%, n=5 
Precision (Intra-day) Low, ≤20%; Mid/High, ≤15%, n=5 
Precision (Inter-day) Low, ≤20%; Mid/High, ≤15%, n=10 
Extraction efficiency Recovery ≤115% and CV ≤15%, n=5 
MRM, multiple reaction monitoring; Low, 0.098 µM; Mid, 1.56 µM; High, 50 µM. Adapted from 
(Food and Drug Administration 2001, United Nations Office on Drugs and Crime 2009) 
 
Specificity is a measure of the selectivity of the method in identifying and quantifying the 
correct peaks (Božović and Kulasingam 2013). Specificity was measured by comparison 
between a mixed sample and individual standard in terms of peak retention time and 
variance in the proportions of the three MRM transitions used for identification. The limit of 
detection (LOD) is a calculation of the lowest analyte concentration the method is able to 
detect and was based on the concentration required to produce a signal-to-noise ratio of 3-
to-1 (Božović and Kulasingam 2013). Linearity is a measure of the analyte response and 
specifies the range over which the response is defined as linear. Accuracy is a measure of 
the variation between the known concentration of a sample and the concentration 
calculated by the method (Božović and Kulasingam 2013). Precision is a measure of the 
variation between the calculated concentrations of samples (Božović and Kulasingam 2013). 
Precision can be split into measuring the variation between samples in the same analysis run 
(intra-day) or between samples run on separate occasions (inter-day). Extraction efficiency 
is a measure of the percentage of analyte that is recovered using the sample extraction 
procedure (United Nations Office on Drugs and Crime 2009). 
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4.3. Results 
4.3.1. Matrix-matched (serum) analytical standard (32 minute run) 
Specificity. 16 of 20 analytes were within the validation limits for retention time variance 
(≤2%) (Table 4.5). Mean retention time variance was 1.0 ± 1.0% and ranged from 0.0 – 3.0%. 
19 of 20 analytes were within validation limits for MRM transition variance (≤20%). Mean 
MRM transition variance was 4.8 ± 6.9% and ranged between 0.0 – 42.7%. 
Limit of detection. Mean limit of detection was 9.5 ± 13.0 nM and ranged between 0.2 nM 
for phloridzin (negative ionisation mode) and 59.2 nM for isovanillic acid (Table 4.5). 
Linearity. 17 of 20 analytes were found to produce a linear response across the complete 
range tested (0 – 50 µM) (Table 4.5). Mean coefficient of determination (R2) was 0.996 ± 
0.003 and ranged between 0.990 – 1.000. 
Accuracy. 4 of 20 analytes were within validation limits for recovery (80 – 120%) at the low 
concentration (0.098 µM) (Table 4.6). Mean recovery at the low concentration was 157.1 ± 
80.9% and ranged between 76.1 – 460.4%. 7 of 20 analytes were within validation limits for 
recovery (85 – 115%) at the mid concentration (1.56 µM). Mean recovery at the mid 
concentration was 116.7 ± 19.7% and ranged between 50.5 – 146.6%. 16 of 20 analytes were 
within the validation limits for recovery (85 – 115%) at the high concentration (50 µM). Mean 
recovery at the high concentration was 91.6 ± 16.5% and ranged between 46.7 – 108.5%. 
Precision. 14 of 20 analytes were within validation limits for intra-day coefficient of variation 
(CV) (≤20%) at the low concentration (0.098 µM) (Table 4.6). Mean intra-day CV at the low 
concentration was 16.3 ± 10.8% and ranged between 5.1 – 45.3%. 19 of 20 analytes were 
within validation limits for intra-day CV (≤15%) at the mid concentration (1.56 µM). Mean 
intra-day CV at the mid concentration was 6.2 ± 3.2% and ranged between 1.3 – 12.3%. 20 
of 20 analytes were within validation limits for intra-day CV (≤15%) at the high concentration 
(50 µM). Mean intra-day CV at the high concentration was 4.6 ± 2.7% and ranged between 
0.9 – 13.5%.  
13 of 20 analytes were within validation limits for inter-day CV (≤20%) at the low 
concentration (Table 4.6). Mean inter-day CV at the low concentration was 18.3 ± 8.2% and 
ranged between 7.9 – 40.8%. 16 of 20 analytes were within validation limits for inter-day CV 
(≤15%) at the mid concentration. Mean inter-day CV at the mid concentration was 9.7 ± 5.0% 
and ranged between 1.9 – 21.9%. 20 of 20 analytes were within validation limits for inter-
day CV (≤15%) at the high concentration. Mean inter-day CV at the high concentration was 
6.0 ± 3.1% and ranged between 2.9 – 14.3%.
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Table 4.5 Validation of specificity, limit of detection, and linearity of a 32 minute HPLC-ESI-MS/MS method for quantifying cyanidin-3-glucoside, its phenolic 
metabolites, and two internal standards in serum. 
Compound 
Specificity 
LOD 
(nM) 
Linearity 
Difference 
between Rta 
(%) 
Difference between  
transition proportionsb (%) Range R2 valuec 
MRM 1 MRM 2 MRM 3 
Cyanidin-3-glucoside 0.5 0.1 1.9 0.7 18.0 0 – 50 µM 0.995 
4-hydroxybenzaldehyde 2.8† 0.1 1.5 8.2 7.9 0 – 12.5 µM 0.993 
Benzoic acid-4-glucuronide 1.5 0.1 1.9 2.4 5.9 0 – 50 µM 0.998 
Ferulic acid 1.1 13.6 12.5 42.7† 8.9 0 – 50 µM 0.991 
Hippuric acid 3.0† 0.3 2.1 12.9 0.5 0 – 50 µM 0.998 
Isovanillic acid 0.0 1.2 1.7 0.0 59.2 0 – 50 µM 0.999 
Isovanillic acid-3-glucuronide 0.1 1.7 2.2 0.2 7.5 0 – 50 µM 0.998 
(Iso)vanillic acid-3/4-sulfate 2.7† 15.4 16.3 5.7 7.1 0 – 50 µM 1.000 
Methyl 3,4-dihydroxybenzoate 2.1† 0.7 4.9 3.1 3.6 0 – 50 µM 0.994 
Phloroglucinaldehyde 0.0 0.7 7.0 0.3 8.4 0 – 6.25 µM 0.997 
Protocatechuic acid 0.6 1.4 2.8 9.0 5.0 0 – 50 µM 0.998 
Protocatechuic acid-3-glucuronide 0.0 3.7 5.5 0.5 3.9 0 – 50 µM 1.000 
Protocatechuic acid-3/4-sulfate 1.7 2.2 2.4 2.8 0.7 0 – 50 µM 0.995 
Protocatechuic acid-4-glucuronide 0.4 2.7 4.2 3.0 5.1 0 – 50 µM 0.999 
Vanillic acid 0.3 5.5 12.8 3.2 23.2 0 – 50 µM 0.998 
Vanillic acid-4-glucuronide 0.2 0.5 3.2 1.5 7.9 0 – 50 µM 0.998 
Phloridzin (-) 0.2 1.8 1.5 4.5 0.2 0 – 12.5 µM 0.996 
Phloridzin (+) 0.0 2.2 18.2 0.7 10.8 0 – 50 µM 0.990 
Scopoletin (-) 1.8 11.4 16.6 1.0 3.9 0 – 50 µM 0.995 
Scopoletin (+) 0.1 0.5 1.3 0.3 1.5 0 – 50 µM 0.991 
Rt, retention time; MRM, multiple reaction monitoring; LOD, limit of detection; R2, coefficient of determination; (-), negative ionisation mode; (+), positive 
ionisation mode. Low, 0.098 µM; Mid, 1.56 µM; High, 50 µM. aUN guideline, ≤2%, n=5. bUN guideline, ≤20%, n=5. cFDA guideline, ≥0.99, n=2. †Outside 
FDA/UN bioanalytical method validation guidelines.  
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Table 4.6 Validation of accuracy and precision of a 32 minute HPLC-ESI-MS/MS method for quantifying cyanidin-3-glucoside, its phenolic 
metabolites, and two internal standards in serum. 
Compound 
Accuracy Precision 
Recovery (%) Intra-day CV (%) Inter-day CV (%) 
Lowa Midb Highb Lowc Midd Highd Lowe Midf Highf 
Cyanidin-3-glucoside 76.1† 50.5† 81.4† 32.3† 11.1 13.5 30.2† 15.2† 14.3 
4-hydroxybenzaldehyde 118.5 123.1† 61.6† 17.0 1.3 3.5 19.8 3.0 9.8 
Benzoic acid-4-glucuronide 125.8† 112.8 106.2 16.4 7.9 5.0 19.9 11.1 4.0 
Ferulic acid 135.2† 132.2† 90.7 11.4 4.4 3.6 10.0 9.0 5.6 
Hippuric acid ND† ND† 99.7 ND† ND† 0.9 ND† ND† 4.2 
Isovanillic acid 197.6† 102.8 90.2 32.9† 5.3 5.7 22.5† 7.5 9.4 
Isovanillic acid-3-glucuronide 136.8† 111.6 98.7 11.5 8.7 4.3 26.1† 6.7 6.9 
(Iso)vanillic acid-3/4-sulfate 134.3† 120.2† 108.5 7.3 8.7 6.6 19.1 18.7† 6.2 
Methyl 3,4-dihydroxybenzoate 169.8† 146.6† 93.5 5.5 2.7 3.3 13.4 8.5 3.3 
Phloroglucinaldehyde 101.1 110.2 46.7† 22.1† 6.2 2.3 19.2 8.1 11.6 
Protocatechuic acid 144.4† 113.7 101.9 8.8 6.8 3.1 11.0 6.4 2.9 
Protocatechuic acid-3-glucuronide 127.6† 119.2† 105.2 6.9 7.7 6.2 12.7 9.9 4.7 
Protocatechuic acid-3/4-sulfate 139.8† 123.5† 104.0 10.5 11.4 4.4 17.0 14.7 4.2 
Protocatechuic acid-4-glucuronide 114.3 110.8 103.5 19.8 4.4 2.1 14.3 11.4 3.5 
Vanillic acid 184.2† 120.4† 93.7 23.5† 3.7 3.3 23.1† 6.1 7.3 
Vanillic acid-4-glucuronide 195.7† 127.7† 104.5 13.9 3.9 3.7 40.8† 8.6 3.0 
Phloridzin (-) 96.7 103.6 64.5† 11.6 5.0 5.8 10.9 9.8 5.1 
Phloridzin (+) 460.4† 122.9† 94.6 45.3† 12.3 8.0 ND† 21.9† 6.2 
Scopoletin (-) 138.0† 123.1† 92.3 8.1 4.4 3.7 7.9 5.9 5.2 
Scopoletin (+) 189.2† 142.2† 91.4 5.1 2.3 2.9 12.1 1.9 3.2 
CV, coefficient of variation; (-), negative ionisation mode; (+), positive ionisation mode. ND, not detected. Low, 0.098 µM; Mid, 1.56 µM; High, 50 
µM. aFDA guideline, 80 – 120%, n=5. bFDA guideline, 85 – 115%, n=5. cFDA guideline, ≤20%, n=5. dFDA guideline, ≤15%, n=5. eFDA guideline, ≤20%, 
n=10. fFDA guideline, ≤15%, n=10. †Outside FDA/UN bioanalytical method validation guidelines. 
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4.3.2. Matrix-matched (urine) analytical standard (15 minute run) 
Specificity. 53 of 53 analytes were within the validation limits for retention time variance 
(≤2%) (Table 4.7). Mean retention time variance was 0.7 ± 0.6% and ranged from 0.0 – 2.0%. 
51 of 53 analytes were within validation limits for MRM transition variance (≤20%). Mean 
MRM transition variance was 6.0 ± 6.6% and ranged between 0.0 – 52.3%. 
Limit of detection. Mean limit of detection was 96.7 ± 541.7 nM and ranged between 0.3 
nM for 4-hydroxyhippuric acid and 3954.7 nM for phenylacetic acid (Table 4.7). 
Linearity. 53 of 53 analytes were found to produce a linear response across the complete 
range tested (0 – 50 µM) (Table 4.7). Mean coefficient of determination (R2) was 0.995 ± 
0.003 and ranged between 0.990 – 1.000. 
Accuracy. 15 of 53 analytes were within validation limits for recovery (80 – 120%) at the low 
concentration (0.098 µM) (Table 4.7). Mean recovery at the low concentration was 203.6 ± 
195.8% and ranged between 2.0 – 956.8%. 37 of 53 analytes were within validation limits for 
recovery (85 – 115%) at the mid concentration (1.56 µM). Mean recovery at the mid 
concentration was 115.0 ± 62.0% and ranged between 15.0 – 366.7%. 48 of 53 analytes were 
within the validation limits for recovery (85 – 115%) at the high concentration (50 µM). Mean 
recovery at the high concentration was 99.8 ± 40.5% and ranged between 21.5 – 364.3%. 
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Table 4.7 Validation of specificity, limit of detection, linearity, and accuracy of a 15 minute HPLC-ESI-MS/MS method for quantifying cyanidin-3-glucoside, its phenolic metabolites, and 
two internal standards in urine. 
Compound 
Specificity 
LOD 
(nM) 
Linearity Accuracy 
Difference 
between Rta 
(%) 
Difference between transition 
proportionsb (%) Range R2 valuec 
Recovery (%) 
MRM 1 MRM 2 MRM 3 Lowd Mide Highe 
2,3/2,4/2,5/3,5-dihydroxybenzoic acid 2.0 0.9 2.4 17.6 2.0 0 - 50 µM 0.997 207.6† 88.6 92.2 
2-hydroxy-4-methoxybenzoic acid 0.0 2.6 2.0 8.0 18.5 0 - 50 µM 0.998 83.1 87.9 95.4 
2-hydroxybenzoic acid 1.4 0.1 0.4 0.9 47.9 0 - 50 µM 0.998 136.4† 85.5 99.4 
2-hydroxycinnamic acid 1.5 1.7 16.9 13.9 22.6 0 - 50 µM 0.995 93.8 98.6 93.2 
3-(3-hydroxyphenyl)propionic acid 1.2 1.4 6.8 17.6 8.1 0 - 50 µM 0.993 331.8† 92.2 86.4 
3-(4-hydroxy-3-methoxyphenyl)propionic acid 0.8 1.4 3.8 6.4 6.4 0 - 50 µM 0.995 294.5† 98.3 97.5 
3-(4-hydroxyphenyl)propionic acid 0.8 11.4 3.6 10.4 9.1 0 - 50 µM 0.992 331.8† 95.5 86.0 
3,4-dihydroxybenzaldehyde 1.2 1.4 4.5 0.7 37.6 0 - 50 µM 0.993 92.3 104.7 89.9 
3,4-dihydroxyphenylacetic acid 1.4 8.9 9.2 16.1 29.2 0 - 50 µM 0.990 271.0† 215.8† 98.6 
3/4-hydroxybenzoic acid 1.0 0.6 18.7 6.0 3.4 0 - 50 µM 0.996 796.4† 80.3† 94.5 
3-hydroxyhippuric acid 1.3 2.5 9.4 6.5 0.4 0 - 50 µM 0.991 283.3† 302.2† 77.0† 
3-hydroxyphenylacetic acid 0.2 4.2 9.5 0.1 0.4 0 - 50 µM 0.990 227.4† 132.3† 87.6 
3-methylhippuric acid 1.4 1.3 2.5 3.0 9.5 0 - 50 µM 0.994 114.1 104.9 89.8 
4-hydroxybenzaldehyde 0.2 11.3 0.2 6.8 32.6 0 - 50 µM 0.997 158.9† 85.9 92.1 
4-hydroxybenzyl alcohol 1.6 3.3 17.1 6.0 29.8 0 - 50 µM 0.992 398.2† 366.7† 111.6 
4-hydroxyhippuric acid 0.0 19.3 10.6 12.2 0.3 0 - 50 µM 0.991 140.1† 125.8† 152.6† 
4-hydroxyphenylacetic acid 0.4 10.2 2.5 17.3 6.2 0 - 50 µM 0.991 578.3† 261.5† 364.3† 
4-methylhippuric acid 0.7 1.8 52.3† 9.4 9.4 0 - 50 µM 0.997 148.0† 103.3 86.6 
α-hydroxyhippuric acid 0.8 17.4 0.5 0.1 16.1 0 - 50 µM 0.997 65.7† 86.3 92.5 
Benzoic acid 0.8 5.3 7.8 15.4 54.3 0 - 50 µM 0.992 956.8† 91.2 87.0 
Benzoic acid-4-glucuronide 0.6 2.8 4.8 3.3 19.3 0 - 50 µM 0.997 19.1† 88.7 90.1 
Benzoylglutamic acid 0.1 2.4 2.2 0.7 1.1 0 - 50 µM 0.995 183.9† 95.6 92.5 
Caffeic acid 0.9 0.2 6.9 1.0 10.3 0 - 50 µM 0.994 208.1† 111.1 85.5 
Chlorogenic acid 0.4 0.8 29.8† 7.6 2.4 0 - 50 µM 0.997 98.2 102.1 95.1 
Cyanidin-3-glucoside 0.0 0.5 10.5 16.9 7.5 0 - 50 µM 0.997 56.3† 65.1† 94.7 
Gallic acid 0.3 0.1 14.4 7.7 116.4 0 - 50 µM 0.999 25.3† 98.3 91.8 
Hippuric acid 0.7 1.5 3.2 4.9 0.4 0 - 50 µM 0.990 245.2† 184.4† 21.5† 
Homovanillic acid 0.7 16.0 10.0 8.5 9.1 0 - 50 µM 0.991 54.1† 15.0† 114.8† 
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Table 4.7 (Continued)           
Compound 
Specificity 
LOD 
(nM) 
Linearity Accuracy 
Difference 
between Rta 
(%) 
Difference between transition 
proportionsb (%) Range R2 valuec 
Recovery (%) 
MRM 1 MRM 2 MRM 3 Lowd Mide Highe 
Isovanillic acid 0.1 1.8 0.7 0.0 45.8 0 - 50 µM 0.996 160.7† 96.2 90.1 
Isovanillic acid-3-glucuronide 2.0 7.2 4.0 5.1 5.7 0 - 50 µM 0.995 398.5† 113.4 96.4 
Isovanillic acid-3-sulfate 0.6 0.8 0.0 2.2 30.7 0 - 50 µM 0.999 4.1† 91.9 109.0 
(Iso)ferulic acid 0.6 6.4 9.5 1.7 9.4 0 - 50 µM 0.997 94.8 90.6 114.4 
Kaempferol 0.0 0.3 0.5 0.2 26.7 0 - 50 µM 0.997 105.1 90.0 90.1 
Methyl 3,4-dihydroxybenzoate 1.0 1.4 4.2 13.2 17.1 0 - 50 µM 0.993 117.7 96.6 89.6 
p-Coumaric acid 0.1 0.4 0.5 3.8 3.9 0 - 50 µM 0.993 2.0† 105.8 93.1 
Phenylacetic acid 0.6 3.2 3.9 8.2 3954.7 0 - 50 µM 0.992 ND ND 92.4 
Phloroglucinaldehyde 0.9 1.4 18.2 17.2 23.3 0 - 50 µM 0.994 116.5 102.0 88.1 
Protocatechuic acid 0.5 0.7 2.2 4.0 12.8 0 - 50 µM 0.994 97.0 93.9 99.1 
Protocatechuic acid-3-glucuronide 0.5 3.5 1.0 3.6 26.6 0 - 50 µM 0.994 93.1 98.1 87.6 
Protocatechuic acid-3/4-sulfate 0.6 3.8 9.3 9.7 1.0 0 - 50 µM 0.994 529.4† 112.2 90.4 
Protocatechuic acid-4-glucuronide 1.4 3.7 4.2 5.8 16.7 0 - 50 µM 0.996 86.8 92.4 89.8 
Rosmarinic acid 0.0 1.9 5.6 0.0 15.2 0 - 50 µM 1.000 89.3 86.0 92.8 
Sinapic acid 0.0 1.0 1.6 2.8 11.1 0 - 50 µM 0.998 121.7† 95.5 93.0 
Syringic acid 0.1 1.0 0.0 1.7 4.9 0 - 50 µM 0.995 155.2† 101.7 89.1 
trans-3-hydroxycinnamic acid 0.2 8.3 8.3 6.5 21.7 0 - 50 µM 0.998 260.3† 106.8 92.4 
trans-Cinnamic acid 1.6 1.1 10.6 13.1 3.4 0 - 50 µM 0.990 109.5 267.9† 142.2† 
Vanillic acid 0.1 2.9 7.8 9.7 14.2 0 - 50 µM 0.998 263.9† 100.9 96.1 
Vanillic acid-4-glucuronide 0.1 7.8 8.0 3.8 3.0 0 - 50 µM 0.995 110.2 134.4† 98.4 
Vanillic acid-4-sulfate 1.7 2.1 4.4 3.6 1.0 0 - 50 µM 0.996 151.7† 138.2† 103.9 
Phloridzin (-) 0.5 0.2 1.3 2.8 19.6 0 - 50 µM 0.999 38.7† 88.0 86.9 
Phloridzin (+) 0.4 2.8 2.3 0.6 14.9 0 - 50 µM 0.992 659.4† 31.7† 88.8 
Scopoletin (-) 0.6 14.8 13.8 6.6 283.7 0 - 50 µM 0.995 78.6† 91.6 111.0 
Scopoletin (+) 0.2 1.4 1.4 1.9 49.8 0 – 50 µM 0.993 142.1† 84.7† 102.2 
Rt, retention time; MRM, multiple reaction monitoring; LOD, limit of detection; R2, coefficient of determination; (-), negative ionisation mode; (+), positive ionisation mode; ND, not 
detected. Low, 0.098 µM; Mid, 1.56 µM; High, 50 µM. aUN guideline, ≤2%, n=5. bUN guideline, ≤20%, n=5. cFDA guideline, ≥0.99, n=2. dFDA guideline, 80 – 120%, n=5. eFDA guideline, 85 – 
115%, n=5. †Outside FDA/UN bioanalytical method validation guidelines.
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Precision. 12 of 53 analytes were within validation limits for intra-day coefficient of variation 
(CV) (≤20%) at the low concentration (0.098 µM) (Table 4.8). Mean intra-day CV at the low 
concentration was 106.8 ± 133.7% and ranged between 5.3 – 710.3%. 38 of 53 analytes were 
within validation limits for intra-day CV (≤15%) at the mid concentration (1.56 µM). Mean 
intra-day CV at the mid concentration was 26.3 ± 35.4% and ranged between 4.4 – 158.3%. 
48 of 53 analytes were within validation limits for intra-day CV (≤15%) at the high 
concentration (50 µM). Mean intra-day CV at the high concentration was 16.0 ± 35.7% and 
ranged between 2.5 – 204.5%. 
7 of 53 analytes were within validation limits for inter-day CV (≤20%) at the low 
concentration (Table 4.8). Mean inter-day CV at the low concentration was 139.9 ± 170.4% 
and ranged between 11.7 – 918.9%. 33 of 53 analytes were within validation limits for inter-
day CV (≤15%) at the mid concentration. Mean inter-day CV at the mid concentration was 
62.1 ± 135.1% and ranged between 4.9 – 806.8%. 44 of 53 analytes were within validation 
limits for inter-day CV (≤15%) at the high concentration. Mean inter-day CV at the high 
concentration was 21.4 ± 39.3% and ranged between 3.6 – 174.8%. 
Extraction efficiency. 9 of 53 analytes were within validation limits for recovery (≤115%) and 
CV (≤15%) at the low concentration (0.098 µM) (Table 4.8). Mean recovery at the low 
concentration was 267.3 ± 219.3% and ranged between 13.0 – 972.3%. Mean CV at the low 
concentration was 46.6 ± 84.3% and ranged between 6.4 – 516.2%. 34 of 53 analytes were 
within validation limits for recovery (≤115%) and CV (≤15%) at the mid concentration (1.56 
µM). Mean recovery at the mid concentration was 140.9 ± 131.6% and ranged between 36.2 
– 601.5%. Mean CV at the mid concentration was 19.1 ± 18.3% and ranged between 6.7 – 
115.0%.  45 of 53 analytes were within validation limits for recovery (≤115%) and CV (≤15%) 
at the high concentration (50 µM). Mean recovery at the high concentration was 75.4 ± 
59.7% and ranged between 23.0 – 462.3%. Mean CV at the high concentration was 20.3 ± 
24.4% and ranged between 4.5 – 107.1%. 
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Table 4.8 Validation of precision and extraction efficiency of a 15 minute HPLC-ESI-MS/MS method for quantifying cyanidin-3-glucoside, its phenolic metabolites, and two internal standards 
in urine. 
Compound 
Precision Extraction Efficiency 
Intra-day CV (%) Inter-day CV (%) Lowe Mide Highe 
Lowa Midb Highb Lowc Midd Highd Recovery 
(%) 
CV 
(%) 
Recovery 
(%) 
CV 
(%) 
Recovery 
(%) 
CV 
(%) 
2,3/2,4/2,5/3,5-dihydroxybenzoic acid 64.8† 14.6 4.7 118.6† 12.0 4.5 818.8† 12.9† 135.8† 27.4† 32.0 13.7 
2-hydroxy-4-methoxybenzoic acid 10.7 7.1 4.7 13.3 8.8 4.6 57.4 14.8 67.8 14.0 59.5 9.9 
2-hydroxybenzoic acid 44.0† 6.0 5.6 85.3† 8.2 5.0 188.9† 18.9† 101.6 13.5 66.8 10.8 
2-hydroxycinnamic acid 8.2 6.0 4.4 15.7 7.9 5.7 66.0 13.0 87.1 13.6 62.8 10.4 
3-(3-hydroxyphenyl)propionic acid 148.6† 8.7 10.7 188.5† 10.1 10.6 371.2† 31.4† 101.5 10.8 54.4 13.0 
3-(4-hydroxy-3-methoxyphenyl)propionic acid 62.3† 13.0 6.3 70.4† 26.5† 5.2 182.8† 10.6† 202.8† 14.3† 74.8 8.9 
3-(4-hydroxyphenyl)propionic acid 148.6† 14.8 11.0 185.7† 136.3† 73.2† 308.5† 37.0† 104.6 7.6 54.4 13.0 
3,4-dihydroxybenzaldehyde 9.7 4.8 5.3 46.7† 4.9 5.4 177.2† 23.0† 67.1 10.3 59.3 14.7 
3,4-dihydroxyphenylacetic acid 62.3† 63.9† 4.0 54.2† 46.6† 12.9 609.5† 47.4† 502.2† 39.9† 58.3 12.3 
3/4-hydroxybenzoic acid 113.7† 7.3 5.1 110.2† 41.2† 4.7 675.1† 19.8† 496.0† 15.4† 74.7 13.6 
3-hydroxyhippuric acid 73.2† 50.0† 51.7† 115.9† 164.0† 35.1† 364.9† 38.6† 242.6† 15.4† 111.0† 67.4† 
3-hydroxyphenylacetic acid 24.1† 34.1† 11.5 390.7† 107.3† 145.9† 358.1† 6.4† 252.7† 19.3† 30.8 7.4 
3-methylhippuric acid 11.7 7.6 6.5 11.7 8.1 9.0 464.5† 12.9† 101.0 12.5 54.4 14.1 
4-hydroxybenzaldehyde 68.5† 10.7 3.9 529.2† 9.6 6.6 173.4† 18.2† 56.6 9.1 73.5 13.6 
4-hydroxybenzyl alcohol 190.4† 111.7† 13.7 133.3† 497.7† 24.4† 694.7† 56.7† 601.5† 35.8† 82.8 10.6 
4-hydroxyhippuric acid 80.5† 43.6† 171.3† 137.2† 123.7† 133.8† 197.8† 325.9† 311.2† 115.0† 462.3† 56.4† 
4-hydroxyphenylacetic acid 70.4† 158.3† 47.4† 161.1† 299.8† 86.6† 136.0† 166.7† 234.6† 29.6† 131.7† 107.1† 
4-methylhippuric acid 39.8† 8.3 8.7 45.4† 7.7 7.7 451.1† 14.8† 101.3 13.4 53.6 10.4 
α-hydroxyhippuric acid 13.3 6.1 5.4 69.6† 8.0 6.2 13.0† 39.1† 47.2 10.5 65.5 11.3 
Benzoic acid 108.4† 50.8† 7.7 736.7† 95.1† 8.4 105.2† 135.6† 72.8 6.9 77.4 8.9 
Benzoic acid-4-glucuronide 199.6† 5.9 7.8 132.6† 6.9 8.7 64.1† 29.4† 53.4 11.5 56.3 9.0 
Benzoylglutamic acid 80.4† 4.4 2.5 83.2† 6.6 6.0 105.6† 54.4† 84.4 11.1 60.7 10.4 
Caffeic acid 16.9 11.1 7.2 64.4† 10.4 6.3 214.9† 17.2† 87.1 14.4 46.2 9.6 
Chlorogenic acid 18.2 5.4 2.7 59.3† 5.5 3.6 233.1† 13.0† 92.5 11.9 61.3 11.5 
Cyanidin-3-glucoside 76.2† 11.4 10.6 50.2† 14.6 11.9 43.4 9.4 43.6 7.8 71.8 10.5 
Gallic acid 317.9† 6.0 6.0 148.8† 10.4 6.0 144.8† 46.8† 76.0 6.7 60.9 14.4 
Hippuric acid 50.9† 118.0† 204.5† 110.9† 806.8† 132.4† 332.5† 33.1† 123.3† 42.8† 192.7† 78.4† 
Homovanillic acid 710.3† 139.2† 14.5 161.8† 131.2† 17.4† 542.7† 32.2† 541.7† 20.3† 75.2† 18.5† 
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Table 4.8 (Continued)   
Compound 
Precision Extraction Efficiency 
Intra-day CV (%) Inter-day CV (%) Lowe Mide Highe 
Lowa Midb Highb Lowc Midd Highd Recovery 
(%) 
CV 
(%) 
Recovery 
(%) 
CV 
(%) 
Recovery 
(%) 
CV 
(%) 
Isovanillic acid 38.3† 5.0 11.1 45.5† 11.2 12.4 135.5† 39.8† 72.4 13.2 88.0 13.3 
Isovanillic acid-3-glucuronide 93.6† 60.7† 4.4 65.0† 64.7† 4.3 217.3† 9.8† 163.2† 28.1† 76.4 9.9 
Isovanillic acid-3-sulfate 345.2† 9.4 6.3 144.9† 8.6 6.6 25.9† 516.2† 71.8 8.6 37.3† 92.9† 
(Iso)ferulic acid 96.3† 13.7 9.0 63.9† 11.5 8.6 972.3† 9.8† 162.7† 18.0† 86.4 7.8 
Kaempferol 101.6† 6.9 7.0 918.9† 10.2 6.9 305.0† 32.9† 56.1 8.9 71.6 12.2 
Methyl 3,4-dihydroxybenzoate 6.2 15.0 7.9 17.7 14.8 8.4 90.5 9.8 86.8 11.9 53.1 13.5 
p-Coumaric acid 515.8† 8.9 4.1 145.0† 7.5 4.0 95.6 10.7 96.9 13.1 56.4 12.6 
Phenylacetic acid ND ND 5.4 ND ND 6.9 ND ND 41.7† 39.0† 64.6 8.8 
Phloroglucinaldehyde 5.3 9.7 6.2 19.2 10.5 7.5 55.3 8.0 46.7 10.0 58.3 10.8 
Protocatechuic acid 88.8† 14.8 5.9 71.9† 11.5 5.4 88.2 13.2 77.2 12.7 64.7 12.8 
Protocatechuic acid-3-glucuronide 13.1 9.0 8.6 14.4 8.9 8.3 222.2† 14.3† 56.5 12.7 62.1 13.9 
Protocatechuic acid-3/4-sulfate 66.0† 12.6 4.2 72.2† 13.0 7.5 107.4† 19.6† 186.9† 19.1† 44.6 4.5 
Protocatechuic acid-4-glucuronide 44.1† 13.1 5.7 85.5† 11.1 6.7 85.4 8.3 73.1 11.0 60.8 15.0 
Rosmarinic acid 16.3 6.4 4.9 19.4 6.1 4.5 55.3 8.5 50.2 11.2 70.3 12.6 
Sinapic acid 62.6† 9.6 6.9 48.3† 9.9 5.8 470.4† 16.7† 92.9 7.3 70.2 11.9 
Syringic acid 12.0 5.1 11.1 44.0† 6.2 10.1 265.9† 9.3† 87.7 13.9 69.7 14.3 
trans-3-hydroxycinnamic acid 34.6† 6.9 6.7 50.6† 5.7 7.4 22.8† 137.8† 65.6 11.2 69.3 9.4 
trans-Cinnamic acid 134.3† 52.0† 33.5† 235.8† 141.3† 174.8† 264.0† 30.3† 127.9† 42.0† 93.6† 98.9† 
Vanillic acid 119.0† 12.6 5.3 144.7† 32.0† 4.5 207.0† 15.3† 208.8† 15.0† 68.9 8.9 
Vanillic acid-4-glucuronide 286.9† 11.5 4.5 201.9† 32.2† 4.3 585.6† 28.6† 103.3 10.5 55.0 10.5 
Vanillic acid-4-sulfate 117.3† 27.0† 6.1 110.2 42.9† 6.4 486.6† 22.9† 298.1† 16.6† 23.0† 52.9† 
Phloridzin (-) 354.5† 7.2 9.3 152.1† 7.2 8.3 75.8† 46.8† 36.2 9.7 55.0 11.4 
Phloridzin (+) 56.8† 39.4† 13.5 364.7† 55.3† 11.3 418.6† 53.8† 59.6 15.0 70.3 14.5 
Scopoletin (-) 32.9† 12.8 5.8 108.5† 12.3 8.4 251.6† 30.7 89.6 12.8† 67.1 7.9 
Scopoletin (+) 89.4† 67.6† 9.8 98.6† 78.4† 7.0 301.0† 48.9† 67.9 77.2† 91.4† 6.5 
CV, coefficient of variation; (-), negative ionisation mode; (+), positive ionisation mode; ND, not detected. Low, 0.098 µM; Mid, 1.56 µM; High, 50 µM. aFDA guideline, ≤20%, n=5. bFDA 
guideline, ≤15%, n=5. cFDA guideline, ≤20%, n=10. dFDA guideline, ≤15%, n=10. eUN guideline, recovery ≤115% and CV ≤15%, n=5. 
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4.4. Discussion 
Studies requiring the detection and quantification of anthocyanins in food products (Merken 
and Beecher 2000) or clinical samples (Cooke et al. 2006) have successfully utilised HPLC 
methods and ultraviolet/visible wavelength (UV-Vis) detection for many years and continue 
to do so whilst updating the methods to include recent advances in HPLC technology such as 
ultra-high performance liquid chromatography (UPLC) (Kalili and de Villiers 2011) and 
hydrophilic interaction chromatography (HILIC) (Willemse et al. 2013). The UV absorbance 
of anthocyanins is caused by the delocalised electrons present within the phenolic ring 
structure (Dearden and Forbes 1959), a trait shared by the phenolic metabolites of 
anthocyanins. However, whilst UV-Vis detection of phenolic acids has been used by many 
studies (Robbins 2003), the difficulty in chromatographically separating high numbers of 
structurally similar phenolic compounds and the poor availability of analytical standards has 
created the need for methods combining the separation of HPLC with the compound 
identification of mass spectrometry in order to study the in vivo metabolism of anthocyanins. 
The present study describes the validation of two LC-MS methods developed for this 
purpose. Validation of analytical methods is important in providing information to users 
about the relative strengths and limitations of the method as well as establishing confidence 
in the reliability of the results obtained (Božović and Kulasingam 2013). The present study 
sought to answer the following questions: 
Are the correct analytes being quantified?  
80% of the analytes tested were within guideline limits for retention time variance using the 
32 minute method with 100% of analytes within guidelines using the 15 minute method. The 
analytes that fell outside the guideline limits (4-hydroxybenzaldehyde, hippuric acid, 
(iso)vanillic acid-3/4-sulfate, methyl 3,4 dihydroxybenzoate) may have been caused by slight 
variations in mobile phase preparation or build-up of impurities within the HPLC guard 
column affecting mobile phase flow. 95% of analytes were within guidelines for MRM 
transition variance using the 32 minute method with 96% of analytes within guidelines using 
the 15 minute method. The analytes that fell outside the guideline limits may have been 
caused by differences in ionisation between the individual reference sample that contained 
only the analyte of interest and the sample spiked with mixed standard containing all the 
tested analytes. Overall, the present study suggests that both methods have acceptable 
levels of specificity and users can be confident that the correct analytes are being quantified. 
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What are the lowest metabolite concentrations that the methods are capable of 
detecting?  
The mean limits of detection were 9.5 nM with a range of 0.2 – 59.2 nM for the 32 minute 
method and 96.7 nM with a range of 0.3 – 3954.7 nM for the 15 minute method. The higher 
limit of detection for the 15 minute method is likely a result of the increased number of 
analytes included in this method compared to the 32 minute method. Overall, the present 
study suggests that both methods are sensitive enough to detect the levels of metabolites 
reported in clinical samples (Czank et al. 2013, Rodriguez-Mateos et al. 2013, de Ferrars et 
al. 2014a, de Ferrars et al. 2014b). 
Is the response linear over the relevant concentration range? 
85% of analytes were within guidelines for linear response over the full range of 
concentrations tested (0 – 50 µM) using the 32 minute method with 100% of analytes within 
guidelines using the 15 minute method. The analytes that fell outside of the guideline limits 
(4-hydroxybenzaldehyde, phloroglucinaldehyde, phloridzin [-]) were caused by a lack of 
linearity above 6.25 µM. However, the range over which a linear response was observed for 
these analytes is still adequate for quantification of the reported concentrations in clinical 
samples. It should be noted that two aldehyde compounds exhibited a non-linear response 
at the higher concentrations. Non-linear responses in LC-MS analysis can be caused by a 
number of factors including saturation during ionisation, detector saturation, and clustering 
of analyte ions at high concentrations (Bakhtiar and Majumdar 2007, Yuan et al. 2012). 
Formation of aldehyde cluster ions has been reported previously (Ostrowski et al. 2014) but 
further study is required to establish if the non-linear response of the aldehyde metabolites 
at high concentrations persists as previous studies have observed that analytes may exhibit 
linear and non-linear characteristics on the same instrument on different days (Yuan et al. 
2012). Overall, the present study suggests that both methods have acceptable levels of 
linearity and users can be confident that the tested analytes will respond linearly over the 
tested concentration range. 
Are the calculated metabolite concentrations close to the ‘true’ concentrations?  
Using the 32 minute method, 20%, 35% and 80% of analytes were within guidelines for 
accuracy at the low, mid and high concentrations, respectively. Using the 15 minute method, 
28%, 70% and 91% of analytes were within guidelines at the low, mid and high 
concentrations, respectively. The levels of accuracy observed at the low concentration 
(0.098 µM) were likely to be caused by proximity to the limits of detection resulting in 
greater levels of variation within the analyte response. However, recoveries were largely 
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within a factor of 10 of 100% recovery which equates to the difference between 1 nM and 
10 nM when quantifying metabolite concentrations. Within the wider context of nutrition 
research, which is subject to large degrees of inter-participant variation (de Roos 2013), this 
level of variation at low concentrations can be considered acceptable. The FDA and UN 
guidelines on which the current validation experiment was designed (Food and Drug 
Administration 2001, United Nations Office on Drugs and Crime 2009) are primarily used in 
pharmacological and toxicological  analyses which routinely detect xenobiotics in genetically 
homogenous laboratory animals resulting in reduced inter-participant variation and are 
therefore capable of accuracy levels currently not possible in nutritional analysis (Gibney et 
al. 2005). Overall, the present study suggests that accuracy at low and mid concentrations 
(≤1.56 µM) is currently a limitation for both methods and users should be cautious about the 
quantification of phenolic metabolites at this level using these methods. 
Are these results consistently repeatable and reproducible? 
Using the 32 minute method, 70%, 95% and 100% of analytes were within guidelines for 
intra-day precision whilst 65%, 80% and 100% of analytes were within guidelines for inter-
day precision at the low, mid and high concentrations, respectively. Using the 15 minute 
method, 23%, 72% and 91% of analytes were within guidelines for intra-day precision whilst 
13%, 62% and 83% of analytes were within guidelines for inter-day precision at the low, mid 
and high concentrations, respectively. The 32 minute method showed improved levels of 
precision compared to the 15 minute method, however, this is likely to be a result of the 
increased number of analytes included in the 15 minute method resulting in reduced dwell 
time per analyte and therefore greater levels of variation as each peak is made up of fewer 
data points (AB SCIEX 2011). Development of new methods often requires compromise 
between the quality of the method and the number of quantifiable analytes. Qualitative 
detection of an extensive list of metabolites was prioritised in the development of these 
methods. For these methods to be suitable for use in nutritional research, a high level of 
precision can be deemed more important than a high level of accuracy. The high level of 
inter-participant variation in nutritional studies places an emphasis on analysing the relative 
changes in metabolite concentrations within participants, which needs good analytical 
precision, rather than quantifying absolute concentration values for which a high level of 
accuracy would be required. Overall, the present study suggests that precision may be a 
limitation of the 15 minute method at lower concentrations (≤1.56 µM) and users should be 
cautious about the quantification of phenolic metabolites at this level using this method. 
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Are the compounds of interest recovered from the biological samples effectively and 
consistently by the sample preparation method? 
Using the PPT method for extraction of urine samples, 17%, 64% and 85% of analytes were 
within guidelines for extraction efficiency at the low, mid and high concentrations, 
respectively. The poor extraction efficiency observed at the lower concentrations (≤1.56 µM) 
may be due to endogenous matrix components not removed during the extraction process 
causing suppression of the analyte ions (Polson et al. 2003). It is also possible that the results 
may be due to the poor accuracy and precision of the 15 minute method at the lower 
concentrations resulting in high CV values. The advantages of low cost and high throughput 
of PPT compared to SPE suggest that future studies aiming to quantify phenolic metabolites 
in urine may wish to consider PPT as a suitable sample preparation method. PPT is unlikely 
to be the most appropriate option for extraction of serum or plasma samples due to the 
greater presence of ion-suppressing proteins and phospholipids in these matrices that are 
only partially removed by PPT (Chang et al. 2007, Bylda et al. 2014). SPE remains the optimal 
sample preparation method for extraction of serum or plasma samples prior to LC-MS 
analysis (Bylda et al. 2014). Overall, the present study suggests that PPT may have limited 
value as a urine sample preparation technique for recovery of metabolites at lower 
concentrations (≤1.56 µM) although this may be difficult to evaluate due to the poor 
accuracy and precision of the method. 
The use of extracted human serum and urine as a matched matrix in sample preparation is 
likely to increase the level of baseline noise compared to samples prepared using mobile 
phase due to matrix effects caused by salts, proteins, or phospholipids present in the 
extracted serum and urine matrices that were not removed during the extraction process 
(Dams et al. 2003). However, while it may have been possible to report improved validation 
results using a mobile phase matrix (de Ferrars et al. 2014c), the use of the extracted serum 
and urine matrices is an advantage of the present study as it provides a more realistic 
representation of the results that can be expected when analysing clinical serum and urine 
samples (Food and Drug Administration 2001, Božović and Kulasingam 2013). These matrix 
effects may have been eliminated via the use of stable-isotope-labelled internal standards 
(Matuszewski et al. 2003) but due to the number of analytes included in the present analysis, 
this was not feasible and analogue internal standards were used. 
The present study highlighted the strengths (specificity, limits of detection, linearity) and 
limitations (accuracy and precision at lower concentrations) of the developed methods. 
These results demonstrate the effect of prioritising qualitative detection of a wide range of 
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anthocyanin metabolites over the focused quantification of a few select metabolites. The 
large number of analytes included in the methods meant that some instrument parameters, 
such as the ion source temperature and gases, had to be chosen based on their suitability 
for the range of metabolites instead of being optimised for a single analyte which may have 
affected detection limits. Whilst acknowledging the limitations of the methods, it should be 
noted that the developed methods are capable of detection and quantification of a greater 
number of phenolic metabolites within a shorter run time than previously published 
methods (Rodriguez-Mateos et al. 2013, Pimpão et al. 2015). 
Whilst the accuracy and precision of the methods may be considered acceptable for 
qualitative analysis and quantifying relative concentrations of anthocyanin metabolites for 
nutritional research, efforts should be made to improve the sensitivity of the HPLC-ESI-
MS/MS methods as a way of improving these aspects of the methods. By increasing 
sensitivity, and therefore improving the limits of detection, the accuracy and precision of the 
methods should be improved (Božović and Kulasingam 2013). Future work should 
investigate potential methods for increasing the sensitivity of the current methods such as 
via the use of hydrophilic interaction chromatography (HILIC) or the use of more sensitive 
instrumentation.  
The use of HILIC in conjunction with electrospray ionisation mass spectrometry has been 
increasing recently with a number of reported bioanalytical applications (Jian et al. 2010) 
including quantification of anthocyanins in fruit and vegetables (Willemse et al. 2013). HILIC 
provides potential advantages over traditional reverse-phase (RP)-HPLC methods due to the 
differences in stationary phases and solvents. In traditional RP-HPLC, water acts as the weak 
solvent and polar organic solvents such as methanol or acetonitrile act as the strong solvent. 
In RP-HPLC, most compounds are eluted in high aqueous/low organic mobile phase 
conditions which are difficult to evaporate within the ESI ion source and therefore can lead 
to poor ionisation. In HILIC, the roles of strong and weak solvents are switched so that 
organic solvents are weak and water is strong. Most compounds are eluted in high 
organic/low aqueous conditions which improves evaporation within the ion source resulting 
in improved ionisation and greater method sensitivity (Nguyen and Schug 2008).  
The use of higher specification, more sensitive instrumentation would also help to improve 
the reliability of the current method by improving the signal-to-noise ratio, lowering the 
limits of detection and therefore improving accuracy and precision of the method at the 
metabolite concentrations reported in clinical samples. By upgrading from the AB SCIEX 3200 
series QTRAP® instrument used in the present study to the next model from the same 
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supplier, the AB SCIEX 4000 series, a factor of 8-10 increase in overall sensitivity could be 
expected with another factor of 8 increase possible via the use of the AB SCIEX 5000 series 
(Impey 2005) and a further factor of 4-5 increase possible via the use of the AB SCIEX 6500 
series (Romanelli et al. 2012). Whilst there will be areas for improvement in all methods, the 
present study demonstrates that the methods developed by our group are capable of 
qualitative detection and quantification of anthocyanin metabolites for the purposes of 
relative concentration comparisons in clinical samples.  
 
4.5. Conclusion 
Validation of analytical methods capable of quantifying phenolic metabolites of 
anthocyanins in clinical samples is crucial for the confident study of in vivo anthocyanin 
metabolism. The present study provides information on the strengths and limitations of 
HPLC-ESI-MS/MS methods for detection and quantification of a wide range of anthocyanin 
metabolites in both human serum and urine. Whilst poor accuracy and precision at low 
concentrations limits the use of these methods in quantifying absolute metabolite 
concentrations in clinical samples, the methods may be considered acceptable for qualitative 
detection and quantification of phenolic metabolites of anthocyanins for the purposes of 
comparing relative concentrations in nutritional studies. 
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Chapter 5. Establishing Robust Metabolic Biomarkers of 
Anthocyanin Consumption. 
 
5.1. Introduction 
Epidemiological studies have suggested that diets high in anthocyanins could reduce the risk 
of cardiovascular disease (Mink et al. 2007, Cassidy et al. 2011, Dohadwala et al. 2011, 
Rodriguez-Mateos et al. 2013). Studies investigating the effects of anthocyanin intake use 
standard methods to establish intake and monitor adherence to dietary restrictions such as 
food frequency questionnaires and food diaries (Jennings et al. 2012, Rodriguez-Mateos et 
al. 2013). However, these methods of estimating and monitoring intake have many 
drawbacks such as misreporting of consumption data and limitations associated with food 
composition databases (Beaton 1994, Thompson et al. 2010) and this can lead to significant 
under or overestimation of intake (Rodriguez-Mateos et al. 2014). A more accurate method 
for monitoring food intake is to measure biomarkers of intake, which are specific compounds 
in the blood that are known to be reliable indicators of consumption (Hedrick et al. 2012). 
Suitable biomarker candidates can be identified via two approaches; discovery-driven and 
hypothesis-driven (Kuhnle 2012). A discovery-driven approach requires little prior 
understanding of the bioavailability or metabolism of the food/compound of interest and 
involves utilising metabolomics analysis to identify all possible metabolites and using 
multivariate analysis to identify suitable biomarker candidates. A hypothesis-driven 
approach starts from an understanding of the metabolism of the food/compound of interest 
and uses this information to create a list of possible candidate biomarkers before analysing 
clinical samples to test the suitability of these candidates. Whichever approach is used, ideal 
biomarkers of intake should satisfy the following criteria: robust, validated methods of 
quantification should exist; biomarker concentration should be sensitive to changes in intake 
of the dietary component of interest; the biomarker should be specific to the dietary 
component of interest, i.e. found in limited quantities within the background diet; and 
finally, a clear understanding of the absorption, distribution, metabolism and excretion 
(ADME) of the biomarker and how this process is affected by factors such as genetics and 
diet composition should exist. (Potischman 2003, Spencer et al. 2008, Jenab et al. 2009, 
Kuhnle 2012).  
A number of biomarkers for measuring the intake of flavonoid-rich foods have been 
proposed. These include using urinary flavonoid levels as a measure of fruit and vegetable 
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intake (Nielsen et al. 2002, Krogholm 2011) and urinary excretion of hippuric acid as a 
measure of flavonoid intake from fruit and vegetables (Penczynski et al. 2015). A discovery-
driven approach has also been used to identify metabolic profiles associated with intake of 
polyphenol-rich foods (Edmands et al. 2015). Biomarkers of intake for specific phenolic 
compounds have also been proposed such as urinary excretion of isoferulic acid as a 
biomarker of chlorogenic acid intake from coffee (Hodgson et al. 2004) and urinary levels of 
phenolic metabolites such as benzoic acid and gallic acid as biomarkers of quercetin and 
epigallocatechin gallate intake respectively (Loke et al. 2009). A number of metabolites, such 
as syringic acid (van Dorsten et al. 2010) and gallic acid (Urpi‐Sarda et al. 2015), have also 
been proposed as suitable urinary biomarkers of intake for anthocyanin-rich foods such as 
wine and grape juice. To the author’s knowledge, none of these biomarkers have been 
accepted as robust and sensitive intake biomarkers and there have been no metabolic 
biomarkers for specific anthocyanin intake proposed to date. 
The present study aimed to use a hypothesis-driven approach to identify metabolites that 
could be used as biomarkers of anthocyanin intake through the use of 13C-labelling to 
improve the accuracy of future clinical intervention studies exploring the bioactivity of 
anthocyanins. Anthocyanins have been demonstrated to be present in low concentrations 
in the blood and urine following intake (Wu et al. 2002, Kay et al. 2005) but they have been 
reported to be extensively metabolised in the body (Czank et al. 2013, de Ferrars et al. 
2014b). Stable isotope labelling has been used in nutritional metabolic research since the 
1930s (Schoenheimer and Rittenberg 1935) but has been used more extensively since the 
late 1970s/early 1980s (Schwartz and Giesecke 1979, Smith 1983) after improvements in 
mass spectrometric techniques simplified the detection of stable isotopes (Turnlund 1989). 
The use of stable isotope labelling is important for the identification of suitable biomarker 
candidates as it allows for mass spectrometry to distinguish between the metabolites 
resulting from a dietary intervention and metabolites resulting from the background diet by 
the change in mass/charge ratio (m/z) which would not be possible with other methods using 
unlabelled interventions. This allows for metabolites only present within the body at high 
concentrations following consumption of foods/compounds of interest, i.e. good biomarkers 
of intake, to be identified. The present study used serum and urine samples from a recently 
conducted 13C-labelled cyanidin-3-glucoside (C3G) intervention (Czank et al. 2013) to 
compare concentrations of 13C-labelled C3G and its 13C-labelled phenolic metabolites in the 
blood and urine following intake, relative to levels present in the blood and urine resulting 
from the background diet composed of naturally abundant 12C. The use of 13C-labelled C3G 
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enabled mass spectrometric discrimination between metabolites resulting from the 
intervention (as they will contain heavy carbon 13) and those originating from the 
background diet (as they will contain molecules comprising naturally abundant carbon 12). 
The present study scanned for 13C and 12C analytes of C3G and 17 recently identified 
metabolites in serum (Czank et al. 2013, de Ferrars et al. 2014a) and 58 metabolites in urine 
(Czank et al. 2013, Rodriguez-Mateos et al. 2013, de Ferrars et al. 2014b, de Ferrars et al. 
2014c) for their potential utility as biomarkers of C3G intake. 
 
5.2. Methods 
5.2.1. Materials and reagents 
Acetonitrile and methanol were purchased from Fisher Scientific (Loughborough, UK). 
Strata-X™ 33 µm polymeric sorbent 500 mg/6 mL solid-phase extraction cartridges, Kinetex® 
pentafluorophenyl (PFP) high-performance liquid chromatography (HPLC) columns (2.6 µm, 
100 x 4.6 mm, 100 Å and 2.6 µm, 50 x 2.1 mm, 100 Å) and SecurityGuard® cartridges (PFP, 
4.6 x 2.0 mm and 2.1 x 2.0 mm) were purchased from Phenomenex (Macclesfield, UK). 
Cyanidin-3-glucoside (kuromanin chloride) was purchased from Extrasynthese (Genay, 
France). The phase II conjugates of phenolic acids (protocatechuic acid-3-glucuronide, 
protocatechuic acid-4-glucuronide, protocatechuic acid-3-sulfate, protocatechuic acid-4-
sulfate, isovanillic acid-3-glucuronide, vanillic acid-4-glucuronide, isovanillic acid-3-sulfate, 
vanillic acid-4-sulfate, benzoic acid-4-glucuronide) were synthesised by the School of 
Chemistry and Centre for Biomolecular Sciences, University of St. Andrews (UK) using 
published methods (Zhang et al. 2012). 3-hydroxyhippuric acid and 4-hydroxyhippuric acid 
were purchased from Alfa Chemistry (Stony Brook, USA). Methyl 3,4-dihydroxybenzoate 
(3,4-dihydroxy-benzoic acid methyl ester) was purchased from Alfa Aesar (Heysham, UK). All 
other materials, reagents, and standards were purchased from Sigma-Aldrich (Dorset, UK), 
including: Acrodisc PTFE syringe filters (13 mm, 0.45 µm), formic acid (FA), dimethyl sulfoxide 
(DMSO), 2,3-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 
2-hydroxy-4-methoxybenzoic acid, 2-hydroxybenzoic acid, 2-hydroxycinnamic acid, 3-(3-
hydroxyphenyl)propionic acid, 3-(4-hydroxy-3-methoxyphenyl)propionic acid, 3,4-
dihydroxybenzaldehyde, 3,4-dihydroxyphenylacetic acid, 3,5-dihydroxybenzoic acid, 3-
hydroxybenzoic acid, 3-hydroxyphenylacetic acid, 3-methylhippuric acid (N-[3-
methylbenzoyl]glycine), 3-(4-hydroxyphenyl)propionic acid, 4-hydroxybenzaldehyde, 4-
hydroxybenzoic acid, 4-hydroxybenzyl alcohol, 4-hydroxyphenylacetic acid, 4-
methylhippuric acid (N-[4-methylbenzoyl]glycine), α-hydroxyhippuric acid 
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([benzoylamino]hydroxyacetic acid), benzoic acid, benzoylglutamic acid, caffeic acid (3,4-
dihydroxycinnamic acid), chlorogenic acid (3-[3,4-dihydroxycinnamoyl]quinic acid), ferulic 
acid (4-hydroxy-3-methoxycinnamic acid), gallic acid (3,4,5-trihydroxybenzoic acid), hippuric 
acid (benzoylaminoacetic acid), homovanillic acid (4-hydroxy-3-methoxyphenylacetic acid), 
isoferulic acid (3-hydroxy-4-methoxycinnamic acid), isovanillic acid (3-hydroxy-4-
methoxybenzoic acid), kaempferol (3,4’,5,7-tetrahydroxyflavone), protocatechuic acid (PCA, 
3,4-dihydroxybenzoic acid), p-coumaric acid (trans-4-hydroxycinnamic acid), 
phloroglucinaldehyde (PGA, 2,4,6-trihydroxybenzaldehyde), phenylacetic acid, phloridzin 
(phloridzin dihydrate), rosmarinic acid ([R]-O-[3,4-dihydroxycinnamoyl]-3-[3,4- 
dihydroxyphenyl]lactic acid), scopoletin (7-hydroxy-5-methoxycoumarin), sinapic acid (4-
hydroxy-3,5-dimethoxy-cinnamic acid), syringic acid (4-hydroxy-3,5-dimethoxy-benzoic 
acid), trans-cinnamic acid, trans-3-hydroxycinnamic acid, and vanillic acid (4-hydroxy-3-
methoxybenzoic acid). Water was 18MΩ/cm Milli-Q quality and all solvents were LC-MS 
grade. 
5.2.2. Clinical intervention study design 
Banked serum and urine samples from a previously conducted anthocyanin intervention 
(Czank et al. 2013) were used for the present analysis. Briefly, samples were originally 
collected from healthy males (n=8; age, 27.8 ± 8.1 y; BMI, 23.2 ± 1.5 kg/m2) prior to (t=0 h) 
and after consuming a 500 mg bolus of isotopically labelled cyanidin-3-glucoside containing 
three 13C-atoms on the A-ring and two 13C-atoms on the B-ring (6,8,10,3’,5’-13C5-C3G, 
hereafter referred to as 13C5-C3G). Participants were asked to arrive on the study day in a 
fasted state (minimum 8 h). Blood samples were collected at regular intervals (t=0.5 h, t=1 
h, t=2 h, t=4 h, t=6 h, t=24 h and t=48 h) following consumption. Individual urine samples 
were collected during the 6 hour study day and total urine voids were collected during the 
6-24h and 24-48 hour periods. An anthocyanin-free meal was provided between 2-4 hours 
post-bolus. Participants were asked to maintain a low anthocyanin diet for the next 48 hours. 
Participants were also asked to avoid any foods containing high levels of anthocyanins and 
13C (Morrison et al. 2000) over the 7 day run-in period and during the intervention. Upon 
collection, the blood samples were left to clot for 1 hour before being centrifuged at 3000 x 
g for 10 min. The serum was then removed and 7 mL were acidified manually to pH 2.4 with 
formic acid using a pH meter. Urine samples were combined with 100 mg of ascorbate per 
500 mL of urine and were also acidified manually to pH 2.4 using formic acid. All samples 
were stored at -80°C until analysis. 
  
 Page | 108 
5.2.3. Serum sample preparation: solid-phase extraction (SPE) 
48 acidified serum samples were extracted via SPE, following previously reported 
methodology (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, SPE cartridges were 
preconditioned with 6 mL of acidified methanol (acidified to pH 2.4 using formic acid) 
followed by 6 mL of acidified water (acidified to pH 2.4 using formic acid). Cartridges were 
loaded with 1 mL acidified water followed by 1 mL of serum spiked with 4 µL of internal 
standard (1 mg/mL phloridzin) and sample tubes were rinsed with a further 1 mL of acidified 
water and loaded onto the cartridge. Samples were eluted at a flow rate of approximately 1 
drop/second. Extraction cartridges were washed with 12 mL of acidified water before being 
dried under vacuum for 30 mins. 5 mL of acidified methanol was added to the cartridges and 
left to soak for 10 mins before the samples were eluted, including a final 2 mL of acidified 
methanol. The eluent was evaporated to approximately 50 μL on a rotary evaporator 
(Thermo SPD Speedvac). Following evaporation, the samples were reconstituted with 200 
μL acidified water and 2.5 μL of a volume indicator (volume control standard; 1 mg/mL 
scopoletin) to allow determination of accurate volume. The samples were then sonicated for 
10 mins with the ultrasonic water bath kept cool using ice, followed by vortex mixing for 10 
seconds, filtration through a 0.45 µm syringe filter and were finally stored at -80°C until 
analysis. 
5.2.4. Urine sample preparation: protein precipitation (PPT) 
Acidified urine samples were pooled to create three time-points for each of the eight 
participants; Baseline (BL), 6-24 hours and 24-48 hours. The 24 pooled urine samples were 
extracted via PPT. Samples were spiked with 4.36 µL of internal standard (1 mg/mL 
phloridzin) and 4 mL of acetonitrile containing 0.1% v/v formic acid, mixed by vortex for 10 
seconds, stored at -20°C for 30 mins and centrifuged at 4000 x g, 8°C for 10 mins. After 
centrifugation, the supernatant was removed, placed into a test tube and evaporated to 
dryness on a Thermo Speedvac concentrator. Samples were reconstituted in 247.6 µL of 
mobile phase diluent (0.1/5/94.9 v/v/v formic acid/methanol/water) and 2.4 µL of 
scopoletin (0.1 mg/mL) added to samples to give a 5 µM internal standard. Samples were 
sonicated for 10 mins with the ultrasonic water bath kept cool using ice, mixed by vortex for 
10 seconds, filtered through a 0.45 µm syringe filter and finally stored at -80°C until analysis. 
5.2.5. Serum chromatography 
HPLC-ESI-MS/MS analysis was carried out using an Agilent (Stockport, UK) 1200 series HPLC 
equipped with a Diode Array Detector (DAD) coupled to an AB SCIEX (Warrington, UK) 3200 
series QTRAP® MS/MS system with Turbo V™ electrospray ionisation source using 
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previously established methods (Czank et al. 2013, de Ferrars et al. 2014c). Briefly, a 
Kinetex® pentafluorophenyl (PFP) (2.6 µm, 100 x 4.6 mm) RP-HPLC column was used with a 
PFP SecurityGuard® cartridge (4.6 x 2.0 mm). The column temperature was set at 37°C, 
injector temperature of 4°C and injection volume of 5 µL. Mobile Phase A was 0.1% (v/v) 
formic acid in water and Mobile Phase B was 0.1% (v/v) formic acid in acetonitrile at a flow 
rate of 1.5 mL min-1 at 0 min, 1 mL min-1 at 7 to 14 min and 1.5 mL min-1 at 14 to 32 min. The 
gradient consisted of 1% B at 0 min, 7.5% B at 7 min, 7.6% B at 14 min, 10% B at 17 min, 12% 
B at 18.5 min, 12.5% B at 20 min, 30% B at 24 min, 90% B at 25 to 28 min, 1% B at 29 to 32 
min. MS/MS source parameters included ionspray voltage, -4000 V / +5500 V; temperature, 
700°C; curtain gas, 40 psi; nebulizer gas and auxiliary gas, 60 psi. Scheduled multiple reaction 
monitoring (sMRM) scans were performed using parameters optimised for the detection of 
analytical standards (Table 5.1). Samples were analysed in negative and positive ionisation 
modes at m/z to detect metabolites from the background diet that contained only the 
naturally abundant 12C carbon atoms. Samples were also analysed at m/z +2, for all 
compounds except cyanidin-3-glucoside, scopoletin and phloridzin, to detect B-ring-derived 
13C-labelled metabolites that contained two 13C carbon atoms. Additionally, methyl 3,4-
dihydroxybenzoate and ferulic acid were analysed at m/z +3 to detect A-ring-derived 13C-
labelled metabolites that contained three 13C carbon atoms. Cyanidin-3-glucoside was 
analysed at m/z +5 due to the compound containing all five 13C carbon atoms. 
Retention time and the detection of three or more of the relevant ion transitions were used 
to confirm the identity of the metabolites. For quantification, the peak area of the most 
intense ion transition was used. An eleven-point calibration (0 – 12.5 µM) curve was 
prepared by spiking a standard mixture of the compounds into a matched-matrix (blank 
serum) and coefficients of determination (R2) were established as linear (0.991 ± 0.007). 
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Table 5.1 sMRM schedule used to analyse the extracted serum samples on the AB SCIEX 3200 QTRAP® instrument. 
Compound 
12C Transitions (m/z) 
precursor/product ions 
13C Transitions (m/z +2) 
precursor/product ions 
13C Transitions (m/z +3) 
precursor/product ions 
13C Transitions (m/z +5) 
precursor/product ions 
Scan time 
range (min) 
Scan 
mode 
Benzoic acid-4-glucuronide 313/175,113,93* 315/177,115,95* N/A N/A 2.0 – 4.0 - 
Protocatechuic acid-4-glucuronide 329.01/153*,113,109 331.01/155*,115,111 N/A N/A 2.4 – 4.4 - 
Protocatechuic acid 153.01/108*,91,81 155.01/110*,93,83 N/A N/A 3.2 – 5.2 - 
Protocatechuic acid-3-glucuronide 329.01/153*,113,109 331.01/155*,115,111 N/A N/A 3.4 – 5.4 - 
Vanillic acid-4-glucuronide 343.01/167,152,113* 345.01/169,154,115* N/A N/A 4.6 – 6.6 - 
Isovanillic acid-3-glucuronide 343.01/167,152,113* 345.01/169,154,115* N/A N/A 4.6 – 6.6 - 
Hippuric acid 177.9/133.9*,77.1,131.8 179.9/135.9*,79.1,133.8 N/A N/A 5.0 – 7.0 - 
Protocatechuic acid-3/4-sulfatea 233.01/153,109*,189 235.01/155,111*,191 N/A N/A 6.3 – 8.3 - 
4-hydroxybenzaldehyde 121.2/107.8,92*,65.1 123.2/109.8,94*,67.1 N/A N/A 7.0 – 9.0 - 
Isovanillic acid 169.01/151.1,125,93* 171.01/153.1,127,95* N/A N/A 7.3 – 11.3 + 
Vanillic acid 167.03/152*,123,108 169.03/154*,125,110 N/A N/A 8.8 – 10.8 - 
(Iso)vanillic acid-3/4-sulfatea 247/167*,152,108 249/169*,154,110 N/A N/A 8.9 – 10.9 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 169/109.8*,109.1,93.2 170/110.8*,110.1,94.2 N/A 11.5 – 13.5 - 
Cyanidin-3-glucoside 449/287*,213,137 N/A N/A 454/292*,218,142 11.9 – 15.9 + 
Phloroglucinaldehyde 153/151*,125,107 155/153*,127,109 N/A N/A 13.7 – 15.7 - 
Ferulic acid 193/178,149,134* 195/180,151,136* 196/181,152,137* N/A 17.8 – 19.8 - 
Scopoletin 193/133.2*,122,94.1 N/A N/A N/A 17.1 – 21.1 + 
Scopoletin 191/104*,147.9,120 N/A N/A N/A 18.1 – 20.1 - 
Phloridzin 437/275,169,107* N/A N/A N/A 22.1 – 26.1 + 
Phloridzin 435/273*,167,123,81 N/A N/A N/A 23.1 – 25.1 - 
*Transition used for quantitation. N/A, compound not analysed using this m/z. aIsomers of this metabolite were unresolvable using this HPLC-ESI-MS/MS method so were quantified as a single 
analyte 
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5.2.6. Urine chromatography 
HPLC-ESI-MS/MS analysis was carried out using an Agilent 1200 series HPLC equipped with 
a DAD coupled to an AB SCIEX 3200 series QTRAP® MS/MS system with Turbo V™ 
electrospray ionisation source using methods adapted from previously established methods 
(Czank et al. 2013, de Ferrars et al. 2014c). Briefly, a Kinetex® PFP (2.6 µm, 50 x 2.1 mm) RP-
HPLC column was used with a PFP SecurityGuard® cartridge (2.1 x 2.0 mm). The column 
temperature was set at 40°C, injector temperature of 4°C and injection volume of 5 µL. 
Mobile Phase A was 0.1% (v/v) formic acid in water and Mobile Phase B was 0.1% (v/v) formic 
acid in acetonitrile at a flow rate of 0.6 mL min-1. The gradient consisted of 1% B at 0 min, 
7.5% B at 7 min, 7.6% B at 9 min, 90% B at 9.5 to 11.5 min, 1% B at 12 to 15 min. MS/MS 
source parameters included ionspray voltage, -4000 V / +5500 V; temperature, 700°C; 
curtain gas, 35 psi; nebulizer gas, 40 psi; auxiliary gas, 45 psi. sMRM scans were performed 
using parameters optimised for the detection of analytical standards (Table 5.2). Samples 
were analysed in negative and positive ionisation modes at m/z to detect metabolites from 
the background diet that contained only the naturally abundant 12C carbon atoms. Samples 
were also analysed at m/z +2, for all compounds except cyanidin-3-glucoside, scopoletin and 
phloridzin, to detect B-ring-derived 13C-labelled metabolites that contained two 13C carbon 
atoms. Additionally, samples were analysed at m/z +3 to detect A-ring-derived 13C-labelled 
metabolites that contained three 13C carbon atoms. Cyanidin-3-glucoside was analysed at 
m/z +5 due to the compound containing all five 13C carbon atoms. 
Retention time and the detection of three or more of the relevant ion transitions were used 
to confirm the identity of the metabolites. For quantification, the peak area of the most 
intense ion transition was used. A nine-point calibration curve (0 – 25 µM) was prepared by 
spiking a standard mixture of the compounds into a matched-matrix (blank urine) and 
coefficients of determination (R2) were established as linear (0.995 ± 0.005). 
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Table 5.2 sMRM schedule used to analyse the extracted urine samples on the AB SCIEX 3200 QTRAP® instrument. 
Compound 
12C Transitions (m/z) 
precursor/product ion 
13C Transitions (m/z +2) 
precursor/product ion 
13C Transitions (m/z +3) 
precursor/product ion 
13C Transitions (m/z +5) 
precursor/product ion 
Scan time 
range (min) 
Scan 
mode 
trans-Cinnamic acid 147/103*,79,64 149/105*,81,66 150/106*,82,67 N/A 0.0 – 1.5 - 
Gallic acid 169.2/125.1*,106.7,78.8 171.2/127.1*,108.7,80.8 172.2/128.1*,109.7,81.8 N/A 0.0 – 1.9 - 
Benzoic acid-4-glucuronide 313.1/175.1,113.1*,93.1 315.1/177.1,115.1*,95.1 316.1/178.1,116.1*,96.1 N/A 0.1 – 2.1 - 
Protocatechuic acid-4-glucuronide 329/153*,113,109 331/155*,115,111 332/156*,116,112 N/A 0.2 – 2.2 - 
α-hydroxyhippuric acid 194.3/176.3,148.3,73.3* 196.3/178.3,150.3,75.3* 197.3/179.3,151.3,76.3* N/A 0.4 – 2.4 - 
Protocatechuic acid 153.1/108.1*,91.1,81.1 155.1/110.1*,93.1,83.1 156.1/111.1*,94.1,84.1 N/A 0.7 – 2.7 - 
Protocatechuic acid-3-glucuronide 329.1/153.1*,113.1,109.1 331.1/155.1*,115.1,111.1 332.1/156.1*,116.1,112.1 N/A 0.7 – 2.7 - 
4-hydroxyhippuric acid 194.2/150.2,100.2*,93.2 196.2/152.2,102.2*,95.2 197.2/153.2,103.2*,96.2 N/A 0.8 – 2.8 - 
Dihydroxycinnamic acid-glucuronidea 355/179,135*,111 357/181,137*,113 358/182,138*,114 N/A 1.0 – 3.0 - 
2,3/2,4/2,5/3,5-dihydroxybenzoic acidd 152.8/109*,107.8,90.8 154.8/111*,109.8,92.8 155.8/112*,110.8,93.8 N/A 1.1 – 3.1 - 
3,4-dihydroxyphenylacetic acid 167.2/123.2*,108.2,95.2 169.2/125.2*,110.2,97.2 170.2/126.2*,111.2,98.2 N/A 1.1 – 3.1 - 
3-hydroxyhippuric acid  194.1/150.1*,148.1,93.1 196.1/152.1*,150.1,95.1 197.1/153.1*,151.1,96.1 N/A 1.1 – 3.1 - 
4-hydroxybenzyl alcohol 123/121*,105,77 125/123*,107,79 126/124*,108,80 N/A 1.1 – 3.1 - 
Protocatechuic acid-3/4-sulfated 233.1/189.1,153.1,109.1* 235.1/191.1,155.1,111.1* 236.1/192.1,156.1,112.1* N/A 1.1 – 3.1 - 
Vanillic acid-4-glucuronide 343.2/167.2,152.2,113.2* 345.2/169.2,154.2,115.2* 346.2/170.2,155.2,116.2* N/A 1.3 – 3.3 - 
3,4-dihydroxybenzaldehyde 136.9/107.9*,92,81 138.9/109.9*,94,83 139.9/110.9*,95,84 N/A 1.6 – 3.6 - 
3/4-hydroxybenzoic acidd 137.1/93.1*,75.1,65.1 139.1/95.1*,77.1,67.1 140.1/96.1*,78.1,68.1 N/A 1.8 – 3.8 - 
Methyl dihydroxybenzoate-sulfateb 247/167,152*,137 249/169,154*,139 250/170,155,140 N/A 1.9 – 3.9 - 
Hippuric acid 177.9/133.9*,131.8,77.1 179.9/135.9*,133.8,79.1 180.9/136.9*,134.8,80.1 N/A 2.0 – 4.0 - 
Isovanillic acid-3-glucuronide 343.1/167.1,152.1,113.1* 345.1/169.1,154.1,115.1* 346.1/170.1,155.1,116.1* N/A 2.1 – 4.1 - 
Isovanillic acid-3-sulfate 247/167*,152,108 249/169*,154,110 250/170*,155,111 N/A 2.1 – 4.1 - 
4-hydroxyphenylacetic acid 151.2/123.2,107.2*,93.2 153.2/125.2,109.2*,95.2 154.2/126.2,110.2*,96.2 N/A 2.5 – 4.5 - 
Vanillic acid-4-sulfate 247.1/167.1*,152.1,108.1 249.1/169.1*,154.1,110.1 250.1/170.1*,155.1,111.1 N/A 2.9 – 4.9 - 
3-hydroxyphenylacetic acid 151.1/136.1,121.1,107.1* 153.1/138.1,123.1,109.1* 154.1/139.1,124.1,110.1* N/A 3.0 – 5.0 - 
4-hydroxybenzaldehyde 121.2/107.8,92.2*,65.2 123.2/109.8,94.2*,67.2 124.2/110.8,95.2*,68.2 N/A 3.1 – 5.1 - 
Dihydroxyphenylacetic acid-sulfatec 247/167*,152,123 249/169*,154,125 250/170*,155,126 N/A 3.3 – 5.3 - 
Isovanillic acid 169.01/151.1,125,93* 171.01/153.1,127,95* 172.01/154.1,128,96* N/A 3.8 – 7.8 + 
Vanillic acid 167.3/152.3*,123.3,108.3 169.3/154.3*,125.3,110.3 170.3/155.3*,126.3,111.3 N/A 4.4 – 6.4 - 
Caffeic acid 179/135*,106,89 181/137*,108,91 182/138*,109,92 N/A 5.1 – 7.1 - 
Benzoylglutamic acid 250/206*,162,121 252/208*,164,123 253/209*,165,124 N/A 5.2 – 7.2 - 
Homovanillic acid 181.1/166.1,137.1*,79.1 183.1/168.1,139.1*,81.1 184.1/169.1,140.1*,82.1 N/A 5.2 – 7.2 - 
Benzoic acid 121/93,92,77* 123/95,94,79* 124/96,95,80* N/A 5.4 – 7.4 - 
Phenylacetic acid 135/119,91*,64 137/121,93*,66 138/122,94*,67 N/A 5.6 – 7.6 - 
Syringic acid 199/155.2,140*,125 201/157.2,142*,127 202/158.2,143*,128 N/A 5.6 – 9.6 + 
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Table 5.2 (Continued)       
Compound 
12C Transitions (m/z) 
precursor/product ion 
13C Transitions (m/z +2) 
precursor/product ion 
13C Transitions (m/z +3) 
precursor/product ion 
13C Transitions (m/z +5) 
precursor/product ion 
Scan time 
range (min) 
Scan 
mode 
3-(4-hydroxyphenyl)propionic acid 165.1/121.1*,97.1,93.1 167.1/123.1*,99.1,95.1 168.1/124.1*,100.1,96.1 N/A 5.7 – 7.7 - 
Hydroxy-methoxycinnamic acid-
glucuronidea 
369/193,173,111* 371/195,175,113* 372/196,176,114 N/A 6.0 – 8.0 - 
3-(3-hydroxyphenyl)propionic acid 165/121*,119,106 167/123*,121,108 168/124*,122,109 N/A 6.2 – 8.2 - 
Methyl 3,4-dihydroxybenzoate 167/107.8*,107.1,91.2 169/109.8*,109.1,93.2 170/110.8*,110.1,94.2 N/A 6.2 – 8.2 - 
Chlorogenic acid 353/191*,161,127 355/193*,163,129 356/194*,164,130 N/A 6.6 – 8.6 - 
4-methylhippuric acid 192.2/148.2,146.2,91.2* 194.2/150.2,148.2,93.2* 195.2/151.2,149.2,94.2* N/A 6.7 – 8.7 - 
3-methylhippuric acid 192.1/148.1,146.1,90.9* 194.1/150.1,148.1,92.9* 195.1/151.1,149.1,93.9* N/A 6.8 – 8.8 - 
2-hydroxybenzoic acid 137/93*,75,65 139/95*,77,67 140/96*,78,68 N/A 7.0 – 9.0 - 
p-Coumaric acid 163/118.9*,116.9,92.9 165/120.9*,118.9,94.9 166/121.9*,119.9,95.9 N/A 7.1 – 9.1 - 
Phloroglucinaldehyde 153/151*,125,107 155/153*,127,109 156/154*,128,110 N/A 7.2 – 9.2 - 
3-(4-hydroxy-3-
methoxyphenyl)propionic acid 
195/136*,121,119 197/138*,123,121 198/139*,124,122 N/A 7.8 – 9.8 - 
trans-3-hydroxycinnamic acid 163.2/119.2*,93.2,91.2 165.2/121.2*,95.2,93.2 166.2/122.2*,96.2,94.2 N/A 8.4 – 10.4 - 
Cyanidin-3-glucoside 449/287*,213,137 N/A N/A 454/292*,218,142 8.8 – 12.8 + 
Scopoletin 193/133.2*,122,94.1 N/A N/A N/A 8.8 – 12.8 + 
Phloridzin 437/275,169,107* N/A N/A N/A 8.9 – 12.9 + 
2-hydroxycinnamic acid 163/119*,117,93 165/121*,119,95 166/122*,120,96 N/A 9.8 – 11.8 - 
(Iso)ferulic acidd 193.1/178.1,149.1,134.1* 195.1/180.1,151.1,136.1* 196.1/181.1,152.1,137.1* N/A 9.8 – 11.8 - 
Scopoletin 191/147.9*,120,104 N/A N/A N/A 9.8 – 11.8 - 
Rosmarinic acid 359.1/197.1,179.1,161.1* 361.1/199.1,181.1,163.1* 362.1/200.1,182.1,164.1* N/A 9.9 – 11.9 - 
Sinapic acid 223/208*,193,164 225/210*,195,166 226/211*,196,167 N/A 9.9 – 11.9 - 
Phloridzin 435.1/273.1,167.1*,123.1 N/A N/A N/A 9.9 – 11.9 - 
Dimethoxy-hydroxycinnamic acid-
glucuronidea 
399/355,223*,173 401/357,225*,175 402/358,226*176 N/A 9.9 – 11.9 - 
2-hydroxy-4-methoxybenzoic acid 167.1/123.1,108.1*,80.1 169.1/125.1,110.1*,82.1 170.1/126.1,111.1*,83.1 N/A 10.0 – 12.0 - 
Kaempferol 285/239*,229,211 287/241*,231,213 288/242*,232,214 N/A 10.1 – 12.1 - 
*Transition used for quantitation. N/A, compound not analysed using this m/z. aPutative metabolite therefore analytical standard not available, 2-hydroxycinnamic acid standard curve used for 
quantitation. bPutative metabolite therefore analytical standard not available, methyl 3,4-dihydroxybenzoate standard curve used for quantitation. cPutative metabolite therefore analytical 
standard not available, 3-(4-hydroxyphenyl)propionic acid standard curve used for quantitation. dIsomers of this metabolite were unresolvable using this HPLC-ESI-MS/MS method so were 
quantified as a single analyte. 
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5.3. Results 
5.3.1. Serum biomarkers 
18 analytes were included in the analysis method to quantify the concentrations present in 
the serum from either the 13C-labelled cyanidin-3-glucoside intervention or from the 
background diet in eight participants across eight time-points (0 – 48 h). Six analytes were 
detected from the 13C-labelled cyanidin-3-glucoside intervention in at least one participant 
(Table 5.3) with concentrations ranging from 0.9 – 146.3 nM. Concentrations of the same 
analytes from the background diet ranged from 0.0 – 3743.5 nM. Hippuric acid was also 
detected at high concentration (1595.9 ± 987.6 nM) from the background diet in all 
participants. Cyanidin-3-glucoside was the analyte from the 13C-labelled cyanidin-3-
glucoside intervention found at the highest concentration (76.9 ± 47.6 nM). PCA-3/4-sulfate 
and hippuric acid were detected in all eight participants and PCA-3-glucuronide was detected 
at the same time-point (1 h) for each of the four participants in which it was detected.  
 
Table 5.3 Anthocyanin metabolite concentrations from 13C5-cyanidin-3-glucoside intervention compared to 12C 
background levels in serum samples. 
Compound n= 
13C Tmax 
(h) 
(mean ± SD) 
12C background 
concentration 
(nM) 
(mean ± SD) 
13C Cmax 
(nM) 
(mean ± SD) 
Background 
adjusted 
concentration 
(nM)  
(mean ± SD) 
Cyanidin-3-glucoside 4 0.9 ± 0.3 0.0 ± 0.0 76.9 ± 47.6 76.9 ± 47.6 
      
B-ring-derived      
4-hydroxybenzaldehyde ND ND ND ND ND 
Benzoic acid-4-glucuronide ND ND ND ND ND 
Ferulic acid 4 25.0 ± 18.0 3.7 ± 7.4 28.4 ± 26.5 24.7 ± 30.2 
Hippuric acid 8 15.3 ± 12.1 1595.9 ± 987.6 25.1 ± 14.9 -1570.8 ± 993.4 
Isovanillic acid ND ND ND ND ND 
IVA-3-glucuronide ND ND ND ND ND 
(I)VA-3/4-sulfate ND ND ND ND ND 
Methyl 3,4-DHB ND ND ND ND ND 
Phloroglucinaldehyde ND ND ND ND ND 
Protocatechuic acid ND ND ND ND ND 
PCA-3/4-sulfate 8 20.6 ± 22.7 16.1 ± 10.9 12.4 ± 9.6 -3.6 ± 16.2 
PCA-3-glucuronide 4 1.0 ± 0.0 0.0 ± 0.0 1.2 ± 0.4 1.2 ± 0.4 
PCA-4-glucuronide ND ND ND ND ND 
Vanillic acid ND ND ND ND ND 
Vanillic acid-4-glucuronide ND ND ND ND ND 
      
A-ring-derived      
Ferulic acid 1 48.0 ± 0.0 0.0 ± 0.0 4.7 ± 0.0 4.7 ± 0.0 
Methyl 3,4-DHB ND ND ND ND ND 
IVA, isovanillic acid; Methyl 3,4-DHB, methyl 3,4-dihydroxybenzoate; PCA, protocatechuic acid. n=, number of 
participants in which metabolite was detected. 13C Tmax, time-point at which the maximum concentration of 13C 
metabolites from the C3G intervention was observed. 12C background concentration is the concentration of 12C 
metabolites detected from the background diet at the 13C Tmax time-point. 13C Cmax, maximum concentration of 
13C metabolites from the C3G intervention observed amongst the eight participants. Background adjusted 
concentration is the 13C Cmax concentration minus the 12C background concentration. ND, not detected. 
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Comparing the levels of metabolites derived from the 13C-labelled cyanidin-3-glucoside 
intervention against those derived from the 12C background diet, cyanidin-3-glucoside itself 
was detected in 13C scans but not in 12C scans indicating there was none in the background 
diet. Four out of the six analytes detected as derived from the 13C-labelled intervention were 
found at concentrations above those derived from the 12C background diet. Hippuric acid 
was detected at much greater concentrations from the background diet than from the 13C-
labelled intervention diet. PCA-3-glucuronide displayed the lowest variation (33.9%) 
between concentrations across all time-points for the four participants in which it was 
detected. Amongst all detected analytes, cyanidin-3-glucoside was found at the highest 
concentration within the 13C-labelled metabolites and was also found at the lowest 
concentrations within the metabolites from the 12C background diet meaning that cyanidin-
3-glucoside had the highest background adjusted concentration (Figure 5.1).  
 
Figure 5.1 Background adjusted concentrations of cyanidin-3-glucoside and its serum metabolites 
detected in eight participants following a 13C5-cyanidin-3-glucoside intervention. 
 
n=8 study participants. Each cross represents data from a single participant in which a 13C-labelled 
analyte was detected and the maximum background adjusted analyte concentration (13C 
concentration minus 12C concentration) calculated to be present in that participant. Dotted line 
represents the point at which the analyte concentration from the 13C-labelled cyanidin-3-
glucoside intervention is equal to the concentration found in the background diet. 
 
Analysis of the metabolite concentration from the 13C-labelled cyanidin-3-glucoside 
intervention compared to the level from the background diet shows that cyanidin-3-
glucoside and PCA-3-glucuronide both peak in concentration at 1 h following intake, while 
B-ring-derived ferulic acid reached concentrations elevated above background first at 0.5 h 
and again at 24 and 48 h following 13C-labelled cyanidin-3-glucoside intake (Figure 5.2). 
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Figure 5.2 13C-labelled serum metabolite concentration compared to 12C background concentration throughout 48 hours following 13C5-cyanidin-3-glucoside intervention. 
 
(A) Cyanidin-3-glucoside. (B) Ferulic acid (B-ring-derived). (C) Protocatechuic acid-3-glucuronide. (D) Ferulic acid (A-ring-derived). 12C, background concentration; 13C, 13C-labelled 
metabolite concentration. Results expressed as mean ± SD. 
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5.3.2. Urine biomarkers 
107 analytes were included in the analysis method to quantify the concentrations present in 
the urine from either detection of the 13C-labelled cyanidin-3-glucoside from the 
intervention bolus or naturally abundant 12C analytes, reflecting compounds derived from 
the background diet in eight participants across eight time-points (0 – 48 h). 36 analytes 
were detected from the 13C-labelled cyanidin-3-glucoside intervention in at least one 
participant (Table 5.4) with concentrations ranging from 0.1 – 217.3 nM. Concentrations of 
the same analytes from the background diet ranged from 0.0 – 4127.1 nM. 3-methylhippuric 
acid was the analyte from the 13C-labelled cyanidin-3-glucoside intervention found at the 
highest concentration (77.3 ± 61.4 nM). 17 analytes were detected in all eight participants. 
Maximal concentrations of A-ring-derived gallic acid and isovanillic acid were detected in 6-
24 hour samples of all eight participants. 11 analytes were detected from the background 
diet at every time-point in all participants; 3/4-hydroxybenzoic acid, 3-hydroxyhippuric acid, 
3-hydroxyphenylacetic acid, 4-hydroxyhippuric acid, 4-hydroxyphenylacetic acid, 
dihydroxycinnamic acid-glucuronide, dimethoxy-hydroxycinnamic acid-glucuronide, 
hippuric acid, homovanillic acid, hydroxy-methoxycinnamic acid-glucuronide, and trans-
cinnamic acid. 
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Table 5.4 Anthocyanin metabolite concentrations from 13C5-cyanidin-3-glucoside intervention compared to 12C 
background levels in urine samples. 
Compound n= 
12C background 
concentration 
(nM)  
(mean ± SD) 
13C Cmax 
(nM) 
(mean ± SD) 
Background 
adjusted 
concentration 
(nM)  
(mean ± SD) 
Cyanidin-3-glucoside ND ND ND ND 
     
B-ring-derived     
2,3/2,4/2,5/3,5-dihydroxybenzoic acid ND ND ND ND 
2-hydroxy-4-methoxybenzoic acid ND ND ND ND 
2-hydroxybenzoic acid ND ND ND ND 
2-hydroxycinnamic acid ND ND ND ND 
3-(3-hydroxyphenyl)propionic acid ND ND ND ND 
3-(4-hydroxy-3-methoxyphenyl)propionic 
acid 
ND ND ND ND 
3-(4-hydroxyphenyl)propionic acid 1 0.0 ± 0.0 0.6 ± 0.0 0.6 ± 0.0 
3,4-dihydroxybenzaldehyde ND ND ND ND 
3,4-dihydroxyphenylacetic acid 3 3.1 ± 5.4 24.4 ± 13.5 21.2 ± 17.8 
3/4-hydroxybenzoic acid 2 1.9 ± 0.0 0.6 ± 0.8 -1.3 ± 0.8 
3-hydroxyhippuric acid 8 203.5 ± 249.5 14.9 ± 12.7 -188.5 ± 253.1 
3-hydroxyphenylacetic acid ND ND ND ND 
3-methylhippuric acid 8 0.2 ± 0.3 77.3 ± 61.4 77.1 ± 61.4 
4-hydroxybenzaldehyde ND ND ND ND 
4-hydroxybenzyl alcohol ND ND ND ND 
4-hydroxyhippuric acid 2 155.4 ± 57.4 0.4 ± 0.4 -154.9 ± 57.1 
4-hydroxyphenylacetic acid 2 59.3 ± 24.1 1.7 ± 0.5 -57.6 ± 23.6 
4-methylhippuric acid 8 0.3 ± 0.3 75.1 ± 62.3 74.8 ± 62.2 
α-hydroxyhippuric acid ND ND ND ND 
Benzoic acid ND ND ND ND 
Benzoic acid-4-glucuronide ND ND ND ND 
Benzoylglutamic acid ND ND ND ND 
Caffeic acid 2 0.0 ± 0.0 0.2 ± 0.2 0.2 ± 0.2 
Chlorogenic acid ND ND ND ND 
Dihydroxycinnamic acid-glucuronide 8 2.3 ± 1.5 0.8 ± 0.7 -1.5 ± 1.9 
Dihydroxyphenylacetic acid-sulfate 2 4.0 ± 5.7 12.9 ± 16.8 8.8 ± 22.5 
Dimethoxy-hydroxycinnamic acid-
glucuronide 
8 5.6 ± 9.9 1.8 ± 1.0 -3.8 ± 9.6 
(Iso)ferulic acid ND ND ND ND 
Gallic acid 8 0.8 ± 0.8 1.2 ± 0.6 0.4 ± 0.7 
Hippuric acid 8 1810.7 ± 1296.9 28.5 ± 18.6 -1782.2 ± 1302.2 
Homovanillic acid 1 58.5 ± 0.0 1.8 ± 0.0 -56.7 ± 0.0 
Hydroxy-methoxycinnamic acid-
glucuronide 
8 12.9 ± 8.5 4.0 ± 3.8 -8.9 ± 7.6 
Isovanillic acid 8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
Isovanillic acid-3-glucuronide ND ND ND ND 
Isovanillic acid-3-sulfate 3 0.0 ± 0.0 1.0 ± 0.6 1.0 ± 0.6 
Kaempferol 4 0.3 ± 0.6 0.3 ± 0.4 0.0 ± 0.2 
Methyl 3,4-dihydroxybenzoate ND ND ND ND 
Methyl dihydroxybenzoate-sulfate 8 2.0 ± 4.5 1.6 ± 1.0 -0.5 ± 5.1 
Protocatechuic acid ND ND ND ND 
Protocatechuic acid-3-glucuronide ND ND ND ND 
Protocatechuic acid-3/4-sulfate ND ND ND ND 
Protocatechuic acid-4-glucuronide ND ND ND ND 
p-Coumaric acid ND ND ND ND 
Phloroglucinaldehyde ND ND ND ND 
Phenylacetic acid ND ND ND ND 
Rosmarinic acid 5 0.0 ± 0.1 0.1 ± 0.1 0.0 ± 0.1 
Sinapic acid ND ND ND ND 
Syringic acid ND ND ND ND 
trans-3-hydroxycinnamic acid 1 0.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.0 
trans-Cinnamic acid 8 3.9 ± 3.6 1.5 ± 0.6 -2.4 ± 3.5 
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Table 5.4 (Continued)     
Compound n= 
12C background 
concentration 
(nM)  
(mean ± SD) 
13C Cmax 
(nM) 
(mean ± SD) 
Background 
adjusted 
concentration 
(nM)  
(mean ± SD) 
Vanillic acid ND ND ND ND 
Vanillic acid-4-glucuronide ND ND ND ND 
Vanillic acid-4-sulfate ND ND ND ND 
     
A-ring-derived     
2,3/2,4/2,5/3,5-dihydroxybenzoic acid ND ND ND ND 
2-hydroxy-4-methoxybenzoic acid ND ND ND ND 
2-hydroxybenzoic acid ND ND ND ND 
2-hydroxycinnamic acid ND ND ND ND 
3-(3-hydroxyphenyl)propionic acid ND ND ND ND 
3-(4-hydroxy-3-methoxyphenyl)propionic 
acid 
ND ND ND ND 
3-(4-hydroxyphenyl)propionic acid ND ND ND ND 
3,4-dihydroxybenzaldehyde ND ND ND ND 
3,4-dihydroxyphenylacetic acid ND ND ND ND 
3/4-hydroxybenzoic acid ND ND ND ND 
3-hydroxyhippuric acid 6 133.3 ± 98.3 1.0 ± 0.9 -132.3 ± 98.6 
3-hydroxyphenylacetic acid ND ND ND ND 
3-methylhippuric acid 8 0.2 ± 0.3 4.6 ± 4.2 4.4 ± 4.2 
4-hydroxybenzaldehyde ND ND ND ND 
4-hydroxybenzyl alcohol ND ND ND ND 
4-hydroxyhippuric acid ND ND ND ND 
4-hydroxyphenylacetic acid 1 40.1 ± 0.0 4.4 ± 0.0 -35.7 ± 0.0 
4-methylhippuric acid 8 0.3 ± 0.3 4.6 ± 4.0 4.3 ± 3.9 
α-hydroxyhippuric acid ND ND ND ND 
Benzoic acid ND ND ND ND 
Benzoic acid-4-glucuronide ND ND ND ND 
Benzoylglutamic acid ND ND ND ND 
Caffeic acid 7 0.4 ± 0.8 1.6 ± 1.9 1.2 ± 1.4 
Chlorogenic acid ND ND ND ND 
Dihydroxycinnamic acid-glucuronide 3 0.8 ± 0.4 0.0 ± 0.0 -0.7 ± 0.4 
Dihydroxyphenylacetic acid-sulfate ND ND ND ND 
Dimethoxy-hydroxycinnamic acid-
glucuronide 
3 4.7 ± 3.5 0.1 ± 0.1 -4.6 ± 3.6 
(Iso)ferulic acid ND ND ND ND 
Gallic acid 8 0.6 ± 0.6 55.3 ± 16.8 54.7 ± 16.2 
Hippuric acid 8 1640.4 ± 1446.7 13.4 ± 11.6 -1627.1 ± 1436.7 
Homovanillic acid 2 73.0 ± 26.5 1.8 ± 1.3 -71.1 ± 25.2 
Hydroxy-methoxycinnamic acid-
glucuronide 
5 13.0 ± 7.9 0.5 ± 0.4 -12.5 ± 7.7 
Isovanillic acid 8 0.0 ± 0.0 0.3 ± 0.2 0.3 ± 0.2 
Isovanillic acid-3-glucuronide ND ND ND ND 
Isovanillic acid-3-sulfate ND ND ND ND 
Kaempferol ND ND ND ND 
Methyl 3,4-dihydroxybenzoate ND ND ND ND 
Methyl dihydroxybenzoate-sulfate 8 2.0 ± 4.5 0.2 ± 0.1 -1.9 ± 4.5 
Protocatechuic acid ND ND ND ND 
Protocatechuic acid-3-glucuronide ND ND ND ND 
Protocatechuic acid-3/4-sulfate ND ND ND ND 
Protocatechuic acid-4-glucuronide ND ND ND ND 
p-Coumaric acid ND ND ND ND 
Phloroglucinaldehyde ND ND ND ND 
Phenylacetic acid ND ND ND ND 
Rosmarinic acid ND ND ND ND 
Sinapic acid ND ND ND ND 
Syringic acid ND ND ND ND 
trans-3-hydroxycinnamic acid ND ND ND ND 
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Table 5.4 (Continued)     
Compound n= 
12C background 
concentration 
(nM)  
(mean ± SD) 
13C Cmax 
(nM) 
(mean ± SD) 
Background 
adjusted 
concentration 
(nM)  
(mean ± SD) 
trans-Cinnamic acid ND ND ND ND 
Vanillic acid ND ND ND ND 
Vanillic acid-4-glucuronide ND ND ND ND 
Vanillic acid-4-sulfate ND ND ND ND 
n=, number of participants in which metabolite was detected. 12C background concentration is the concentration 
of 12C metabolites detected from the background diet at the 13C Tmax time-point (time-point at which the 
maximum concentration of 13C metabolites from the C3G intervention was observed). 13C Cmax, maximum 
concentration of 13C metabolites from the C3G intervention observed amongst the eight participants. Background 
adjusted concentration is the 13C Cmax concentration minus the 12C background concentration. ND, not detected. 
 
16 analytes showed concentrations of 13C-labelled metabolites above those present in 
baseline samples (reflecting background concentrations) (Figure 5.3 & Figure 5.4). Hippuric 
acid was detected at much greater concentrations from the background diet than from the 
13C-labelled cyanidin-3-glucoside intervention. A-ring-derived gallic acid displayed the lowest 
variation (29.6%) between concentrations for the participants in which it was detected. 
Analysis of the metabolite concentrations following the 13C-labelled cyanidin-3-glucoside 
intervention compared to the level from the 12C background diet (Figure 5.5 & Figure 5.6) 
shows that most analytes increase marginally from baseline to 24-48 hours post-
intervention. 
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Figure 5.3 Background adjusted concentrations of urinary B-ring-derived metabolites detected in eight participants following a 13C5-cyanidin-3-glucoside intervention. 
 
n=8 study participants. Each cross represents data from a single participant in which a 13C-labelled analyte was detected and the maximum background adjusted analyte concentration 
(13C concentration minus 12C concentration) calculated to be present in that participant. Dotted line represents the point at which the analyte concentration from the 13C-labelled cyanidin-
3-glucoside intervention is equal to the concentration found in the background diet. 
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Figure 5.4 Background adjusted concentrations of urinary A-ring-derived metabolites detected in eight participants following a 13C5-cyanidin-3-glucoside intervention. 
 
n=8 study participants. Each cross represents data from a single participant in which a 13C-labelled analyte was detected and the maximum background adjusted analyte 
concentration (13C concentration minus 12C concentration) calculated to be present in that participant. Dotted line represents the point at which the analyte concentration 
from the 13C-labelled cyanidin-3-glucoside intervention is equal to the concentration found in the background diet.
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Figure 5.5 13C-labelled B-ring-derived urinary metabolite concentration compared to 12C background 
concentration throughout 48 hours following 13C5-cyanidin-3-glucoside intervention. 
 
(A) 3-(4-hydroxyphenyl)propionic acid. (B) 3,4-dihydroxyphenylacetic acid. (C) 3-methylhippuric acid. (D) 4-
methylhippuric acid. (E) Caffeic acid. (F) Dihydroxyphenylacetic acid-sulfate. (G) Gallic acid. (H) Isovanillic 
acid-3-sulfate. (I) Kaempferol. (J) Rosmarinic acid. (K) trans-3-hydroxycinnamic acid. 12C, background 
concentration; 13C, 13C-labelled metabolite concentration. Results expressed as mean ± SD. 
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Figure 5.6 13C-labelled A-ring-derived urinary metabolite concentration compared to 12C background 
concentration throughout 48 hours following 13C5-cyanidin-3-glucoside intervention. 
 
(A) 3-methylhippuric acid. (B) 4-methylhippuric acid. (C) Caffeic acid. (D) Gallic acid. (E) Isovanillic acid. 12C, 
background concentration; 13C, 13C-labelled metabolite concentration. Results expressed as mean ± SD. 
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5.4. Discussion 
Epidemiological studies and human trials investigating the bioactivity of anthocyanins 
currently use tools such as food frequency questionnaires to record subjects’ food 
consumption and then use this to estimate flavonoid intake. The present study investigated 
the possibility of monitoring anthocyanin intake through quantifying characteristic 
metabolites as biomarkers of intake. 
Four serum metabolites were detected from the 13C5-C3G intervention at concentrations 
exceeding those seen in the background diet. The parent anthocyanin, cyanidin-3-glucoside, 
and ferulic acid were detected at the highest concentrations above background levels but 
were only detected in four out of eight participants and showed high inter-participant 
variability making these analytes poor biomarker candidates. PCA-3-glucuronide showed 
little variation in terms of the time-point and concentration at which it was detected; 
however, it was only detected in half of the participants and at concentrations only slightly 
above background levels, therefore ruling out this metabolite as a potential biomarker. 
Hippuric acid and sulfate conjugates of PCA were detected in all eight of the study 
participants; however, the concentrations detected from the 13C5-C3G intervention were 
typically lower than those detected in the background. Hippuric acid was detected at very 
high concentrations from the background diet, making it difficult to isolate specific changes 
in labelled metabolite concentration and therefore is a particularly poor candidate as an 
anthocyanin biomarker of intake. The results of this study do not present any suitable serum 
biomarkers of anthocyanin intake. Further study may identify possible biomarker candidates 
within the serum but urine may represent a more promising source of biomarkers and 
should be the focus of future research. 
16 urinary metabolites were detected from the 13C5-C3G intervention at concentrations 
exceeding those seen in the background diet. The four metabolites with the highest levels 
above the background diet were the B-ring-derived 3,4-dihydroxyphenylacetic acid, 3-
methylhippuric acid, 4-methylhippuric acid and A-ring-derived gallic acid. However, 3,4-
dihydroxyphenylacetic acid was only detected in three out of eight participants and is 
therefore not a suitable biomarker candidate. The other three metabolites were all detected 
in each of the eight participants. 3-methylhippuric acid (77.1 ± 61.4 nM) and 4-
methylhippuric acid (74.8 ± 62.2 nM) were both found at higher concentrations above 
background than gallic acid (54.7 ± 16.2 nM) but they also showed greater levels of inter-
individual variation amongst the participants (79.6% & 83.2% vs 29.6%, respectively). This 
suggests that gallic acid may be the best candidate for a urinary biomarker of anthocyanin 
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intake as it meets the criteria of being found in all participants, at levels above those found 
in the background diet and with little inter-individual variation. However, while gallic acid 
was found to be present above background levels in this study, the 13C5-C3G trial was 
conducted by asking volunteers to limit their intake of black tea which is one of the main 
sources of gallic acid in the diet (Neveu et al. 2010). Previous studies have shown that 24 
hours after intake of 500 mL of black tea, levels of gallic acid in the urine can reach up to 2.6 
µM (Del Rio et al. 2010b) which is well in excess of the nanomolar concentrations detected 
in the present study. An increase in the background level of gallic acid present in the urine 
to micromolar concentrations following regular consumption of black tea may limit the 
utility of gallic acid to be used as a biomarker of intake in studies of free-living individuals. 
Previous studies, however, have also reported gallic acid as a possible biomarker of 
anthocyanin intake in 24 h urine samples (Ito et al. 2005, Urpi‐Sarda et al. 2015) suggesting 
that gallic acid may be a useful biomarker of anthocyanin intake in studies that control the 
diet of participants and therefore limit the contribution of background sources. Further 
research is required to establish the viability of gallic acid as a urinary biomarker of 
anthocyanin intake. 
A potentially more promising approach may be to look for a characteristic metabolite profile 
of anthocyanin intake rather than a single representative metabolite. A number of studies 
have used a metabolomics approach to identify metabolic signatures present following 
intake of anthocyanin-rich foods or beverages (van Dorsten et al. 2010, Khymenets et al. 
2015). In isolation, gallic acid may be a suitable biomarker of anthocyanin intake. However, 
it seems likely that a panel of metabolites combining gallic acid with other metabolites that 
were present following the C3G intervention at concentrations in excess of those resulting 
from the background diet such as 3,4-dihydroxyphenylacetic acid, 3-methylhippuric acid, 
and 4-methylhippuric acid may represent an improved biomarker of anthocyanin intake. 
Future studies should investigate the utility of this approach. 
One limitation of the present analysis was, of the 18 serum metabolites and 23 urine 
metabolites previously reported (Czank et al. 2013), only six serum metabolites and seven 
urine metabolites were detected in this study. Analysis of the extraction efficiency of the 
internal standard, phloridzin, shows that the mean recoveries in serum (104.8 ± 23.6%) and 
urine (72.0 ± 27.6%) were acceptable, which suggests that there were no issues with the 
sample preparation methods that could have affected the recovery of the anthocyanin 
metabolites in the present study.  
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Analysis of the peak areas obtained from the QC samples that were included in this sample 
run show that the response for both QC standards, scopoletin and phloridzin, were within 
the normal limits for both ionisation modes (Table 5.5) which suggests that there were no 
issues with instrument response that could have affected the detection of anthocyanin 
metabolites in the present study. 
 
Table 5.5 QC sample response obtained in the present study compared to expected response based 
on previous QC samples. 
Compound 
Peak area  
(counts per second)  
(mean ± SD) 
Expected range  
(counts per second) 
Scopoletin (-) 1.02x106 ± 4.08x104 8.38x105 – 1.53x106 
Phloridzin (-) 1.42x107 ± 5.76x105 7.79x106 – 1.52x107 
Scopoletin (+) 2.86x106 ± 1.13x105 2.62x106 – 5.02x106 
Phloridzin (+) 1.90x105 ± 1.27x104 3.61x104 – 2.02x105 
(-), negative ionisation mode; (+), positive ionisation mode. 
 
A possible explanation for the lower number of metabolites detected in this study compared 
to those reported previously (Czank et al. 2013) is the difference in sensitivity between the 
instruments used in the two studies. The previously reported method (Czank et al. 2013) 
used an AB SCIEX 4000 QTRAP® mass spectrometer which is capable of sensitivity that is 
eight to ten times greater than is possible with the AB SCIEX 3200 QTRAP® instrument used 
in the present study (Impey 2005). The concentrations detected in the present study are 
close to the limit of detection for the current method and so this difference in sensitivity 
between the two instruments could explain why some metabolites could not be detected in 
this investigation.  
The difficulty in identifying suitable biomarkers in this investigation (as well as any dietary 
flavonoid intervention) is largely due to the high level of inter-participant variation in terms 
of metabolites detected, their concentrations and the time of their maximal plasma 
concentration. High levels of inter-participant variation are common in nutrition research 
(de Roos 2013) due to genetic differences between study participants causing differences in 
the way nutrients are metabolised (Minihane 2010, Wakeling and Ford 2012). This presents 
a challenge when attempting to identify reliable biomarkers of intake as an ideal biomarker 
should be applicable across the general population. Flavonoids pose an additional problem 
due to the apparent role of gut microbiota in their metabolism (Forester and Waterhouse 
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2008, Selma et al. 2009) which creates the potential for further variation amongst the 
population via differences in individuals’ microbiomes (Arumugam et al. 2011). However, 
these problems should not deter future research into suitable biomarkers of anthocyanin 
intake as these biomarkers have the potential to greatly increase the accuracy of future 
anthocyanin clinical interventions. The use of a signature panel of metabolites as a 
biomarker of anthocyanin intake may help to mitigate some of these issues by removing the 
reliance on a single metabolite and reducing the effect of inter-individual variation. 
The present study investigated both serum and urine samples as sources of metabolic 
biomarkers. Future work should focus on urinary biomarkers as a greater number of 
anthocyanin metabolites are present at much higher concentrations (Czank et al. 2013, de 
Ferrars et al. 2014a) making them easier to detect and quantify compared to serum 
metabolites. There are also practical considerations given that the goal of identifying 
biomarkers of intake is to improve accuracy of intake data/background diet and compliance 
in studies. Collection of urine samples can be done at home by untrained volunteers whereas 
collection of blood samples requires the volunteers to visit the study centre in order to have 
their blood taken by a trained professional (Spencer et al. 2008). Based on these limitations, 
establishing urinary biomarkers of anthocyanin intake should be a priority. 
 
5.5. Conclusion 
The present study suggests gallic acid is the most suitable urinary biomarker of anthocyanin 
intake, provided the background diet is stable in tea intake. Further studies are needed in 
order to establish the sensitivity of this metabolite in response to changing levels of 
anthocyanin consumption before it can be considered an acceptable biomarker of intake to 
be used in future epidemiological study of anthocyanins. Alternatively, gallic acid may be 
used, alongside a number of other metabolites identified in the present study, as part of a 
signature panel of metabolites characteristic of anthocyanin intake. 
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Chapter 6. The Effects of Different Metabolite Profiles on 
sVCAM-1 and IL-6 Expression in TNF-α and CD40L-stimulated 
HUVEC. 
 
6.1. Introduction 
Cardiovascular disease is responsible for over a quarter of all deaths in the UK every year 
(British Heart Foundation 2015). Epidemiological studies have reported that anthocyanin-
rich diets can reduce the risk of cardiovascular disease (McCullough et al. 2012, Cassidy et 
al. 2013). This finding has been supported by clinical trials that have observed positive effects 
on vascular measures such as blood pressure (Erlund et al. 2008) and flow-mediated dilation 
(Rodriguez-Mateos et al. 2013) and also by in vitro studies that have shown positive effects 
on expression of relevant cytokines following consumption of anthocyanins (Speciale et al. 
2013, Huang et al. 2014). However, bioavailability studies have reported very low 
concentrations of anthocyanins in the blood following consumption (Mazza et al. 2002, 
Milbury et al. 2002). Recent studies have demonstrated that anthocyanins are extensively 
metabolised within the body (Czank et al. 2013) suggesting that the metabolites may be 
responsible for the observed vascular bioactivity of anthocyanins. 
One of the main drivers of cardiovascular disease is the process of atherosclerosis whereby 
blood vessels become stiffened and occluded by formation of plaques within the vasculature 
leading to outcomes such as hypertension and myocardial infarction (Vogel 1997). The initial 
stages of atherosclerosis are characterised by chronic inflammation within the vascular 
endothelium (Libby et al. 2002). This process is initiated by the reaction of endothelial cells 
to increase expression of proinflammatory cytokines such as cell adhesion molecules and 
selectins in response to insults such as smoking and high oxidised LDL (oxLDL) levels (Tedgui 
and Mallat 2006). These cytokines attract monocytes, trigger their transformation into 
activated macrophages and facilitate their adhesion to and passage through the 
endothelium into the intima (Granger et al. 2004). Once through the endothelial layer, the 
macrophages are able to differentiate into foam cells leading to the formation of fatty 
streaks that can progress to form the atherosclerotic plaques that ultimately lead to the 
pathologies associated with cardiovascular disease (Granger et al. 2004).  
Tumour necrosis factor-α (TNF-α) and cluster of differentiation 40 ligand (CD40L) are 
signalling molecules produced by a number of cell types including activated macrophages 
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and endothelial cells in response to proinflammatory stimuli. TNF-α is released by activated 
cells in the vasculature and activates endothelial cells to upregulate adhesion molecules and 
other proinflammatory mediators via the nuclear factor-κB (NF-κB) and mitogen-activated 
protein kinase (MAPK) signalling pathways (Baud and Karin 2001). CD40L is a 
transmembrane protein expressed in activated T-cells that when bound with CD40 receptor 
can trigger a cascade of proinflammatory cytokines within endothelial cells (Déchanet et al. 
1997). As such, TNF-α and CD40L are commonly used to stimulate an inflammatory response 
within endothelial cell types in vitro (Xia et al. 2009, Wu et al. 2012). VCAM-1 is a cell 
adhesion molecule expressed in endothelial cells involved in the attachment and migration 
of monocytes across the endothelium (Carter and Wicks 2001). VCAM-1 acts through 
interactions with integrin α4β1 and activation of NOX leading to production of reactive 
oxygen species and further inflammatory progression (Blankenberg et al. 2003). IL-6 is 
produced in response to infection and following binding with its receptor, IL-6R, acts via 
downstream signal transducer and activator of transcription (STAT), and janus kinase (JAK) 
signalling pathways to induce inflammatory gene expression (Schuett et al. 2009, Brasier 
2010). VCAM-1 and IL-6 are both downstream signalling molecules within the TNF-α/CD40L-
stimulated inflammatory response and are commonly used as in vitro biomarkers of 
inflammation in endothelial cells (Hidalgo et al. 2012, Wang et al. 2012), therefore 
embodying a vascular model of initiation of inflammation. 
Recently the focus of research into the vascular bioactivity of anthocyanins has shifted away 
from the parent compounds (as found in the diet) and towards studying their phenolic 
metabolites (as found in the circulation). Recent work published by our group has 
investigated the effect of anthocyanin metabolites, both individually (Amin et al. 2015, 
Edwards et al. 2015) and as simple combinations (di Gesso et al. 2015, Warner et al. 2016), 
on the expression of proinflammatory cytokines such as VCAM-1 and IL-6 in HUVEC. 
However, neither of these approaches accurately reflects the in vivo metabolite profiles with 
respect to diversity and complexity of mixtures reported following consumption. The 
present study aimed to address this by investigating the effect of treatments composed of 
the metabolite profiles reported in the serum following an anthocyanin feeding trial (Czank 
et al. 2013, de Ferrars et al. 2014a) on VCAM-1 and IL-6 expression in HUVEC. The 
pharmacokinetic data (Figure 6.1) was used to create three different metabolite mixtures 
that reflect the metabolites present (profile and concentration) within the blood at three 
distinct peaks/time-points post-consumption (1, 6 and 24 hours) (de Ferrars et al. 2014a).  
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The aim of the present study was to establish the impact of distinct metabolite profiles on 
vascular inflammation following consumption of anthocyanins. 
 
Figure 6.1 Pharmacokinetic data from a 13C-labelled cyanidin-3-glucoside feeding trial showing total 13C 
metabolite concentration in serum across 48 hours in eight participants. 
 
Results displayed as mean ± SD, n=8. Serum kinetic data was used to establish three treatments that reflect 
the metabolite composition at three distinct peak concentrations observed at 1, 6 and 24 hours post-
consumption. The effect of the three treatments on expression of VCAM-1 and IL-6 in TNF-α and CD40L-
stimulated HUVEC was investigated. Adapted from (Czank et al. 2013, de Ferrars et al. 2014a). 
 
6.2. Methods 
6.2.1. Materials and reagents 
Cyanidin-3-glucoside was obtained from Extrasynthese (Genay, France) and prepared at a 
concentration of 40 mM in 100% dimethyl sulfoxide (DMSO, molecular biology grade; Sigma-
Aldrich, Dorset, UK). Phase II conjugates of phenolic acids (benzoic acid-4-glucuronide, PCA-
4-glucuronide, PCA-3-sulfate, PCA-4-sulfate, vanillic acid-4-glucuronide, isovanillic acid-3-
glucuronide, vanillic acid-4-sulfate, and isovanillic acid-3-sulfate) were synthesised at the 
School of Chemistry and Centre for Biomolecular Sciences, University of St. Andrews (UK) via 
recently published methods (Zhang et al. 2012). Primary stock solution of synthetic 
treatments were made at a concentration of 200 mM in 100% DMSO with the exception of 
PCA-3-sulfate, PCA-4-sulfate, and isovanillic acid-3-sulfate which were prepared at 25 mM 
concentrations (in 50:50 DMSO:MilliQ water), while vanillic acid-4-sulfate was prepared at 
50 mM concentrations (in 50:50 DMSO:MilliQ water). Commercial standards, PCA, PGA, 
vanillic acid, isovanillic acid, 4-hydroxybenzaldehyde, ferulic acid, and hippuric acid were 
purchased from Sigma-Aldrich (Dorset, UK) and prepared at a concentration of 5 mg/mL in 
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100% DMSO. Cryo-preserved, early passage HUVEC from pooled donors, human large vessel 
endothelial cell basal media, human large vessel endothelial cell growth media supplement, 
antibiotic supplement, and trypsin were purchased from Caltag Medsystems (Buckingham, 
UK). Trypsin neutralising solution was purchased from Lonza (Slough, UK). Cryo-preserved 
D1.1 Jurkat cells were obtained from the American Type Culture Collection (ATCC, LGC 
Standards, Teddington, UK). DuoSet® human VCAM-1 enzyme-linked immunosorbent assay 
(ELISA) kit, DuoSet® human IL-6 ELISA kit, 96-well microplates, reagent diluent, substrate 
solution, and plate sealers were purchased from R & D Systems (Abingdon, UK). CD40L 
monoclonal antibody was purchased from Enzo Life Sciences (Exeter, UK). 96-well 
microplates were purchased from BD Falcon (Oxford, UK). Fetal bovine serum, RPMI-1640 
media, penicillin/streptomycin, and L-glutamine were purchased from PAA (Pasching, 
Austria). Water-soluble tetrazolium salt-1 reagent [WST-1, (4-[3-(4-Iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate)] was purchased from Roche Applied 
Science (Burgess Hill, UK). Lyophilised recombinant human TNF-α was purchased from 
Invitrogen (Paisley, UK). Ethanol was purchased from Fisher Scientific (Loughborough, UK). 
Nunclon™ 75 cm2 flasks, Nunclon™ 24-well plates, DMSO, trypan blue, fibronectin, and 
BAY11-7085 were purchased from Sigma-Aldrich, (Dorset, UK). 
6.2.2. Treatment preparation 
Stock solutions of the metabolites were prepared in DMSO and used to prepare 250 µM 
working solutions in human large vessel endothelial cell basal media. The working solutions 
were then used to prepare treatments (Table 6.1) to replicate previously reported 
metabolite profiles identified at 1, 6 and 24 hours post-consumption (P-1, P-6, P-24; 
respectively) of 500mg 13C5-labelled C3G (Czank et al. 2013, de Ferrars et al. 2014a) (Figure 
6.1). 
Concentration response was established by treatment with the mixtures at concentrations 
10 fold above and below the peak concentration identified previously in the human study 
(Czank et al. 2013, de Ferrars et al. 2014a) [P-1 (0.19, 1.9, 19 µM), P-6 (0.2, 2.0, 20 µM), and 
P-24 (0.4, 4.4, 44 µM)]. 
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Table 6.1 Composition of treatments P-1, P-6, and P-24. 
Compound 
Concentration (µM) 
P-1 P-6 P-24 
4-hydroxybenzaldehyde 0.01 0.01 0.01 
Benzoic acid-4-glucuronide 0.01 0.04 0.04 
Cyanidin-3-glucoside 0.05 - - 
Ferulic acid 0.29 0.21 0.59 
Hippuric acid 0.07 0.23 1.94 
Isovanillic acid 0.12 - - 
Isovanillic acid-3-glucuronide 0.01 0.02 - 
Isovanillic acid-3-sulfate - - 0.17 
Phloroglucinaldehyde 0.03 0.55 0.05 
Protocatechuic acid 0.04 0.08 0.01 
Protocatechuic acid-3-sulfate 0.07 0.02 0.02 
Protocatechuic acid-4-glucuronide 0.02 0.03 - 
Protocatechuic acid-4-sulfate 0.07 0.02 0.02 
Vanillic acid 1.10 0.80 1.36 
Vanillic acid-4-glucuronide 0.01 0.02 - 
Vanillic acid-4-sulfate - - 0.17 
Total 1.90 2.03 4.38 
P-1, P-6, P-24 are treatments designed to replicate previously reported metabolite profiles identified at 1, 6, and 
24 hours respectively, post-consumption of 500 mg of 13C5-labelled C3G (Czank et al. 2013, de Ferrars et al. 
2014a). A dash represents a metabolite that is not found in that particular treatment. 
 
6.2.3. HUVEC culture 
HUVEC were maintained in human large vessel endothelial cell basal media supplemented 
with antibiotics and growth factors at 37°C with 5% CO2 in 75 cm2 flasks coated with 
fibronectin (0.26 µg/cm2). HUVEC were cultured to 90-95% confluence prior to being split 
using 0.025% trypsin and all experiments were conducted using HUVEC at passage two to 
four. 
6.2.4. D1.1 Jurkat cell culture 
D1.1 Jurkat cells were cultured in RPMI-1640 media supplemented with 1% 
penicillin/streptomycin, 10% FBS, and 2 mM L-glutamine was used to culture at 37°C with 
5% CO2 in 75 cm2 flasks. Cell density was maintained between 2.5 x 105 and 1 x 106 cells/mL 
and density was calculated using a haemocytometer and trypan blue staining. 
6.2.5. Cytotoxicity assay 
The effect of treatments on cell viability was measured using the WST-1 cell proliferation 
assay. HUVEC were seeded in a fibronectin-coated (0.41 µg/cm2) 96-well plate at ~20,000 
cells/well and grown to confluence at 37°C, 5% CO2. The culture media was then removed 
and replaced with 100 µL of each treatment prepared in human large vessel endothelial cell 
basal media at the highest concentration used in the activity assays. Controls consisted of 
0.07% DMSO in media with no HUVEC (blank), media (control), 0.07% DMSO in media 
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(vehicle control), and PBS (WST-1 negative control). The quintuplicate samples were 
incubated for 24 hours at 37°C, 5% CO2 before 10 µL of WST-1 reagent was added to each 
well. The plate was incubated at 37°C, 5% CO2 for a further 2 hours before absorbance 
readings were taken at 450 nm with a reference wavelength of 650 nm using a BMG 
microplate reader (FLUOstar Omega, BMG Labtech, Aylesbury, UK). 
6.2.6. TNF-α induced sVCAM-1 and IL-6 expression in HUVEC: Time-course assay 
HUVEC were cultured using the procedure outlined previously and seeded into triplicate 24-
well, fibronectin-coated (0.25 µg/cm2) plates at a density of ~80,000 cells/well. The plates 
were incubated at 37°C, 5% CO2 until the cells reached 90-95% confluence. The culture 
media was removed and HUVEC were pre-incubated with control samples in 600 µl human 
large vessel endothelial cell basal media for 30 minutes prior to the addition of TNF-α (10 
ng/mL). Control samples consisted of unstimulated HUVEC in media (basal), TNF-α only 
(positive control), 0.07% DMSO in media (vehicle control), and BAY11-7085 (1 µM, 1 hour 
pre-incubation, negative control). The plates were incubated for either 6, 18 or 24 hours at 
37°C, 5% CO2 before the media was removed and stored at -80°C until analysis. 
6.2.7. TNF-α stimulation of sVCAM-1 and IL-6 expression in HUVEC 
HUVEC were cultured and seeded into 24-well plates using the procedure outlined 
previously. Upon reaching 90-95% confluence, the culture media was removed and HUVEC 
were pre-incubated with treatments in 600 µl human large vessel endothelial cell basal 
media for 30 minutes prior to the addition of TNF-α (10 ng/mL). Control samples consisted 
of unstimulated HUVEC in media (basal), TNF-α only (positive control), 0.07% DMSO in media 
(vehicle control), and BAY11-7085 (1 µM, 1 hour pre-incubation, negative control). The 
plates were incubated for 24 hours at 37°C, 5% CO2 before the media was removed and 
stored at -80°C until analysis. 
6.2.8. CD40L stimulation of sVCAM-1 and IL-6 expression in HUVEC 
HUVEC were cultured and seeded into 24-well plates using the procedure outlined 
previously. Upon reaching 90-95% confluence, the culture media was removed and HUVEC 
were pre-incubated with treatments in 600 µl human large vessel endothelial cell basal 
media for 30 minutes prior to the addition of D1.1 Jurkat cells (1 x 106 cells/well). Control 
samples consisted of unstimulated HUVEC in media (basal), D1.1 Jurkat cells only (positive 
control), 0.07% DMSO in media (vehicle control), and D1.1 Jurkat cells pre-incubated for 1 
hour with 10 µg/mL CD40L monoclonal antibody (negative control). The plates were 
incubated for 24 hours at 37°C, 5% CO2 before the media was removed and stored at -80°C 
until analysis. 
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6.2.9. sVCAM-1 ELISA 
Expression of sVCAM-1 was measured using a DuoSet® ELISA kit according to the 
manufacturer’s instructions. Prior to analysis, samples were centrifuged at 4°C, 13000 rpm 
for 10 mins to remove D1.1 Jurkat cells and cell debris. TNF-α-stimulated HUVEC media was 
diluted 1:2 and CD40L-stimulated HUVEC media was diluted 1:4 with reagent diluent. The kit 
used a mouse anti-human VCAM-1 capture antibody (2 µg/mL in PBS) and biotinylated sheep 
anti-human VCAM-1 detection antibody (200 ng/mL in reagent diluent). Colorimetric assay 
was used to quantify sVCAM-1 expression by measuring absorbance at 450 nm with a 
reference wavelength of 570 nm using a BMG microplate reader. 
6.2.10. IL-6 ELISA 
Expression of IL-6 was measured using a DuoSet® ELISA kit according to the manufacturer’s 
instructions. Prior to analysis, samples were centrifuged at 4°C, 13000 rpm for 10 mins to 
remove D1.1 Jurkat cells and cell debris. TNF-α-stimulated HUVEC media was diluted 1:4 and 
CD40L-stimulated HUVEC media was diluted 1:1 with reagent diluent. The kit used a mouse 
anti-human IL-6 capture antibody (2 µg/mL in PBS) and biotinylated goat anti-human IL-6 
detection antibody (50 ng/mL in reagent diluent). Colorimetric assay was used to quantify 
IL-6 expression by measuring absorbance at 450 nm with a reference wavelength of 570 nm 
using a BMG microplate reader. 
6.2.11. Statistical analysis 
For cytotoxicity and ELISA data, one-way analysis of variance (ANOVA) with LSD post-hoc test 
was performed on either three (ELISA) or five (cytotoxicity) biological replicates (with each 
biological replicate representing the mean of two technical replicates) using SPSS for 
Windows statistical software package (version 22, IBM, New York, USA). Significance was 
determined at the 5% confidence level. Statistical analysis was conducted on raw data with 
mean values graphed as either percentage of positive control (cytotoxicity and activity 
assays) or fold change from basal (time-course assays) with error bars representing standard 
deviation. 
 
6.3. Results 
6.3.1. Cytotoxicity assay 
Three treatments (19 µM P-1, 20 µM P-6, and 44 µM P-24) were utilised in the sVCAM-1 and 
IL-6 activity assays, reflecting concentrations that are tenfold higher than peak 
concentrations identified previously (Czank et al. 2013, de Ferrars et al. 2014a). 19 µM P-1, 
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20 µM P-6, 44 µM P-24, TNF-α positive control, CD40L negative control and TNF-α negative 
control were screened for cytotoxicity (Figure 6.2). No significant reduction in HUVEC 
viability was observed, with the exception of TNF-α positive control and the maximum 
concentration 44 µM P-24 treatment. TNF-α negative control showed a significant increase 
in viability. 
 
Figure 6.2 Cytotoxicity of treatment compounds in HUVEC as measured by WST-1 assay following 24 hour 
incubation. 
 
Cell viability (mean absorbance as percentage of control absorbance) for control (media), vehicle control 
(0.07% DMSO in media), WST-1 negative control (PBS), TNF-α positive control (10 ng/mL TNF-α), CD40L 
negative control (10 µg/mL CD40L monoclonal antibody), TNF-α negative control (1 µM BAY11-7085 
antibody), 19 µM P-1, 20 µM P-6, and 44 µM P-24. Data shown as mean ± SD, n=5. Significance relative to 
vehicle control, **p≤0.01, ***p<0.001, one-way ANOVA with LSD post-hoc test. 
 
6.3.2. TNF-α induced sVCAM-1 expression time-course validation 
Expression of sVCAM-1 in HUVEC was measured following incubation with TNF-α positive 
control for 6, 18 or 24 hours to establish optimal incubation time (Figure 6.3). Both the 18 
hour (38.4 fold increase from basal) and 24 hour (31.2 fold increase from basal) time-points 
showed a significantly higher response compared to the 6 hour time-point (5.9 fold increase 
from basal). There was no significant difference between the response at 18 and 24 hours. 
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Figure 6.3 sVCAM-1 production in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) for 6, 18 or 24 hours before cell 
supernatant quantitation of sVCAM-1 expression via ELISA. Data expressed as mean ± SD, n=3. a,bDifferent 
letters represent statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
6.3.3. TNF-α induced sVCAM-1 expression 
Compared to unstimulated HUVEC, incubation with TNF-α positive control led to a 95.4 fold 
increase in sVCAM-1 expression which was significantly inhibited (66.2 ± 3.3%) when HUVEC 
were pre-treated with BAY11-7085 as a TNF-α negative control to inhibit phosphorylation of 
IκBα and block the NF-κB signalling pathway, therefore reducing expression of sVCAM-1. 
(Figure 6.4). 
 
Figure 6.4 sVCAM-1 production in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) for 24 hours before cell supernatant 
quantitation of sVCAM-1 expression via ELISA. TNF-α negative control was pre-treated with 1 µM BAY11-
7085 antibody for 1 hour prior to TNF-α stimulation. Data expressed as mean ± SD, n=3. Significance relative 
to positive control, ***p<0.001, one-way ANOVA with LSD post-hoc test. 
 
The effect of three previously reported metabolite profiles (Czank et al. 2013, de Ferrars et 
al. 2014a) (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) on expression of sVCAM-1 in TNF-α-
stimulated HUVEC was investigated in HUVEC following 24 hours. After 24 hours, all three 
treatments showed a significant reduction in sVCAM-1 expression compared to vehicle 
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control (Figure 6.5). 2.0 µM P-6 (58.4 ± 2.5%) and 4.4 µM P-24 (50.7 ± 0.6%) both showed a 
greater reduction in sVCAM-1 expression than 1.9 µM P-1 (46.9 ± 2.9%).  
 
Figure 6.5 sVCAM-1 production following treatment with anthocyanin metabolites in TNF-α-stimulated 
HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) and vehicle control (0.07% DMSO in 
media) or treatments (1.9 µM P-1, 2.0 µM P-6, 4.4 µM P-24) for 24 hours before cell supernatant 
quantitation of sVCAM-1 expression via ELISA. Data expressed as mean ± SD, n=3. Significance relative to 
vehicle control, ***p<0.001, one-way ANOVA with LSD post-hoc test. a,b,cDifferent letters represent 
statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
Concentration response was established by incubating HUVEC with the metabolite profiles 
at cumulative concentrations 10 fold above and below the peak concentration identified 
previously in the human study (Czank et al. 2013, de Ferrars et al. 2014a) [P-1 (0.19, 1.9, 19 
µM), P-6 (0.2, 2.0, 20 µM), and P-24 (0.4, 4.4, 44 µM)]. All treatments showed significant 
reductions in sVCAM-1 expression relative to vehicle control (Figure 6.6) with the greatest 
response observed at the highest concentrations tested (19 µM P-1, 59.3 ± 2.8%; 20 µM P-
6, 65.1 ± 0.5%; 44 µM P-24, 66.2 ± 3.5%). 
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Figure 6.6 sVCAM-1 production following treatment with anthocyanin metabolites in TNF-α-stimulated 
HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) and vehicle control (0.07% DMSO in 
media) or treatments (0.19 µM P-1, 1.9 µM P-1, 19 µM P-1; 0.2 µM P-6, 2.0 µM P-6, 20 µM P-6; 0.4 µM P-
24, 4.4 µM P-24, 44 µM P-24) for 24 hours before cell supernatant quantitation of sVCAM-1 expression via 
ELISA. Data expressed as mean ± SD, n=3. Significance relative to vehicle control, ***p<0.001, one-way 
ANOVA with LSD post-hoc test. a,b,cDifferent letters represent statistical differences between groups, 
p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
6.3.4. TNF-α induced IL-6 expression time-course assay validation 
Expression of IL-6 in HUVEC was measured following incubation with TNF-α positive control 
for 6, 18 or 24 hours to establish optimal incubation time (Figure 6.7). No significant 
difference was observed between the various incubation periods. 
 
Figure 6.7 IL-6 production in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) for 6, 18 or 24 hours before cell 
supernatant quantitation of IL-6 expression via ELISA. Data expressed as mean ± SD, n=3. aDifferent letters 
represent statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
6.3.5. TNF-α induced IL-6 expression 
Compared to unstimulated HUVEC, incubation with TNF-α positive control led to a 6.0 fold 
increase in IL-6 expression which was not significantly inhibited (0.9 ± 3.2%) by pre-
treatment of HUVEC with TNF-α negative control (Figure 6.8). 
 
 Page | 140 
Figure 6.8 IL-6 production in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) for 24 hours before cell supernatant 
quantitation of IL-6 expression via ELISA. TNF-α negative control was pre-treated with 1 µM BAY11-7085 
antibody for 1 hour prior to TNF-α stimulation. Data expressed as mean ± SD, n=3. Significance relative to 
positive control, ***p<0.001, one-way ANOVA with LSD post-hoc test. 
 
The effect of three previously reported metabolite profiles (Czank et al. 2013, de Ferrars et 
al. 2014a) (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) on expression of IL-6 in TNF-α-
stimulated HUVEC was investigated in HUVEC following 24 hours. After 24 hours, all three 
treatments showed a significant reduction in IL-6 expression compared to vehicle control 
(Figure 6.9). The metabolite profile identified at 6h post-consumption (2.0 µM P-6; 36.6 ± 
4.6%) showed the greatest activity on IL-6 expression (1.9 µM P-1; 15.6 ± 4.1% and 4.4 µM 
P-24; 20.3 ± 3.7%).  
 
Figure 6.9 IL-6 production following treatment with anthocyanin metabolites in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) and vehicle control (0.07% DMSO in 
media) or treatments (1.9 µM P-1, 2.0 µM P-6, 4.4 µM P-24) for 24 hours before cell supernatant 
quantitation of IL-6 expression via ELISA. Data expressed as mean ± SD, n=3. Significance relative to vehicle 
control, ***p<0.001, one-way ANOVA with LSD post-hoc test. a,b,cDifferent letters represent statistical 
differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
Concentration response was established by incubating HUVEC with the metabolite profiles 
at cumulative concentrations 10 fold above and below the peak concentration identified 
previously in the human study (Czank et al. 2013, de Ferrars et al. 2014a) [P-1 (0.19, 1.9, 19 
µM), P-6 (0.2, 2.0, 20 µM), and P-24 (0.4, 4.4, 44 µM)]. All treatments showed a significant 
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reduction in IL-6 expression compared to vehicle control except for 0.19 µM P-1 and 0.2 µM 
P-6 (Figure 6.10). The greatest reductions were observed from 19 µM P-1 (28.5 ± 8.9%), 2.0 
µM P-6 (36.6 ± 4.6%), and 44 µM P-24 (35.6 ± 0.9%). 
 
Figure 6.10 IL-6 production following treatment with anthocyanin metabolites in TNF-α-stimulated HUVEC. 
 
HUVEC were incubated with TNF-α positive control (10 ng/mL TNF-α) and vehicle control (0.07% DMSO in 
media) or treatments (0.19 µM P-1, 1.9 µM P-1, 19 µM P-1; 0.2 µM P-6, 2.0 µM P-6, 20 µM P-6; 0.4 P-24, 
4.4 µM P-24, 44 µM P-24) for 24 hours before cell supernatant quantitation of IL-6 expression via ELISA. 
Data expressed as mean ± SD, n=3. Significance relative to vehicle control, **p≤0.01, ***p<0.001, one-way 
ANOVA with LSD post-hoc test. a,b,c,dDifferent letters represent statistical differences between groups, 
p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
6.3.6. CD40L induced sVCAM-1 expression 
Compared to unstimulated HUVEC, incubation with CD40L positive control led to a 
significant increase in sVCAM-1 expression which was significantly inhibited (97.8 ± 1.4%) via 
pre-treatment of HUVEC with CD40L negative control (Figure 6.11). 
 
Figure 6.11 sVCAM-1 production in CD40L-stimulated HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) for 24 
hours before cell supernatant quantitation of sVCAM-1 expression via ELISA. CD40L negative control was 
pre-treated with 10 µg/mL CD40L monoclonal antibody for 1 hour prior to CD40L stimulation. Data 
expressed as mean ± SD, n=3. Significance relative to positive control, ***p<0.001, one-way ANOVA with 
LSD post-hoc test. 
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The effect of three previously reported metabolite profiles (Czank et al. 2013, de Ferrars et 
al. 2014a) (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) on expression of sVCAM-1 in CD40L-
stimulated HUVEC was investigated in HUVEC following 24 hours. After 24 hours incubation, 
none of the three treatments showed significant reduction in sVCAM-1 expression compared 
to vehicle control (Figure 6.12).  
 
Figure 6.12 sVCAM-1 production following treatment with anthocyanin metabolites in CD40L-stimulated 
HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) and 
vehicle control (0.07% DMSO in media) or treatments (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) for 24 
hours before cell supernatant quantitation of sVCAM-1 expression via ELISA. Data expressed as mean ± SD, 
n=3. Significance relative to vehicle control, *p≤0.05, one-way ANOVA with LSD post-hoc test. aDifferent 
letters represent statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
Concentration response was established by incubating HUVEC with the metabolite profiles 
at cumulative concentrations 10 fold above and below the peak concentration identified 
previously in the human study (Czank et al. 2013, de Ferrars et al. 2014a) [P-1 (0.19, 1.9, 19 
µM), P-6 (0.2, 2.0, 20 µM), and P-24 (0.4, 4.4, 44 µM)]. None of the treatments showed a 
significant reduction in sVCAM-1 expression compared to vehicle control (Figure 6.13). 
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Figure 6.13 sVCAM-1 production following treatment with anthocyanin metabolites in CD40L-stimulated 
HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) and 
vehicle control (0.07% DMSO in media) or treatments (0.19 µM P-1, 1.9 µM P-1, 19 µM P-1; 0.2 µM P-6, 
2.0 µM P-6, 20 µM P-6; 0.4 µM P-24, 4.4 µM P-24, 44 µM P-24) for 24 hours before cell supernatant 
quantitation of sVCAM-1 expression via ELISA. Data expressed as mean ± SD, n=3. Significance relative to 
vehicle control, *p≤0.05, one-way ANOVA with LSD post-hoc test. aDifferent letters represent statistical 
differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
6.3.7. CD40L induced IL-6 expression 
Compared to unstimulated HUVEC, incubation with CD40L positive control led to a 2.0 fold 
increase in IL-6 expression which was not significantly inhibited (17.4 ± 8.8%) via pre-
treatment of HUVEC with CD40L negative control (Figure 6.14). 
 
Figure 6.14 IL-6 production in CD40L-stimulated HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) for 24 
hours before cell supernatant quantitation of IL-6 expression via ELISA. CD40L negative control was pre-
treated with 10 µg/mL CD40L monoclonal antibody for 1 hour prior to CD40L stimulation. Data expressed 
as mean ± SD, n=3. Significance relative to positive control, **p≤0.01, one-way ANOVA with LSD post-hoc 
test. 
 
The effect of three previously reported metabolite profiles (Czank et al. 2013, de Ferrars et 
al. 2014a) (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) on expression of IL-6 in CD40L-
stimulated HUVEC was investigated in HUVEC following 24 hours. After 24 hours, none of 
the three treatments showed a significant reduction in IL-6 expression compared to vehicle 
control (Figure 6.15).  
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Figure 6.15 IL-6 production following treatment with anthocyanin metabolites in CD40L-stimulated HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) and 
vehicle control (0.07% DMSO in media) or treatments (1.9 µM P-1, 2.0 µM P-6, and 4.4 µM P-24) for 24 
hours before cell supernatant quantitation of IL-6 expression via ELISA. Data expressed as mean ± SD, n=3. 
Significance relative to vehicle control, *p≤0.05, one-way ANOVA with LSD post-hoc test. aDifferent letters 
represent statistical differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
 
Concentration response was established by incubating HUVEC with the metabolite profiles 
at cumulative concentrations 10 fold above and below the peak concentration identified 
previously in the human study (Czank et al. 2013, de Ferrars et al. 2014a) [P-1 (0.19, 1.9, 19 
µM), P-6 (0.2, 2.0, 20 µM), and P-24 (0.4, 4.4, 44 µM)]. Significant reductions in IL-6 
expression relative to vehicle control (Figure 6.16) were observed at the highest 
concentrations tested (19 µM P-1, 40.2 ± 12.9%; 20 µM P-6, 41.2 ± 16.1%; 44 µM P-24, 49.8 
± 17.3%). 
 
Figure 6.16 IL-6 production following treatment with anthocyanin metabolites in CD40L-stimulated HUVEC. 
 
HUVEC were incubated with CD40L positive control (1 x 106 CD40L-expressing D1.1 Jurkat cells/well) and 
vehicle control (0.07% DMSO in media) or treatments (0.19 µM P-1, 1.9 µM P-1, 19 µM P-1; 0.2 µM P-6, 
2.0 µM P-6, 20 µM P-6; 0.4 µM P-24, 4.4 µM P-24, 44 µM P-24) for 24 hours before cell supernatant 
quantitation of IL-6 expression via ELISA. Data expressed as mean ± SD, n=3. Significance relative to vehicle 
control, *p≤0.05, **p≤0.01, one-way ANOVA with LSD post-hoc test. a,bDifferent letters represent statistical 
differences between groups, p≤0.05, one-way ANOVA with LSD post-hoc test. 
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6.4. Discussion 
Initial studies into the bioactivity of anthocyanins in vitro used parent compounds at 
supraphysiological concentrations (Xu et al. 2004, Xia et al. 2007). More recently, work in 
our lab and elsewhere has begun to use individual phenolic metabolites at physiological 
concentrations (Amin et al. 2015, Edwards et al. 2015, Krga et al. 2016) in order to better 
represent the compounds present in the body following anthocyanin consumption. Limited 
studies have been conducted in our lab using mixtures of metabolites (di Gesso et al. 2015, 
Warner et al. 2016) providing information on the additive effects of metabolites in 
combination whilst still not perfectly representing the metabolic profiles observed following 
anthocyanin consumption. Some studies have used extracted serum containing phenolic 
metabolites of proanthocyanidins (Guerrero et al. 2013) to investigate bioactivity, however, 
this approach comes with limitations such as the high level of proteins and other serum 
components present that cannot be controlled for. To the author’s knowledge, the present 
study is the first to study the bioactivity of anthocyanin metabolites using metabolite 
profiles, under controlled conditions and at physiologically appropriate concentrations, as 
reported in serum following the consumption of anthocyanins (Czank et al. 2013, de Ferrars 
et al. 2014a). Concentration response was also investigated by the inclusion of metabolite 
profiles at cumulative concentrations 10 fold above and below the peak concentration, and 
within the range reported amongst eight participants post-consumption of 500 mg of 13C-
labelled cyanidin-3-glucoside (Czank et al. 2013, de Ferrars et al. 2014a).  
In the present study, significant reductions in sVCAM-1 and IL-6 expression were observed 
when HUVEC were treated with three previously reported anthocyanin metabolite profiles 
(Czank et al. 2013, de Ferrars et al. 2014a) in an experimental model of inflammation 
involving TNF-α-stimulation (Figure 6.5 & Figure 6.9). This demonstrates that relatively low 
concentrations (average, 0.22 µM; range 0.01 µM to 1.94 µM; Table 6.2) of individual 
component metabolites can have significant bioactive effects when in combination. 
The treatments showed reductions in TNF-α and CD40L-stimulated VCAM-1 expression of 
greater than 46.9 ± 5.8% and 32.7 ± 12.2% respectively, which compares to similar studies 
reporting greater than 40% reduction of TNF-α-stimulated VCAM-1 expression by treatment 
with 2.4 µM of parent un-metabolised flavonoids (Wu et al. 2012) and greater than 10% 
reduction of CD40L-stimulated VCAM-1 expression by 1 µM cyanidin-3-glucoside (Xia et al. 
2009) in HUVEC. 
The present study also showed reductions in TNF-α and CD40L-stimulated IL-6 expression of 
greater than 15.6 ± 11.0% and 24.0 ± 4.0% respectively. 
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Table 6.2 Composition of treatments. 
1.9 µM P-1 2.0 µM P-6 4.4 µM P-24 
Compound µM % Compound µM % Compound µM % 
4-hydroxybenzaldehyde 0.01 0.5 4-hydroxybenzaldehyde 0.01 0.5 4-hydroxybenzaldehyde 0.01 0.2 
Benzoic acid-4-glucuronide 0.01 0.5 Benzoic acid-4-glucuronide 0.04 2.0 Benzoic acid-4-glucuronide 0.04 0.9 
Cyanidin-3-glucoside 0.05 2.6 Cyanidin-3-glucoside - - Cyanidin-3-glucoside - - 
Ferulic acid 0.29 15.3 Ferulic acid 0.21 10.3 Ferulic acid 0.59 13.5 
Hippuric acid 0.07 3.7 Hippuric acid 0.23 11.3 Hippuric acid 1.94 44.3 
Isovanillic acid 0.12 6.3 Isovanillic acid - - Isovanillic acid - - 
Isovanillic acid-3-glucuronide 0.01 0.5 Isovanillic acid-3-glucuronide 0.02 1.0 Isovanillic acid-3-glucuronide - - 
Isovanillic acid-3-sulfate - - Isovanillic acid-3-sulfate - - Isovanillic acid-3-sulfate 0.17 3.9 
PCA 0.04 2.1 PCA 0.08 3.9 PCA 0.01 0.2 
PCA-3-sulfate 0.07 3.7 PCA-3-sulfate 0.02 1.0 PCA-3-sulfate 0.02 0.5 
PCA-4-glucuronide 0.02 1.1 PCA-4-glucuronide 0.03 1.5 PCA-4-glucuronide - - 
PCA-4-sulfate 0.07 3.7 PCA-4-sulfate 0.02 1.0 PCA-4-sulfate 0.02 0.5 
PGA 0.03 1.6 PGA 0.55 27.1 PGA 0.05 1.1 
Vanillic acid 1.10 57.9 Vanillic acid 0.80 39.4 Vanillic acid 1.36 31.1 
Vanillic acid-4-glucuronide 0.01 0.5 Vanillic acid-4-glucuronide 0.02 1.0 Vanillic acid-4-glucuronide - - 
Vanillic acid-4-sulfate - - Vanillic acid-4-sulfate - - Vanillic acid-4-sulfate 0.17 3.9 
Total 1.90 100.0 Total 2.03 100.0 Total 4.38 100.0 
 
Mean 0.14  Mean 0.17  Mean 0.40  
Minimum 0.01  Minimum 0.01  Minimum 0.01  
Maximum 1.10  Maximum 0.80  Maximum 1.94  
PCA, protocatechuic acid; PGA, phloroglucinaldehyde. A dash represents a metabolite that is not found in that particular treatment. 
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This compares to previous studies reporting greater than 10% reduction of TNF-α-stimulated 
IL-6 expression by 5 µM apigenin (Gerritsen et al. 1995) and greater than 12% reduction of 
CD40L-stimulated IL-6 expression by 1 µM cyanidin-3-glucoside (Xia et al. 2007) in HUVEC. 
The present study suggests that bioactivity of anthocyanin metabolites is sustained across 
changing metabolic profiles during a 24 hour period and provides an explanation for the 
effects on cardiovascular function seen beyond 1-2 hours in anthocyanin feeding studies 
(Kropat et al. 2013, Rodriguez-Mateos et al. 2013) as different metabolite profiles exert 
differential effects across time. It also suggests that bioactivity of anthocyanins is not 
reduced following microbial catabolism and subsequent phase II metabolism (methylation, 
glucuronidation, and sulfation), which are processes generally considered to detoxify and 
increase rates of elimination in the body (Zamek-Gliszczynski et al. 2006). 
Vanillic acid makes up a large proportion (>31%) of the metabolites within each treatment 
profile (Table 6.2), which suggests that this metabolite, a methylated form of PCA produced 
from the anthocyanin B-ring, may be an important factor in the observed bioactivity of 
anthocyanins. Indeed, previous in vitro studies using vanillic acid in isolation have 
demonstrated significant bioactivity in reducing expression of VCAM-1 and IL-6 in 
CD40L/oxLDL-stimulated HUVEC (Amin et al. 2015), reducing IL-6 expression in LPS-
stimulated mouse peritoneal macrophages (Kim et al. 2011) and reducing superoxide 
production in angiotensin II-stimulated HUVEC (Edwards et al. 2015). However, the 
concentrations of vanillic acid used in this study (1-2 µM) are relatively low which suggests 
that it is unlikely that vanillic acid alone is responsible for the observed bioactivity. This is 
supported by recent in vitro analysis of TNF-α production in LPS-stimulated THP-1 monocytes 
which indicated additive effects when vanillic acid is combined with other phenolic 
metabolites such as PCA and 4-hydroxybenzoic acid (di Gesso et al. 2015). Future work 
should focus on investigating the nature of this additive effect. 
Examination of the structural composition of the P-1, P-6, and P-24 treatments (Table 6.3 & 
Table 6.4) highlights some interesting elements in relation to the observed bioactivity in this 
study. In terms of structural groups, there is a shift away from contributions by benzoic acids 
in early metabolite profiles observed at 1 hour post-consumption towards greater 
contribution by hippuric acid in later metabolite profiles observed at 6 and 24 hours post-
consumption. Hippuric acid can be found in the blood at mM concentrations in healthy 
individuals (Vanholder et al. 2003) which suggests that the maintenance of bioactivity seen 
across the P-1, P-6, and P-24 treatments is unlikely to be due to the µM increases reported 
following anthocyanin consumption. There is also a decrease in contribution from early 
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metabolite profiles observed at 1 hour to later profiles observed at 24 hours post-
consumption of compounds containing hydroxyl and methoxy groups relative to an increase 
in sulfate and glycine conjugates, suggesting that the presence of sulfate and glycine 
conjugates may be important in maintaining bioactivity in relation to inflammatory 
response. This is supported by previous work in our lab looking at the structure-activity 
relationship of anthocyanin phase II-metabolites affecting expression of VCAM-1 and IL-6 in 
HUVEC which observed maximal reductions in cytokine expression following treatment with 
sulfate conjugates of PCA (Amin et al. 2015). Further research is required in order to fully 
understand the nature of the relationship between metabolite structure and bioactivity.  
 
Table 6.3 Structural composition of treatments. 
P-1 P-6 P-24 
Structural group %a Structural group %a Structural group %a 
Anthocyanins 2.6 Anthocyanins 0.0 Anthocyanins 0.0 
Benzaldehydes 2.1 Benzaldehydes 27.6 Benzaldehydes 1.4 
Benzoic acids 76.3 Benzoic acids 50.7 Benzoic acids 40.9 
Hippuric acids 3.7 Hippuric acids 11.3 Hippuric acids 44.3 
Phenylpropanoic acids 15.3 Phenylpropanoic acids 10.3 Phenylpropanoic acids 13.5 
      
Structural group %b Structural group %b Structural group %b 
Hydroxyl 94.7 Hydroxyl 84.7 Hydroxyl 47.0 
Glucuronide 2.6 Glucuronide 5.4 Glucuronide 0.9 
Glycine 3.7 Glycine 11.3 Glycine 44.3 
Methoxy 80.5 Methoxy 51.7 Methoxy 52.3 
Sulfate 7.4 Sulfate 2.0 Sulfate 8.7 
aSum of percentage contributions towards total treatment composition by compounds in each respective 
structural group. bSum of percentage contributions towards total treatment contribution by compounds 
containing each respective functional group. 
 
Concentration response was established by incubating HUVEC with the metabolite profiles 
at cumulative concentrations 10 fold above and below the peak concentration identified 
previously in the human study (Czank et al. 2013, de Ferrars et al. 2014a). In many cases a 
non-linear concentration response was observed with maximal bioactivity at the mean 
concentrations (1.9-4.4 µM) suggesting no increased bioactivity would be conferred by 
increasing anthocyanin intake beyond the 500 mg used in the 13C-labelled cyanidin-3-
glucoside study (Czank et al. 2013). Previous studies in our lab have also reported non-linear, 
bimodal concentration responses in relation to flavonoid bioactivity (Kay et al. 2012, Amin 
et al. 2015, di Gesso et al. 2015) with maximal bioactivity often observed at the 1 µM level. 
Previous studies investigating concentration response of blueberry flavonoids in relation to 
in vivo biomarkers such as flow-mediated dilation have also observed a bimodal response 
with a maximal response seen following intake of 766 mg of blueberry flavonoids (Rodriguez-
Mateos et al. 2013).  
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Table 6.4 Structural information on metabolites included in treatments. 
Structure Common Name IUPAC Name Configurationa 
Anthocyanins 
 
Cyanidin-3-glucoside (2S,3R,4S,5R,6R)-2-[2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-chromen-3-yl]oxy-6-
(hydroxymethyl)oxane-3,4,5-triol  
 
R1,R2 = OH  
 
Benzoic acids 
 
Protocatechuic acid 
Benzoic acid-4-glucuronide 
Protocatechuic acid-4-glucuronide 
Protocatechuic acid-3-sulfate 
Protocatechuic acid-4-sulfate 
Vanillic acid 
Isovanillic acid 
Vanillic acid-4-glucuronide 
Isovanillic acid-3-glucuronide 
Vanillic acid-4-sulfate 
Isovanillic acid-3-sulfate 
 
3,4-Dihydroxybenzoic acid 
6-(4-Carboxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2- carboxylic acid 
6-(4-Carboxy-2-hydroxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid  
5-Carboxy-2-hydroxyphenyl sulfate  
4-Carboxy-2-hydroxyphenyl sulfate 
4-Hydroxy-3-methoxybenzoic acid 
3-Hydroxy-4-methoxybenzoic acid  
6-(4-Carboxy-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid  
6-(5-Carboxy-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid  
4-Carboxy-2-methoxyphenyl sulfate  
5-Carboxy-2-methoxyphenyl sulfate 
R2,R3 = OH  
R3 = O-GlcA  
R2 = OH, R3 = O-GlcA  
R2 = OSO3-, R3 = OH  
R2 = OH, R3 = OSO3- 
R2 = OCH3, R3 = OH 
R2 = OH, R3 = OCH3  
R2 = OCH3, R3 = O-GlcA  
R2 = O-GlcA, R3 = OCH3  
R2 = OCH3, R3 = OSO3- 
R2 = OSO3-, R3 = OCH3 
Phenylpropanoic acids 
 
Ferulic acid 3-(4-Hydroxy-3-methoxyphenyl)-prop-2-anoic acid  
 
R1 = OCH3, R2 = OH  
 
Benzaldehydes 
 
Phloroglucinaldehyde 
4-hydroxybenzaldehyde 
2,4,6-Trihydroxybenzaldehyde 
4-hydroxybenzaldehyde 
R1,R3,R5 = OH 
R3 = OH 
Hippuric acids 
 
Hippuric acid 2-Benzamidoacetic acid R1,R2 = H 
aR1-R5 represents hydrogen (H) or position of a functional group such as: OH, hydroxyl; OCH3, methoxy; O-GlcA, O-glucuronide; SO3-, sulfate. Adapted from (de Ferrars et al. 2014c). 
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However, in the present study, a number of cases (Figure 6.10A, Figure 6.10C, Figure 6.16) 
did show a linear concentration response with increased bioactivity at the highest treatment 
concentrations. Recent studies within our lab investigating the effect of metabolite 
combinations on inflammatory biomarkers have also observed linear concentration 
responses (Warner et al. 2016). The high vanillic acid content of the treatments in the 
present study may provide an explanation for the observed linear response as previous 
studies have noted linear concentration responses in relation to this particular metabolite 
(Amin et al. 2015). Further investigation is required in order to establish the concentration 
response relationship of serum anthocyanin metabolite profiles in inflammation. 
The significant reductions in sVCAM-1 and IL-6 associated with the 1.9 µM P-1, 2.0 µM P-6, 
and 4.4 µM P-24 treatments that were seen in TNF-α-stimulated HUVEC were not replicated 
following CD40L stimulation. This suggests that the phenolic metabolites are not acting upon 
the MAPK signalling pathway which is activated following both TNF-α and CD40L stimulation 
(Pamukcu et al. 2011, Hayden and Ghosh 2014) as we would expect to observe similar results 
following both TNF-α and CD40L stimulation if the phenolic metabolites affected this 
pathway. The possibility remains that anthocyanin metabolites exert their effect through 
interaction with the TNF receptor as a number of studies have reported the ability of 
anthocyanins and their metabolites to inhibit the effect of TNF-α stimulation (Krga et al. 
2016, Warner et al. 2016). However, inhibition of proinflammatory cytokine expression by 
anthocyanin metabolites following CD40L stimulation has also been reported (Amin et al. 
2015) suggesting that the phenolic metabolites are likely to be acting downstream of the 
TNF and CD40 receptors. Future studies may wish to investigate the effect of anthocyanin 
metabolite profiles on the MAPK and NF-κB pathways in more detail by exploring their effect 
on expression of transcription factors such as AP-1 and c-JUN via phosphorylation of P38 and 
JNK, as has been demonstrated previously using anthocyanins (Oak et al. 2006) and PCA (Lin 
et al. 2007), and thus represents a possible upstream target for anthocyanin metabolites. 
Future study of the effect of anthocyanin metabolite profiles on p38 and JNK 
phosphorylation may provide more information on the mechanism behind their observed 
bioactivity.  
The results of the present study suggest that the phenolic metabolites may be exerting their 
effect via the canonical pathway of TNF-α signalling, upstream of the IKK and NF-κB proteins 
which are common to both the canonical TNF-α and non-canonical CD40L signalling 
pathways (Figure 6.17) (Hayden and Ghosh 2014).  
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Figure 6.17 Activation of MAPK and NF-κB signalling pathways via TNF-α and CD40L stimulation. 
 
CD40(L), cluster of differentiation 40 (ligand); ERK, extracellular signal-regulated kinases; ; IκBα, NF-κB 
inhibitory protein; IKK, inhibitory-κB kinase; JNK, c-Jun N-terminal kinases; MKK, mitogen-activated protein 
kinase kinases; P, phosphate; p38, mitogen-activated protein kinase; p50, nuclear factor-κB p50 subunit; p65, 
NF-κB p65 subunit; TNF-α, tumour necrosis factor-α; TNFR1, TNF receptor 1. Adapted from (Pamukcu et al. 
2011, Hayden and Ghosh 2014, Sabio and Davis 2014). 
 
In comparison to the non-canonical, CD40L-stimulated pathway of NF-κB signalling, a 
number of signalling molecules are unique to the canonical pathway such as TNFR1-
associated death domain protein (TRADD), transforming growth factor-β activated kinase 
(TAK1), and NF-κB essential modulator (NEMO) (Hayden and Ghosh 2014, Sabio and Davis 
2014) but further work is required to identify the mechanism by which the phenolic 
metabolites exert their bioactive effect. The results of the present study may also indicate 
the potential for phenolic metabolites to have an additive effect if acting across multiple 
signalling pathways. This is supported by recent studies demonstrating that flavonoids and 
phenolic acids can affect the expression of many microRNAs (Milenkovic et al. 2013), both 
in vitro and in vivo, and anthocyanins can modulate the expression of over 1200 genes in the 
aorta of apoE-deficient mice, including many genes involved in oxidative stress, monocyte 
infiltration, and the progression of atherosclerosis such as chemokines and cell adhesion 
molecules (Mauray et al. 2012). Further research using additional stimuli associated with 
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atherosclerosis development such as angiotensin II, peroxynitrite (ONOO-), and oxidised 
low-density lipoprotein (oxLDL), and exploring alternative signalling pathways such as the 
PI3K/Akt pathway is needed to explore the possible additive effects of anthocyanin 
metabolites. 
Another possibility is that the lack of significant reductions in sVCAM-1 seen in the CD40L-
stimulated HUVEC is due to increased variability caused by the co-incubation of HUVEC with 
CD40L-expressing D1.1 Jurkat cells. The significant reduction in CD40L-stimulated VCAM-1 
expression caused by the vehicle control was not replicated in the TNF-α-stimulated VCAM-
1 expression. A possible explanation for this observation is cytotoxicity of DMSO towards the 
D1.1 Jurkat cells resulting in reduced sVCAM-1 expression, however, further investigation 
would be required to validate this hypothesis. Future studies could mitigate these issues via 
the use of soluble CD40L protein. This method was considered cost-prohibitive in the present 
study. The P-1 and P-6 metabolite composition treatments had no effect on cell viability, 
while a modest effect was observed for the P-24 composition treatment (90% viability) when 
incubated with tenfold higher concentration than the reported mean (43.8 µM). The TNF-α 
positive control reduced viability by 19.2% which is similar to previous studies that have 
shown 20 – 25% reduction in HUVEC viability following 24 hour incubation with TNF-α 
(Louise and Obrig 1991, Ramana et al. 2004). The TNF-α negative control, BAY11-7085, mildly 
increased cell viability and was used as an inhibitor of both sVCAM-1 and IL-6 expression for 
the negative control in this study. However, despite BAY11-7085 being commonly used in 
this context (Dumont et al. 2012, Lee et al. 2012), it did not significantly reduce IL-6 
expression following either TNF-α or CD40L stimulation in this study. BAY11-7085 exerts its 
effect on IL-6 expression via inhibition of IκBα phosphorylation therefore blocking activation 
and nuclear translocation of NF-κB (Pierce et al. 1997). A possible explanation for the lack of 
IL-6 inhibition compared to sVCAM-1 observed in this study is that while BAY11-7085 was 
able to inhibit the NF-κB pathway and therefore inhibit expression of sVCAM-1 which relies 
on binding of NF-κB to its promoter region for transcription (Carter and Wicks 2001), BAY11-
7085 has been shown to unable to inhibit activation of the MAPK pathway by TNF-α (Pierce 
et al. 1997) and therefore was unable to prevent downstream expression of IL-6 (Sabio and 
Davis 2014). Future studies should consider alternative compounds that have shown the 
ability to inhibit IL-6 such as cardamonin (Yu et al. 2014) and nobiletin (Sawa et al. 2008). 
Future work should aim to expand upon the work presented here in a number of ways. 
Firstly, via the use of primary vascular cell lines to validate the observations made using 
HUVEC in the present study. HUVEC are widely used in vascular research due to the fact they 
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are relatively inexpensive and easy to culture but there is evidence to suggest that 
alternative cell lines such as human aortic endothelial cells (HAEC) or human coronary artery 
endothelial cells (HCAEC) may provide results that are more relevant to in vivo situation 
when studying inflammatory cytokines such as VCAM-1 and IL-6 (Bouïs et al. 2001). Time 
course studies revealed optimal assay incubations of 24h for sVCAM-1 and IL-6 expression. 
A 30 minute pre-treatment time was used in the present study but future work may also 
benefit from an investigation into the effect of different pre-treatment times on the 
bioactivity of the metabolites and metabolite profiles. Another possible area for future study 
is to investigate the expression of membrane-bound instead of soluble VCAM-1. The soluble 
form of VCAM-1 was measured in the present study as it simpler to quantify (Vastag et al. 
1999), is a valid biomarker of inflammation (Carter and Wicks 2001) and is commonly used 
as an endpoint for flavonoid bioactivity studies in HUVEC (Xia et al. 2009, Jia et al. 2013). 
Additional analysis of the effect on membrane-bound VCAM-1 would provide further insight 
into the pathways through which anthocyanin metabolites exert their bioactivity. Finally, 
future research should aim to include analysis of mRNA production to accompany the 
analysis of sVCAM-1 and IL-6 protein expression. Analysis of mRNA production would 
provide information on whether the observed effects on sVCAM-1 and IL-6 protein 
expression were due to pre- or post-translational effects. This information would help to 
establish the mechanism and pathway through which the anthocyanin metabolites are 
having their effect. Analysis of mRNA would also help to show whether there were any 
effects on sVCAM-1 and IL-6 mRNA production caused by the anthocyanin metabolites in 
CD40L-stimulated HUVEC that were not seen in the protein expression results. 
 
6.5. Conclusion 
In summary, the present study utilised a novel treatment design to mimic time-specific 
metabolite profiles in order to demonstrate that low concentrations of anthocyanin 
metabolites, in combination, can reduce TNF-α-stimulated expression of sVCAM-1 and IL-6, 
two important biomarkers of inflammation associated with atherosclerosis and CVD. 
Furthermore, the active concentrations are achievable following consumption of 500 mg of 
cyanidin-3-glucoside and therefore achievable through the diet. The increased bioactivity of 
the 6 and 24 hour post-consumption profiles suggests that bioactive compounds are 
maintained within the blood for many hours after consumption of the parent compound. 
These findings provide valuable insight into the role of anthocyanins in promoting good 
health.  
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Chapter 7. General Discussion and Future Perspectives 
 
7.1. General Discussion 
Anthocyanins are polyphenol pigments found in many commonly consumed fruits and 
vegetables such as berries, grapes, and red cabbage (Crozier et al. 2010, Del Rio et al. 2010a). 
Evidence from epidemiological studies (Jennings et al. 2012, Cassidy et al. 2015) and 
randomised controlled trials (Dohadwala et al. 2011, Rodriguez-Mateos et al. 2013) suggests 
that diets high in anthocyanins are associated with a reduced risk of cardiovascular disease. 
Instability at neutral pH (Rein 2005) and the poor bioavailability of anthocyanins observed in 
feeding trials (Manach et al. 2005) suggested that the parent compounds were likely not 
responsible for the observed bioactivity of anthocyanins and that the metabolites of 
anthocyanins may be key to their bioactivity. Recent studies have confirmed that 
anthocyanins are metabolised to produce a wide range of phenolic compounds (Czank et al. 
2013, de Ferrars et al. 2014b) and that these metabolites can have positive effects on 
inflammatory and vascular function, which are known biomarkers of cardiovascular disease 
(Rodriguez-Mateos et al. 2013, Amin et al. 2015, di Gesso et al. 2015, Warner et al. 2016).  
The present thesis aimed to contribute to our understanding of anthocyanin metabolism and 
its importance in cardiovascular health via four approaches (Figure 7.1): providing 
information on the stability of phenolic metabolites in biological matrices for future clinical 
studies; improving current LC-MS methods for quantifying anthocyanin metabolites in serum 
and urine samples to increase throughput and afford lower limits of detection; investigating 
phenolic metabolites as biomarkers of anthocyanin intake with the goal of improving 
accuracy of consumption monitoring; and investigating the effect of physiologically relevant 
anthocyanin metabolite profiles on expression of proinflammatory biomarkers. 
The shift away from studying the parent anthocyanins and towards their phenolic 
metabolites has required the development of methods capable of detecting and quantifying 
large numbers of metabolites at nanomolar concentrations in biological matrices. Due to 
their absorption within both the visible spectrum at 465 – 550 nm and UV spectrum at 270 
– 280 nm, anthocyanins have typically been detected and quantified using HPLC with DAD 
detector methodology (Hong and Wrolstad 1990, Cao and Prior 1999). DAD detection of 
phenolic acids is also possible (Robbins 2003) but can be restrictive in terms of detection 
limits, and the number of metabolites that can be quantified within the same method due 
to the need for chromatographic separation. 
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Figure 7.1 Experimental scheme for the assessment of stability, quantification methods, biomarker utility, and bioactivity of 
anthocyanin metabolites. 
 
HPLC, high-performance liquid chromatography; ESI, electrospray ionisation; MS, mass spectrometry; SPE, solid-phase 
extraction; PPT, protein precipitation; D&S, dilute-and-shoot; 13C5-C3G, 13C-labelled cyanidin-3-glucoside; HUVEC, human 
umbilical vein endothelial cells; WST-1, water-soluble tetrazolium salt-1; TNF-α, tumour necrosis factor-α; sVCAM-1, soluble 
vascular cell adhesion molecule-1; IL-6, interleukin-6; CD40L, cluster of differentiation 40 ligand. 
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By combining HPLC separation with mass spectrometry detection, highly specific and 
sensitive methods for the quantification of phenolic metabolites of anthocyanins in 
biological samples have been developed (Rodriguez-Mateos et al. 2013, Pimpão et al. 2014, 
McKay et al. 2015, Xie et al. 2016), including an HPLC-ESI-MS/MS method with a 32 minute 
run time developed by our group that was used for the detection and quantification of 45 
phenolic metabolites in serum and urine samples from a 13C-labelled C3G intervention 
(Czank et al. 2013, de Ferrars et al. 2014c). In chapters 3 and 4, the present thesis describes 
the development and validation of this method. Improvements to the method were deemed 
necessary in order to allow detection of novel metabolites potentially below the LOD of the 
current method, to improve the accuracy and precision of metabolite quantification via 
increased signal-to-noise ratios within the in vivo concentration range, and to increase 
throughput to facilitate the analysis of large sample sets in future clinical studies.  
Addition of ammonium buffers to the mobile phase was investigated as a means of 
improving ionisation efficiency and increasing sensitivity. Alternative methods of improving 
ionisation efficiency such as flow splitting were also considered. Flow splitting involves post-
column splitting of the mobile phase flow to send the majority direct to the waste while a 
small proportion enters the ion source. This has the effect of greatly reducing the volume of 
solvent within the ion source which speeds up evaporation and therefore improves 
ionisation. Ultimately, it was decided that this approach would be complicated to set up and 
similar results could be achieved through optimisation of HPLC parameters. Addition of 
ammonium buffers to the mobile phase was considered the best option for increasing 
method sensitivity in the present study. Ionisation of analytes in ESI-MS is a complex process 
affected by many factors but it has been suggested that small amounts (≤10 mM) of volatile 
buffer salts such ammonium acetate or ammonium formate can lead to improved ionisation 
efficiency of analytes due to the increased presence of ions within the mobile phase 
(Banerjee and Mazumdar 2012, Hua and Jenke 2012) and previous studies have reported 
optimal sensitivity for the detection of flavonoids when using ammonium-buffered mobile 
phases (Rauha et al. 2001, de Rijke et al. 2003) but no studies have explored the effect on 
ionisation of phenolic acids. The present study provides data that suggests that both 10 mM 
ammonium acetate and 10 mM ammonium formate have a negative effect on phenolic acid 
ionisation across a range of pH values and that their use should be avoided.  
Switching to a shorter HPLC column (50 mm vs 100 mm) with a smaller internal diameter 
(2.1 mm x 4.6 mm), reducing the mobile phase flow rate to 0.6 mL min-1, and optimising 
various HPLC parameters, including column temperature and mobile phase gradient, yielded 
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a method that was able to detect and quantify a greater number of metabolites (53 vs 45) in 
less than half the run time (15 min vs 32 min) compared to the previous method (de Ferrars 
et al. 2014c). The new 15 minute method also compares favourably in terms of quantifiable 
metabolites and/or run time against methods previously reported in the literature for 
quantification of phenolic metabolites in biological samples (Rodriguez-Mateos et al. 2013, 
Pimpão et al. 2014, McKay et al. 2015, Xie et al. 2016). The present thesis describes the 
validation of both the new 15 minute method and the previous 32 minute method. 
Validation of the 32 minute method has been reported previously (de Ferrars et al. 2014c) 
but the decision was taken to re-validate in the present study as the previous validation was 
conducted at only one concentration and used a spiked mobile phase matrix. Validation at 
three concentrations in a matched-matrix (extracted serum), as recommended in the FDA 
guidelines for bioanalytical method validation (Food and Drug Administration 2001), 
provided a more realistic understanding of the relative strengths and limitations of the 
method. Validation of both methods revealed good specificity, linearity, and LODs but 
limitations in terms of accuracy and precision at the lower concentrations (0.098 µM and 
1.56 µM). This may limit the future use of these methods in the quantification of absolute 
metabolite concentrations in clinical samples but, due to the high levels of inter-participant 
variation that exist in clinical nutrition research and low metabolite concentrations detected, 
both methods can be utilised for detection of metabolite profiles and quantification of 
relative concentrations. Validation of the new 15 minute method highlights the need for 
continued development of the method in order to further reduce LODs and improve 
accuracy and precision at the lower concentrations. The validation of analytical methods 
following FDA guidelines as described in the present thesis is crucial to provide confidence 
in the results obtained using them. Whilst a number of anthocyanin feeding studies report 
validation results for their analytical methods (Cooke et al. 2006, Giordano et al. 2007, 
Nakamura et al. 2009), there are still many that do not which makes it difficult to compare 
the quality of analytical methods within the field. The lack of published validation data 
should be addressed if the standard of clinical analysis in nutrition is to be improved. 
Assessment of the health effects associated with anthocyanin consumption relies upon 
accurate estimations of dietary intake. It has been suggested that, due to problems with 
misreporting of intake and inaccurate or incomplete database values for anthocyanin 
content in dietary sources associated with traditional methods of estimating dietary intake 
such as food frequency questionnaires (Beaton 1994, Thompson et al. 2010), quantifying the 
levels of characteristic metabolites in the body may offer an improved method of monitoring 
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anthocyanin consumption (Hedrick et al. 2012). In chapter 5, the present thesis aimed to use 
serum and urine samples from a recently conducted 13C-labelled cyanidin-3-glucoside trial 
(Czank et al. 2013) to identify metabolites present in all participants at concentrations above 
those resulting from the background diet as potential biomarkers of anthocyanin intake. 
Gallic acid in urine was found to be the best candidate in the present study based upon its 
detection at similar concentrations above background levels across all eight participants. 
Previous studies have also suggested a role for gallic acid in determining anthocyanin 
consumption (Ito et al. 2005, Urpi‐Sarda et al. 2015) but the present study is the first to use 
13C-labelling to identify potential metabolic biomarkers of anthocyanin intake. The detection 
of 13C-labelled metabolites is an important advantage of the present study as it allowed a 
distinction to be made between metabolites present within the background diet and 
metabolites present due to the consumption of the labelled anthocyanin. A limitation of the 
present study is the non-detection of a number of metabolites that had been observed 
within the same serum and urine samples by a previous study (Czank et al. 2013). The 
differences in observed metabolites between the two studies may be due to a decrease in 
method sensitivity in the present study, possibly caused by the change in MS 
instrumentation or by the increase in the number of metabolites analysed by the method 
used in the present study. The poor accuracy and precision of the analytical method at lower 
concentrations may also have negatively affected the quantification of metabolites in the 
present study resulting in possible metabolite biomarkers being ruled out incorrectly. Future 
studies may wish to reinvestigate potential biomarkers of anthocyanin intake using more 
sensitive analytical methods. Following the identification of any additional candidate 
metabolites as biomarkers of anthocyanin intake, the next step towards their use in 
monitoring anthocyanin intake in clinical studies would be to assess the responsiveness of 
the metabolites to changes in anthocyanin intake. This could be achieved by asking 
volunteers to consume varying amounts of cyanidin-3-glucoside on separate days, with a 
one week washout period in between each occasion, and collect urine samples to monitor 
the concentration of the metabolite biomarker candidates and assess how urine metabolite 
levels are affected by the changes in anthocyanin intake. Once this concentration response 
has been established, any potential biomarkers of anthocyanin intake should be validated 
using samples from large clinical trials to evaluate their effectiveness within the wider 
population as biomarkers of anthocyanin intake, how this is affected by differences in 
genetics and gut microbiota, and how this analytical approach compares against traditional 
diet monitoring methods. 
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The present thesis investigated the bioactivity of anthocyanin metabolite profiles at 
physiological concentrations in a vascular cell model. Recent in vitro studies have reported 
positive effects on vascular and inflammatory biomarkers in a range of cell types following 
incubation with anthocyanin metabolites but these studies have typically used metabolites 
either in isolation (Amin et al. 2015, Edwards et al. 2015) or in equimolar combinations (di 
Gesso et al. 2015, Warner et al. 2016) with neither approach accurately representing the in 
vivo situation following anthocyanin consumption. These studies provide information 
regarding additive effects of metabolites in combination and how bioactivity is affected by 
methylation/sulfation/glucuronidation. This data is important to our understanding of the 
mechanisms behind the bioactivity of anthocyanins but is perhaps more relevant to a 
pharmaceutical approach in which the most active metabolites or metabolite combinations 
can be isolated and provided to consumers at an optimal dose to improve cardiovascular 
health. In order to provide better nutritional advice about the types of foods to eat, when to 
eat them, and how much to eat, it is necessary to have data on the bioactivity of 
physiologically relevant metabolite profiles. To the author’s knowledge, the present study is 
the first to study the bioactivity of anthocyanin metabolite profiles in vitro in the 
combinations and concentrations at which they were observed in vivo and therefore 
provides more physiologically relevant information regarding the bioactivity of 
anthocyanins. The effect on expression of two proinflammatory cytokines, sVCAM-1 and IL-
6, was investigated in CD40L and TNF-α-stimulated HUVEC. It was found that the metabolite 
profiles were capable of inhibiting the expression of sVCAM-1 and IL-6 following TNF-α 
stimulation and that the 6 h and 24 h metabolite profiles were more active than the 1 h 
profile suggesting that bioactive compounds are produced during anthocyanin metabolism 
and remain active for at least 24 hours following consumption. This is an important finding 
of the present study and suggests a role for gut microbiota in the production of bioactive 
metabolites. A recent study investigated the effect of blueberry polyphenols on vascular 
function in vivo and reported a correlation between peaks in total metabolite concentration 
at 1-2 h and 6 h following consumption, and improvements in FMD (Rodriguez-Mateos et al. 
2013) but the present study is the first to investigate the effect of a physiologically relevant 
24 h anthocyanin metabolite profile on expression of proinflammatory cytokines in vitro.  
 
  
 Page | 160 
In summary, the key outcomes of the present thesis are: 
 Unlike the parent anthocyanin, the stability of phenolic metabolites within a serum 
matrix over 240 hours was unaffected by either pH or up to five freeze/thaw cycles. 
 Use of 10 mM ammonium formate (pH 3-5) or 10 mM ammonium acetate (pH4-6) buffer 
solutions as aqueous mobile phase did not increase the sensitivity of an HPLC-ESI-MS/MS 
method for quantifying anthocyanin metabolites in biological samples. 
 As a urine sample preparation technique, protein precipitation was capable of delivering 
limits of detection for anthocyanin metabolites equal to those obtained using solid-
phase extraction, with reduced cost and increased throughput. 
 Compared to an existing 32 minute HPLC-ESI-MS/MS method, similar chromatographic 
separation and method sensitivity was achieved in 15 minutes by changing the following 
method parameters: 
 Column length: 100 mm to 50 mm 
 Column diameter: 4.6 mm to 2.1 mm 
 Column temperature: 37°C to 40°C 
 Flow rate: 1.5 mL min-1/1.0 mL min-1 to 0.6 mL min-1 
 Gradient: 1% B at 0 min 
7.5% B at 7 min 
7.6% B at 14 min 
10% B at 17 min 
12% B at 18.5 min 
12.5% B at 20 min 
30% B at 24 min 
90% B at 25 to 28 min 
1% B at 29 to 32 min 
to 1% B at 0 min 
7.5% B at 7 min 
7.6% B at 9 min 
90% B at 9.5 to 11.5 min 
1% B at 12 to 15 min 
 
 According to FDA and UN guidelines on bioanalytical method validation, both the 
existing 32 minute and developed 15 minute HPLC-ESI-MS/MS methods had acceptable 
linearity, specificity and sensitivity with limits of detection in the nanomolar range. 
Accuracy and precision were acceptable at 50 µM but outside guidelines at 1.56 µM and 
0.098 µM for both methods. 
 Urine represents the most likely source of anthocyanin intake biomarkers with gallic acid 
identified as the most promising metabolite candidate in this study. 
 Anthocyanin metabolite profiles observed in serum at 1, 6 and 24 hours post-
consumption of 13C-labelled cyanidin-3-glucoside were able to significantly reduce 
expression of the proinflammatory cytokines sVCAM-1 and IL-6 in TNF-α-stimulated 
HUVEC. 
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7.2. Future Perspectives 
The present thesis describes the development of an HPLC-ESI-MS/MS method for the 
quantification of anthocyanin metabolites in biological matrices. A range of approaches were 
evaluated for improving the existing method such as the addition of ammonium salts to the 
mobile phase, alternative sample extraction methods, and optimisation of HPLC parameters. 
Future work should aim to continue the development of this method in a number of key 
areas. In chapter 3, a PPT method was suggested as an alternative sample extraction method 
for urine samples but due to the high level of ion-suppressing matrix components present in 
serum, SPE is still necessary for these samples. At present, the analytical method uses 
individual SPE cartridges in an offline process which is time-consuming and expensive. 
Sample processing throughput could be increased via the use of an automated online SPE 
system or by switching to a 96-well plate SPE format. Future development of this method 
should also focus on improving method sensitivity and reducing LODs. One possible route 
for improving sensitivity is via the use of HILIC HPLC columns. HILIC columns are well-suited 
to ESI mass spectrometry applications due to the nature of the stationary phases and 
solvents used (Nguyen and Schug 2008). In traditional RP-HPLC gradient methods, mobile 
phases are initially mostly aqueous with increasing amounts of organic solvents added 
gradually to elute the analytes of interest from the stationary phase. In HILIC, the opposite 
is the case with predominantly organic mobile phases and water acting as the strong solvent 
(Hemström and Irgum 2006). This means that when using traditional RP-HPLC methods, high 
volumes of aqueous solvent enter the ion source which can lead to poor evaporation and 
ionisation efficiency. HILIC can deliver improved ionisation efficiency, and therefore 
increased method sensitivity, due to the higher volumes of organic solvent resulting in faster 
evaporation within the ion source (Jandera 2011). Due to the potential for improved 
ionisation and sensitivity, the use of HILIC in combination with ESI mass spectrometry has 
increased in recent years (Jian et al. 2010) and a number of recent studies have reported the 
use of HILIC in the quantification of anthocyanins (Willemse et al. 2013, Sun et al. 2015, 
Deineka et al. 2016) suggesting that the technique may also be suitable for analysis of 
phenolic metabolites. Switching from RP-HPLC to HILIC would require further method 
development but has the potential to deliver improvements in method sensitivity that are 
necessary to deliver high quality quantification of anthocyanin metabolites. 
The short-term effect of acidification and freeze/thaw cycling on the stability of anthocyanin 
metabolites in biological samples was investigated in the present thesis. However, the long-
term storage stability of phenolic metabolites in biological matrices is still unknown. This is 
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relevant as the time between collection of biological samples from the first participants and 
sample analysis in a large clinical study can be considerable, often up to 12 months. The long-
term storage stability of anthocyanins in juice matrices has been extensively studied due to 
the commercial need for storage of juices prior to consumption. These studies typically 
follow FDA guidance for accelerated storage stability studies (Food and Drug Administration 
2003) and store juices at 25°C for six months to mimic the effect of 12 months storage at 
ambient temperature and under these conditions, anthocyanins have been shown to be 
unstable with losses of up to 90% during storage (Hager et al. 2008, Wilkes et al. 2013, Mäkilä 
et al. 2016). Long-term stability of phenolic acids, such as hydroxycinnamic acids, in juice 
matrices has also been studied and found to result in losses of 20 – 40% following storage 
(Wilkes et al. 2013, Mäkilä et al. 2016). To the author’s knowledge, no studies have been 
conducted that explore the stability of anthocyanins or their metabolites in biological 
matrices over a similar timescale. Future studies may wish to fill this gap in our knowledge 
by conducting a 12 month storage stability study in which serum and/or urine aliquots are 
spiked with anthocyanins and phenolic acids at a known concentration and then stored at -
80°C for 12 months to mimic the storage of clinical samples prior to analysis. Analysis at 1, 
3, 6 and 12 months by LC-MS to monitor the anthocyanin and phenolic acid concentrations 
against an external standard at each timepoint would provide valuable information on the 
stability of clinical samples from anthocyanin interventions. Whilst there is evidence to 
suggest that the temperatures of -20°C or -80°C at which clinical samples are typically stored 
may protect anthocyanins and their phenolic metabolites from degradation during storage 
(de Ancos et al. 2000), due to the time and money invested in the collection of clinical 
samples it would surely be useful to confirm their stability during long-term storage. 
The extensive list of phenolic anthocyanin metabolites quantified in the present thesis is 
based upon reported metabolites from recent studies (Rodriguez-Mateos et al. 2013, de 
Ferrars et al. 2014a, de Ferrars et al. 2014b), particularly those observed in a recent 13C-
labelled C3G feeding trial (Czank et al. 2013). However, whilst a large number of metabolites 
were detected in the biological samples collected during this trial, only 43.9% of the 13C 
isotope tracer was recovered suggesting that either the labelled compound was retained 
within the tissues, eliminated outside the 48 hour sampling window of the study, or that 
there are more metabolite compounds still to be identified. Future studies should explore 
the formation of glutathione conjugates of anthocyanins and their phenolic metabolites. 
Glutathione is present at millimolar concentrations in cells with particularly high 
concentrations found in the liver, and has a role in the conjugation and detoxification of 
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xenobiotics (Arrick and Nathan 1984, Pompella et al. 2003). MSn techniques were not used 
in the present thesis but could be used by future studies to identify glutathione conjugates 
via analysis of fragmentation patterns. Glutathione conjugates of quercetin (Galati et al. 
2001, Hong and Mitchell 2006) and catechin (Moridani et al. 2001) flavonoids have been 
reported suggesting that conjugates of anthocyanins and their phenolic metabolites to 
glutathione or its constituent glutamic acid, cysteine, and glycine residues may also exist. 
Along with the identification of novel metabolites, future work should also seek to improve 
the availability of analytical standards via synthesis of compounds not currently 
commercially available such as phase II sulfate and glucuronide conjugates. Greater 
availability of analytical standards would simplify the optimisation of methods to confirm 
detection and accurately quantify novel metabolites such as glutathione conjugates. 
Currently, many novel metabolites can only be tentatively identified based upon analysis of 
their fragmentation pattern using MSn techniques and while synthesis of analytical standards 
can be an expensive and slow process, it is important for the confirmation of metabolite 
detection. Synthesis of stable isotopically-labelled analytical standards could also provide 
the opportunity to improve the accuracy and precision of analytical methods via their use as 
internal standards (Stokvis et al. 2005). Analytical standards that are structurally identical to 
their metabolite counterparts apart from the presence of a stable isotope label can be used 
as internal standards that elute at the same time as the metabolite of interest meaning they 
are subject to the same matrix effects resulting in greater accuracy and precision when 
comparing metabolite response against internal standard response to quantify metabolite 
concentrations (Stokvis et al. 2005). Due to the current unavailability of stable isotopically-
labelled analytical standards, the present thesis used phloridzin and scopoletin as internal 
standards due their structural similarity to the metabolites of interest. If available, and 
feasible due to the number of metabolites included in the method, future studies should 
consider the use of stable isotopically-labelled analytical standards as internal standards to 
minimise matrix effects and improve the accuracy and precision of the method.  
The 1 h, 6 h, and 24 h timepoints used in the analysis of anthocyanin metabolite bioactivity 
in the present thesis were chosen as they represented peaks in total metabolite 
concentration observed in the previously conducted 13C5-C3G trial (Czank et al. 2013, de 
Ferrars et al. 2014a) but anthocyanin metabolites were still detected at 48 hours following 
consumption. Few previous studies had collected samples beyond 24 hours as it was 
believed that anthocyanins were quickly eliminated within the first few hours following 
consumption. Now that it has been observed that anthocyanins are in fact metabolised 
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extensively and that these metabolites are present in the circulation for at least 48 hours 
following consumption, it would be useful to understand how long anthocyanin metabolites 
remain in circulation and how long the metabolite profile retains bioactivity. In the short 
term, the effect of the reported 48 h metabolite profile on IL-6 and sVCAM-1 protein 
expression should be explored to compare against the results obtained for the 1 h, 6 h, and 
24 h profiles in the present study. In the long term, it would be informative to conduct a 
similar 13C-labelled anthocyanin feeding trial with sample collection extended beyond 48 
hours, perhaps to 72 or 96 hours, to capture the full extent of anthocyanin metabolism as 
this is currently unknown. Characterisation of the metabolite profiles present at 48 hours 
and beyond and investigation of their bioactivity would inform future nutritional advice by 
providing data relating to how often anthocyanins should be consumed to maintain the 
optimal levels of bioactive metabolites within the circulation. 
The present thesis investigated the effect of physiologically relevant anthocyanin metabolite 
profiles on levels of proinflammatory cytokines in HUVEC. The next step for this work would 
be to analyse the effect on mRNA levels to see if the observed effect on sVCAM-1 and IL-6 
protein expression in TNF-α-stimulated HUVEC is replicated by a corresponding reduction in 
mRNA. No effect was observed in the present study on sVCAM-1 or IL-6 expression following 
CD40L stimulation so analysis of mRNA levels would also provide information on possible 
post-transcriptional regulation of this pathway. HUVEC were used in the present study due 
to their ease of use and low cost but alternative cell types such as human coronary artery 
endothelial cells (HCAEC) or THP-1 monocytes have also been used previously (di Gesso et 
al. 2015, Edwards et al. 2015) and future studies should look to replicate this analysis in these 
cell types to fully understand the effect of anthocyanin metabolites on vascular function. 
Anthocyanins have been shown to act upon a number of proinflammatory signalling 
pathways including MAPK (Xie et al. 2011, Jeong et al. 2013) and NF-κB (Paixão et al. 2012, 
Lee et al. 2014) and the effect of anthocyanin metabolite profiles on these pathways should 
also be explored to elucidate the mechanism responsible for their observed bioactivity. In 
the future it may even be possible to monitor the real-time effect of anthocyanin 
metabolites on protein expression in live cells using a novel technique that pulls magnetised 
carbon nanotubes through cell membranes, collecting specific proteins as they pass through 
the cell that can be quantified without the need for cell lysis (Yang et al. 2014). This technique 
will require further development before it becomes a viable alternative to current protein 
analysis methods but has already been demonstrated to have no effect on cell viability or 
MAPK signalling pathway activity (Cai et al. 2007, Yang et al. 2014). This approach to 
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quantifying protein expression could enable an experiment in which vascular cells could be 
incubated with media containing an anthocyanin metabolite profile and the effect on 
proinflammatory cytokine expression over 24 hours could be monitored. This technique 
would negate the issue of heterogeneity between cell populations affecting results that is 
possible with the current approach that requires culture and treatment of multiple cell 
populations with lysing at various timepoints to compare levels of protein expression. 
In addition to in vitro work, in vivo analysis of anthocyanin metabolite profile bioactivity 
could be attempted via an approach similar to that used in a recent study (Rodriguez-Mateos 
et al. 2013). Participants could be fed a 500 mg dose of cyanidin-3-glucoside with metabolite 
profiles established over 96 hours in addition to monitoring of vascular measures such as 
FMD and blood pressure, and levels of proinflammatory cytokines such as sVCAM-1 and IL-
6 in circulation to investigate the bioactivity of different metabolite profiles in vivo. 
Characterisation of each participant’s microbiome could also be undertaken to try and 
identify any microbial profiles that could be characterised as producing more or less active 
metabolite profiles based on the analysis of vascular biomarkers. The long-term goal of this 
work should be to produce an ‘interactome-like’ analysis of how anthocyanins, microbiota, 
and pro-inflammatory cytokines interact with each other to establish whether there may be 
a microbiotic profile that produces more active metabolites than others, and if so, whether 
there is a particular anthocyanin or group of anthocyanins that promote the growth of this 
microbiotic profile. Understanding how the relationship between anthocyanins and gut 
microbiota can be exploited to maximise the effect of anthocyanin consumption on 
cardiovascular disease may be an important area of future research in this field.  
Studies investigating the metabolism of anthocyanins have observed large variation in the 
metabolites detected and their concentrations (Czank et al. 2013, de Ferrars et al. 2014b). 
Alongside genetic variations within the population leading to differences in absorption and 
metabolism (Minihane 2010, Wakeling and Ford 2012), differences in gut microbiota are also 
believed to play a role in inter-participant variability (Selma et al. 2009). Recent studies have 
suggested that changes in the microbiotic profile can affect the metabolism of anthocyanins 
(Sánchez-Patán et al. 2012, Boto-Ordóñez et al. 2014) whilst consumption of anthocyanins 
can lead to changes in microbiota populations (Queipo-Ortuño et al. 2012, Jiménez-Girón et 
al. 2014). Future studies should investigate this relationship with two aims: identifying 
microbiota profiles that produce particularly bioactive metabolites; and investigating 
anthocyanin consumption as a probiotic promoter of beneficial microbiota. In the long term, 
technological developments in mass spectrometry may enable much lower limits of 
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detection leading to detection of metabolites below current limits and improved accuracy 
and precision when quantifying metabolites in biological samples at the concentrations used 
in the present thesis. A recent study demonstrated the application of an advanced 
microarray for mass spectrometry (MAMS) technique using matrix-assisted laser 
desorption/ionisation-mass spectrometry (MALDI-MS) to quantify metabolite 
concentrations in single yeast cells and identify metabolically distinct phenotypes within the 
cell population (Ibáñez et al. 2013). To date, in vitro analysis of anthocyanin metabolism has 
been limited to cell types such as caco-2 endothelial cells that can be cultured in volumes 
large enough to produce detectable metabolite concentrations (Kay et al. 2009, Kamiloglu 
et al. 2015) or, due to the difficulty of culturing isolated colonic bacteria (Allen-Vercoe 2013), 
simulated gut fermentation systems that provide limited information on the metabolic 
variation between different bacterial species (Aura et al. 2005, Sánchez-Patán et al. 2012). 
Future studies may be able to combine improvements in colonic bacteria culture (Sommer 
2015) with advanced mass spectrometry techniques (Ibáñez et al. 2013) to compare the 
metabolite profiles produced by different bacterial species following incubation with 
anthocyanins and improve our understanding of role of the gut microbiota in the positive 
health effects related to consumption of anthocyanins. 
 
In conclusion, this thesis contributes to the current literature on anthocyanin metabolism by 
providing practical advice on metabolite stability to future clinical studies, further 
developing analytical methods for the detection and quantification of phenolic metabolites 
in biological samples, investigating potential candidates as biomarkers of anthocyanin 
intake, and by assessing the vascular bioactivity of novel physiologically relevant 
anthocyanin metabolite profiles. Additional work is required to further refine the analytical 
methods discussed in the present thesis and to fully elucidate the role of anthocyanin 
metabolites in maintaining cardiovascular health. 
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Glossary 
ADME  Absorption, distribution, metabolism, and excretion 
ANOVA  Analysis of variance 
BL  Baseline 
BMI  Body mass index 
C3G   Cyanidin-3-glucoside 
CβG  Cytosolic β-glucosidase 
CD40   Cluster of differentiation 40 
CD40L  Cluster of differentiation 40 ligand 
Cmax   Maximum concentration 
COMT  Catechol-O-methyltransferase 
CV   Coefficient of variation 
CVD   Cardiovascular disease 
Cy   Cyanidin 
D&S  Dilute-and-shoot 
DAD   Diode array detector 
DMSO  Dimethyl sulfoxide 
Dp   Delphinidin 
ELISA   Enzyme-linked immunosorbent assay 
eNOS   Endothelial nitric oxide synthase 
ERK   Extracellular signal-regulated kinase 
ESI   Electrospray ionisation 
FDA  Food and Drug Administration 
FGF2  Fibroblast growth factor 2  
FMD   Flow-mediated dilation 
GLUT  Glucose transporter 
H2O2  Hydrogen peroxide   
HAEC   Human aortic endothelial cells 
HCAEC  Human coronary artery endothelial cells 
HILIC  Hydrophilic interaction chromatography 
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HPLC   High-performance liquid chromatography 
HUVEC  Human umbilical vein endothelial cells 
ICAM   Intercellular adhesion molecule 
IFN-γ  Interferon-γ 
IKK   Inhibitory-κB kinase 
IL   Interleukin 
iNOS   Inducible nitric oxide synthase 
JAK   Janus kinase 
JNK   c-Jun N-terminal kinase 
LC  Liquid chromatography 
LDL   Low-density lipoprotein 
LOD  Limit of detection 
LPH   Lactase phloridzin hydrolase 
LPS   Lipopolysaccharide 
LSD  Least significant difference 
MALDI Matrix-assisted laser desorption/ionisation 
MAMS Microarray mass spectrometry 
MAPK  Mitogen-activated protein kinase 
MCP-1  Monocyte chemoattractant protein-1 
M-CSF Macrophage colony-stimulating factor 
MKK  Mitogen-activated protein kinase kinase 
mRNA  Messenger ribonucleic acid 
MRM  Multiple reaction monitoring 
MRP   Multidrug resistance protein 
MS   Mass Spectrometry 
Mv  Malvidin 
m/z   Mass to charge ratio. 
NADPH  Nicotinamide adenine dinucleotide phosphate 
ND  Not detected 
NF-κB  Nuclear factor-κB 
NO   Nitric oxide 
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NOX   NADPH oxidase 
O2-   Superoxide 
ONOO-  Peroxynitrite 
oxLDL  Oxidised low-density lipoprotein 
p38   Mitogen-activated protein kinase p38 subunit 
p50   NF-κB p50 subunit 
p65   NF-κB p65 subunit 
PCA   Protocatechuic acid 
PECAM-1  Platelet endothelial cellular adhesion molecule-1 
PFP   Pentafluorophenyl 
Pg  Pelargonidin 
PGA   Phloroglucinaldehyde 
Pn  Peonidin 
PPT  Protein precipitation 
Pt  Petunidin 
R2  Coefficient of determination 
ROS   Reactive oxygen species 
RP   Reverse-phase 
Rt   Retention time 
SD   Standard deviation 
SGLT-1  Sodium-dependent glucose transporter-1 
sMRM Scheduled multiple reaction monitoring 
SOD   Superoxide dismutase 
SPE   Solid-phase extraction 
STAT   Signal transducer and activator of transcription 
SULT   Sulfotransferase 
sVCAM-1 Soluble vascular cell adhesion molecule-1 
Tmax   Time of maximum concentration 
TNF-α  Tumour necrosis factor-α 
TNFR1  TNF receptor 1 
TOF   Time-of-flight 
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TRADD TNFR1-associated death domain protein 
UDPGT  Uridine 5’-diphospho-glucuronosyltransferase 
UN  United Nations 
UPLC  Ultra-high performance liquid chromatography 
UV  Ultraviolet 
VCAM-1  Vascular cell adhesion molecule-1 
 
  
 Page | 171 
Bibliography 
AB SCIEX. (2011). "Scheduled MRM algorithm tutorial." from 
http://sciex.com/documents/downloads/literature/scheduled-MRM-algorithm-
tutorial.pdf. 
 
Adachi, J., C. Kumar, Y. Zhang, J. V. Olsen and M. Mann (2006). "The human urinary proteome 
contains more than 1500 proteins, including a large proportion of membrane proteins." 
Genome Biology 7(9): R80. 
 
Aktan, F. (2004). "iNOS-mediated nitric oxide production and its regulation." Life Sciences 
75(6): 639-653. 
 
Allen-Vercoe, E. (2013). "Bringing the gut microbiota into focus through microbial culture: 
Recent progress and future perspective." Current Opinion in Microbiology 16(5): 625-629. 
 
Amarowicz, R., R. Carle, G. Dongowski, A. Durazzo, R. Galensa, D. Kammerer, G. Maiani and 
M. K. Piskula (2009). "Influence of postharvest processing and storage on the content of 
phenolic acids and flavonoids in foods." Molecular Nutrition & Food Research 53(S2): S151-
S183. 
 
Amin, H. P., C. Czank, S. Raheem, Q. Zhang, N. P. Botting, A. Cassidy and C. D. Kay (2015). 
"Anthocyanins and their physiologically relevant metabolites alter the expression of IL‐6 and 
VCAM‐1 in CD40L and oxidized LDL challenged vascular endothelial cells." Molecular 
Nutrition & Food Research 59(6): 1095-1106. 
 
Anttonen, M. J. and R. O. Karjalainen (2005). "Environmental and genetic variation of 
phenolic compounds in red raspberry." Journal of Food Composition and Analysis 18(8): 759-
769. 
 
Arrick, B. A. and C. F. Nathan (1984). "Glutathione metabolism as a determinant of 
therapeutic efficacy: A review." Cancer Research 44(10): 4224-4232. 
 
Arumugam, M., J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D. R. Mende, G. R. Fernandes, 
J. Tap, T. Bruls and J.-M. Batto (2011). "Enterotypes of the human gut microbiome." Nature 
473(7346): 174-180. 
 
Aura, A. M., P. Martin-Lopez, K. A. O’Leary, G. Williamson, K. M. Oksman-Caldentey, K. 
Poutanen and C. Santos-Buelga (2005). "In vitro metabolism of anthocyanins by human gut 
microflora." European Journal of Nutrition 44(3): 133-142. 
 
Bakhtiar, R. and T. K. Majumdar (2007). "Tracking problems and possible solutions in the 
quantitative determination of small molecule drugs and metabolites in biological fluids using 
liquid chromatography–mass spectrometry." Journal of Pharmacological and Toxicological 
Methods 55(3): 227-243. 
 
 Page | 172 
Banerjee, S. and S. Mazumdar (2012). "Electrospray ionization mass spectrometry: A 
technique to access the information beyond the molecular weight of the analyte." 
International Journal of Analytical Chemistry 2012. 
 
Baud, V. and M. Karin (2001). "Signal transduction by tumor necrosis factor and its relatives." 
Trends in Cell Biology 11(9): 372-377. 
 
Beaton, G. H. (1994). "Approaches to analysis of dietary data: Relationship between planned 
analyses and choice of methodology." The American Journal of Clinical Nutrition 59(1): 253S-
261S. 
 
Beaudry, F. and P. Vachon (2006). "Electrospray ionization suppression, a physical or a 
chemical phenomenon?" Biomedical Chromatography 20(2): 200-205. 
 
Bhagwat, S., D. B. Haytowitz and J. M. Holden (2011). "Usda database for the flavonoid 
content of selected foods, release 3.1." Beltsville: US Department of Agriculture: 03-01. 
 
Bitsch, I., M. Janssen, M. Netzel, G. Strass and T. Frank (2004a). "Bioavailability of 
anthocyanidin-3-glycosides following consumption of elderberry extract and blackcurrant 
juice." International Journal of Clinical Pharmacology and Therapeutics 42(5): 293-300. 
 
Bitsch, R., M. Netzel, S. Sonntag, G. Strass, T. Frank and I. Bitsch (2004b). "Urinary excretion 
of cyanidin glucosides and glucuronides in healthy humans after elderberry juice ingestion." 
BioMed Research International 2004(5): 343-345. 
 
Blanco-Colio, L. M., M. Valderrama, L. A. Alvarez-Sala, C. Bustos, M. Ortego, M. A. Hernández-
Presa, P. Cancelas, J. Gómez-Gerique, J. Millán and J. Egido (2000). "Red wine intake prevents 
nuclear factor-κB activation in peripheral blood mononuclear cells of healthy volunteers 
during postprandial lipemia." Circulation 102(9): 1020-1026. 
 
Blankenberg, S., S. Barbaux and L. Tiret (2003). "Adhesion molecules and atherosclerosis." 
Atherosclerosis 170(2): 191-203. 
 
Boto-Ordóñez, M., M. Urpi-Sarda, M. I. Queipo-Ortuño, S. Tulipani, F. J. Tinahones and C. 
Andres-Lacueva (2014). "High levels of bifidobacteria are associated with increased levels of 
anthocyanin microbial metabolites: A randomized clinical trial." Food & Function 5(8): 1932-
1938. 
 
Bouïs, D., G. A. Hospers, C. Meijer, G. Molema and N. H. Mulder (2001). "Endothelium in 
vitro: A review of human vascular endothelial cell lines for blood vessel-related research." 
Angiogenesis 4(2): 91-102. 
 
Božović, A. and V. Kulasingam (2013). "Quantitative mass spectrometry-based assay 
development and validation: From small molecules to proteins." Clinical Biochemistry 46(6): 
444-455. 
 
 Page | 173 
Brasier, A. R. (2010). "The nuclear factor-κB–interleukin-6 signalling pathway mediating 
vascular inflammation." Cardiovascular Research 86(2): 211-218. 
 
British Heart Foundation. (2015). "Cardiovascular disease statistics." from 
https://www.bhf.org.uk/~/media/files/research/heart-statistics/cardiovascular-disease-
statistics---headline-statistics.docx. 
 
Bub, A., B. Watzl, D. Heeb, G. Rechkemmer and K. Briviba (2001). "Malvidin-3-glucoside 
bioavailability in humans after ingestion of red wine, dealcoholized red wine and red grape 
juice." European Journal of Nutrition 40(3): 113-120. 
 
Bylda, C., R. Thiele, U. Kobold and D. A. Volmer (2014). "Recent advances in sample 
preparation techniques to overcome difficulties encountered during quantitative analysis of 
small molecules from biofluids using LC-MS/MS." Analyst 139(10): 2265-2276. 
 
Cai, D., C. A. Doughty, T. B. Potocky, F. J. Dufort, Z. Huang, D. Blair, K. Kempa, Z. Ren and T. 
C. Chiles (2007). "Carbon nanotube-mediated delivery of nucleic acids does not result in non-
specific activation of B lymphocytes." Nanotechnology 18(36): 365101. 
 
Cai, H. (2005). "Hydrogen peroxide regulation of endothelial function: Origins, mechanisms, 
and consequences." Cardiovascular Research 68(1): 26-36. 
 
Cao, G. and R. L. Prior (1999). "Anthocyanins are detected in human plasma after oral 
administration of an elderberry extract." Clinical Chemistry 45(4): 574-576. 
 
Carter, R. A. and I. P. Wicks (2001). "Vascular cell adhesion molecule 1 (CD106): A 
multifaceted regulator of joint inflammation." Arthritis & Rheumatism 44(5): 985-994. 
 
Cassidy, A., K. J. Mukamal, L. Liu, M. Franz, A. H. Eliassen and E. B. Rimm (2013). "High 
anthocyanin intake is associated with a reduced risk of myocardial infarction in young and 
middle-aged women." Circulation 127(2): 188-196. 
 
Cassidy, A., É. J. O'Reilly, C. Kay, L. Sampson, M. Franz, J. Forman, G. Curhan and E. B. Rimm 
(2011). "Habitual intake of flavonoid subclasses and incident hypertension in adults." The 
American Journal of Clinical Nutrition 93(2): 338-347. 
 
Cassidy, A., G. Rogers, J. J. Peterson, J. T. Dwyer, H. Lin and P. F. Jacques (2015). "Higher 
dietary anthocyanin and flavonol intakes are associated with anti-inflammatory effects in a 
population of US adults." The American Journal of Clinical Nutrition 102(1): 172-181. 
 
Castañeda-Ovando, A., M. d. L. Pacheco-Hernández, M. E. Páez-Hernández, J. A. Rodríguez 
and C. A. Galán-Vidal (2009). "Chemical studies of anthocyanins: A review." Food Chemistry 
113(4): 859-871. 
 
Cech, N. B. and C. G. Enke (2001). "Practical implications of some recent studies in 
electrospray ionization fundamentals." Mass Spectrometry Reviews 20(6): 362-387. 
 
 Page | 174 
Chalker-Scott, L. (1999). "Environmental significance of anthocyanins in plant stress 
responses." Photochemistry and Photobiology 70(1): 1-9. 
 
Chang, M. S., Q. Ji, J. Zhang and T. A. El‐Shourbagy (2007). "Historical review of sample 
preparation for chromatographic bioanalysis: Pros and cons." Drug Development Research 
68(3): 107-133. 
 
Chao, P.-Y., Y.-P. Huang and W.-B. Hsieh (2013). "Inhibitive effect of purple sweet potato leaf 
extract and its components on cell adhesion and inflammatory response in human aortic 
endothelial cells." Cell Adhesion & Migration 7(2): 237-245. 
 
Charepalli, V., L. Reddivari, S. Radhakrishnan, R. Vadde, R. Agarwal and J. K. P. Vanamala 
(2015). "Anthocyanin-containing purple-fleshed potatoes suppress colon tumorigenesis via 
elimination of colon cancer stem cells." The Journal of Nutritional Biochemistry 26(12): 1641-
1649. 
 
Chun, O. K., S. J. Chung and W. O. Song (2007). "Estimated dietary flavonoid intake and major 
food sources of US adults." The Journal of Nutrition 137(5): 1244-1252. 
 
Cooke, D. N., S. Thomasset, D. J. Boocock, M. Schwarz, P. Winterhalter, W. P. Steward, A. J. 
Gescher and T. H. Marczylo (2006). "Development of analyses by high-performance liquid 
chromatography and liquid chromatography/tandem mass spectrometry of bilberry 
(Vaccinium myrtilus) anthocyanins in human plasma and urine." Journal of Agricultural and 
Food Chemistry 54(19): 7009-7013. 
 
Crozier, A., D. Del Rio and M. N. Clifford (2010). "Bioavailability of dietary flavonoids and 
phenolic compounds." Molecular Aspects of Medicine 31(6): 446-467. 
 
Crozier, A., I. B. Jaganath and M. N. Clifford (2009). "Dietary phenolics: Chemistry, 
bioavailability and effects on health." Natural Product Reports 26(8): 1001-1043. 
 
Czank, C., A. Cassidy, Q. Zhang, D. J. Morrison, T. Preston, P. A. Kroon, N. P. Botting and C. D. 
Kay (2013). "Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: 
A 13C-tracer study." The American Journal of Clinical Nutrition 97(5): 995-1003. 
 
Dams, R., M. A. Huestis, W. E. Lambert and C. M. Murphy (2003). "Matrix effect in bio-
analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and 
biofluid." Journal of the American Society for Mass Spectrometry 14(11): 1290-1294. 
 
Day, A. J., F. J. Cañada, J. C. Dıáz, P. A. Kroon, R. McLauchlan, C. B. Faulds, G. W. Plumb, M. 
R. A. Morgan and G. Williamson (2000). "Dietary flavonoid and isoflavone glycosides are 
hydrolysed by the lactase site of lactase phlorizin hydrolase." FEBS Letters 468(2–3): 166-
170. 
 
Day, A. J., M. S. DuPont, S. Ridley, M. Rhodes, M. J. C. Rhodes, M. R. A. Morgan and G. 
Williamson (1998). "Deglycosylation of flavonoid and isoflavonoid glycosides by human small 
intestine and liver β-glucosidase activity." FEBS Letters 436(1): 71-75. 
 Page | 175 
 
Day, A. J., J. M. Gee, M. S. DuPont, I. T. Johnson and G. Williamson (2003). "Absorption of 
quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: The role of 
lactase phlorizin hydrolase and the sodium-dependent glucose transporter." Biochemical 
Pharmacology 65(7): 1199-1206. 
 
de Ancos, B., E. Ibanez, G. Reglero and M. P. Cano (2000). "Frozen storage effects on 
anthocyanins and volatile compounds of raspberry fruit." Journal of Agricultural and Food 
Chemistry 48(3): 873-879. 
 
de Ferrars, R., C. Czank, Q. Zhang, N. Botting, P. Kroon, A. Cassidy and C. Kay (2014a). "The 
pharmacokinetics of anthocyanins and their metabolites in humans." British Journal of 
Pharmacology 171(13): 3268-3282. 
 
de Ferrars, R. M., A. Cassidy, P. Curtis and C. D. Kay (2014b). "Phenolic metabolites of 
anthocyanins following a dietary intervention study in post‐menopausal women." Molecular 
Nutrition & Food Research 58(3): 490-502. 
 
de Ferrars, R. M., C. Czank, S. Saha, P. W. Needs, Q. Zhang, K. S. Raheem, N. P. Botting, P. A. 
Kroon and C. D. Kay (2014c). "Methods for isolating, identifying, and quantifying anthocyanin 
metabolites in clinical samples." Analytical Chemistry 86(20): 10052-10058. 
 
de Pascual-Teresa, S., D. A. Moreno and C. García-Viguera (2010). "Flavanols and 
anthocyanins in cardiovascular health: A review of current evidence." International Journal 
of Molecular Sciences 11(4): 1679-1703. 
 
de Rijke, E., H. Zappey, F. Ariese, C. Gooijer and U. A. T. Brinkman (2003). "Liquid 
chromatography with atmospheric pressure chemical ionization and electrospray ionization 
mass spectrometry of flavonoids with triple-quadrupole and ion-trap instruments." Journal 
of Chromatography A 984(1): 45-58. 
 
de Roos, B. (2013). "Personalised nutrition: Ready for practice?" Proceedings of the Nutrition 
Society 72(01): 48-52. 
 
Dearden, J. and W. Forbes (1959). "Light absorption studies: Part xiv. The ultraviolet 
absorption spectra of phenols." Canadian Journal of Chemistry 37(8): 1294-1304. 
 
Déchanet, J., C. Grosset, J. L. Taupin, P. Merville, J. Banchereau, J. Ripoche and J. F. Moreau 
(1997). "CD40 ligand stimulates proinflammatory cytokine production by human endothelial 
cells." The Journal of Immunology 159(11): 5640-5647. 
 
Deineka, V., I. Saenko, L. Deineka and I. Blinova (2016). "Hydrophilic interaction 
chromatography as an alternative to reversed-phase HPLC in determining anthocyanins and 
betacyanins." Journal of Analytical Chemistry 71(3): 297-301. 
 
Del Rio, D., G. Borges and A. Crozier (2010a). "Berry flavonoids and phenolics: Bioavailability 
and evidence of protective effects." British Journal of Nutrition 104 Suppl 3: S67-90. 
 Page | 176 
 
Del Rio, D., L. Calani, F. Scazzina, L. Jechiu, C. Cordero and F. Brighenti (2010b). 
"Bioavailability of catechins from ready-to-drink tea." Nutrition 26(5): 528-533. 
 
di Gesso, J. L., J. S. Kerr, Q. Zhang, S. Raheem, S. K. Yalamanchili, D. O'Hagan, C. D. Kay and 
M. A. O'Connell (2015). "Flavonoid metabolites reduce tumor necrosis factor‐α secretion to 
a greater extent than their precursor compounds in human THP‐1 monocytes." Molecular 
Nutrition & Food Research 59(6): 1143-1154. 
 
Dohadwala, M. M., M. Holbrook, N. M. Hamburg, S. M. Shenouda, W. B. Chung, M. Titas, M. 
A. Kluge, N. Wang, J. Palmisano, P. E. Milbury, J. B. Blumberg and J. A. Vita (2011). "Effects 
of cranberry juice consumption on vascular function in patients with coronary artery 
disease." The American Journal of Clinical Nutrition 93(5): 934-940. 
 
Dumont, O., H. Mylroie, A. Sperone, A. Bauer, S. Hamdulay, N. Ali, J. Boyle, A. Samarel, D. 
Haskard and A. Randi (2012). "Protein kinase Cε activity induces anti-inflammatory and anti-
apoptotic genes via an ERK1/2 and NF-κB-dependent pathway to enhance vascular 
protection." Biochemical Journal 447: 193-204. 
 
Edmands, W. M., P. Ferrari, J. A. Rothwell, S. Rinaldi, N. Slimani, D. K. Barupal, C. Biessy, M. 
Jenab, F. Clavel-Chapelon, G. Fagherazzi, M.-C. Boutron-Ruault, V. A. Katzke, T. Kühn, H. 
Boeing, A. Trichopoulou, P. Lagiou, D. Trichopoulos, D. Palli, S. Grioni, R. Tumino, P. Vineis, 
A. Mattiello, I. Romieu and A. Scalbert (2015). "Polyphenol metabolome in human urine and 
its association with intake of polyphenol-rich foods across European countries." The 
American Journal of Clinical Nutrition 102(4): 905-913. 
 
Edwards, M., C. Czank, G. M. Woodward, A. Cassidy and C. D. Kay (2015). "Phenolic 
metabolites of anthocyanins modulate mechanisms of endothelial function." Journal of 
Agricultural and Food Chemistry 63(9): 2423-2431. 
 
Epstein, F. H. and R. Ross (1999). "Atherosclerosis—an inflammatory disease." New England 
Journal of Medicine 340(2): 115-126. 
 
Erlund, I., R. Koli, G. Alfthan, J. Marniemi, P. Puukka, P. Mustonen, P. Mattila and A. Jula 
(2008). "Favorable effects of berry consumption on platelet function, blood pressure, and 
HDL cholesterol." The American Journal of Clinical Nutrition 87(2): 323-331. 
 
Fang, J. (2014). "Some anthocyanins could be efficiently absorbed across the gastrointestinal 
mucosa: Extensive presystemic metabolism reduces apparent bioavailability." Journal of 
Agricultural and Food Chemistry 62(18): 3904-3911. 
 
Feild, T. S., D. W. Lee and N. M. Holbrook (2001). "Why leaves turn red in autumn. The role 
of anthocyanins in senescing leaves of red-osier dogwood." Plant Physiology 127(2): 566-
574. 
 
Felgines, C., S. Talavéra, M.-P. Gonthier, O. Texier, A. Scalbert, J.-L. Lamaison and C. Rémésy 
(2003). "Strawberry anthocyanins are recovered in urine as glucuro- and sulfoconjugates in 
humans." The Journal of Nutrition 133(5): 1296-1301. 
 Page | 177 
 
Felgines, C., S. Talavera, O. Texier, A. Gil-Izquierdo, J.-L. Lamaison and C. Remesy (2005). 
"Blackberry anthocyanins are mainly recovered from urine as methylated and 
glucuronidated conjugates in humans." Journal of Agricultural and Food Chemistry 53(20): 
7721-7727. 
 
Fernandes, I., J. Azevedo, A. Faria, C. a. o. Calhau, V. de Freitas and N. Mateus (2009). 
"Enzymatic hemisynthesis of metabolites and conjugates of anthocyanins." Journal of 
Agricultural and Food Chemistry 57(2): 735-745. 
 
Fernandes, I., V. de Freitas, C. Reis and N. Mateus (2012). "A new approach on the gastric 
absorption of anthocyanins." Food & Function 3(5): 508-516. 
 
Fernandes, I., A. Faria, V. de Freitas, C. Calhau and N. Mateus (2015). "Multiple-approach 
studies to assess anthocyanin bioavailability." Phytochemistry Reviews 14(6): 899-919. 
 
Fernández-Peralbo, M. A. and M. D. Luque de Castro (2012). "Preparation of urine samples 
prior to targeted or untargeted metabolomics mass-spectrometry analysis." Trends in 
Analytical Chemistry 41: 75-85. 
 
Fitzgerald, R. L., T. L. Griffin, Y.-M. Yun, R. A. Godfrey, R. West, A. J. Pesce and D. A. Herold 
(2012). "Dilute and shoot: Analysis of drugs of abuse using selected reaction monitoring for 
quantification and full scan product ion spectra for identification." Journal of Analytical 
Toxicology 36(2): 106-111. 
 
Fleschhut, J., F. Kratzer, G. Rechkemmer and S. E. Kulling (2006). "Stability and 
biotransformation of various dietary anthocyanins in vitro." European Journal of Nutrition 
45(1): 7-18. 
 
Food and Drug Administration (2001). "Guidance for industry: Bioanalytical method 
validation." 
 
Food and Drug Administration (2003). "Guidance for industry: Stability testing of new drug 
substances and products." 
 
Forester, S. C. and A. L. Waterhouse (2008). "Identification of cabernet sauvignon 
anthocyanin gut microflora metabolites." Journal of Agricultural and Food Chemistry 56(19): 
9299-9304. 
 
Fossen, T., R. Slimestad and Ø. M. Andersen (2003). "Anthocyanins with 4′-glucosidation 
from red onion, Allium cepa." Phytochemistry 64(8): 1367-1374. 
 
Frank, T., M. Janßen, M. Netzel, G. Straß, A. Kler, E. Kriesl and I. Bitsch (2005). 
"Pharmacokinetics of anthocyanidin‐3‐glycosides following consumption of Hibiscus 
sabdariffa L. Extract." The Journal of Clinical Pharmacology 45(2): 203-210. 
 
 Page | 178 
Frank, T., M. Netzel, G. Strass, R. Bitsch and I. Bitsch (2003). "Bioavailability of anthocyanidin-
3-glucosides following consumption of red wine and red grape juice." Canadian Journal of 
Physiology and Pharmacology 81(5): 423-435. 
 
Galati, G., M. Y. Moridani, T. S. Chan and P. J. O’Brien (2001). "Peroxidative metabolism of 
apigenin and naringenin versus luteolin and quercetin: Glutathione oxidation and 
conjugation." Free Radical Biology and Medicine 30(4): 370-382. 
 
Gerritsen, M. E., W. W. Carley, G. E. Ranges, C.-P. Shen, S. A. Phan, G. F. Ligon and C. A. Perry 
(1995). "Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene 
expression." The American Journal of Pathology 147(2): 278. 
 
Gibney, M. J., M. Walsh, L. Brennan, H. M. Roche, B. German and B. van Ommen (2005). 
"Metabolomics in human nutrition: Opportunities and challenges." The American Journal of 
Clinical Nutrition 82(3): 497-503. 
 
Giordano, L., W. Coletta, P. Rapisarda, M. B. Donati and D. Rotilio (2007). "Development and 
validation of an LC‐MS/MS analysis for simultaneous determination of delphinidin‐3‐
glucoside, cyanidin‐3‐glucoside and cyanidin‐3‐(6‐malonylglucoside) in human plasma and 
urine after blood orange juice administration." Journal of Separation Science 30(18): 3127-
3136. 
 
Gould, K. S. (2004). "Nature's swiss army knife: The diverse protective roles of anthocyanins 
in leaves." Journal of Biomedicine and Biotechnology 2004(5): 314-320. 
 
Grace, P. B., N. S. Mistry, M. H. Carter, A. J. C. Leathem and P. Teale (2007). "High throughput 
quantification of phytoestrogens in human urine and serum using liquid 
chromatography/tandem mass spectrometry (LC–MS/MS)." Journal of Chromatography B 
853(1–2): 138-146. 
 
Graham, A., N. Hogg, B. Kalyanaraman, V. O'Leary, V. Darley-Usmar and S. Moncada (1993). 
"Peroxynitrite modification of low‐density lipoprotein leads to recognition by the 
macrophage scavenger receptor." FEBS Letters 330(2): 181-185. 
 
Granger, D. N., T. Vowinkel and T. Petnehazy (2004). "Modulation of the inflammatory 
response in cardiovascular disease." Hypertension 43(5): 924-931. 
 
Guerrero, L., M. Margalef, Z. Pons, M. Quiñones, L. Arola, A. Arola-Arnal and B. Muguerza 
(2013). "Serum metabolites of proanthocyanidin-administered rats decrease lipid synthesis 
in HepG2 cells." The Journal of Nutritional Biochemistry 24(12): 2092-2099. 
 
Gustavsson, E., M. Andersson, N. Stephanson and O. Beck (2007). "Validation of direct 
injection electrospray LC‐MS/MS for confirmation of opiates in urine drug testing." Journal 
of Mass Spectrometry 42(7): 881-889. 
 
Hager, A., L. Howard, R. Prior and C. Brownmiller (2008). "Processing and storage effects on 
monomeric anthocyanins, percent polymeric color, and antioxidant capacity of processed 
black raspberry products." Journal of Food Science 73(6): H134-H140. 
 Page | 179 
 
Hansson, G. K. (2005). "Inflammation, atherosclerosis, and coronary artery disease." New 
England Journal of Medicine 352(16): 1685-1695. 
 
Harborne, J. (1958). "Spectral methods of characterizing anthocyanins." Biochemical Journal 
70(1): 22. 
 
Harborne, J. B. and C. A. Williams (2000). "Advances in flavonoid research since 1992." 
Phytochemistry 55(6): 481-504. 
 
Hayden, M. S. and S. Ghosh (2014). "Regulation of NF-κB by TNF family cytokines." Seminars 
in Immunology 26(3): 253-266. 
 
Hedrick, V., A. Dietrich, P. Estabrooks, J. Savla, E. Serrano and B. Davy (2012). "Dietary 
biomarkers: Advances, limitations and future directions." Nutrition Journal 11(1): 109. 
 
Hemström, P. and K. Irgum (2006). "Hydrophilic interaction chromatography." Journal of 
Separation Science 29(12): 1784-1821. 
 
Henriksen, T., R. K. Juhler, B. Svensmark and N. B. Cech (2005). "The relative influences of 
acidity and polarity on responsiveness of small organic molecules to analysis with negative 
ion electrospray ionization mass spectrometry (ESI-MS)." Journal of the American Society for 
Mass Spectrometry 16(4): 446-455. 
 
Hertog, M. G., E. J. Feskens, P. C. Hollman, M. B. Katan and D. Kromhout (1994). "Dietary 
flavonoids and cancer risk in the Zutphen Elderly Study." Nutrition and Cancer 22(2): 175-
184. 
 
Hertog, M. G., E. J. Feskens, D. Kromhout, P. Hollman and M. Katan (1993). "Dietary 
antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study." The 
Lancet 342(8878): 1007-1011. 
 
Hidalgo, M., S. Martin-Santamaria, I. Recio, C. Sanchez-Moreno, B. de Pascual-Teresa, G. 
Rimbach and S. de Pascual-Teresa (2012). "Potential anti-inflammatory, anti-adhesive, 
anti/estrogenic, and angiotensin-converting enzyme inhibitory activities of anthocyanins 
and their gut metabolites." Genes & Nutrition 7(2): 295-306. 
 
Hodgson, J. M., S. Yee Chan, I. B. Puddey, A. Devine, N. Wattanapenpaiboon, M. L. Wahlqvist, 
W. Lukito, V. Burke, N. C. Ward, R. L. Prince and K. D. Croft (2004). "Phenolic acid metabolites 
as biomarkers for tea- and coffee-derived polyphenol exposure in human subjects." British 
Journal of Nutrition 91(02): 301-305. 
 
Hollman, P. C. H., M. G. L. Hertog and M. B. Katan (1996). "Analysis and health effects of 
flavonoids." Food Chemistry 57(1): 43-46. 
 
 Page | 180 
Hong, V. and R. E. Wrolstad (1990). "Use of HPLC separation/photodiode array detection for 
characterization of anthocyanins." Journal of Agricultural and Food Chemistry 38(3): 708-
715. 
 
Hong, Y.-J. and A. E. Mitchell (2006). "Identification of glutathione-related quercetin 
metabolites in humans." Chemical Research in Toxicology 19(11): 1525-1532. 
 
Hooper, L., P. A. Kroon, E. B. Rimm, J. S. Cohn, I. Harvey, K. A. Le Cornu, J. J. Ryder, W. L. Hall 
and A. Cassidy (2008). "Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-
analysis of randomized controlled trials." The American Journal of Clinical Nutrition 88(1): 
38-50. 
 
Hua, Y. and D. Jenke (2012). "Increasing the sensitivity of an LC–MS method for screening 
material extracts for organic extractables via mobile phase optimization." Journal of 
Chromatographic Science 50(3): 213-227. 
 
Huang, H., G. Chen, D. Liao, Y. Zhu and X. Xue (2016). "Effects of berries consumption on 
cardiovascular risk factors: A meta-analysis with trial sequential analysis of randomized 
controlled trials." Scientific Reports 6(23625). 
 
Huang, W.-Y., J. Wang, Y.-M. Liu, Q.-S. Zheng and C.-Y. Li (2014). "Inhibitory effect of malvidin 
on TNF-α-induced inflammatory response in endothelial cells." European Journal of 
Pharmacology 723(0): 67-72. 
 
Hughes, L. A., I. C. Arts, T. Ambergen, H. A. Brants, P. C. Dagnelie, R. A. Goldbohm, P. A. van 
den Brandt and M. P. Weijenberg (2008). "Higher dietary flavone, flavonol, and catechin 
intakes are associated with less of an increase in BMI over time in women: A longitudinal 
analysis from the Netherlands Cohort Study." The American Journal of Clinical Nutrition 
88(5): 1341-1352. 
 
Hui, C., X. Qi, Z. Qianyong, P. Xiaoli, Z. Jundong and M. Mantian (2013). "Flavonoids, flavonoid 
subclasses and breast cancer risk: A meta-analysis of epidemiologic studies." PLOS ONE 8(1): 
e54318. 
 
Ibáñez, A. J., S. R. Fagerer, A. M. Schmidt, P. L. Urban, K. Jefimovs, P. Geiger, R. Dechant, M. 
Heinemann and R. Zenobi (2013). "Mass spectrometry-based metabolomics of single yeast 
cells." Proceedings of the National Academy of Sciences 110(22): 8790-8794. 
 
Impey, G. A. B. M. S. (2005). "Method transfer: Extending compatibility in a multiple 
instrument laboratory." from 
http://www3.appliedbiosystems.com/cms/groups/psm_marketing/documents/generaldoc
uments/cms_041961.pdf. 
 
Ito, H., M.-P. Gonthier, C. Manach, C. Morand, L. Mennen, C. Rémésy and A. Scalbert (2005). 
"Polyphenol levels in human urine after intake of six different polyphenol-rich beverages." 
British Journal of Nutrition 94(04): 500-509. 
 
 Page | 181 
Jandera, P. (2011). "Stationary and mobile phases in hydrophilic interaction 
chromatography: A review." Analytica Chimica Acta 692(1–2): 1-25. 
 
Jenab, M., N. Slimani, M. Bictash, P. Ferrari and S. A. Bingham (2009). "Biomarkers in 
nutritional epidemiology: Applications, needs and new horizons." Human Genetics 125(5-6): 
507-525. 
 
Jennings, A., A. A. Welch, S. J. Fairweather-Tait, C. Kay, A.-M. Minihane, P. Chowienczyk, B. 
Jiang, M. Cecelja, T. Spector, A. Macgregor and A. Cassidy (2012). "Higher anthocyanin intake 
is associated with lower arterial stiffness and central blood pressure in women." The 
American Journal of Clinical Nutrition 96(4): 781-788. 
 
Jeong, J.-W., W. Lee, S. Shin, G.-Y. Kim, B. Choi and Y. Choi (2013). "Anthocyanins 
downregulate lipopolysaccharide-induced inflammatory responses in BV2 microglial cells by 
suppressing the NF-κB and Akt/MAPKs signaling pathways." International Journal of 
Molecular Sciences 14(1): 1502-1515. 
 
Jia, Z., P. V. A. Babu, H. Si, P. Nallasamy, H. Zhu, W. Zhen, H. P. Misra, Y. Li and D. Liu (2013). 
"Genistein inhibits TNF-α-induced endothelial inflammation through the protein kinase 
pathway A and improves vascular inflammation in C57BL/6 mice." International Journal of 
Cardiology 168(3): 2637-2645. 
 
Jian, W., R. W. Edom, Y. Xu and N. Weng (2010). "Recent advances in application of 
hydrophilic interaction chromatography for quantitative bioanalysis." Journal of Separation 
Science 33(6-7): 681-697. 
 
Jiménez-Girón, A., I. Muñoz-González, P. J. Martín-Álvarez, M. V. Moreno-Arribas and B. 
Bartolomé (2014). "Towards the fecal metabolome derived from moderate red wine intake." 
Metabolites 4(4): 1101-1118. 
 
Jurd, L. (1963). "Anthocyanins and related compounds. I. Structural transformations of 
flavylium salts in acidic solutions." The Journal of Organic Chemistry 28(4): 987-991. 
 
Kalili, K. M. and A. de Villiers (2011). "Recent developments in the HPLC separation of 
phenolic compounds." Journal of Separation Science 34(8): 854-876. 
 
Kalt, W., Y. Liu, J. E. McDonald, M. Vinqvist-Tymchuk and S. A. E. Fillmore (2014). 
"Anthocyanin metabolites are abundant and persistent in human urine." Journal of 
Agricultural and Food Chemistry 62(18): 3926-3934. 
 
Kamiloglu, S., E. Capanoglu, C. Grootaert and J. Van Camp (2015). "Anthocyanin absorption 
and metabolism by human intestinal Caco-2 cells—a review." International Journal of 
Molecular Sciences 16(9): 21555-21574. 
 
Karlsen, A., L. Retterstøl, P. Laake, I. Paur, S. Kjølsrud-Bøhn, L. Sandvik and R. Blomhoff 
(2007). "Anthocyanins inhibit nuclear factor-κB activation in monocytes and reduce plasma 
concentrations of pro-inflammatory mediators in healthy adults." The Journal of Nutrition 
137(8): 1951-1954. 
 Page | 182 
 
Karmann, K., C. Hughes, J. Schechner, W. C. Fanslow and J. S. Pober (1995). "CD40 on human 
endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule 
expression." Proceedings of the National Academy of Sciences 92(10): 4342-4346. 
 
Kay, C. D. (2006). "Aspects of anthocyanin absorption, metabolism and pharmacokinetics in 
humans." Nutrition Research Reviews 19(1): 137-146. 
 
Kay, C. D., L. Hooper, P. A. Kroon, E. B. Rimm and A. Cassidy (2012). "Relative impact of 
flavonoid composition, dose and structure on vascular function: A systematic review of 
randomised controlled trials of flavonoid-rich food products." Molecular Nutrition & Food 
Research 56(11): 1605-1616. 
 
Kay, C. D., P. A. Kroon and A. Cassidy (2009). "The bioactivity of dietary anthocyanins is likely 
to be mediated by their degradation products." Molecular Nutrition & Food Research 53(S1): 
S92-S101. 
 
Kay, C. D., G. Mazza and B. J. Holub (2005). "Anthocyanins exist in the circulation primarily 
as metabolites in adult men." The Journal of Nutrition 135(11): 2582-2588. 
 
Kay, C. D., G. Mazza, B. J. Holub and J. Wang (2004). "Anthocyanin metabolites in human 
urine and serum." British Journal of Nutrition 91(06): 933-942. 
 
Kent, K., K. Charlton, S. Roodenrys, M. Batterham, J. Potter, V. Traynor, H. Gilbert, O. Morgan 
and R. Richards (2015). "Consumption of anthocyanin-rich cherry juice for 12 weeks 
improves memory and cognition in older adults with mild-to-moderate dementia." European 
Journal of Nutrition: 1-9. 
 
Keppler, K. and H.-U. Humpf (2005). "Metabolism of anthocyanins and their phenolic 
degradation products by the intestinal microflora." Bioorganic & Medicinal Chemistry 
13(17): 5195-5205. 
 
Khymenets, O., C. Andres-Lacueva, M. Urpi-Sarda, R. Vazquez-Fresno, M. M. Mart, G. 
Reglero, M. Torres and R. Llorach (2015). "Metabolic fingerprint after acute and under 
sustained consumption of a functional beverage based on grape skin extract in healthy 
human subjects." Food & Function 6(4): 1288-1298. 
 
Kim, M.-C., S.-J. Kim, D.-S. Kim, Y.-D. Jeon, S. J. Park, H. S. Lee, J.-Y. Um and S.-H. Hong (2011). 
"Vanillic acid inhibits inflammatory mediators by suppressing NF-κB in lipopolysaccharide-
stimulated mouse peritoneal macrophages." Immunopharmacology and Immunotoxicology 
33(3): 525-532. 
 
Kong, J.-M., L.-S. Chia, N.-K. Goh, T.-F. Chia and R. Brouillard (2003). "Analysis and biological 
activities of anthocyanins." Phytochemistry 64(5): 923-933. 
 
  
 Page | 183 
Krga, I., L.-E. Monfoulet, A. Konic-Ristic, S. Mercier, M. Glibetic, C. Morand and D. Milenkovic 
(2016). "Anthocyanins and their gut metabolites reduce the adhesion of monocyte to TNFα-
activated endothelial cells at physiologically relevant concentrations." Archives of 
Biochemistry and Biophysics 599: 51-59. 
 
Krogholm, K. (2011). Flavonoids as fruit and vegetable intake biomarkers - development, 
validation and application of flavonoid biomarkers in nutritional research, University of 
Copenhagen & Technical University of Denmark. 
 
Kropat, C., D. Mueller, U. Boettler, K. Zimmermann, E. H. Heiss, V. M. Dirsch, D. Rogoll, R. 
Melcher, E. Richling and D. Marko (2013). "Modulation of Nrf2‐dependent gene transcription 
by bilberry anthocyanins in vivo." Molecular Nutrition & Food Research 57(3): 545-550. 
 
Kuhnle, G. G. C. (2012). "Nutritional biomarkers for objective dietary assessment." Journal 
of the Science of Food and Agriculture 92(6): 1145-1149. 
 
Kuntz, S., H. Asseburg, S. Dold, A. Römpp, B. Fröhling, C. Kunz and S. Rudloff (2015a). 
"Inhibition of low-grade inflammation by anthocyanins from grape extract in an in vitro 
epithelial-endothelial co-culture model." Food & Function 6(4): 1136-1149. 
 
Kuntz, S., S. Rudloff, H. Asseburg, C. Borsch, B. Fröhling, F. Unger, S. Dold, B. Spengler, A. 
Römpp and C. Kunz (2015b). "Uptake and bioavailability of anthocyanins and phenolic acids 
from grape/blueberry juice and smoothie in vitro and in vivo." British Journal of Nutrition 
113(07): 1044-1055. 
 
Lambert, N., P. A. Kroon, C. B. Faulds, G. W. Plumb, W. R. McLauchlan, A. J. Day and G. 
Williamson (1999). "Purification of cytosolic β-glucosidase from pig liver and its reactivity 
towards flavonoid glycosides." Biochimica et Biophysica Acta 1435(1–2): 110-116. 
 
Lamport, D. J., L. Dye, J. D. Wightman and C. L. Lawton (2012). "The effects of flavonoid and 
other polyphenol consumption on cognitive performance: A systematic research review of 
human experimental and epidemiological studies." Nutrition and Aging 1(1): 5-25. 
 
Lee, C.-C., S.-H. Huang, Y.-T. Yang, Y.-W. Cheng, C.-H. Li and J.-J. Kang (2012). "Motorcycle 
exhaust particles up-regulate expression of vascular adhesion molecule-1 and intercellular 
adhesion molecule-1 in human umbilical vein endothelial cells." Toxicology in Vitro 26(4): 
552-560. 
 
Lee, S. G., B. Kim, Y. Yang, T. X. Pham, Y.-K. Park, J. Manatou, S. I. Koo, O. K. Chun and J.-Y. 
Lee (2014). "Berry anthocyanins suppress the expression and secretion of proinflammatory 
mediators in macrophages by inhibiting nuclear translocation of NF-κB independent of nrf2-
mediated mechanism." The Journal of Nutritional Biochemistry 25(4): 404-411. 
 
Li, G., Y. Zhu, Y. Zhang, J. Lang, Y. Chen and W. Ling (2013). "Estimated daily flavonoid and 
stilbene intake from fruits, vegetables, and nuts and associations with lipid profiles in 
Chinese adults." Journal of the Academy of Nutrition and Dietetics 113(6): 786-794. 
 
 Page | 184 
Libby, P., P. M. Ridker and A. Maseri (2002). "Inflammation and atherosclerosis." Circulation 
105(9): 1135-1143. 
 
Lin, H. H., J. H. Chen, C. C. Huang and C. J. Wang (2007). "Apoptotic effect of 3, 4‐
dihydroxybenzoic acid on human gastric carcinoma cells involving JNK/p38 MAPK signaling 
activation." International Journal of Cancer 120(11): 2306-2316. 
 
Loke, W. M., A. M. Jenner, J. M. Proudfoot, A. J. McKinley, J. M. Hodgson, B. Halliwell and K. 
D. Croft (2009). "A metabolite profiling approach to identify biomarkers of flavonoid intake 
in humans." The Journal of Nutrition 139(12): 2309-2314. 
 
Louise, C. B. and T. G. Obrig (1991). "Shiga toxin-associated hemolytic-uremic syndrome: 
Combined cytotoxic effects of shiga toxin, interleukin-1 beta, and tumor necrosis factor 
alpha on human vascular endothelial cells in vitro." Infection and Immunity 59(11): 4173-
4179. 
 
Maaser, C., S. Schoeppner, T. Kucharzik, M. Kraft, E. Schoenherr, W. Domschke and N. 
Luegering (2001). "Colonic epithelial cells induce endothelial cell expression of ICAM-1 and 
VCAM-1 by a NF-κB-dependent mechanism." Clinical & Experimental Immunology 124(2): 
208-213. 
 
Mäkilä, L., O. A. Laaksonen, A.-L. M. Alanne, M. K. Kortesniemi, H. P. Kallio and B. Yang (2016). 
"Stability of hydroxycinnamic acid derivatives, flavonol glycosides and anthocyanins in black 
currant juice." Journal of Agricultural and Food Chemistry. 
 
Mallet, C. R., Z. Lu and J. R. Mazzeo (2004). "A study of ion suppression effects in electrospray 
ionization from mobile phase additives and solid-phase extracts." Rapid Communications in 
Mass Spectrometry 18(1): 49-58. 
 
Manach, C., A. Scalbert, C. Morand, C. Rémésy and L. Jiménez (2004). "Polyphenols: Food 
sources and bioavailability." The American Journal of Clinical Nutrition 79(5): 727-747. 
 
Manach, C., G. Williamson, C. Morand, A. Scalbert and C. Rémésy (2005). "Bioavailability and 
bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies." The American 
Journal of Clinical Nutrition 81(1): 230S-242S. 
 
Matheny, H. E., T. L. Deem and J. M. Cook-Mills (2000). "Lymphocyte migration through 
monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH 
oxidase." The Journal of Immunology 164(12): 6550-6559. 
 
Matuszewski, B. K., M. L. Constanzer and C. M. Chavez-Eng (2003). "Strategies for the 
assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS." 
Analytical Chemistry 75(13): 3019-3030. 
 
Mauray, A., C. Felgines, C. Morand, A. Mazur, A. Scalbert and D. Milenkovic (2012). "Bilberry 
anthocyanin-rich extract alters expression of genes related to atherosclerosis development 
in aorta of apo E-deficient mice." Nutrition, Metabolism and Cardiovascular Diseases 22(1): 
72-80. 
 Page | 185 
 
Mazza, G., C. D. Kay, T. Cottrell and B. J. Holub (2002). "Absorption of anthocyanins from 
blueberries and serum antioxidant status in human subjects." Journal of Agricultural and 
Food Chemistry 50(26): 7731-7737. 
 
McCullough, M. L., J. J. Peterson, R. Patel, P. F. Jacques, R. Shah and J. T. Dwyer (2012). 
"Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults." 
The American Journal of Clinical Nutrition 95(2): 454-464. 
 
McGhie, T. K., G. D. Ainge, L. E. Barnett, J. M. Cooney and D. J. Jensen (2003). "Anthocyanin 
glycosides from berry fruit are absorbed and excreted unmetabolized by both humans and 
rats." Journal of Agricultural and Food Chemistry 51(16): 4539-4548. 
 
McGhie, T. K. and M. C. Walton (2007). "The bioavailability and absorption of anthocyanins: 
Towards a better understanding." Molecular Nutrition & Food Research 51(6): 702-713. 
 
McKay, D. L., C.-Y. O. Chen, C. A. Zampariello and J. B. Blumberg (2015). "Flavonoids and 
phenolic acids from cranberry juice are bioavailable and bioactive in healthy older adults." 
Food Chemistry 168: 233-240. 
 
Merken, H. M. and G. R. Beecher (2000). "Measurement of food flavonoids by high-
performance liquid chromatography:  A review." Journal of Agricultural and Food Chemistry 
48(3): 577-599. 
 
Milbury, P. E., G. Cao, R. L. Prior and J. Blumberg (2002). "Bioavailablility of elderberry 
anthocyanins." Mechanisms of Ageing and Development 123(8): 997-1006. 
 
Milbury, P. E., J. A. Vita and J. B. Blumberg (2010). "Anthocyanins are bioavailable in humans 
following an acute dose of cranberry juice." The Journal of Nutrition 140(6): 1099-1104. 
 
Milenkovic, D., B. Jude and C. Morand (2013). "miRNA as molecular target of polyphenols 
underlying their biological effects." Free Radical Biology and Medicine 64: 40-51. 
 
Minihane, A. M. (2010). "Fatty acid–genotype interactions and cardiovascular risk." 
Prostaglandins, Leukotrienes and Essential Fatty Acids 82(4): 259-264. 
 
Mink, P. J., C. G. Scrafford, L. M. Barraj, L. Harnack, C.-P. Hong, J. A. Nettleton and D. R. Jacobs 
(2007). "Flavonoid intake and cardiovascular disease mortality: A prospective study in 
postmenopausal women." The American Journal of Clinical Nutrition 85(3): 895-909. 
 
Miyazaki, K., K. Makino, E. Iwadate, Y. Deguchi and F. Ishikawa (2008). "Anthocyanins from 
purple sweet potato Ipomoea batatas cultivar Ayamurasaki suppress the development of 
atherosclerotic lesions and both enhancements of oxidative stress and soluble vascular cell 
adhesion molecule-1 in apolipoprotein E-deficient mice." Journal of Agricultural and Food 
Chemistry 56(23): 11485-11492. 
 
 Page | 186 
Moridani, M. Y., H. Scobie, P. Salehi and P. J. O'Brien (2001). "Catechin metabolism: 
Glutathione conjugate formation catalyzed by tyrosinase, peroxidase, and cytochrome 
p450." Chemical Research in Toxicology 14(7): 841-848. 
 
Morrison, D. J., B. Dodson, C. Slater and T. Preston (2000). "13C natural abundance in the 
British diet: Implications for 13C breath tests." Rapid Communications in Mass Spectrometry 
14(15): 1321-1324. 
 
Mülleder, U., M. Murkovic and W. Pfannhauser (2002). "Urinary excretion of cyanidin 
glycosides." Journal of Biochemical and Biophysical Methods 53(1–3): 61-66. 
 
Mullen, W., C. A. Edwards, M. Serafini and A. Crozier (2008). "Bioavailability of pelargonidin-
3-O-glucoside and its metabolites in humans following the ingestion of strawberries with and 
without cream." Journal of Agricultural and Food Chemistry 56(3): 713-719. 
 
Nakamura, Y., H. Matsumoto, M. Morifuji, H. Iida and Y. Takeuchi (2009). "Development and 
validation of a liquid chromatography tandem mass spectrometry method for simultaneous 
determination of four anthocyanins in human plasma after black currant anthocyanins 
ingestion." Journal of Agricultural and Food Chemistry 58(2): 1174-1179. 
 
Németh, K., G. W. Plumb, J.-G. Berrin, N. Juge, R. Jacob, H. Y. Naim, G. Williamson, D. M. 
Swallow and P. A. Kroon (2003). "Deglycosylation by small intestinal epithelial cell β-
glucosidases is a critical step in the absorption and metabolism of dietary flavonoid 
glycosides in humans." European Journal of Nutrition 42(1): 29-42. 
 
Neveu, V., J. Perez-Jiménez, F. Vos, V. Crespy, L. du Chaffaut, L. Mennen, C. Knox, R. Eisner, 
J. Cruz, D. Wishart and A. Scalbert (2010). "Phenol-explorer: An online comprehensive 
database on polyphenol contents in foods. Database, doi: 10.1093/database/bap024 
(version 1.5.2, available at  http://www.phenol-explorer.eu)." Database 2010. 
 
Nguyen, H. P. and K. A. Schug (2008). "The advantages of ESI-MS detection in conjunction 
with HILIC mode separations: Fundamentals and applications." Journal of Separation Science 
31(9): 1465-1480. 
 
Nielsen, I. L. F., L. O. Dragsted, G. Ravn-Haren, R. Freese and S. E. Rasmussen (2003). 
"Absorption and excretion of black currant anthocyanins in humans and watanabe heritable 
hyperlipidemic rabbits." Journal of Agricultural and Food Chemistry 51(9): 2813-2820. 
 
Nielsen, S. E., R. Freese, P. Kleemola and M. Mutanen (2002). "Flavonoids in human urine as 
biomarkers for intake of fruits and vegetables." Cancer Epidemiology Biomarkers & 
Prevention 11(5): 459-466. 
 
Nurmi, T., J. Mursu, M. Heinonen, A. Nurmi, R. Hiltunen and S. Voutilainen (2009). 
"Metabolism of berry anthocyanins to phenolic acids in humans." Journal of Agricultural and 
Food Chemistry 57(6): 2274-2281. 
 
  
 Page | 187 
Oak, M. H., J. Bedoui, S. F. Madeira, K. Chalupsky and V. Schini‐Kerth (2006). "Delphinidin 
and cyanidin inhibit PDGFAB‐induced VEGF release in vascular smooth muscle cells by 
preventing activation of p38 MAPK and JNK." British Journal of Pharmacology 149(3): 283-
290. 
 
Ohnishi, R., H. Ito, N. Kasajima, M. Kaneda, R. Kariyama, H. Kumon, T. Hatano and T. Yoshida 
(2006). "Urinary excretion of anthocyanins in humans after cranberry juice ingestion." 
Bioscience, Biotechnology, and Biochemistry 70(7): 1681-1687. 
 
Oliveira, H. l., I. Fernandes, N. r. F. Brás, A. Faria, V. De Freitas, C. a. o. Calhau and N. Mateus 
(2015). "Experimental and theoretical data on the mechanism by which red wine 
anthocyanins are transported through a human MKN-28 gastric cell model." Journal of 
Agricultural and Food Chemistry 63(35): 7685-7692. 
 
Ostrowski, W., A. Wojakowska, M. Grajzer and M. Stobiecki (2014). "Mass spectrometric 
behavior of phenolic acids standards and their analysis in the plant samples with LC/ESI/MS 
system." Journal of Chromatography B 967: 21-27. 
 
Paixão, J., T. C. Dinis and L. M. Almeida (2012). "Malvidin-3-glucoside protects endothelial 
cells up-regulating endothelial NO synthase and inhibiting peroxynitrite-induced NF-kB 
activation." Chemico-Biological Interactions 199(3): 192-200. 
 
Pamukcu, B., G. Y. Lip, V. Snezhitskiy and E. Shantsila (2011). "The CD40-CD40L system in 
cardiovascular disease." Annals of Medicine 43(5): 331-340. 
 
Passamonti, S., A. Vanzo, U. Vrhovsek, M. Terdoslavich, A. Cocolo, G. Decorti and F. Mattivi 
(2005). "Hepatic uptake of grape anthocyanins and the role of bilitranslocase." Food 
Research International 38(8–9): 953-960. 
 
Passamonti, S., U. Vrhovsek and F. Mattivi (2002). "The interaction of anthocyanins with 
bilitranslocase." Biochemical and Biophysical Research Communications 296(3): 631-636. 
 
Peiffer, D. S., N. P. Zimmerman, L.-S. Wang, B. W. Ransom, S. G. Carmella, C.-T. Kuo, J. 
Siddiqui, J.-H. Chen, K. Oshima and Y.-W. Huang (2014). "Chemoprevention of esophageal 
cancer with black raspberries, their component anthocyanins, and a major anthocyanin 
metabolite, protocatechuic acid." Cancer Prevention Research 7(6): 574-584. 
 
Penczynski, K. J., D. Krupp, A. Bring, K. Bolzenius, T. Remer and A. E. Buyken (2015). "Relative 
validation of 24-h urinary hippuric acid excretion as a biomarker for dietary flavonoid intake 
from fruit and vegetables in healthy adolescents." European Journal of Nutrition: 1-10. 
 
Pérez-Jiménez, J., L. Fezeu, M. Touvier, N. Arnault, C. Manach, S. Hercberg, P. Galan and A. 
Scalbert (2011). "Dietary intake of 337 polyphenols in French adults." The American Journal 
of Clinical Nutrition 93(6): 1220-1228. 
 
  
 Page | 188 
Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins and M. E. Gerritsen 
(1997). "Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell 
adhesion molecule expression show anti-inflammatory effects in vivo." Journal of Biological 
Chemistry 272(34): 21096-21103. 
 
Pietrini, F., M. Iannelli and A. Massacci (2002). "Anthocyanin accumulation in the illuminated 
surface of maize leaves enhances protection from photo‐inhibitory risks at low temperature, 
without further limitation to photosynthesis." Plant, Cell & Environment 25(10): 1251-1259. 
 
Pimpão, R. C., T. Dew, M. E. Figueira, G. J. McDougall, D. Stewart, R. B. Ferreira, C. N. Santos 
and G. Williamson (2014). "Urinary metabolite profiling identifies novel colonic metabolites 
and conjugates of phenolics in healthy volunteers." Molecular Nutrition & Food Research 
58(7): 1414-1425. 
 
Pimpão, R. C., M. R. Ventura, R. B. Ferreira, G. Williamson and C. N. Santos (2015). "Phenolic 
sulfates as new and highly abundant metabolites in human plasma after ingestion of a mixed 
berry fruit purée." British Journal of Nutrition 113(03): 454-463. 
 
Polson, C., P. Sarkar, B. Incledon, V. Raguvaran and R. Grant (2003). "Optimization of protein 
precipitation based upon effectiveness of protein removal and ionization effect in liquid 
chromatography–tandem mass spectrometry." Journal of Chromatography B 785(2): 263-
275. 
 
Pompella, A., A. Visvikis, A. Paolicchi, V. De Tata and A. F. Casini (2003). "The changing faces 
of glutathione, a cellular protagonist." Biochemical Pharmacology 66(8): 1499-1503. 
 
Potischman, N. (2003). "Biologic and methodologic issues for nutritional biomarkers." The 
Journal of Nutrition 133(3): 875S-880S. 
 
Prior, R. L., X. Wu, L. Gu, T. J. Hager, A. Hager and L. R. Howard (2008). "Whole berries versus 
berry anthocyanins: Interactions with dietary fat levels in the c57bl/6j mouse model of 
obesity." Journal of Agricultural and Food Chemistry 56(3): 647-653. 
 
Queipo-Ortuño, M. I., M. Boto-Ordóñez, M. Murri, J. M. Gomez-Zumaquero, M. Clemente-
Postigo, R. Estruch, F. C. Diaz, C. Andrés-Lacueva and F. J. Tinahones (2012). "Influence of red 
wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers." 
The American Journal of Clinical Nutrition 95(6): 1323-1334. 
 
Rabassa, M., A. Cherubini, R. Zamora-Ros, M. Urpi-Sarda, S. Bandinelli, L. Ferrucci and C. 
Andres-Lacueva (2015). "Low levels of a urinary biomarker of dietary polyphenol are 
associated with substantial cognitive decline over a 3-year period in older adults: The 
Invecchiare in Chianti Study." Journal of the American Geriatrics Society 63(5): 938-946. 
 
Raju, B., M. Ramesh, R. M. Borkar, R. Padiya, S. K. Banerjee and R. Srinivas (2012). 
"Identification and structural characterization of in vivo metabolites of ketorolac using liquid 
chromatography electrospray ionization tandem mass spectrometry (LC/ESI‐MS/MS)." 
Journal of Mass Spectrometry 47(7): 919-931. 
 
 Page | 189 
Ramalingam, P. and Y. T. Ko (2016). "Validated LC–MS/MS method for simultaneous 
quantification of resveratrol levels in mouse plasma and brain and its application to 
pharmacokinetic and brain distribution studies." Journal of Pharmaceutical and Biomedical 
Analysis 119: 71-75. 
 
Ramana, K. V., A. Bhatnagar and S. K. Srivastava (2004). "Aldose reductase regulates TNF-α-
induced cell signaling and apoptosis in vascular endothelial cells." FEBS Letters 570(1–3): 
189-194. 
 
Rangel-Huerta, O. D., B. Pastor-Villaescusa, C. M. Aguilera and A. Gil (2015). "A systematic 
review of the efficacy of bioactive compounds in cardiovascular disease: Phenolic 
compounds." Nutrients 7(7): 5177-5216. 
 
Rauha, J.-P., H. Vuorela and R. Kostiainen (2001). "Effect of eluent on the ionization efficiency 
of flavonoids by ion spray, atmospheric pressure chemical ionization, and atmospheric 
pressure photoionization mass spectrometry." Journal of Mass Spectrometry 36(12): 1269-
1280. 
 
Rein, M. (2005). Copigmentation reactions and color stability of berry anthocyanins, 
University of Helsinki. 
 
Rice-Evans, C. (1995). "Plant polyphenols: Free radical scavengers or chain-breaking 
antioxidants?" Biochemical Society Symposia 61: 103-116. 
 
Robbins, R. J. (2003). "Phenolic acids in foods:  An overview of analytical methodology." 
Journal of Agricultural and Food Chemistry 51(10): 2866-2887. 
 
Rodriguez-Mateos, A., C. Rendeiro, T. Bergillos-Meca, S. Tabatabaee, T. W. George, C. Heiss 
and J. P. Spencer (2013). "Intake and time dependence of blueberry flavonoid–induced 
improvements in vascular function: A randomized, controlled, double-blind, crossover 
intervention study with mechanistic insights into biological activity." The American Journal 
of Clinical Nutrition 98(5): 1179-1191. 
 
Rodriguez-Mateos, A., D. Vauzour, C. Krueger, D. Shanmuganayagam, J. Reed, L. Calani, P. 
Mena, D. Del Rio and A. Crozier (2014). "Bioavailability, bioactivity and impact on health of 
dietary flavonoids and related compounds: An update." Archives of Toxicology: 1-51. 
 
Romanelli, A., L. Olson, T. Biesenthal and H. Ghobarah. (2012). "The AB SCIEX triple quadtm 
6500 and QTRAP(r) 6500 systems for bioanalysis - a new level of sensitivity." from 
http://sciex.com/Documents/tech%20notes/6500%20System%20for%20High%20Sensitivit
y%20Bioanalysis%20TN%205780212-01.pdf. 
 
Sabio, G. and R. J. Davis (2014). "TNF and MAP kinase signalling pathways." Seminars in 
Immunology 26(3): 237-245. 
 
Sadilova, E., F. Stintzing and R. Carle (2006). "Thermal degradation of acylated and 
nonacylated anthocyanins." Journal of Food Science 71(8): C504-C512. 
 Page | 190 
 
Sánchez-Patán, F., C. Cueva, M. Monagas, G. E. Walton, G. R. Gibson M, J. E. Quintanilla-
López, R. Lebrón-Aguilar, P. J. Martín-Álvarez, M. V. Moreno-Arribas and B. Bartolomé 
(2012). "In vitro fermentation of a red wine extract by human gut microbiota: Changes in 
microbial groups and formation of phenolic metabolites." Journal of Agricultural and Food 
Chemistry 60(9): 2136-2147. 
 
Sawa, Y., T. Ueki, M. Hata, K. Iwasawa, E. Tsuruga, H. Kojima, H. Ishikawa and S. Yoshida 
(2008). "LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic 
endothelium." Journal of Histochemistry and Cytochemistry 56(2): 97-109. 
 
Scalbert, A., I. T. Johnson and M. Saltmarsh (2005). "Polyphenols: Antioxidants and beyond." 
The American Journal of Clinical Nutrition 81(1): 215S-217S. 
 
Scalbert, A. and G. Williamson (2000). "Dietary intake and bioavailability of polyphenols." 
The Journal of Nutrition 130(8): 2073S-2085S. 
 
Schoenheimer, R. and D. Rittenberg (1935). "Deuterium as an indicator in the study of 
intermediary metabolism. I." Journal of Biological Chemistry 111(1): 163-168. 
 
Schuett, H., M. Luchtefeld, C. Grothusen, K. Grote and B. Schieffer (2009). "How much is too 
much? Interleukin-6 and its signalling in atherosclerosis." Thrombosis and Haemostasis 
102(2): 215-222. 
 
Schwartz, R. and C. C. Giesecke (1979). "Mass spectrometry of a volatile Mg chelate in the 
measurement of stable 26 Mg when used as a tracer." Clinica Chimica Acta 97(1): 1-8. 
 
Selma, M. a. V., J. C. Espín and F. A. Tomás‐Barberán (2009). "Interaction between phenolics 
and gut microbiota: Role in human health." Journal of Agricultural and Food Chemistry 
57(15): 6485-6501. 
 
Sesink, A. L. A., I. C. W. Arts, M. Faassen-Peters and P. C. H. Hollman (2003). "Intestinal uptake 
of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin hydrolase." The 
Journal of Nutrition 133(3): 773-776. 
 
Smith, D. L. (1983). "Determination of stable isotopes of calcium in biological fluids by fast 
atom bombardment mass spectrometry." Analytical Chemistry 55(14): 2391-2393. 
 
Sommer, M. O. (2015). "Advancing gut microbiome research using cultivation." Current 
Opinion in Microbiology 27: 127-132. 
 
Speciale, A., S. Anwar, R. Canali, J. Chirafisi, A. Saija, F. Virgili and F. Cimino (2013). "Cyanidin-
3-O-glucoside counters the response to TNF-alpha of endothelial cells by activating Nrf2 
pathway." Molecular Nutrition & Food Research 57(11): 1979-1987. 
 
 Page | 191 
Speciale, A., F. Cimino, A. Saija, R. Canali and F. Virgili (2014). "Bioavailability and molecular 
activities of anthocyanins as modulators of endothelial function." Genes & Nutrition 9(4): 1-
19. 
 
Spencer, J. P., M. M. Abd El Mohsen, A.-M. Minihane and J. C. Mathers (2008). "Biomarkers 
of the intake of dietary polyphenols: Strengths, limitations and application in nutrition 
research." British Journal of Nutrition 99(01): 12-22. 
 
Stintzing, F. C. and R. Carle (2004). "Functional properties of anthocyanins and betalains in 
plants, food, and in human nutrition." Trends in Food Science & Technology 15(1): 19-38. 
 
Stokvis, E., H. Rosing and J. H. Beijnen (2005). "Stable isotopically labeled internal standards 
in quantitative bioanalysis using liquid chromatography/mass spectrometry: Necessity or 
not?" Rapid Communications in Mass Spectrometry 19(3): 401-407. 
 
Sun, Y., B. Xia, X. Chen, C. Duanmu, D. Li and C. Han (2015). "Rapid quantification of four 
anthocyanins in red grape wine by hydrophilic interaction liquid chromatography/triple 
quadrupole linear ion trap mass spectrometry." Journal of AOAC International 98(6): 1628-
1631. 
 
Talavéra, S., C. Felgines, O. Texier, C. Besson, J.-L. Lamaison and C. Rémésy (2003). 
"Anthocyanins are efficiently absorbed from the stomach in anesthetized rats." The Journal 
of Nutrition 133(12): 4178-4182. 
 
Tanaka, Y., N. Sasaki and A. Ohmiya (2008). "Biosynthesis of plant pigments: Anthocyanins, 
betalains and carotenoids." The Plant Journal 54(4): 733-749. 
 
Tedgui, A. and Z. Mallat (2006). "Cytokines in atherosclerosis: Pathogenic and regulatory 
pathways." Physiological Reviews 86(2): 515-581. 
 
Thilakarathna, S. H. and H. Rupasinghe (2013). "Flavonoid bioavailability and attempts for 
bioavailability enhancement." Nutrients 5(9): 3367-3387. 
 
Thompson, F. E., A. F. Subar, C. M. Loria, J. L. Reedy and T. Baranowski (2010). "Need for 
technological innovation in dietary assessment." Journal of the American Dietetic 
Association 110(1): 48. 
 
Tresserra-Rimbau, A., E. B. Rimm, A. Medina-Remón, M. A. Martínez-González, R. de la Torre, 
D. Corella, J. Salas-Salvadó, E. Gómez-Gracia, J. Lapetra, F. Arós, M. Fiol, E. Ros, L. Serra-
Majem, X. Pintó, G. T. Saez, J. Basora, J. V. Sorlí, J. A. Martínez, E. Vinyoles, V. Ruiz-Gutiérrez, 
R. Estruch and R. M. Lamuela-Raventós (2014). "Inverse association between habitual 
polyphenol intake and incidence of cardiovascular events in the PREDIMED study." Nutrition, 
Metabolism and Cardiovascular Diseases 24(6): 639-647. 
 
Turnlund, J. R. (1989). "The use of stable isotopes in mineral nutrition research." The Journal 
of Nutrition 119(1): 7-14. 
 
 Page | 192 
United Nations Office on Drugs and Crime (2009). "Guidance for the validation of analytical 
methodology and calibration of equipment used for testing of illicit drugs in seized materials 
and biological specimens." 
 
Urpi‐Sarda, M., M. Boto‐Ordóñez, M. I. Queipo‐Ortuño, S. Tulipani, D. Corella, R. Estruch, F. 
J. Tinahones and C. Andres‐Lacueva (2015). "Phenolic and microbial‐targeted metabolomics 
to discovering and evaluating wine intake biomarkers in human urine and plasma." 
Electrophoresis 36(18): 2259-2268. 
 
van Dorsten, F. A., C. H. Grün, E. J. van Velzen, D. M. Jacobs, R. Draijer and J. P. van 
Duynhoven (2010). "The metabolic fate of red wine and grape juice polyphenols in humans 
assessed by metabolomics." Molecular Nutrition & Food Research 54(7): 897-908. 
 
Vanholder, R., R. De Smet, G. Glorieux, A. Argilés, U. Baurmeister, P. Brunet, W. Clark, G. 
Cohen, P. P. De Deyn and R. Deppisch (2003). "Review on uremic toxins: Classification, 
concentration, and interindividual variability." Kidney International 63(5): 1934-1943. 
 
Vanzo, A., M. Terdoslavich, A. Brandoni, A. M. Torres, U. Vrhovsek and S. Passamonti (2008). 
"Uptake of grape anthocyanins into the rat kidney and the involvement of bilitranslocase." 
Molecular Nutrition & Food Research 52(10): 1106-1116. 
 
Vassiliadis, E., N. Barascuk and M. A. Karsdal (2012). "Atherofibrosis-a unique and common 
process of the disease pathogenesis of atherosclerosis and fibrosis-lessons for biomarker 
development." American Journal of Translational Research 5(1): 1-14. 
 
Vastag, M., J. Skopál, Z. Voko, É. Csonka and Z. Nagy (1999). "Expression of membrane-bound 
and soluble cell adhesion molecules by human brain microvessel endothelial cells." 
Microvascular Research 57(1): 52-60. 
 
Vitaglione, P., G. Donnarumma, A. Napolitano, F. Galvano, A. Gallo, L. Scalfi and V. Fogliano 
(2007). "Protocatechuic acid is the major human metabolite of cyanidin-glucosides." The 
Journal of Nutrition 137(9): 2043-2048. 
 
Vogel, R. A. (1997). "Coronary risk factors, endothelial function, and atherosclerosis: A 
review." Clinical Cardiology 20(5): 426-432. 
 
Wakeling, L. A. and D. Ford (2012). "Polymorphisms in genes involved in the metabolism and 
transport of soy isoflavones affect the urinary metabolite profile in premenopausal women 
following consumption of a commercial soy supplement as a single bolus dose." Molecular 
Nutrition & Food Research 56(12): 1794-1802. 
 
Walgren, R. A., J.-T. Lin, R. K.-H. Kinne and T. Walle (2000). "Cellular uptake of dietary 
flavonoid quercetin 4′-β-glucoside by sodium-dependent glucose transporter SGLT1." 
Journal of Pharmacology and Experimental Therapeutics 294(3): 837-843. 
 
Wallace, T. C. (2011). "Anthocyanins in cardiovascular disease." Advances in Nutrition: An 
International Review Journal 2(1): 1-7. 
 Page | 193 
 
Wallace, T. C., M. Slavin and C. L. Frankenfeld (2016). "Systematic review of anthocyanins 
and markers of cardiovascular disease." Nutrients 8(1): 32. 
 
Wang, J., Y. Liao, J. Fan, T. Ye, X. Sun and S. Dong (2012). "Apigenin inhibits the expression of 
IL-6, IL-8, and ICAM-1 in DEHP-stimulated human umbilical vein endothelial cells and in vivo." 
Inflammation 35(4): 1466-1476. 
 
Wang, S. Y., C.-T. Chen and C. Y. Wang (2009). "The influence of light and maturity on fruit 
quality and flavonoid content of red raspberries." Food Chemistry 112(3): 676-684. 
 
Wang, X., Y. Y. Ouyang, J. Liu and G. Zhao (2014a). "Flavonoid intake and risk of CVD: A 
systematic review and meta-analysis of prospective cohort studies." British Journal of 
Nutrition 111(01): 1-11. 
 
Wang, X., X. Zhao, L. Gu, C. Lv, B. He, Z. Liu, P. Hou, K. Bi and X. Chen (2014b). "Simultaneous 
determination of five free and total flavonoids in rat plasma by ultra HPLC–MS/MS and its 
application to a comparative pharmacokinetic study in normal and hyperlipidemic rats." 
Journal of Chromatography B 953–954: 1-10. 
 
Warner, E. F., Q. Zhang, K. S. Raheem, D. O’Hagan, M. A. O’Connell and C. D. Kay (2016). 
"Common phenolic metabolites of flavonoids, but not their unmetabolized precursors, 
reduce the secretion of vascular cellular adhesion molecules by human endothelial cells." 
The Journal of Nutrition 146(3): 465-473. 
 
Warth, B., M. Sulyok, P. Fruhmann, H. Mikula, F. Berthiller, R. Schuhmacher, C. Hametner, 
W. A. Abia, G. Adam and J. Fröhlich (2012). "Development and validation of a rapid multi‐
biomarker liquid chromatography/tandem mass spectrometry method to assess human 
exposure to mycotoxins." Rapid Communications in Mass Spectrometry 26(13): 1533-1540. 
 
Wei, L., X. Wang, P. Zhang, Y. Sun, L. Jia, J. Zhao, S. Dong and L. Sun (2016). "An UPLC–MS/MS 
method for simultaneous quantitation of two coumarins and two flavonoids in rat plasma 
and its application to a pharmacokinetic study of Wikstroemia indica extract." Journal of 
Chromatography B 1008: 139-145. 
 
Whyte, A. R., G. Schafer and C. M. Williams (2015). "Cognitive effects following acute wild 
blueberry supplementation in 7- to 10-year-old children." European Journal of Nutrition: 1-
12. 
 
Wiczkowski, W., D. Szawara-Nowak and J. Romaszko (2016). "The impact of red cabbage 
fermentation on bioavailability of anthocyanins and antioxidant capacity of human plasma." 
Food Chemistry 190: 730-740. 
 
Wilkes, K., L. R. Howard, C. Brownmiller and R. L. Prior (2013). "Changes in chokeberry 
(Aronia melanocarpa l.) polyphenols during juice processing and storage." Journal of 
Agricultural and Food Chemistry 62(18): 4018-4025. 
 
 Page | 194 
Willemse, C. M., M. A. Stander and A. de Villiers (2013). "Hydrophilic interaction 
chromatographic analysis of anthocyanins." Journal of Chromatography A 1319: 127-140. 
 
Williamson, G. (2013). "Possible effects of dietary polyphenols on sugar absorption and 
digestion." Molecular Nutrition & Food Research 57(1): 48-57. 
 
Woodward, G., P. Kroon, A. Cassidy and C. Kay (2009). "Anthocyanin stability and recovery: 
Implications for the analysis of clinical and experimental samples." Journal of Agricultural 
and Food Chemistry 57(12): 5271-5278. 
 
World Health Organisation (2014). Global status report on noncommunicable diseases. 
 
Wu, C. H., F. H. Lu, C. S. Chang, T. C. Chang, R. H. Wang and C. J. Chang (2003). "Relationship 
among habitual tea consumption, percent body fat, and body fat distribution." Obesity 
Research 11(9): 1088-1095. 
 
Wu, T., Z. Yu, Q. Tang, H. Song, Z. Gao, W. Chen and X. Zheng (2013). "Honeysuckle 
anthocyanin supplementation prevents diet-induced obesity in C57BL/6 mice." Food & 
Function 4(11): 1654-1661. 
 
Wu, W.-B., D.-K. Hung, F.-W. Chang, E.-T. Ong and B.-H. Chen (2012). "Anti-inflammatory and 
anti-angiogenic effects of flavonoids isolated from Lycium barbarum Linnaeus on human 
umbilical vein endothelial cells." Food & Function 3(10): 1068-1081. 
 
Wu, X., G. R. Beecher, J. M. Holden, D. B. Haytowitz, S. E. Gebhardt and R. L. Prior (2006). 
"Concentrations of anthocyanins in common foods in the United States and estimation of 
normal consumption." Journal of Agricultural and Food Chemistry 54(11): 4069-4075. 
 
Wu, X., G. Cao and R. L. Prior (2002). "Absorption and metabolism of anthocyanins in elderly 
women after consumption of elderberry or blueberry." The Journal of Nutrition 132(7): 
1865-1871. 
 
Wu, X., L. Gu, R. L. Prior and S. McKay (2004). "Characterization of anthocyanins and 
proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant 
capacity." Journal of Agricultural and Food Chemistry 52(26): 7846-7856. 
 
Xia, M., W. Ling, H. Zhu, J. Ma, Q. Wang, M. Hou, Z. Tang, H. Guo, C. Liu and Q. Ye (2009). 
"Anthocyanin attenuates CD40-mediated endothelial cell activation and apoptosis by 
inhibiting CD40-induced MAPK activation." Atherosclerosis 202(1): 41-47. 
 
Xia, M., W. Ling, H. Zhu, Q. Wang, J. Ma, M. Hou, Z. Tang, L. Li and Q. Ye (2007). "Anthocyanin 
prevents CD40-activated proinflammatory signaling in endothelial cells by regulating 
cholesterol distribution." Arteriosclerosis, Thrombosis, and Vascular Biology 27(3): 519-524. 
 
  
 Page | 195 
Xie, C., J. Kang, M. E. Ferguson, S. Nagarajan, T. M. Badger and X. Wu (2011). "Blueberries 
reduce pro-inflammatory cytokine TNF-α and IL-6 production in mouse macrophages by 
inhibiting NF-κB activation and the MAPK pathway." Molecular Nutrition & Food Research 
55(10): 1587-1591. 
 
Xie, L., S. G. Lee, T. M. Vance, Y. Wang, B. Kim, J.-Y. Lee, O. K. Chun and B. W. Bolling (2016). 
"Bioavailability of anthocyanins and colonic polyphenol metabolites following consumption 
of aronia berry extract." Food Chemistry 211: 860-868. 
 
Xu, J.-W., K. Ikeda and Y. Yamori (2004). "Upregulation of endothelial nitric oxide synthase 
by cyanidin-3-glucoside, a typical anthocyanin pigment." Hypertension 44(2): 217-222. 
 
Yang, Z., L. Deng, Y. Lan, X. Zhang, Z. Gao, C.-W. Chu, D. Cai and Z. Ren (2014). "Molecular 
extraction in single live cells by sneaking in and out magnetic nanomaterials." Proceedings 
of the National Academy of Sciences 111(30): 10966-10971. 
 
Yu, H., W. Jiang, H. Du, Y. Xing, G. Bai, Y. Zhang, Y. Li, H. Jiang, Y. Zhang, J. Wang, P. Wang and 
X. Bai (2014). "Involvement of the Akt/NF-κB pathways in the HTNV-mediated increase of IL-
6, CCL5, ICAM-1, and VCAM-1 in HUVECs." PLOS ONE 9(4): e93810. 
 
Yuan, L., D. Zhang, M. Jemal and A. F. Aubry (2012). "Systematic evaluation of the root cause 
of non‐linearity in liquid chromatography/tandem mass spectrometry bioanalytical assays 
and strategy to predict and extend the linear standard curve range." Rapid Communications 
in Mass Spectrometry 26(12): 1465-1474. 
 
Zamek-Gliszczynski, M. J., K. A. Hoffmaster, K.-i. Nezasa, M. N. Tallman and K. L. R. Brouwer 
(2006). "Integration of hepatic drug transporters and phase II metabolizing enzymes: 
Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites." 
European Journal of Pharmaceutical Sciences 27(5): 447-486. 
 
Zamora-Ros, R., V. Knaze, L. Luján-Barroso, N. Slimani, I. Romieu, M. Touillaud, R. Kaaks, B. 
Teucher, A. Mattiello and S. Grioni (2011). "Estimation of the intake of anthocyanidins and 
their food sources in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
study." British Journal of Nutrition 106(07): 1090-1099. 
 
Zamora-Ros, R., C. Not, E. Guinó, L. Luján-Barroso, R. M. García, S. Biondo, R. Salazar and V. 
Moreno (2013). "Association between habitual dietary flavonoid and lignan intake and 
colorectal cancer in a Spanish case–control study (the Bellvitge Colorectal Cancer Study)." 
Cancer Causes & Control 24(3): 549-557. 
 
Zeng, Y., S. Li, X. Wang, T. Gong, X. Sun and Z. Zhang (2015). "Validated LC-MS/MS method 
for the determination of scopoletin in rat plasma and its application to pharmacokinetic 
studies." Molecules 20(10): 18988-19001. 
 
Zhang, Q., K. S. Raheem, N. P. Botting, A. M. Z. Slawin, C. D. Kay and D. O'Hagan (2012). 
"Flavonoid metabolism: The synthesis of phenolic glucuronides and sulfates as candidate 
metabolites for bioactivity studies of dietary flavonoids." Tetrahedron 68(22): 4194-4201. 
 
 Page | 196 
Zhao, Y., P. M. Vanhoutte and S. W. Leung (2015). "Vascular nitric oxide: Beyond eNOS." 
Journal of Pharmacological Sciences 129(2): 83-94. 
 
Zhou, S. and K. D. Cook (2001). "A mechanistic study of electrospray mass spectrometry: 
Charge gradients within electrospray droplets and their influence on ion response." Journal 
of the American Society for Mass Spectrometry 12(2): 206-214. 
 
Zhu, Y., W. Ling, H. Guo, F. Song, Q. Ye, T. Zou, D. Li, Y. Zhang, G. Li and Y. Xiao (2013). "Anti-
inflammatory effect of purified dietary anthocyanin in adults with hypercholesterolemia: A 
randomized controlled trial." Nutrition, Metabolism and Cardiovascular Diseases 23(9): 843-
849. 
 
Zou, T.-B., D. Feng, G. Song, H.-W. Li, H.-W. Tang and W.-H. Ling (2014). "The role of sodium-
dependent glucose transporter 1 and glucose transporter 2 in the absorption of cyanidin-3-
O-β-glucoside in Caco-2 cells." Nutrients 6(10): 4165-4177. 
 
 
